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3ABSTRACT
Coronary heart disease (CHD) mortality rates have fallen since the 1960s in the UK.
The prevalence of type 2 diabetes (T2DM), in contrast, has increased markedly in
recent decades. Few attempts have been made to examine the reasons for these
striking, divergent time trends.
The CHD mortality and T2DM prevalence trends likely reflect in part
contemporaneous trends in incidence of these conditions. The broad aim of this thesis
is therefore to analyse recent trends in CHD and T2DM incidence in the UK, in
relation to trends in aetiological exposures and treatment use, and in relation to each
other.
This epidemiological research involves statistical analysis of pre-collected data from
different UK-based observational data sources, each used according to their strengths:
the British Regional Heart Study cohort, The Health Improvement Network primary
care database, and the Whitehall II cohort.
The principal findings are that favourable time trends in major modifiable aetiological
exposures (smoking, blood pressure and HDL and non-HDL cholesterol) may explain
half of a 62% decline in major CHD incidence in men over 25 years. Findings for
women are similar. Much of the blood pressure decline, and a third of the non-HDL
cholesterol decline was associated with increased preventive medication use.
Conversely, unfavourable rising adiposity levels limited the scale of the decline in
major CHD incidence, and explain an estimated one quarter of a rise in T2DM
incidence since the 1980s. Major CHD incidence declined faster among those with
T2DM, than without, corresponding to an attenuation of excess risk of CHD
associated with T2DM.
By highlighting what can be achieved in terms of reducing CHD, while showing the
adverse impact of rising obesity levels, the results provide evidence to help inform
future efforts to reduce CHD further and curb the rise in T2DM, in the UK and in
other locations.
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5FREQUENTLY USED ABBREVIATIONS
Data sources
BRHS British Regional Heart Study
THIN The Health Improvement Network (primary care database)
Disease outcomes
CHD Coronary heart disease
CVD Cardiovascular disease
MI Myocardial infarction
T1DM Type 1 diabetes mellitus
T2DM Type 2 diabetes mellitus
Exposures
BMI Body mass index
BP Blood pressure
DBP Diastolic blood pressure
HDL High – density lipoprotein (cholesterol)
LDL Low – density lipoprotein (cholesterol)
SBP Systolic blood pressure
Statistical terms
CI Confidence interval
GEE Generalised estimating equation
SD Standard deviation
6TABLE OF CONTENTS
Declaration statement………………………………………………………….
Abstract…………………………………………………………………..…….
Acknowledgements……………………………………………………………..
Frequently used abbreviations…………………………………………………
Table of contents………………………………………………………………
List of chapter subsections…………………………………………………….
List of tables……………………………………………………………………
List of figures………………………………………………………………….
Chapter 1 Introduction…………………………………………………...
Chapter 2 Review of the existing literature……………………………...
Chapter 3 Methodology………………………………………………….
Chapter 4 Estimating recent time trends in incidence of major coronary heart
disease and type 2 diabetes in the UK using data from The Health
Improvement Network and two cohort studies
Chapter 5 Analysing the role of trends in aetiological exposures in the time
trend in major coronary heart disease incidence in the British
Regional Heart Study
Chapter 6 Analysing the role of trends in aetiological exposures in the time
trend in major coronary heart disease incidence in the Whitehall II
cohort
Chapter 7 Assessing the role of medication in the time trends in the major
coronary aetiological exposures in the British Regional Heart Study
Chapter 8 Analysing the trend in type 2 diabetes incidence in the British
Regional Heart Study
Chapter 9 Analysing the relationship between the time trends in incidence of
major coronary heart disease and type 2 diabetes using data from The
Health Improvement Network and the British Regional Heart Study
Chapter 10 Implications…………………………………………………...
Appendix A Lists of Read codes to identify disease cases in The Health
Improvement Network database
References ………………………………………………………………...
Page
2
3
4
5
6
7
13
16
17
27
106
144
205
234
263
287
309
340
373
382
7LIST OF CHAPTER SUBSECTIONS
Chapter 1 Introduction
1.1 Introduction and rationale for thesis
1.2 Thesis objectives
1.3 Overview of methodology
1.4 Disease definitions
1.5 Structure of the thesis
1.6 Thesis publications
Chapter 2 Review of the existing literature
2.1 Introduction
2.2 Time trends in major coronary heart disease in the UK
2.2.1 Time trend in CHD mortality in the UK
2.2.1.1 Overall time trends among men and women
2.2.1.2 Age-specific time trends
2.2.1.3 Time trends within different socio-demographic groups
2.2.2 Time trend in major CHD incidence and case fatality in the UK
2.2.2.1 Time trends in major CHD incidence
2.2.2.2 Time trends in major CHD case fatality
2.2.2.3 Summary of major CHD incidence and case fatality trends
2.3 Time trends in type 2 diabetes in the UK
2.3.1 Time trend in T2DM prevalence in the UK
2.3.1.1 Overall time trends among men and women
2.3.1.2 Age-specific time trends
2.3.1.3 Time trends within different socio-demographic groups
2.3.2 Time trend in T2DM incidence and relative mortality in the UK
2.3.2.1 Time trends in major T2DM incidence
2.3.2.2 Time trends in relative mortality among patients with T2DM
2.3.2.3 Summary of T2DM incidence and relative mortality trends
2.4 Continuing healthcare burden of coronary heart disease and type
2 diabetes
2.4.1 Continuing healthcare burden of coronary heart disease
2.4.2 Continuing healthcare burden of type 2 diabetes
2.5 Considerations when evaluating time trends in incidence of major
coronary heart disease and type 2 diabetes
2.5.1 Considerations when establishing the extent of the incidence time
trends (towards objectives i and ii)
2.5.2 Candidate factors to explain a decline in major CHD incidence
(towards objective iii)
2.5.2.1 Major established modifiable aetiological exposures
2.5.2.2 Preventive treatments
2.5.3 Candidate factors to explain a rise in T2DM incidence (towards
objective iv)
2.5.3.1 Major established modifiable aetiological exposures
2.5.4 T2DM and risk of major CHD (towards objective v)
82.6 Current literature examining reasons for the time trends in major
coronary heart disease and type 2 diabetes in the UK
2.6.1 Reasons for time trends in major CHD
2.6.1.1 WHO MONICA Project
2.6.1.2 IMPACT Policy model project
2.6.1.3 Summary of extent of literature explaining UK CHD trends
2.6.2 Reasons for time trends in T2DM in the UK
2.7 Worldwide picture
2.7.1 Describing and explaining time trends in major CHD
2.7.2 Describing and explaining time trends in T2DM
2.8 Summary of literature review findings
Chapter 3 Methodology
3.1 Introduction
3.2 The British Regional Heart Study
3.2.1 Description of data source
3.2.2 Description of follow-up
3.2.3 Intended use of data source
3.2.4 Assessment of disease cases
3.2.5 Repeated assessment of coronary and diabetic risk factors
3.2.6 Sub-study 1: Investigating comparability between the risk factor
ascertainment methods used at each time point
3.2.7 Sub-study 2: Deriving physical activity at 5 years follow-up
3.2.8 Description of study population
3.2.9 Strengths in relation to intended analyses
3.3 The Health Improvement Network Database
3.3.1 Description of data source
3.3.2 Description of follow-up
3.3.3 Intended use of data source
3.3.4 Identification of cases of major CHD or T2DM
3.3.5 Ascertainment of socio-demographic characteristics
3.3.6 Description of study population
3.3.7 Strengths in relation to intended analyses
3.4 The Whitehall II Study
3.4.1 Description of data source
3.4.2 Description of follow-up
3.4.3 Intended use of data source
3.4.4 Assessment of major CHD events
3.4.5 Repeated assessment of coronary risk factors
3.4.6 Sub-study 1: Derivation of HDL cholesterol at baseline
3.4.7 Description of study population
3.4.8 Strengths in relation to intended analyses
9Chapter 4 Estimating recent time trends in incidence of major
coronary heart disease and type 2 diabetes in the UK using data from
The Health Improvement Network and two cohort studies
4.1 Introduction
4.2 Methods
4.2.1 Data sources
4.2.2 THIN study sample
4.2.3 Follow-up
4.2.4 Principal outcome as a first major CHD event
4.2.5 Principal outcome as a first diagnosis of T2DM
4.2.6 Socio-demographic characteristics
4.2.7 Statistical methods
4.2.8 Analyses using BRHS and Whitehall II data
4.2.8.1 BRHS
4.2.8.2 Whitehall II cohort – incidence of major CHD only
4.2.9 Secondary analyses to further assess comparability between data
sources
4.3 Results - Time trend in incidence of major coronary heart
disease: The Health Improvement Network
4.4 Results - Time trend in incidence of type 2 diabetes: The Health
Improvement Network
4.5 Results – Comparison with British Regional Heart Study and
Whitehall II cohort
4.5.1 Major CHD incidence
4.5.1.1 BRHS overall incidence rates
4.5.1.2 Whitehall II overall incidence rates
4.5.1.3 Time trends in major CHD incidence in the different studies
4.5.2 T2DM incidence
4.5.2.1 BRHS overall incidence rates – all men
4.5.2.2 BRHS overall incidence rates – survivors
4.5.2.3 Time trends in incidence of T2DM in the different studies
4.6 Discussion
4.6.1 Summary of main findings
4.6.2 Strengths and limitations of analysis of THIN database
4.6.3 Comparisons with the analyses of BRHS and Whitehall II cohort
data
4.6.4 Comparison with other published data
4.6.4.1 Decline in incidence of major CHD
4.6.4.2 Rise in incidence of T2DM
4.6.5 Interpretation of findings
4.6.5.1 Is the decline in major CHD incidence a true epidemiological
change in the population?
4.6.5.2 Is the rise in T2DM incidence a true epidemiological change
in the population?
4.6.5.3 Relation to trends in mortality of CHD and prevalence of
T2DM
4.6.5.4 Impact of variations in trends by socio-demographic group
4.6.6 Chapter conclusions/ post-script
10
Chapter 5 Analysing the role of trends in aetiological exposures in
the time trend in major coronary heart disease incidence in the
British Regional Heart Study
5.1 Introduction
5.2 Methods
5.2.1 Data source
5.2.2 Principal outcome of a first major CHD event
5.2.3 Aetiological exposures
5.2.4 Statistical methods
5.2.5 Participants included in analysis
5.3 Results - Time trends in major coronary risk factors
5.4 Results - Analysis of relation of trends in risk factors to trends in
major coronary heart disease incidence
5.5 Discussion
5.5.1 Summary of main findings
5.5.2 Comparison with other studies
5.5.3 Strengths and limitations
5.5.4 Interpretation of findings
5.5.5 Chapter conclusions/ postscript
Chapter 6 Analysing the role of trends in aetiological exposures in
the time trend in major coronary heart disease incidence in the
Whitehall II cohort
6.1 Introduction
6.2 Methods
6.2.1 Data source
6.2.2 Principal outcome of a first major CHD event
6.2.3 Coronary risk factors
6.2.4 Statistical methods
6.2.5 Participants included in analysis
6.3 Results – Time trends in the major coronary risk factors in
Whitehall II
6.4 Results - Analysis of relation of trends in risk factors to trends in
major coronary heart disease incidence
6.5 Discussion
6.5.1 Summary of main findings
6.5.2 Comparison between men and women in Whitehall II
6.5.3 Comparison between employment grade in Whitehall II
6.5.4 Comparison of men in Whitehall II with the BRHS findings
6.5.5 Strengths and limitations
6.5.6 Interpretation of findings
6.5.7 Chapter conclusions/ postscript
11
Chapter 7 Assessing the role of medication in the time trends in the
major coronary aetiological exposures in the British Regional Heart
Study
7.1 Introduction
7.2 Methods
7.2.1 Data source
7.2.2 Coronary risk factors as the principal outcomes
7.2.3 Medication use
7.2.4 Potential confounding variables: factors associated with
dyslipidemia and hypertension
7.2.5 Statistical methods
7.2.6 Participants included in analysis
7.3 Results – Examining the role of medication in the risk factor
changes
7.4 Discussion
7.4.1 Summary of main findings
7.4.2 Comparison with other studies
7.4.3 Strengths and limitations
7.4.4 Interpretation of findings
7.4.5 Chapter conclusions/ postscript
Chapter 8 Analysing the trend in type 2 diabetes incidence in the
British Regional Heart Study
8.1 Introduction
8.2 Methods
8.2.1 Data source
8.2.2 Principal outcome as a first diagnosis of T2DM
8.2.3 BMI as the key explanatory factor
8.2.4 Confounding factors
8.2.5 Participants included in analysis
8.2.6 Statistical methods
8.3 Results
8.3.1 Comparison of incidence of T2DM in the three separate time-
periods
8.3.2 Time trend in mean BMI
8.3.3 Contribution of time trend in BMI to time trend in T2DM incidence
8.4 Discussion
8.4.1 Summary of main findings
8.4.2 Comparison with other studies
8.4.3 Strengths and limitations
8.4.4 Interpretation of findings
8.4.5 Chapter conclusions/ Postscript
12
Chapter 9 Analysing the relationship between the time trends in
incidence of major coronary heart disease and type 2 diabetes using
data from The Health Improvement Network and the British
Regional Heart Study
9.1 Introduction
9.2 Methods
9.2.1 Data sources
9.2.2 Methods to address chapter objective 1 - Temporal trend in survival
time from T2DM diagnosis to a major CHD event
9.2.3 Methods to address chapter objective 2 - Temporal trend in
incidence of major CHD among patients with and without T2DM and
changing relationship between T2DM and major CHD incidence over
time
9.2.4 Methods to address chapter objective 3 - Role of rising T2DM in
decline in major CHD incidence
9.2.5 Validation of findings for objective 3 using the BRHS
9.3 Results
9.3.1 Objective 1 – Temporal trend in survival time from T2DM diagnosis
to a major CHD event
9.3.2 Objective 2 – Temporal trend in incidence of major CHD among
patients with and without T2DM and changing relationship between
T2DM and major CHD incidence over time
9.3.3 Objective 3 – Role of rising T2DM in decline in major CHD
incidence
9.4 Discussion
9.4.1 Summary of main findings
9.4.2 Strengths and limitations
9.4.3 Comparison with other studies
9.4.4 Interpretation of findings
Chapter 10 Implications
10.1 Introduction – summary of all main findings
10.1.1 Recap of thesis aim
10.1.2 Findings in relation to thesis objectives
10.1.3 Novelty of the present findings (What this study adds)
10.2 Public health implications
10.2.1 Implications for the UK
10.2.2 Implications for other countries
10.3 Implications for epidemiology and epidemiological research
10.3.1 Epidemiological implications
10.3.2 Lessons learnt from research methods
10.3.3 Suggestions for further research
10.4 Concluding statement
13
LIST OF TABLES
Table 2.1 Studies assessing the contributions of risk factor and treatment trends
to CHD trends in different countries
Table 3.1 Attrition and questionnaire response rates in the British Regional
Heart Study
Table 3.2 Key characteristics of the British Regional Heart Study men at baseline
(1978-80)
Table 3.3 Total numbers of General Practices and patients contributing data to
THIN and coverage of the UK population by calendar year
Table 3.4 Demographic characteristics of THIN patients by calendar year
Table 3.5 Follow-up phases for the Whitehall II study and response rates
Table 3.6 Key characteristics of the Whitehall II cohort at baseline (1985-1988)
Table 4.1 Rates of incidence of major CHD per 1000 person-years by age, gender
and calendar period: THIN database
Table 4.2 Major CHD incidence rates in 1995-1997 and 2006-2008 and absolute
changes in incidence between the two periods, overall and by demographic group
Table 4.3 Major CHD rate ratio per annum increase in calendar time between
1995 and 2008, and corresponding percentage decline in incidence, overall and
by demographic group
Table 4.4 Rates of incidence of T2DM per 1000 person-years by age, gender and
calendar period: THIN database
Table 4.5 T2DM incidence rates in 1995-1997 and 2006-2008 and absolute
changes in incidence between the two periods, overall and by demographic group
Table 4.6 T2DM rate ratio per annum increase in calendar time between 1995
and 2008, and corresponding percentage increase in incidence, overall and by
demographic group
Table 4.7 Rates of incidence of major CHD per 1000 person-years by age and
calendar period: British Regional Heart Study men
Table 4.8 Rates of incidence of major CHD per 1000 person-years by age and
calendar period: Whitehall II men
Table 4.9 Rates of incidence of major CHD per 1000 person-years by age and
calendar period: Whitehall II women
Table 4.10 Average annual age-gender-adjusted percentage declines in incidence
of major CHD between 1980 and 2008 in the different data sources, overall and
according to socio-demographic characteristics
14
Table 4.11 Rates of incidence of T2DM per 1000 person-years by age and
calendar period: British Regional Heart Study men
Table 4.12 Rates of incidence of T2DM per 1000 person-years by age and
calendar period: British Regional Heart Study men who have survived to 2007
(end of follow-up)
Table 4.13 Average annual age-gender-adjusted percentage increases in incidence
of T2DM between 1985 and 2008 in the different data sources, overall and
according to socio-demographic characteristics
Table 5.1 Men included in the analyses by age and questionnaire time-point
Table 5.2 Smoking, alcohol consumption, physical activity, BMI, SBP, HDL
cholesterol, non-HDL cholesterol by age group and follow-up time
Table 5.3 Fall in the hazard of a first major CHD event per annum and over 25
years. Percentage of this fall explained by the risk factors from Cox regression
analyses with time-dependent covariates
Table 6.1 Numbers of participants contributing data in each study phase by age
group (participants with complete risk factor data and no prior MI)
Table 6.2 Distribution of major coronary risk factors by age and study phase:
men
Table 6.3 Distribution of major coronary risk factors by age and study phase:
women
Table 6.4 Age-adjusted population-averaged time trends in coronary risk factors
among men and women over 12 years from 1985-8 (baseline) to 1997-9 (phase 5)
Table 6.5 Fall in hazard of a first major CHD event among all participants in
Whitehall II between 1985 and 2004 and percentage of this fall explained by risk
factor time trends
Table 6.6 Fall in hazard of a first major CHD event among men and women in
Whitehall II between 1985 and 2004 and percentage of the fall explained by risk
factor time trends, separate results for each gender
Table 6.7 Fall in hazard of a first major CHD event among all participants in
Whitehall II between 1985 and 2004 and percentage of this fall explained by risk
factor time trends, separate results for each employment grade
Table 7.1 Mean age-adjusted changes over 20 years from 1978-80 to 1998-2000 in
SBP, DBP, HDL cholesterol and non-HDL cholesterol and predicted levels for a
60-year old in 1978-80 and in 1998-2000, overall and according to medication use
between the two time-points
Table 7.2 Mean changes over 20 years from 1978-80 to 1998-2000 in SBP, DBP,
HDL cholesterol and non-HDL cholesterol, overall and according to medication
15
use between the two time-points, adjusting for age and risk factors for
hypertension or hypercholesterolemia
Table 7.3 Baseline level, 20-year level, and change in risk factors for high SBP or
DBP according to blood pressure lowering medication use between baseline and
20-years
Table 7.4 Baseline level, 20-year level, and change in risk factors for low HDL
cholesterol, or high non-HDL cholesterol according to lipid-regulating
medication use between baseline and 20-years
Table 7.5 Mean changes over 20 years from 1978-80 to 1998-2000 in HDL
cholesterol and non-HDL cholesterol and predicted levels for a 60-year old in
1978-80 and in 1998-2000, overall and according to medication use between the
two time-points, adjusting for the non-significant systematic differences between
the baseline and 20-year assay techniques
Table 7.6 Mean age-adjusted changes over 20 years from 1978-80 to 1998-2000 in
SBP, DBP, HDL cholesterol and non-HDL cholesterol and predicted levels for a
60-year old in 1978-80 and in 1998-2000, overall and according to medication use
between the two time-points, among men who did not experience an MI before
the 1998-2000 examination
Table 8.1 Incidence rates of T2DM, per 1000 person-years by age and calendar
period
Table 8.2 Hazard ratios for T2DM comparing the periods 1984-1992, 1992-1999
and 1999-2007, and percentage of the hazard ratios explained by the higher BMI
levels in the later periods
Table 8.3 Hazard ratios for T2DM comparing the periods 1984-1992 and 1999-
2007, and percentage of the hazard ratio explained by BMI, adjusting for
potential confounding factors
Table 9.1 1-, 3-, and 5-year incidence of a major CHD event, following a new
T2DM diagnosis, according to calendar year of T2DM diagnosis
Table 9.2 Decline in major CHD incidence over time, comparing populations
with and without T2DM
Table 9.3 Crude and age-sex-standardised major CHD incidence rates according
to calendar period and T2DM status. Age-sex-adjusted rate ratios of major
CHD incidence, comparing populations with and without T2DM, in each
calendar period
Table 9.4 Crude and age-standardised major CHD incidence rates according to
calendar period and T2DM status, by gender. Age-adjusted rate ratios of major
CHD incidence, comparing populations with and without T2DM, in each
calendar period
16
Table 9.5 Fall in rate of major CHD between 1995-1998 and 2005-2008 among
men and women in the THIN population, and % of the fall “explained” by rising
T2DM prevalence
Table 9.6 Fall in hazard of major CHD between 1979 and 2004 among men in the
BRHS cohort, and % of the fall “explained” by rising T2DM prevalence
LIST OF FIGURES
Figure 3.1 The 24 towns constituting the British Regional Heart Study
Figure 3.2 Timeline for the British Regional Heart Study, illustrating follow-up of
study men and collection of data used in the thesis
Figure 3.3 HDL cholesterol against Apolipoprotein-A1 among participants at
baseline in Whitehall II, according to age and gender
Figure 4.1 Flowchart illustrating derivation of THIN cohort for analysis of time
trend in major CHD incidence
Figure 4.2 Flowchart illustrating derivation of THIN cohort for analysis of time
trend in T2DM incidence
Figure 4.3 Trends over calendar time in use of different types of Read codes for
incident major CHD among patients aged 30 years and over in the THIN
database
Figure 4.4 Trends over calendar time in use of different types of Read codes for
incident diabetes among patients aged 30 years and over (therefore assumed to
be T2DM) in the THIN database
Figure 4.5 Time trend in the rate of incidence of major CHD per 1000 person-
years by gender: THIN database
Figure 4.6 Time trend in the rate of incidence of T2DM per 1000 person-years by
gender: THIN database
Figure 5.1 Mean age and age range of men in the British Regional Heart Study
over the course of the follow-up
Figure 8.1 Trend over time in incidence of T2DM and in mean BMI, by age
group
Figure 9.1 1-, 3-, and 5-year incidence of a major CHD event, following a new
T2DM diagnosis, according to calendar year of T2DM diagnosis
17
Chapter 1 Introduction
1.1 Introduction and rationale for thesis
This thesis considers time trends in the UK in coronary heart disease (CHD) and in
type 2 diabetes mellitus (T2DM). Strong evidence suggests that striking and divergent
time trends in these two related major non-communicable diseases have occurred in
the UK in recent decades. In particular, the “headline” statistics are a fall in mortality
from CHD of almost three quarters from 1961 to the present1, compared with a rise in
prevalence of T2DM of around 5% per annum since the 1990s2-6.
Understanding the reasons for these contrasting disease time trends could yield
potentially important public health implications in terms of informing future efforts to
reduce CHD mortality and T2DM prevalence in the UK, through gaining insight into
which determinants may be most influential. For T2DM this is especially important as
the rising T2DM prevalence and associated co-morbidities represent a growing
healthcare burden in the UK7, 8, as is detailed in chapter 2, section 2.4.2. For CHD,
although CHD mortality has fallen, the condition remains the leading cause of
premature death in the UK among both men and women, responsible for over 25,000
premature deaths in 20089. In addition, knowledge of the influences on the UK CHD
time trend could provide insights which may help to control the emerging epidemics
of CHD occurring in middle and lower income countries10, 11.
While the major aetiological factors for CHD are largely established, as summarised
in chapter 2, section 2.5.2.1, few studies have examined how much favourable trends
in these aetiological factors and in increasing use of effective cardiovascular
treatments (particularly those for prevention of CHD) have actually contributed to the
18
decline in CHD mortality. The few studies of this type12-15 examining the UK CHD
decline have used ecological data and are subject to limitations of ecological analyses;
very few studies worldwide have used data on individuals within a single
population16-18 to study CHD time trends. Even fewer formal attempts have been
made to explain the rising T2DM prevalence4, 19.
The decline in CHD mortality could represent a decline in CHD incidence or an
increase in survival. Previous studies of trends suggest that the decline in CHD
mortality reflects, at least in part, a decline in incidence of major CHD events
(principally heart attacks), that is, the proportion of men and women developing major
CHD events in the first place20-24. Similarly the rise in prevalence of T2DM may
reflect at least in part rising incidence of T2DM4, 6, 25, 26, although evidence on trends
in incidence is limited reflecting a paucity of suitable data sources. Therefore, a key
step towards understanding the time trends in CHD mortality and T2DM prevalence is
to examine time trends in incidence of these two conditions.
T2DM is associated with an estimated two-fold increased risk of CHD27-33. It might
therefore be expected that the increased prevalence of T2DM would lead to an
increase in CHD. Thus the relationship between the opposing trends in these related
conditions is another important question to address. In particular, the degree to which
the decline in CHD mortality has been curtailed by the increase in T2DM prevalence,
or is likely to be curtailed in the future, is of interest.
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1.2 Thesis objectives
The overall aim of this thesis is therefore to use individual-level data from relevant
data sources to examine recent trends in major CHD and T2DM incidence in the UK
both in relation to changes in risk factors and treatment use and in relation to each
other. The specific objectives of the thesis are to:
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i) Estimate recent time trends in incidence of major CHD in the UK
ii) Estimate recent time trends in incidence of T2DM in the UK
iii) Examine the potential contribution of secular time trends in major
aetiological factors and preventative medications to the time trend in
incidence of major CHD:
iii)a) Examine the possible contribution of secular time trends in major
aetiological factors to the time trend in incidence of major CHD
iii)b) Examine the contribution of increased preventative medication use to the
time trends in the major aetiological factors
iv) Examine the possible contribution of secular time trends in major
aetiological factors (particularly rising adiposity levels) to the time trend in
incidence of T2DM
v) Examine the paradox that CHD has declined while T2DM has increased.
v)a) Estimate whether the time trend in incidence of major CHD among
individuals with T2DM differs from the time trend in incidence of major CHD
among those without T2DM, and if so, how the excess risk of major CHD among
those with T2DM has changed over time.
v)b) Estimate the potential decline in major CHD incidence had no increase in
T2DM occurred and the extent to which rising T2DM prevalence has curtailed the
decline in major CHD incidence.
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1.3 Overview of methodology
The method used to carry out this epidemiological research is statistical analysis of
pre-collected data, from a combination of different UK-based observational data
sources. The principal data source used is the British Regional Heart Study (BRHS)34,
35, an established cohort study, which has followed up 7735 British men for CHD
outcomes for over 30 years from 1978 to the present. A second data source used is
The Health Improvement Network (THIN) national primary care database36,
comprising routinely collected data on General Practice consultations. Data from the
London-based Whitehall II cohort37 of male and female civil servants followed-up
from recruitment in 1985-8 is also used. The data sources are each used according to
their respective strengths. Statistical models are constructed to relate the time trends
in CHD and T2DM to concurrent time trends in associated factors and treatment use.
All statistical analyses have been carried out using Stata versions 10-12 (Stata Corp.,
College Station, Texas).
1.4 Disease definitions
Coronary heart disease (CHD), which normally results from atherosclerosis of the
coronary arteries, when severe, is associated with specific clinical syndromes
including angina pectoris and myocardial infarction (MI). Angina pectoris is
typically chest pain of limited duration which occurs on exercise or stress, reflecting
ischaemia of the myocardium (lack of oxygen to the heart muscle due to restricted
blood flow). Angina may be stable or unstable. Unstable angina, as distinct from
stable angina, is more severe, and is characterised by prolonged chest pain occurring
even at rest, or new-onset chest pain occurring during ordinary activity of low
exertion, or previously diagnosed angina that has become more frequent, longer in
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duration, or triggered at lower levels of physical exertion38. MI, that is, a “heart
attack”, is a more severe form of CHD, where the blood supply is cut off altogether
from part of the heart muscle causing the cells to die (infarction). An estimated 25%
or more of MIs are “silent”, resulting in no discernible symptoms, only detected
retrospectively for example through electrocardiograms (ECGs)39. However, in the
majority of cases, an MI has serious manifestations, usually severe chest pain, often
accompanied by shortness of breath, nausea, palpitations, sweating and anxiety, and
can lead to unconsciousness and death. The term “acute coronary syndrome” is often
used to describe unstable angina and MI, as distinct from the stable angina.
Focus in this thesis will be on “major” CHD events, defined as an MI, predominantly
not silent, or death with CHD as the underlying cause (which might be assumed to be
an MI). The rationale for this is two-fold. First, angina is notoriously difficult to
define and ascertain, hindering reliable estimation of the patterns and trends in angina,
compared with MIs, for which clear defining criteria have been established. Second,
the defined major CHD events represent the most severe forms of CHD, which may
result in death (and therefore contribute substantially to the CHD mortality trend), and
with serious health consequences, and therefore are a substantial public health burden.
The current universal clinical definition of an acute MI, given by the Joint European
Society of Cardiology, American College of Cardiology, American Heart Association,
and World Heart Federation Task Force40, relies primarily on the [direct quote]
“detection of rise and/or fall of cardiac biomarkers (preferably troponin) with at least
one value above the 99th percentile of the upper reference limit (URL) together with
evidence of myocardial ischaemia with at least one of the following: symptoms of
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ischaemia, ECG changes indicative of new ischaemia, development of pathological Q
waves in the ECG, imaging evidence of new loss of viable myocardium or new
regional wall motion abnormality”. MIs may be classified into two types: ST segment
elevation MI (STEMI) and non-ST segment elevation MI (NSTEMI). The first
(STEMI) indicates MIs where Q waves are evident on the ECG. In the case of the
second (NSTEMI), there is no Q waves evidence on the ECG, but other markers of an
MI are observed (so as to be distinguished from unstable angina). In the thesis
distinction will not be made between NSTEMI and STEMI.
The term diabetes loosely refers to a patient with high blood sugar/glucose. There are
two main types of diabetes: type 1 diabetes (T1DM) and type 2 diabetes (T2DM),
although other forms also exist such as gestational diabetes, associated with
pregnancy. T1DM, also called insulin-dependent diabetes or juvenile onset diabetes,
is characterised by an absolute deficiency of insulin, leading to lack of blood sugar
control; the condition tends to be first diagnosed in childhood or early adulthood. In
T2DM, also called non-insulin dependent diabetes or adult onset diabetes, the lack of
blood sugar control arises from the body cells not responding to the insulin produced.
T2DM is generally first acquired in adulthood. The current World Health
Organisation (WHO) definition41 for diabetes (which applies to both types) is a
fasting blood glucose level over 7mmol/L or a blood glucose level>11.1mmol/L after
a 2 hour oral glucose tolerance test (GTT). “Normal” blood glucose levels range
between about 4 to 8 mmol/L, varying with meal times; a fasting blood glucose level
should be under 6 mmol/L. People with glucose levels above the normal range, but
below the limits for diabetes (that is, fasting glucose under 7mmol/L and blood
glucose after GTT between 7.8mmol/L and 11.1mmol/L) are defined as having
24
impaired glucose tolerance (IGT), which is seen as a precursor to T2DM (and as such
is also called pre-diabetes). People with slightly raised fasting blood glucose but
normal blood glucose levels are defined as having impaired fasting glycaemia, which
may also lead on to T2DM. The focus of this thesis is on T2DM. Patients with T2DM
comprise the vast majority (over 90%) of diabetes cases, thus representing the
majority of the diabetes health burden42. Moreover, levels of T1DM have not
increased to the same extent as T2DM. Also, T2DM, like CHD, and unlike T1DM, is
considered largely preventable through modification of risk factors43, thus a study of
the influences on the rise in T2DM has arguably more immediate and tenable public
health implications, in terms of elucidating measures to reduce T2DM in the
population.
1.5 Structure of the thesis
The structure of the thesis is as follows: In chapter 2 existing literature related to time
trends in CHD and T2DM is discussed. Chapter 3 details the three different data
sources used to address the thesis objectives. The results of the analyses related to the
thesis objectives are presented in chapters 4, 5, 6, 7, 8, and 9. Specifically, chapter 4
examines time trends in incidence of major CHD and T2DM overall and according to
different socio-demographic characteristics, comparing results from the different data
sources, in line with objectives i) and ii). Chapter 5 examines the role of time trends
in major aetiological factors to the time trend in major CHD incidence, using BRHS
data (objective iii)a)). Chapter 6 serves as a validation study, repeating the analyses
of chapter 5 in the Whitehall II cohort, thereby providing means to verify and lend
support to the findings of chapter 5. Chapter 7 then considers the role of medication
use on the time trends in the major aetiological factors (objective iii)b)), again using
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BRHS data. Chapter 8 presents results related to objective iv), to examine the role of
time trends in aetiological factors (principally adiposity) to the time trend in incidence
of T2DM, again with use of BRHS data. Chapter 9 then considers the relationship
between the time trends in T2DM and CHD, addressing objective v), using both
BRHS and THIN data. Each results chapter comprises a brief background specific to
the analyses presented in the chapter; a description of methods specific to the chapter
including statistical methods; results of analyses presented as tables and graphs, and
summarised in the text; and a discussion including a summary of the main findings,
details of strengths and limitations of the analyses, a comparison with existing related
literature, and an interpretation of the findings. The main findings of all the results
chapters, and their interpretation, are brought together in the concluding chapter 10,
along with a discussion of the implications for public health and for future research.
1.6 Thesis publications
Four first-author papers44-47 based on the material in this thesis have been published in
peer-reviewed journals to date. These are listed below, along with accompanying
related editorials48:
1. Hardoon, S. L., Whincup, P. H., Lennon, L. T., Wannamethee, S. G., Capewell, S.,
Morris, R. W. (2008). How much of the recent decline in the incidence of myocardial
infarction in British men can be explained by changes in cardiovascular risk factors?
Evidence from a prospective population-based study. Circulation 117(5), 598-604
doi:10.1161/CIRCULATIONAHA.107.705947.
 Accompanying editorial: Luepker R.V. (2008) Decline in Incident Coronary
Heart Disease: Why Are the Rates Falling? Circulation;117(5):592-593,
doi:10.1161/CIRCULATIONAHA.107.747477
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2. Hardoon, S. L., Whincup, P. H., Wannamethee, S. G., Lennon, L. T., Capewell, S.,
Morris, R. W. (2010). Assessing the impact of medication use on trends in major
coronary risk factors in older British men: a cohort study. Eur J Cardiovasc Prev
Rehabil 17(5), 502-508 doi:10.1097/HJR.0b013e3283378865.
3. Hardoon, S. L., Morris, R. W., Thomas, M. C., Wannamethee, S. G., Lennon, L. T.,
Whincup, P. H. (2010). Is the recent rise in type 2 diabetes incidence from 1984 to
2007 explained by the trend in increasing BMI?: evidence from a prospective study of
British men. Diabetes Care 33(7), 1494-1496 doi:10.2337/dc09-2295
4. Hardoon, S. L., Morris, R. W., Whincup, P. H., Shipley, M.J., Britton, A. R., Masset,
G., Stringhini, S., Sabia, S., Kivimaki, M., Singh-Manoux, A., Brunner, E. J. (2012).
Rising adiposity curbing decline in incidence of myocardial infarction: 20-year
follow-up of British men and women in the Whitehall II cohort. Eur Heart Journal.
33(4):478-85 doi: 10.1093/eurheartj/ehr142
.
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Chapter 2 Review of the existing literature
2.1 Introduction
In this chapter existing studies and data sources on time trends in coronary heart
disease (CHD) and type 2 diabetes (T2DM) are reviewed, providing a more detailed
background and rationale for the thesis.
Section 2.2 details literature on time trends in CHD mortality and morbidity in the
UK. In particular, section 2.2.1 presents literature of time trends in CHD mortality,
and section 2.2.2 presents literature on time trends in major CHD morbidity,
comparing incidence and case fatality trends.
Section 2.3 details literature on time trends in T2DM in the UK. Section 2.3.1
presents literature on time trends in T2DM prevalence, while section 2.3.2 compares
T2DM incidence and relative survival trends.
Section 2.4 presents a summary of the continuing CHD and T2DM health-care burden
in the UK, emphasizing the need for the research.
Section 2.5 provides an overview of the various factors to consider when evaluating
the time trends in incidence of major CHD or T2DM. Section 2.5.1 concerns those
factors which may influence the observed time trend in incidence, but rather than
contributing to a true epidemiological shift in the population, these factors may be
thought of as confounding the true time trend estimates, potentially leading to under
or overestimation of the true time trends. These influences will need to be taken into
account when addressing the first two objectives, to evaluate the extent of the time
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trends in incidence. The next sections deal with factors to consider when examining
the reasons for the (remaining) true epidemiological trend in incidence of major CHD
or T2DM, once these other influences have been taken into account (to address
objectives iii and iv). Section 2.5.2 is a brainstorm of possible candidate factors
which may help to explain a decline in major CHD incidence, based on the literature
of the aetiology of CHD. These are major known aetiological exposures which have
had the potential to change over time in the population and preventive treatments,
where uptake has increased. Section 2.5.3 is similarly a literature-based brainstorm of
possible candidate factors which may help to explain a rise in T2DM incidence.
Section 2.5.4 then discusses the association of T2DM with CHD, which provides
background to the final objective relating the time trends in major CHD and T2DM to
each other.
Section 2.6 details existing studies formally examining reasons for the time trends in
CHD and T2DM in the UK, which address similar questions to those in the thesis, and
therefore studies to which the thesis results may be compared. Section 2.6.1 concerns
studies formally analysing reasons for the trends in CHD in the UK, while section
2.6.2 concerns studies formally analysing reasons for the trends in T2DM in the UK.
Section 2.7 provides a summary of the worldwide picture of CHD and T2DM time
trends for comparison. First, variations in time trends in CHD and T2DM between
different countries, particularly in relation to the “epidemiologic transition” in the
developing world, are briefly described. Then, previous studies examining reasons
for the time trends in countries other than the UK are explored.
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2.2 Time trends in major coronary heart disease in the UK
2.2.1 Time trend in CHD mortality in the UK
2.2.1.1 Overall time trends among men and women
Information on time trends in the UK in mortality from CHD may be obtained from a
combination of different sources including routinely collected data, government and
other official reports, and published research papers. Much of the data on time trends
in CHD mortality, particularly that derived from routine data sources, is helpfully
collated on The British Heart Foundation (BHF) Statistics website
(www.heartstats.org). In particular, a recent update1 (Feb 2011) on time trends in
CHD mortality reports trends from 1961 to 2009 based on routinely collected official
data (England and Wales: Office for National Statistics (ONS); Scotland: General
Register Office; Northern Ireland: Statistics and Research Agency). The key finding
is that CHD death rates in the UK have declined continuously from 1961 to 2009
among both men and women. The age-standardised annual CHD mortality rate fell
by 73% among men over this 49 year period, from approximately 428 CHD deaths
per 100,000 population/year in 1961 to 115 deaths per 100,000 population/year in
2009. The decline in women was 78%, from 240 CHD deaths per 100,000 in 1961 to
52 deaths per 100,000 in 2009. The decline was relatively slow over the earlier years
from 1961 to the mid 80s, after which point it became more marked (declines of
approximately 15% and 30% for men and women respectively over the 25 year period
from 1961 to 1985 compared with declines of approximately 68% and 69% for men
and women over 25 years from 1985 to 2009). This pattern is particularly apparent
among men. It is the more rapid period of decline, from the 1980s to the present,
which is the focus of this thesis.
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Published material reporting on time trends in CHD mortality in the UK using the
same data sources give similar findings, as might be expected49. O’Hara et al50
reported a decline of just over 50% between the periods 1985-89 and 2002-2006
among both men and women in the UK (using data from the World Health
Organisation, WHO), which agrees closely with the trends reported on the BHF
Statistics website. A “joinpoint” analysis51 was used which predicts time-points at
which a change in the rate of mortality decline has occurred (“change-points”). It was
found that the rate of decline in men tended to increase over the period from -2.99%
in 1985-1993 to -4.84% in 1993-2003 to finally -7.29% in 2003-2006. A similar
pattern was observed among women. An average annual age-adjusted decline of -
4.8% occurred among men from 1978-80 to 1998-2000 in the British Regional Heart
Study20 (BRHS), the principal data source used for this thesis. This corresponded to a
63% decline over the whole 20-year period, comparable to the above findings.
2.2.1.2 Age-specific time trends
The above-mentioned report on CHD mortality trends1 on the BHF Statistics website
also shows trends in the age-standardised CHD mortality rate restricted to those aged
under 75 years, which represents the premature mortality rate. In contrast to the
overall CHD mortality rates, the premature CHD mortality rate remained relatively
constant among both men and women between 1961 and the mid 1980s, but then
declined consistently and sharply from this point to the present (by approximately
75% in both men and women). The report also highlights somewhat distinct trends in
the CHD mortality rates occurring among younger age groups; those aged 55 and
under (the early mortality rate), compared to the overall picture which is dominated
by the higher mortality rates in the older ages. It alerts to an apparent 25% increase in
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the early CHD mortality rate in the first part of the period from 1961 to 1975 among
both men and women. Moreover, while declines in CHD mortality occurred after this
point in this age group, there is some suggestion that the decline has slowed in the
most recent years, in contrast to the continuing decline in older age groups. This
observation is supported by separate analyses of these routine data sources in three
recently published papers52-54, in which time trends in CHD mortality are estimated
for different age-groups. However it is important to note that in the papers some of
the rate of change estimates are imprecise - based on limited numbers of deaths in
younger age-groups and with correspondingly wide confidence intervals (CIs) - and
occur over just a few years. These could therefore be random fluctuations in the trends
rather than a true change. Continued monitoring of the CHD mortality rates is
therefore needed to confirm the slowing decline. The observed slowing of the decline
in younger age groups nevertheless does reflect trends observed in other countries
with a comparable risk profile (USA55, New Zealand56, Australia57).
2.2.1.3 Time trends within different socio-demographic groups
Plots of the standardised mortality ratios for CHD mortality over time by constituent
country1 (relative to England) show the highest CHD mortality rates generally to have
been in Scotland throughout the period from 1961 to 2009, followed by Northern
Ireland, Wales and then England with the lowest mortality rates. The standardised
mortality ratios have fluctuated over time but the net change over the 49 year period is
small. This suggests that the total declines in CHD mortality have been broadly
similar across the different countries, although the extent of the declines may have
varied in different years of this period. A separate analysis of General Register Office
for Scotland data compared CHD mortality time trends between 1981 and 1999 in
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rural and urban areas of Scotland58 and found a slightly faster decline among rural
areas and small towns compared with urban areas, from a similar starting level (at
least a -48% change compared with -42%).
The BHF Statistics website CHD statistics publication9 (2010) shows time trends in
CHD mortality rates in Great Britain from 1994 to 2008 by fifths of social
deprivation, as measured using the Carstairs index for local authorities, using data
from the Office for National Statistics and General Register Office for Scotland.
There is a clear gradient, with higher total and premature CHD mortality rates with
increasing deprivation among both men and women, and this gradient persists over
the whole period. There is some suggestion that the absolute difference in CHD
mortality rates between the deprivation quintiles has narrowed slightly. However, the
relative differences comparing the most deprived to least deprived quintile have
increased (from 1.3 in 1994 to 1.6 in 2008 in men, with similar figures for women),
suggesting a smaller relative decline in CHD mortality in the more deprived quintiles.
Separate earlier data also from the BHF Statistics website, shows that over the period
from 1978 to 1998, the relative CHD mortality rates, comparing manual and non-
manual men and women, tended to increase over time, so that manual men and
women remained at excess risk of CHD mortality compared with non-manual men
and women (data from the ONS). A number of papers on trends in CHD mortality
according to socio-economic background support these findings54, 59-61, including a
previous analysis of BRHS data61, which showed again a persistence or even an
increase in the relative difference in CHD mortality comparing manual to non-manual
men (approximately 75% increase in the relative risk from 1978 to 2005). Moreover,
regarding the previously mentioned slowing of the decline in CHD mortality in
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younger age groups in recent years, it has been shown that the slowing of the decline
in Scotland in 1986-2006 is limited to the two most deprived fifths of social
deprivation (defined using the Scottish Index of Multiple Deprivation), leading to a
widening social inequality in CHD death54.
A study on time trends in CHD mortality in the UK between 1979 and 2003 according
to country of birth62, using data from the Office for National Statistics, revealed some
variations in the CHD mortality time trends by country of birth. CHD mortality
among men born in India, Pakistan or Bangladesh was higher relative to men born in
England and Wales at the start of the period in 1979 (rate ratios of approximately 1.5,
1.2 and 1.4 respectively). These rate ratios increased over time, indicating a slower
decline among men born in India, Pakistan and Bangladesh. Indeed, by 1999-2003,
the CHD mortality rate for men born in Pakistan and Bangladesh was approximately
double that for men born in England and Wales. CHD mortality trends among men
born in the Caribbean and Africa were more similar to that for men born in England
and Wales. The patterns among women were broadly similar, although as event
numbers were smaller, estimates are less precise. Trends by ethnicity (as opposed to
country of birth) are not readily available as country of birth rather than ethnicity has
previously been recorded on death certificates. Country of birth is seen as a good
proxy for ethnic group among older people63, 64. Among younger age-groups, who
may be descendents of migrants, there is less correspondence between country of birth
and ethnicity. However, since CHD predominantly affects older age groups, the time
trends reported here may be a reasonable reflection of time trends by ethnicity.
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2.2.2 Time trend in major CHD incidence and case fatality in the UK
The decline in CHD mortality may be attributed to either a decline in the incidence of
major CHD (that is, fewer individuals experiencing a major CHD event which could
result in death) or an improvement in survival following a major CHD event (that is,
those who do experience a major CHD event are surviving longer), or indeed some
combination of the two. The available data on major CHD incidence and case fatality
time trends in the UK is detailed below.
2.2.2.1 Time trends in major CHD incidence
Much of the available data on time trends in major CHD incidence is again
summarised on the BHF Statistics website, and principally comes from independent
major studies of cardiovascular disease (Oxford Myocardial Infarction Incidence
Study Group (OXMIS), WHO MONICA (MONItoring trends and determinants in
CArdiovascular disease) project, and the BRHS). Starting with the earlier data, the
OXMIS study reported an average annual decline in age-standardised incidence of
major CHD (defined as non-fatal definite MI or fatal CHD) of 1.2% in men and 0.3%
in women aged 30 to 69 years between 1966-7 and 1994-5 in Oxfordshire23. This
corresponds to a total decline among men over the period of 32.7%, from an age-
standardised incident rate of 433.8 per 100,000 in 1966-7 to 291.8 per 100,000 in
1994-5, and a smaller, non-significant total decline among women of 8.2% from
102.3 per 100,000 to 93.9 per 100,000. Note though that the event numbers were
small among women leading to imprecise time trend estimates (CIs are wide). The
WHO MONICA project estimated more recent trends from the mid 1980s to mid
1990s in incidence of major CHD (defined again as CHD death or non-fatal MI)
across 37 populations in 21 countries, including two populations in the UK; Glasgow
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and Belfast22. In Glasgow from 1985 to 1994, an average annual decline in incidence
of major CHD of 1.4% was observed in men and an average annual increase of 0.2%
was observed in women. In Belfast from 1983 to 1993, an average annual decline in
incidence of major CHD of 4.6% was observed in men and an average annual decline
of 2.4% was observed in women. A previous analysis of BRHS data found an average
annual decline in risk of a first major CHD event (defined as a CHD death or non-
fatal myocardial infarction) of 3.5% over an overlapping time-period between 1978-
80 and 1998-2000 among older British men, adjusting for age20. A decline in
recurrent major CHD events of 3.9% per annum also occurred. More up-to-date data
for Scotland has also very recently been made available on incidence rates of major
CHD in the BHF Statistics publication on trends in cardiovascular morbidity1. The
publication reports on recent trends in Scotland between 1986 and 2008 in incidence
of major CHD, defined here as hospitalisations for MI or deaths with CHD as a cause
(based on a combination of mortality data and hospitalisation data). A 60% decline in
incidence occurred in Scotland between 1986 and 2008 in both men and women (all
ages), from incidence rates of 525 events and 242 events per 100,000 in men and
women respectively in 1986 to rates of 213 events and 95 events per 100,000 in men
and women in 2006, average annual declines of 2.6% and 2.7% in men and women
respectively.
Additional data on trends in emergency hospitalisations for MI in Scotland between
1990 and 200021 suggest that the rate of hospitalisations for MI declined by
approximately 30% over the 10 years, among both men and women. This corresponds
to an average annual decline of 3.5%, which agrees closely with the time trend in all
first major CHD events in the BRHS, which covers this same time-period. A further
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recently published paper (post conception of thesis) used data from The Health
Improvement Network (THIN) primary care database, a second data source used in
this thesis, to estimate trends in incidence of a first MI by UK country24. Incident MI
is determined as a record of an MI event in the general practice records for the patient.
The study reported average annual percentage declines in incidence of MI of 3.1%
and 2.8% in men and women respectively aged 35 years and over in England between
1996 and 2005. Comparable declines occurred in Wales (3.3% and 4.6%), while more
modest declines were observed in Scotland (1.9% and 0.6%) and Northern Ireland
(0% and 0.8%).
2.2.2.2 Time trends in major CHD case fatality
There is evidence to suggest that case fatality following major CHD events has also
declined over time. In Oxfordshire, according to data from the BHF Heartstats
cardiovascular morbidity publication9, case fatality (defined here as the proportion of
all incident hospitalised major CHD events resulting in death within 30 days plus
CHD deaths outside of hospital) appeared to decline by approximately one-quarter
from 1968 to 1998 among both men and women and in all age-groups. A faster
relative decline was seen in younger age groups (for example of 27% in 35-39 year
old men from 35.5% of events fatal in 1968-1973 to 25.9% in 1994-1998; average
annual decline of 1.2%) than older age groups (of 23% in 75-79 year old men from
83.4% to 64.5%; average annual decline of 1.0%). The OXMIS study presents a
further analysis of the declines in age-standardised case fatality between 1966-67 and
1994-523. The fatality rate (defined as 28 day case fatality in 1966-67 and 30 day case
fatality in 1994-5) fell among men aged 30-69 years from 56.7% of major CHD
events being fatal in 1966-67 to 41.0% fatal in 1994-5 (average annual relative
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decline of 1.2%). The fatality rate fell among women aged 30-69 years from 64.6%
in 1966-67 to 44.1% in 1994-5 (average annual relative decline of 1.4%). Slightly
larger declines in case fatality were observed over more recent periods in Belfast and
Glasgow (WHO MONICA22). In Glasgow, between 1985 and 1994, average annual
declines of 1.3% and 2.1% occurred among men and women respectively, aged 35-64
years. In Belfast, between 1978 and 1996, average annual declines of 1.5% and 1.7%
occurred among men and women respectively, aged 35-64 years. Time trends in case
fatality (death within 28 days of a major CHD event) among men in the BRHS have
been reported for the period 1978 to 199565. Adjusting for age, the case fatality rate
fell by 2.1% per annum. More recent estimates from the THIN database, suggest
considerable average annual declines in 30-day case fatality between 1996 and 2005
among men age 35 years and over of 12.0%, 18.4%, 9.5% and 8.6% in England,
Wales, Scotland and Northern Ireland respectively24. The corresponding estimated
declines among women were similarly large: 11.0%, 12.6%, 9.0% and 13.0%.
Crude 30-day case fatality among patients admitted to hospital for MI (that is,
excluding fatal events among patients who do not reach hospital) also declined in
Scotland by 23% over 10 years from 25.1% in 1986 to 19.4% in 1995 (data from the
Scottish Morbidity Record Database linking all hospital admission records to all
mortality data for 5.1 million patients in Scotland66). This corresponds to an average
annual relative decline of 2.6%. Adjusting for age, deprivation category and prior
hospital admissions, the 10-year decline was 46% in men and 27% in women (average
annual declines of 6% and 3%). Separate analyses using the same data source showed
28-day case fatality among patients admitted to hospital in Scotland for MI declined
by 79% between 1981-83 and 1997-1999 (average annual decline of approximately
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1.5%)58. The analyses showed further that the decline appeared greater in remote
rural areas than in urban and more accessible areas (82-3% in remote areas versus 73-
4% in accessible areas). Since fatality rates were initially higher in remote areas, this
suggests an attenuation of the excess risk over time. A third more recent study of
patients (male and female 18 years and over) hospitalised with MI in Scotland21 found
that 30-day case fatality fell by 12.6% over 10 years from 22.2% in 1990 to 19.4% in
2000, an average annual decline of 1.4%. In Southern Derbyshire, a larger average
annual age-sex adjusted relative decline of 9% in the odds of 30-day case fatality
occurred between 1995 and 1999 among patients hospitalised with MI67. The authors
associate the large decline with the prior publication (1994) of the landmark 4S study
on the effectiveness of statins in patients with CHD68. In Nottingham, over an earlier
period from 1982 to 1992, the age-sex adjusted odds of inpatient mortality among
patients hospitalised with confirmed MI did not appear to change over time69.
2.2.2.3 Summary of major CHD incidence and case fatality trends
These results together suggest annual changes in incidence of major CHD in various
parts of the UK from the 1960s to the present varying among men between no change
and a decline of 3.5%, and varying among women between an increase of 0.2% and a
decline of 4.6%. The variations in the estimates could reflect the differing time-
periods and locations (although variations in the estimates even occurred over the
same time-period and location). The differences could also reflect the previously
mentioned difficulty in capturing accurately and consistently incidence of major CHD
events. Imprecision in the estimates, particularly for women with lower event
numbers, is another possible explanation. It is also possible that different ways of
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defining major CHD events (e.g. all major events versus hospitalisations only) could
account for differing trends.
The various data sources together suggest a modest decline in overall case fatality
(whether defined as fatal hospitalisations only or also including out of hospital deaths)
of roughly 1 to 2% per annum before around 1995. Data later than 1995 is limited but
one study found declines of above 10% per annum in overall case fatality between
1996 and 2005 across the UK24, and a second found a 9% decline in the odds of case
fatality for hospitalised cases in Derbyshire between 1995 and 199967. This suggests
a much faster rate of decline in case fatality post 1995. However caution is needed in
interpreting these findings as the results from the national study may be subject to
over-fitting as CIs are narrower than might be expected given the number of events,
while the Derbyshire study is specific to a small region and a short 5-year period.
Also, since case fatality rates begin at lower levels in the more recent studies, the
larger relative decline may yet be consistent with a comparable absolute decline to
that in previous years.
The overall picture appears to be that declines in both incidence of major CHD and in
case fatality have occurred in recent decades, and so both have contributed to the
parallel decline in CHD mortality. The WHO MONICA study, which formally
assessed the relative contributions of major CHD incidence and case fatality on the
mortality trends, is discussed in section 2.6.1.1. However the varying incidence and
survival estimates described above suggest the need for further investigations to draw
firmer conclusions on the extent of the declines in incidence and case fatality. Also,
there is a lack of data on trends beyond 2000, particularly in incidence of major CHD
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(apparently just one study outside of Scotland24). Compared with CHD mortality
rates, UK data on time trends in major CHD incidence and case fatality are limited,
particularly for the most recent calendar years. This reflects that the quality and
extent of data on CHD incidence and case fatality is poorer than that for CHD
mortality as morbidity data is not necessarily recorded routinely and consistently,
unlike CHD mortality via death certification9.
2.3 Time trends in type 2 diabetes in the UK
2.3.1 Time trend in T2DM prevalence in the UK
2.3.1.1 Overall time trends among men and women
Routine data from the repeated cross-sectional surveys of the Health Survey for
England (HSE), suggests self-reported diagnoses of diabetes to have approximately
doubled between 1994 and 2006 in England, among both men and women70. Note that
diabetes here is T1DM and T2DM combined, despite the reference to T2DM in the
paper title. Over the 14 years, age-standardised prevalence of diabetes increased from
3.74% in 1994 to 7.25% in 2006 in men (an average annual increase of 4.8%), and
from 2.28% to 4.88% among women (an average annual increase of 5.6%). A similar
picture has been observed in Wales. In Cardiff and the Vale of Glamorgan diabetes
prevalence rose between 1996 and 2004 by 46% from 2.4% to 3.5% (average annual
increase of 4.3%)71. A third study, using diabetes register data covering 32 general
practices in North Tyneside observed a larger average annual increase of 10% in
diabetes prevalence from 1.14% in 1991 to 2.99% in 200172. The faster rate of
increase possibly reflects differences in patient characteristics and demographics in
this region relative to the rest of the country, or lower starting prevalence given the
earlier baseline.
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While these studies do not distinguish between T1DM and T2DM, other studies
suggest further that this rise in overall diabetes prevalence reflects primarily a rise in
T2DM, which also form the majority of diabetic cases. For example, a recent paper
(post conception of this thesis) estimated time trends in prevalence of overall diabetes,
and T1DM and T2DM separately, between 1996 and 2005 among men and women
aged 10-79 years across the UK, using the THIN primary care database6. The study
found a 4.9% per annum increase in all diabetes (corresponding to a rise of 54% over
10 years from 2.8% to 4.3%), in line with the findings from HSE and Cardiff. A
comparable 4.7% per annum increase in T2DM was observed (corresponding to a
58% increase over 10 years from 2.5% to 3.9%), while in contrast, a more modest
24% increase in T1DM prevalence occurred (from 0.33% to 0.41%). Similarly, a
study using repeated cross-sectional data from 10 general practices across the Poole
area of England, observed a rise in the age-adjusted prevalence of all diabetes from
1983 to 1996 of 61%, adjusting for age and sex5. Prevalence of T2DM increased by
72% from 0.7 to 1.23%, while T1DM increased by 38% from 0.25% to 0.33%,
adjusting for age and sex. This study, which predates the others described, suggests
further that T2DM prevalence has been rising since the 1980s.
Further studies have focussed specifically on estimating time trends in T2DM
prevalence. Data from the Doctors Independent Network (DIN), a primary care
database comprising 74 general practices from across England and Wales, showed
prevalence of T2DM to have increased between 1994 and 2001 by 50% among men
from 18 to 27 cases per 1000 person-years (average annual increase of 6%) and by
30% among women from 16 to 23 per 1000 person-years (average annual increase of
4%)2. Among men in the BRHS, we observed an average annual increase in the
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prevalence of self-reported T2DM between 1978-2005 of 7%. Moreover, T2DM
prevalence appeared to rise at an increasing rate over time, with average annual
increases of 4.3% from 1978 to 1985; 5.5% from 1985 to 1992; 6.9% from 1992 to
1996; 5.6% from 1996 to 2000; 10.6% from 2000 to 2003; and 11.8% from 2003 to
20063. In line with the findings in Poole, the results suggests rising T2DM as far back
as the beginning of the 1980s. Finally analysis of data from the DARTS (Diabetes
Audit and Research in Tayside Scotland) clinical information system, showed T2DM
prevalence (defined as a diagnosis of diabetes at aged 35 or over or at a younger age if
not on insulin) to have risen over the 12 years from 1993 to 2004 in this region by
6.7% per annum, from 1,492 per 100,000 in 1993 to 3,130 per 100,000 in 20044. This
corresponds to more than a doubling in prevalence over the period.
2.3.1.2 Age-specific time trends
Among those studies reporting time trends in T2DM by age-group, the general
consensus appears to be that increases have occurred in all age groups. In the DIN
primary care database, between 1994 and 2001 average annual increases in prevalence
of T2DM among men in England and Wales by age group were as follows: 3.7%,
6.0%, 3.4%, 5.8%, 6.1% and 1.7% for ages 35-44 years, 45-54 years, 55-64 years, 65-
74 years, 75-84 years and 85+ years respectively2. Among women, average annual
increases were: 6.0%, 6.8%, 2.8%, 6.4%, 5.3% and 5.1% respectively. Analysis of
BRHS data showed similar average annual increases to have occurred among all age-
groups in this cohort of older British men: 5.4%, 5.6%. 7.1%, 6.8% and 7.5% among
men aged 50-54 years, 55-59 years, 60-64 years, 65-69 years and 70-74 years
respectively3. Data from the Health Survey for England also showed increases in
prevalence of all diabetes among all age groups70.
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2.3.1.3 Time trends within different socio-demographic groups
According to the analysis of BRHS data, T2DM prevalence increased at a faster rate
in Scotland compared with the rest of Britain (11.7% per annum between 1978 and
2005 in Scotland compared with 7.5% in Southern England, 6.2% in the Midlands and
Wales, and 6.1% in Northern England)3. No other studies show time trends by UK
country, but comparing the estimates from different regional studies suggests a similar
pattern: in England and Wales (DIN data), the average annual increase between 1994
and 2001 was 4% and 6% among men and women respectively2, while over a similar
period from 1993 to 2004, the increase in Scotland (DARTS data) among men and
women combined was closer to 7%4.
The BRHS analysis also showed that as for CHD mortality, the least favourable time
trend in T2DM prevalence occurred in the lowest socio-economic group, defined
according to longest occupation held. Among men in unskilled occupations, the
average annual age-adjusted increase in T2DM prevalence was 8.9% compared to
5.8% in professional occupations3. In the three intermediate groups the average
annual increase was between 7 and 8%. Another study considered trends in
prevalence of all diabetes between 1994 and 2006 in relation to socio-economic status
using data from The Health Survey for England70. That study found an increase over
the period in the T2DM prevalence ratio comparing the lowest to highest socio-
economic status quintiles during the study period, when defined as longest-held
occupation or education level, among women. This indicates a faster rise in
prevalence among women of lower socio-economic status. For men, no difference in
the prevalence levels or time trends in prevalence by occupation or education level
was observed, but the T2DM prevalence ratio comparing highest to lowest household
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income quintiles did increase, suggesting that the increase in prevalence has been
more marked in poorer households in more recent years. The study also looked at
levels of undiagnosed diabetes (defined as glycated haemoglobin≥6.5% in individuals
not known to be diabetic) by social class in 2003-2006. It found that levels of
undiagnosed diabetes were higher in lower socio-economic groups, suggesting that if
anything, the observed inequalities in diabetes prevalence in the most recent years
may underestimate the true extent of the differences.
The 2004 Health Survey for England shows that between 1999 and 2004 T2DM
prevalence increased faster among Indian men (from 19.2% to 24.3%) and Black
Caribbean men (17.6% to 26.5%) aged 55 and over, compared with the men of the
same age in general population (6.9% to 9.7%)73. By contrast, among Pakistani and
Bangladeshi men, the prevalence appeared to fall. Among women aged 55 and over,
the largest increase occurred among Pakistani women from 28.3% to 44.4%. A large
increase also occurred among Indian women aged 55 and over (15.3% to 20.5%). The
trend among Black Caribbean women was comparatively modest, while a decline
occurred among Bangladeshi women.
2.3.2 Time trend in T2DM incidence and relative mortality in the UK
As for the decline in CHD mortality, the rise in T2DM prevalence may be attributed
to either a decline in the incidence of T2DM or an improvement in survival among
patients with T2DM, or some combination of the two. Some distinctions to note
between CHD mortality and T2DM prevalence, when evaluating the roles of
incidence and survival: First, the favourable decline in CHD mortality reflects either a
decline in incidence of major CHD or a fall in case fatality, both of which are
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favourable trends too. In contrast, the unfavourable rise in prevalence could reflect
either an unfavourable rise in incidence or a favourable fall in mortality among T2DM
patients (or both). Thus, although rising T2DM prevalence is an important issue in
terms of the increasing public health burden, one could argue that if the rise is seen to
reflect mainly improved survival, as opposed to more people developing T2DM, then
it is not necessarily an entirely bad news story. An interesting debate in Diabetologia
in 2005 on whether “there is really an epidemic of T2DM”19, 74, 75 highlights this: The
“for” case considered that rising prevalence alone arguably constitutes an epidemic
(irrespective of why prevalence is rising) given the growing major public health
burden it entails – thus, yes, there is an epidemic19. However the “against” case
argued that there is only an epidemic if, following the traditional definition for
communicable diseases, an increase in the number of new cases has occurred, that is,
incidence has risen, resulting from unfavourable trends in aetiological exposures 74, 75.
The reasoning was that rising prevalence could be the result of a change in the
population structure or the result of a favourable improvement in survival74, 75 –
changes that do not necessarily indicate a “problem” to resolve and (in the case of
improved survival) could be conceived as public health “success story”. Thus to really
understand the extent of the issue, it is important to find out why prevalence is rising,
and particularly the role of incidence75. In essence, by establishing the relative roles of
survival and incidence, the very nature of the rising T2DM prevalence as a positive or
negative trend, is defined.
A second point to note is that prevalence of T2DM may theoretically rise even if both
incidence and mortality remain constant4, if the numbers of people developing T2DM
is consistently greater than the number of T2DM patients dying. Third, when looking
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at mortality among patients with T2DM, what is being considered is mortality from
any cause. In contrast, for CHD, interest instead lies in case fatality following a CHD
event.
2.3.2.1 Time trends in major T2DM incidence
Two studies have reported on time trends in incidence of T2DM as well as
prevalence. Analysis of the UK-wide THIN primary care database (published
subsequent to the drafting of this thesis) revealed a rise in T2DM incidence between
1996 and 2005 among men and women 10-79 years of age, comparable in size to the
rise in prevalence6. A 66% increase in T2DM incidence was observed, corresponding
to an average annual increase of 5.2% per annum. The paper found a similar rate of
increase among women and men (69% versus 63%). The study in Tayside, Scotland,
using data from DARTS, observed an average annual age-adjusted increase in T2DM
incidence of 6.3% over 12 years from 1993 to 20044. The study did not break down
the trends by gender. An earlier report considered the change in incidence of diabetes
(T1DM and T2DM combined) between 1994 and 199826. This study involved analysis
of 208 general practices contributing to the General Practice Research Database
(GPRD), which is an electronic routine database of general practice records, akin to
THIN but comprising different practices (although some practices contribute to both
THIN and the GPRD). A 26% rise in incidence was observed between 1994 and
1998, corresponding to an average annual increase of 4.8% per annum. Again, similar
increases occurred among women and men (28% versus 25%). A further more recent
analysis of 197 practices in the GPRD , reported that incidence of type 2 diabetes
among patients aged 30 years and over had risen between 1996 and 2006 from 2.23 to
4.37 per 1000 person years in women (average annual increase of 6.3%) and from
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3.00 to 5.24 per 1000 person years in men (average annual increase of 5.2%)25. The
study also highlighted that the age of first diagnosis appears to be falling, particularly
among women, while the proportion of all new diagnoses occurring in those aged 30-
44 is rising, from 7.9% and 7.5% of diagnoses in men and women respectively in
1996 to 7.9% and 15.8% in 2006.
2.3.2.2 Time trends in relative mortality among patients with T2DM
Two studies also report on time trends in mortality. The paper on patients in DARTS
in Tayside, Scotland shows mortality among patients with T2DM to have fallen from
69.0 deaths per 1,000 people with T2DM in 1993 to 53.9 deaths per 1,000 people with
T2DM in 2003, a significant decline of 3.7% per annum4. The paper on patients in
the UK-wide GPRD reports comparable figures of age-adjusted declines in early
mortality (that is, within 24 months of diagnosis of T2DM) of 2.7% per annum among
men and 5.6% per annum among women between 1996 and 200625. Among men the
early mortality rate fell from 47.9 deaths per 1000 cases in 1996 to 25.2 deaths per
1000 in 2006, while among women, the rate fell from 37.4 to 27.6 per 1000. A
second paper using data from the GPRD and by the same authors goes further to look
at relative mortality76, that is, the mortality rate among patients with T2DM relative to
the general population. As the authors argue, to establish whether time trends in
survival are contributing to the rising prevalence, it is not enough to look at overall
mortality rates among diabetic patients. This is because a fall in mortality rates
among diabetic patients would not lead to rising prevalence, unless the fall is larger
than that for the general population. Age and sex-standardised mortality rates for men
and women in the UK in 10 year age groups, taken from Interim Life tables for the
UK, were used to compute expected survival rates for the general population. The
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expected rates were then compared with observed rates in a sample of GPRD patients
with T2DM and relative mortality rates computed as the observed rate among T2DM
patients divided by the expected rate for the general population. Adjusting for
duration of diabetes, age and gender, relative mortality fell by 13% from 1996 to 2001
and by 26% per annum between 2001 and 2006. For example, among men diagnosed
with T2DM for less than one year, relative mortality fell from 1.41 in 1996-1997 to
1.23 in 2006. Among women diagnosed with T2DM for less than one year, relative
mortality fell from 1.40 in 1996-1997 to 1.09 in 2006. Among patients diagnosed
with T2DM more than a year prior, relative mortality rates also declined, but less
sharply as relative mortality was already closer to 1.
2.3.2.3 Summary of T2DM incidence and relative mortality trends
Data on incidence and survival is sparser than that for T2DM prevalence, again
reflecting a lack of suitable data sources, consistently monitoring incidence or
survival over a period. The available data suggests that, between the 1990s and 2000s
at least, the rising T2DM prevalence may be a combination of the positive influence
of improved survival alongside the negative influence of rising incidence (around 5%
per annum). The DARTS study formally assesses the relative contributions of
incidence and mortality over the period – this is discussed in section 2.6.2. However,
data on time trends in incidence and survival before and after this period is limited,
and thus the influences outside of this period are less clear.
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2.4 Continuing healthcare burden of coronary heart disease and type
2 diabetes
2.4.1 Continuing healthcare burden of coronary heart disease
The favourable time trends in CHD mortality and morbidity represent a good news
story. In 1999 the Department of Health publication “Our Healthier Nation” set a
target to reduce the death rate from CHD in England by at least two-fifths by 201077.
The extent of the decline in CHD mortality has resulted in this target being met in
2007. Similarly, the target set by the Welsh Assembly Government to reduce CHD
mortality in 65-74 year olds from 600 per 100,000 in 2002 to 400 per 100,000 in
201278 was met in 2006. The target set by the Scottish Executive was to reduce
mortality rates from CHD among people under 75 years by 60% between 1995 and
201079. Mortality estimates for 2010 are not yet available but the time trend so far
suggests this target is on course to have been met by 2010 too.
However despite the favourable decline, and despite meeting the targets, CHD
remains a considerable public health concern and there is still much room for
improvement. At least up until 2008 (latest date of data availability), CHD has
remained the leading single cause of all deaths and of premature deaths, cited as a
cause of 18% of all deaths in 2008 among men and 13% among women, and cited as a
cause of 18% of premature deaths in men and 9% in women9. This corresponds to
over 88,000 deaths in the UK in 2008 due to CHD, of which over 28,000 were
premature. CHD also represents a considerable economic cost. According to the
2010 BHF Statistics CHD statistics publication, in the year 2006, the total cost to the
UK of CHD was estimated to be almost £9 billion9. This is above average per capita
compared to other countries within the European Union80. Moreover, the cost of
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CHD has risen over time, despite the declining major CHD incidence rates. Earlier
studies give estimates of the total economic burden of CHD as £7.06 billion in 199981
and of £8.5 billion in 200482. Approximately £3.2 billion (36% of the total CHD
costs) was for health care. The largest proportion of this expenditure was for inpatient
care (73% of the total cost), which implies it is the major forms of CHD which
necessitate hospital stay which constitute the greatest health care costs.
That CHD remains the leading cause of death emphasizes the potential value of
analysing the trend in CHD, as a means to inform efforts to reduce CHD mortality
further. The observation that the greater part of CHD healthcare costs are for major
CHD events emphasizes the value of investigating the incidence of major CHD events
in particular, which is the focus of this thesis.
2.4.2 Continuing healthcare burden of type 2 diabetes
According to figures from the Quality and Outcomes Framework (QOF), the known
diagnosed population of people with diabetes (T1DM and T2DM combined) in the
UK stood at 2.8 million in 201083, corresponding to a prevalence of 4.3%. The
majority of these cases are T2DM. Due to the nature of this initially silent condition,
there are likely to be additional patients with diabetes, yet undiagnosed. Thus the true
prevalence is likely to be even higher. Indeed, data from the HSE84, suggests that in
2003, prevalence of undiagnosed diabetes (defined as glycated haemoglobin≥6.5% in
individuals not known to be diabetic) was as high as 3.0% in men, and 0.7% in
women.
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Diabetes in general and T2DM in particular represent a considerable and growing
public health burden in the UK, both in terms of costs directly related to the condition,
and in terms of complications such as cardiovascular (CVD) events, vision loss, renal
complications, and peripheral damage to legs and feet7. A recent study showed
average total primary care costs (including consultation and prescribing costs) for
T2DM patients to have risen from £602 per person per year in 1997 to £1080 per
person per year in 20078, corresponding to a 79% increase, a two-thirds higher per
person cost and a larger relative increase than that for the general population. A
companion study estimated further that 9.3% of hospital admissions were for patients
with diabetes (mainly T2DM), amounting to a total cost of £3 650 869 per 100,000
population, or 12.6% of the total hospital expenditure85. This represents an increase in
the relative burden of diabetes, as the authors previously estimated diabetes
admissions to correspond to 7% of all admissions and to 8.7% of all hospital
expenditure 10 years prior in 199486. Moreover, the burden is projected to grow.
Projected total annual healthcare costs for patients with T2DM (all NHS financial
costs including inpatient costs, outpatient costs, community care, primary care, and
drug costs) were £1.8 billion in 2010 rising to almost £2.1 billion in 20607. Since the
future projection assumes incidence rates to remain constant, it may well be an
underestimate of the true future burden, if incidence continues to rise at the rates
observed in the few studies of incidence trends. This emphasizes the need to examine
incidence trends.
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2.5 Considerations when evaluating time trends in incidence of major
coronary heart disease and type 2 diabetes
2.5.1 Considerations when establishing the extent of the incidence time trends
(towards objectives i and ii)
In the previous sections 2.2 and 2.3, the existing literature on time trends in CHD and
T2DM was examined. The existing studies suggest that changes in incidence of
major CHD and T2DM have occurred alongside the time trends in CHD mortality and
T2DM prevalence and may therefore have contributed to the CHD mortality decline
and T2DM prevalence rise. However it was noted above that data on incidence is
poorer relative to data on CHD mortality or T2DM prevalence trends, with a limited
range of suitable data sources which have captured incident events over a number of
years. Thus the extent of the time trends in incidence is less certain than for CHD
mortality and T2DM prevalence.
As well as the limited number of suitable data sources, establishing the extent of the
time trends in incidence is also hindered by incident events not necessarily being
recorded consistently over time, particularly if the guidelines for and methods of
identifying and defining cases of T2DM or CHD have changed during the period of
interest. Changes in the identification and recording of cases may alter the numbers of
patients identified (with new patients being identified as having major CHD or T2DM
who may not have been previously identified as such, or vice versa). In turn, these
changes may induce an apparent trend in incidence over time. Estimates of time
trends may therefore be confounded by the changing identification methods and may
be to an extent an artefact of changes in how the diseases are defined, rather than a
true epidemiological shift in the population.
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The possible influences under this heading include changes in case ascertainment (that
is, the proportion of all events occurring that are known and do not go undiagnosed),
changes in diagnostic criteria and, for fatal CHD events, which may be ascertained
from death certificates, changes in the coding of cause of death. In terms of major
CHD incidence, given the nature of major CHD events, normally with evident serious
manifestations, case ascertainment is unlikely to be a major issue, unlike for T2DM
which can go undiagnosed. A major change in the diagnosis of MI occurred in 2000,
with the introduction of the measurement of cardiac troponins as the new reference
standard for diagnosing myocardial injury87, compared with the prior World Health
Organisation (WHO) definition of acute MI of unequivocal electrocardiogram (ECG)
changes and/or unequivocal enzyme changes88, 89. The potential impact of the
introduction of the use of troponins is an increased sensitivity, with more events
classed as major CHD events which might not have been previously classed as such90-
92. In terms of fatal events, cause of death as recorded on death certificates is coded in
the UK using the International Classification of Diseases (ICD) coding system.
During the period from the 1960s to the present, the ICD system has been revised a
number of times, which may have implications for both the estimates of the time
trends in major CHD incidence and in CHD mortality. The principal changes
occurred in 1968 (ICD-7 to ICD-8) and in 2001 (ICD-9 to ICD-10). In addition, the
rules for coding changed over the period 1984-92 whereby direct causes of death
could be coded less often, while more secondary causes could be coded more often.
In terms of T2DM incidence, diagnostic criteria for diabetes changed in the late
1990s, with the publishing of new criteria from the American Diabetes Association in
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199793 and then from WHO in 199994. The key differences between these new
criteria, and the existing WHO criteria used before this time95, were the greater
emphasis on the use of fasting glucose (as opposed to previous criteria based mainly
on the post-load glucose measurements) along with a reduced diagnostic fasting
glucose threshold to indicate diabetes of 7.0 mmol / l rather than 7.8 mmol/ l
previously. The change in the type of measurements taken, from use of post-load
glucose measurements to fasting glucose has been shown to lead to different patients
being identified as having T2DM96.
It is also possible that the ascertainment of T2DM has increased over time. A patient
may have T2DM without knowing and without a diagnosis. In the light of increasing
awareness of the condition among both patients and practitioners, more patients are
being tested for T2DM and so the proportion of patients with undiagnosed T2DM
may have declined over time. This would lead to an apparent rise in incidence when
in fact the number of diabetes cases may not have changed; it is simply that more
cases are being uncovered. Public health policy changes could have lead to an
increase in testing. Specifically, recommendations on cardiovascular prevention from
the late 1990s97 and the introduction of Quality and Outcomes Framework (QOF;
www.pcc.nhs.uk) for managing patients in General Practice in 2004 may have
increased T2DM ascertainment.
Another factor which may lead to observed changes in incidence over time is a
change in the population structure. That is, if the distributions of age, gender or other
socio-demographic characteristics in the population change over time, since CHD and
T2DM risks are known to vary by these characteristics. However, interest in this
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thesis lies primarily in explaining time trends occurring within the different
demographic groups, or adjusting for demographic characteristics, rather than
assessing whether changes in demographic characteristics of a population may explain
the trends seen. In this way focus is on those modifiable factors which have changed
over time in a fixed population, with thus arguably more immediate public health
implications in terms of potential to influence future time trends through management
of these factors. Trends due to changing population demographics, by contrast, while
important for assessing the health burden, are less informative for identifying ways to
reduce numbers of events.
In Chapter 4 of the thesis, the first results chapter, the magnitude of recent trends in
incidence of major CHD and T2DM is estimated (objectives i and ii). Absolute and
relative changes in incidence over time are estimated using the various data sources at
hand, and the findings are considered alongside the existing data described in the
previous sections. The trends are both adjusted for and stratified by demographic
characteristics, to account for shifts in the population structure. In addition, the likely
impact of the changes in diagnostic criteria, case ascertainment, and the public health
policy measures are considered when interpreting the results of the analyses, in order
to evaluate the extent to which the trends are true or an artefact of the
diagnostic/ascertainment changes.
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2.5.2 Candidate factors to explain a decline in major CHD incidence (towards
objective iii)
Having established the extent of the true epidemiological trends in incidence in major
CHD in chapter 4, accounting for population shifts and diagnostic changes, the next
steps in the thesis are to examine the reasons for the trend (objective iii). Towards this
objective, in this section, a likely group of possible “candidate” factors are identified,
which may help to explain the trend seen, and so should be considered in the analyses.
This “brainstorm” of possible factors is based on the literature of the aetiology of
CHD, and trials of preventive treatments.
There are two groups of factors. The first group comprises major aetiological factors
(lifestyle or clinical) with established likely causal associations with CHD. The
lifestyle factors may operate at least in part through alteration of major modifiable
clinical factors. Importantly however, an established association with the disease is
not enough in itself to influence the time trend. The distribution of the factor needs to
also have changed over time in the population in a direction in accord with the time
trend in the disease. Specifically, to potentially explain the decline in CHD, a
favourable change in the factor is needed. The results chapters addressing objective iii
will look therefore first at how these major factors have changed over time, and then,
once the extent of any trends in these factors have been established, their potential
contribution to the trend in major CHD incidence may be evaluated.
The second group comprises preventive treatments (medications, surgical
interventions) which may directly influence risk of the disease, or indirectly through
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altering the major aetiological exposures. Provided uptake of these treatments has
increased over time, they may also help to explain a decline in major CHD incidence.
2.5.2.1 Major established modifiable aetiological exposures
The three major modifiable aetiological factors for CHD are cigarette smoking98, 99,
high blood pressure100, 101 and dyslipidemia102, 103. Each factor is widely distributed
in the population, is associated with a high relative risk for CHD, and is modifiable
and reversible (a reduction in the factor is associated with a fall in CHD risk). They
are therefore key candidates for explaining a decline in major CHD incidence,
dependent on the time trends in these factors.
The risk of incident CHD is two to three fold higher among smokers compared to
non-smokers98. It is estimated that 24 to 30% of all CHD is attributable to smoking98.
In younger age groups, among whom CHD events are rare, this figure is even higher
(closer to 75%). CHD mortality100 and CHD incidence101 have been shown to
increase more or less in a continuous monotonic log-linear fashion with increasing
systolic blood pressure (SBP) and diastolic blood pressure (DBP) within all age
groups, from a usual SBP of 115mmHg and a usual DBP of 75mmHg upwards.
Dyslipidemia102, 103 principally refers to raised total and low density lipoprotein
(LDL) cholesterol levels, but increasingly low high density lipoprotein (HDL)
cholesterol has also been implicated in increasing CHD risk. As for blood pressure,
continuous monotonic log-linear relationships have been found between CHD
mortality103 and CHD incidence102 and total cholesterol, HDL cholesterol, non-HDL
cholesterol (the difference between total and HDL cholesterol, thus mainly reflecting
LDL cholesterol) and the total-to-HDL ratio. Moreover, HDL and non-HDL
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cholesterol have been shown to operate on CHD risk largely independently of one
another102.
A further major modifiable lifestyle risk factor which may be implicated is high
adiposity104-106. Different adiposity measures (body mass index (BMI), waist
circumference, waist-to-hip ratio) have been shown to be similarly associated with
CHD risk, with hazard ratios of approximately 1.3 for a 1 standard deviation increase
in each measure (corresponding to 4·56 kg/m2 higher BMI, 12·6 cm higher waist
circumference, and 0·083 higher waist-to-hip ratio), adjusting for age, sex and
smoking status106. Meanwhile, physical activity has been shown to be protective
against CHD risk107-111, operating partly independently of adiposity107, 110, 111.
Moderate physical activity levels (in terms of amount or intensity) are associated with
a 20 to 25% reduced risk of CHD compared to low physical activity levels, while high
physical activity levels are associated with a 30 to 35% reduced risk111 . Meanwhile,
sedentary individuals are estimated to have almost twice the risk of CHD compared
with those with high activity112. Diabetes has also been shown to be a major clinical
risk factor for CHD27-33. The relationship between diabetes, particularly T2DM, and
CHD risk, which is a key aspect of this thesis, is considered in detail in a separate
section 2.5.4.
Various aspects of diet have been associated with risk of CHD113, although the
evidence is not as robust as for the other established risk factors, reflecting the
complexity of diet and difficulty in accurately and precisely ascertaining levels of
consumption of different dietary factors for the purposes of study. The dietary
patterns principally associated with reducing CHD risk include high fruit and
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vegetable consumption114, replacement of saturated fats with unsaturated fats115-118
and limiting salt intake119. In addition, both abstaining from alcohol120 and excessive
drinking (particularly binge drinking patterns121) are associated with increased CHD
risk, compared to regular alcohol consumption.
The roles of the above factors have generally been long established. A number of
other different factors have been connected to CHD risk. These include psychosocial
factors122-126 (notably depression123-127); genetic factors128-133; factors in gestation134,
135, from birth (for example low birth weight)136 and in childhood and earlier life (life-
course influences)137-139; and a range of emerging novel risk factors140 (including C-
reactive protein, homocysteine level, leukocyte count, periodontal disease). While
many of these factors may well play a role in explaining time trends in CHD, focus in
this thesis is on the roles of the major established modifiable clinical and lifestyle
factors described. This is for several reasons. First, to attribute the time trend in CHD
to a particular factor, a causal relationship is assumed and at present evidence for a
causal relationship between these emerging factors and CHD is generally weaker than
for the established factors. Second, some of the novel factors may be considered
markers of CHD rather than independent aetiological exposures, potentially useful for
identifying patients at high risk of CHD, but less useful here where the purpose is to
explain time trends. Third, the driver behind the search for novel factors has been the
evidence from studies of population attributable risks of CHD, which suggest that the
established factors do not fully account for all CHD cases occurring141, but this view
has been questioned more recently142. The INTERHEART study for example,
estimated population attributable risk fractions (PARFs) of the major factors for non-
fatal MI, using data from 52 countries143. The study found PARFs of 90% in men and
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94% in women, (both old and young and in all regions of the world) for the combined
effects of smoking, dyslipidemia, hypertension, diabetes, obesity, diet (fruit and
vegetable consumption), alcohol use, physical activity and psychosocial factors. That
is, virtually all of the variations in risk of MI between individuals could be attributed
to differences in the established major factors. A previous analysis of data from the
BRHS found the three factors dyslipidemia, hypertension and smoking together
corresponded to a PARF of 86% for major CHD144. Given that the major factors may
explain much of the variations in CHD risk between individuals, one may also expect
the major factors to explain much of the variations in CHD risk over time.
Assuming the age-distribution remains constant over time, secular temporal trends in
major CHD risk may be seen to be the result of variations in CHD risk according to
year of analysis arising from period effects (changing aetiological exposures with
calendar year close to the time of the event), but could also reflect variations in CHD
risk by year of birth arising from cohort effects (changing exposures according to
birth year). If variations in CHD risk by birth cohort are seen, this would suggest a
role of cohort effects, which include birth and early-life factors. Birth cohort effects
and life-course influences are beyond the scope of this thesis, the focus being on the
roles of recent trends in aetiological exposures. However, studies which have
investigated age, period and birth cohort effects on CHD incidence/mortality have
tended to show appreciable period effects, with possible cohort effects, but with
period effects dominating (particularly in the most recent decades – the period of
interest for the thesis)52, 145-147. Therefore life-course influences may anyway have
less potential to explain the major CHD incidence trends seen, than the major
aetiological exposures.
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The “metabolic syndrome” indicates the presence of a cluster of the major clinical risk
factors in combination (diabetes or impaired glucose tolerance, hypertension,
dyslipidemia, and (abdominal) obesity)148. It has been suggested that the metabolic
syndrome may predict CHD risk more strongly than the individual risk factors.
However, studies have tended to show that presence of the metabolic syndrome
predicts risk of CHD no more strongly than the individual risk factors in
combination149. Thus, for the purposes of this thesis, it is arguably sufficient to
consider the role of the individual risk factors, alone and in combination, on the time
trend in major CHD.
2.5.2.2 Preventive treatments
The key treatments shown to be effective in reducing risk of major CHD events and
currently used in primary prevention of major CHD (as recommended by NICE150, 151
and Joint British Societies’ guidelines113), that is among those with angina or at high
risk of developing CHD, (as opposed to solely as treatment post-MI) are evidence-
based medications, specifically lipid-lowering medications (predominantly statins)68,
152-155 to lower total and LDL cholesterol levels, and anti-hypertensive medications,
to lower blood pressure156-160.
The potential effectiveness of lipid-lowering medications in preventing major CHD
events was recognised following publication of the first randomised controlled trials
of statins in the early 1990s68. Meta-analyses of randomised controlled trials show
consistently around 30% reduction in risk of major CHD events among patients
without history of major CHD152-155.
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There are several different types of anti-hypertensive medications including chiefly;
beta-blockers, calcium channel blockers, ACE-inhibitors, angiotensin receptor
blockers and thiazide-type diuretics. Meta-analyses of randomised controlled trials
show all these drugs to be similarly safe and effective in preventing major CHD
events in relation to their blood pressure lowering effects158-160, regardless of existing
CVD and blood pressure levels before treatment (around 11-17% reductions in risk of
a CHD event160). Combinations of the drugs may confer added benefit161.
Aspirin and other anti-thrombotics, used in secondary prevention, have also been
recommended in the past for primary prevention113. However, recent meta-analyses,
considering specifically the use of aspirin for primary prevention, did not show
conclusive evidence of benefits in terms of CVD risk reduction, while at the same
time reporting significant risk of bleeding as a side-effect162, 163. A low absolute risk
reduction is outweighed by the side effects. Therefore the relative benefit of aspirin
for primary prevention is uncertain.
Some studies have suggested considerable potential for preventing CVD events when
these different types of medication are used in combination, notably Wald and Law, in
their paper proposing the “Polypill”164. The proposed pill combines six different
treatment components: a statin (to lower cholesterol), three anti-hypertensive drugs (to
lower blood pressure), aspirin (for platelet function) and folic acid (for serum
homocysteine). The estimated effect of this medication combination was as much as
an 88% reduction in CHD events. The authors conclude by suggesting prescribing of
the pill to all over a certain age as a primary prevention measure. Similarly, Yusuf
postulated a cumulative effect of a 75% risk reduction, for the combination of aspirin,
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two anti-hypertensive drugs (beta blockers and ACE inhibitors), and a lipid lowering
drug, assuming independent effects165. These estimated effects have been met with
some scepticism; particularly regarding the independence of the different drugs
(although other studies suggest the independence assumption may indeed be valid166).
There is also concern regarding the blanket prescribing to anyone of a certain age,
leading to so-termed “medicalising of the population”167. However, the estimated
combined effects suggest, depending on uptake levels, the various medications have
the potential to help explain a good proportion of the decline in CHD.
In addition to drugs, surgical interventions (revascularisations), namely coronary
artery bypass grafts (CABGs) or percutaneous coronary interventions (PCIs), may be
indicated for major CHD prevention for certain groups (those with the most severe
forms of angina)168. However, while seen to alleviate symptoms, the evidence
regarding the effectiveness in terms of reducing risk of future major CHD events (and
therefore a contributor to the decline in major CHD incidence) is less conclusive
(although CABG may lead to a better prognosis than PCI)168.
In the past, some studies (predominantly observational) have suggested that use of
hormone replacement therapy among post-menopausal women is associated with a
reduced risk of CHD169. However there is a growing body of clinical trial evidence
conversely supporting no benefit or even an increased risk of CHD with use of
hormone replacement therapy170-173, which now outweighs the earlier suggestions of
favourable effects.
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2.5.3 Candidate factors to explain a rise in T2DM incidence (towards objective
iv)
As for major CHD, having established the extent of the true epidemiological trends in
incidence in T2DM in chapter 4, accounting for population shifts and diagnostic
changes, the next steps in the thesis are to examine the reasons for the trend (objective
iv). This section comprises a literature-based “brainstorm” of possible “candidate”
factors which may help to explain the trend seen, and so should be considered in the
analyses.
As for major CHD, major modifiable aetiological factors with established likely
causal associations with T2DM are identified. However, for the factor to explain the
rise in T2DM, an unfavourable change in the factor needs to have occurred over time
in the population. The results chapters addressing objectives 4 will look therefore first
at how these major factors have changed over time, and then, once the extent of any
trends in these factors have been established, their potential contribution to the trend
in T2DM incidence may be evaluated.
Preventive treatments were identified as possible explanations for the decline in major
CHD incidence. However, since rising use of treatments which reduce risk of the
disease are generally thought of as a favourable change over time, treatment use is
unlikely to explain the unfavourable time trend in T2DM, and so is not considered
here. That said, recent studies suggest statins used in CHD prevention may be
associated with increased risk of T2DM174; other drugs indicated for other conditions
may also have adverse metabolic effects or be associated with increased T2DM risk.
This is considered further in the results chapter 8 addressing objective iv.
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2.5.3.1 Major established modifiable aetiological exposures
T2DM has some risk factors in common with CHD, although the relative importances
of the risk factors differ. The most important modifiable factor implicated in
increasing risk of T2DM is high adiposity43. The association between adiposity and
T2DM is well-established43, following findings from major prospective observational
studies such as the Nurses Health Study175, the Health Professionals Study176, and the
studies of Pima Indians177, showing striking “dose-response” relationships between
BMI and subsequent risk of T2DM. For example, among women in the Nurses Health
Study175, the age-adjusted 14-year relative risks of T2DM, compared to women with a
BMI <22kg/m2 at baseline, were 2.9, 4.3, 5.0, 8.1, 15.8, 27.6, 40.3, 54.0, and 93.2 for
BMIs of 22.0-22.9, 23.0-23.9, 24.0-24.9, 25.0-26.9, 27.0-28.9, 29.0-30.9, 31.0-32.9,
33.0-34.9 and ≥35.0kg/m2 respectively. Moreover, the study also showed that,
compared to women whose weight remained stable between age 18 and the study
baseline (aged 35 to 55 years), women who lost weight were at significantly reduced
risk of T2DM, while women who gained weight were at increased risk, implying that
reducing adiposity levels can reduce risk of T2DM. Studies suggest a PARF of T2DM
from overweight and obesity combined of generally around 36 to 50%178-181, but
ranging from 3%181 to 77%182. The wide variation may be explained in part by
differences in the prevalence of overweight and obesity between different populations.
Consideration of biological mechanisms for the relationship between adiposity and
T2DM suggests visceral adipose tissue to be the component of adiposity particularly
implicated in the development of insulin resistance and T2DM183, 184. However, recent
studies have shown BMI generally to be as strong a predictor as the abdominal
adiposity measures180, 185, 186, reflecting the high correlation between BMI and
abdominal adiposity.
66
Other factors with established associations with T2DM are physical activity187, 188
and aspects of diet189-198, which may operate partly through changing adiposity levels,
but also partly independently. A recent meta-analysis found that regular participation
in moderate physical activity was associated with a significant 30% lower risk of
T2DM relative to being sedentary: relative risk of 0.69 (95% CI 0.58 to 0.83)188.
After adjustment for BMI, the relative risk was attenuated to 0.83 (95% CI 0.76 to
0.90), but remained significant, suggesting that the effects of physical activity is in
part through BMI, but in part independent of BMI. Moreover, even light intensity
activity could be beneficial187. Investigating the role of diet is complex, and as such,
is not fully understood. Several studies, including the Nurses’ Health Study193 and
Health Professionals study197, highlighted a significant association between a poor
“Western-style” diet (high in red meat, processed meat, French fries, high-fat dairy
products, refined grains, and sweets and desserts) and risk of T2DM, even after
adjustment for BMI. Individual dietary elements which may reduce T2DM risk
include replacing saturated fats with unsaturated fats191, 194, 196, 198, a diet with a low
glycaemic index192, 195, milk and dairy consumption190 , and limiting intake of red
meat and processed meat189 .
Cigarette smoking199, alcohol consumption 200and blood pressure201, 202 may also
possibly play a role in T2DM risk, although the evidence for these factors is weaker.
A recent meta-analysis estimated the relative risk comparing smokers to non-smokers
to be 1.44 (95% CI 1.31 to 1.58), with evidence of a dose-response relationship199.
Moderate alcohol consumption may be associated with up to a 40% lower risk,
relative to lifetime-abstainers, as well as a lower risk relative to heavy drinkers200.
The MONICA Augsberg study reported the risk of T2DM among people with
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hypertension to be roughly double that for people with normal blood pressure,
regardless of BMI, indicating a possible effect independent of BMI202.
The above factors together have been shown to explain most of the cases of T2DM in
various populations: Among women in the US (Nurses’ Health Study), the PARF of
T2DM was 87% for the combination of overweight/obesity, low physical activity, and
poor diet (high in trans fats and glycaemic load, low in cereal fibre, low ratio of
polyunsaturated to saturated fat)203. Being a smoker or teetotal increased the PARF
only very modestly to 88% and 91% respectively. In Finland, overweight/obesity,
lack of exercise, excess alcohol consumption, smoking, and low vitamin D amounted
to a PARF of 82%182. In Hawaii, overweight/obesity, lack of exercise, poor diet (high
red meat, low fibre), being teetotal and smoking corresponded to a PARF of 78% in
men and 83% in women; socio-demographic characteristics (age, ethnicity, education)
and hypertension increased the PARFs to 92% and 95% in men and women
respectively179. Moreover, favourable changes in the major risk factors (BMI,
physical activity and diet) can lead to substantial reductions in risk of T2DM204.
Specific to women, development of transient diabetes during pregnancy (gestational
diabetes) is associated an increased risk of subsequently developing T2DM205
(studies suggest between a 17% and 63% increased risk in the 5 to 16 years following
the affected pregnancy206).
As for CHD, increasing research is being carried out to explore the relationship
between psychosocial factors207 (notably depression207, 208), genetic factors177, 209-211,
and T2DM risk. However, research into these factors is relatively recent so as yet
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evidence is weaker, and, as outlined above, the established risk factors may already
explain much of the T2DM burden. Life-course influences (particularly low birth
weight212, 213, and adiposity levels throughout the life-course214-216) have been shown
to be associated with risk of T2DM, independent of current adiposity levels.
However, as for CHD, birth cohort effects and therefore life-course influences are
beyond the scope of this thesis, the focus being on recent trends in aetiological
exposures, reflecting that recent time trends may more likely reflect period rather than
cohort effects217. Other factors (dyslipidemia and polycystic ovary syndrome) have
been previously postulated to influence T2DM risk, but current evidence does not
support this218.
2.5.4 T2DM and risk of major CHD (towards objective v)
Diabetes (T1DM and T2DM) is associated with a substantially elevated risk of a
major CHD event, with the risk among patients with diabetes generally shown to be at
least two-fold greater than that of patients without diabetes27-33. The excess risk
among women with diabetes, compared to women without diabetes, is greater than
that for men, such that relative CHD advantage of being female in the general
population is all but lost in the diabetic population219. A recent meta-analysis of 37
studies27 showed the fatal CHD rate to be 5.4% for diabetics, compared with 1.6%
among people without diabetes, with corresponding pooled relative risks comparing
diabetics to non-diabetics of 3.50 (95% CI 2.70 to 4.53) for women and 2.06 (95% CI
1.81 to 2.34) for men. The authors attribute the gender difference in the relative risks
in part to women with diabetes having a more adverse risk profile in terms of major
CHD risk factors, relative to women without diabetes, than men. Possible treatment
gender bias is also put forward as a potential explanation. More recently, The
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Emerging Risk Factors Collaboration meta-analysis estimated a hazard ratio of 2.32
(95% CI 2.11 to 2.56) for all vascular deaths, comparing diabetes versus no diabetes29.
In the BRHS, age-adjusted hazard ratios of a major CHD event, compared to no
diabetes or prior MI were 1.70 (95% CI 1.20 to 2.42) and 2.93 (95% CI 1.81 to 4.74)
for late onset diabetes (aged over 60 years at onset) and early onset diabetes (aged
under 60 years at onset) respectively33. A subsequent large UK-population based
study (using data from the General Practice Research Database)28, similarly observed
the hazard ratios of incident MI comparing those with and without T2DM to be 2.13
(95% CI 2.01 to 2.26) and 2.95 (95% CI 2.75 to 3.17) among men and women
respectively, adjusting for age, smoking, BMI, hypertension and abnormal lipids. As
well as the gender difference, the hazard ratios varied with age, with the largest
hazard ratios seen in the younger age groups. For example, the hazard ratios in the
35-54 years age group were 2.69 (95% CI 2.07 to 3.49) and 4.86 (95% CI 2.78 to
8.51) in men and women respectively. There was also some suggestion that, adjusting
for age, the longer the duration of T2DM, the greater the risk of MI. This has been
observed in other studies too30, including in the BRHS33. In line with inequalities in
the general population, among diabetic patients, the more deprived patients have a
higher prevalence of CVD and a more adverse risk profile (in terms of smoking status
and obesity), relative to their less deprived counterparts220, 221.
In terms of explaining the excess risk of CHD among diabetics, one reason is that
diabetic patients tend to have more adverse levels of the major established CHD risk
factors (particularly blood pressure, lipid levels, and BMI) than their diabetes-free
counterparts, as reported in the meta-analysis27 (described above), and also observed
other studies, including the UK population-based study28 and Framingham cohort222.
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The relative risk of CHD comparing those with and without T2DM is attenuated after
adjustment for these risk factors, indicating that the excess risk among diabetics
operates in part through these factors27. However, as the relative risk is not fully
attenuated, the diabetic condition itself is also thought to be an independent risk factor
for CHD, primarily through glucose intolerance. Indeed studies have shown a dose-
response relationship between glucose level (whether measured as fasting glucose,
non-fasting glucose or the HbA1c level) and CHD risk223-225, supporting a possible
casual relationship between glucose intolerance and CHD. This dose-response
relationship is seen not only among those with diabetes, but below the diabetes
threshold among those with impaired glucose tolerance226. The mechanism by which
glucose intolerance raises CHD risk is not fully resolved but possibilities include a
direct toxic effect of high glucose levels, (for example, in promoting cellular damage
or causing atherosclerosis through accumulation of “advanced glycation endpoints”
on blood vessel walls or increasing oxidative stress)226.
Current NICE public health guidance227 promotes use of lipid-regulating drugs, anti-
hypertensive drugs, and therapies to lower glucose levels in the management of
T2DM, to help lower CHD risk. Meta-analyses of trials of lipid-lowering drugs
among diabetic patients reveal significant reductions in CHD events, and that diabetic
patients benefit at least as much as non-diabetic patients228, 229. Patients with diabetes
also benefit from use of anti-hypertensive medications230, 231, although the evidence
for the effectiveness of glucose therapies on reducing CHD risk is more mixed232-237,
with certain drugs recently withdrawn from practice due to possibly increased CHD
risk238. Improved management of T2DM may attenuate the excess risk of CHD
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among patients with T2DM. The thesis will explore whether the relative risk of CHD
among patients with T2DM has changed over time.
2.6 Current literature examining reasons for the time trends in major
coronary heart disease and type 2 diabetes in the UK
2.6.1 Reasons for time trends in major CHD
The previous sections have summarised the available literature on time trends in CHD
morbidity and mortality and discussed factors which might have influenced the time
trends such as clinical and lifestyle risk factors and use of preventive treatments. Very
few studies in the UK however have attempted to understand and directly analyse the
relationship between the CHD morbidity or mortality decline and concurrent trends in
the various factors, to ascertain which factors may be responsible for the favourable
decline in CHD. That is, studies which address similar questions to those in the thesis,
and studies therefore to which the thesis results may be compared. This partially
reflects a lack of suitable data on CHD morbidity and risk factor levels239. Indeed,
apparently there are only two studies of this kind involving UK populations: The
WHO MONICA project (based on a series of ad-hoc population surveys) and the
IMPACT policy model (based on modelling of population data from different data
sources) (Table 2.1, studies identified by a *). These projects, detailed below, have
made important contributions to our understanding of the reasons for the trends in
CHD morbidity and mortality in recent decades in various countries and dominate the
research worldwide in this area.
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2.6.1.1 WHO MONICA Project
The motivation for the WHO MONICA (MONItoring trends and determinants in
CArdiovascular disease) Project240, 241 came from the 1978 Bethesda Conference on
the Decline of CHD mortality which highlighted the need for monitoring of trends in
CVD in different countries. The aim was to monitor over the next decade time trends
in CVD mortality, as well as CVD risk factors and treatment use, in different
populations across the world, enabling both analyses of trends within each population
and analyses of trends combining the data from the different populations (facilitated
by use of common data collection methods). The principal objective was to “measure
the trends in CVD mortality and CHD and cerebrovascular disease morbidity and to
assess the extent to which these trends are related to changes in known risk factors,
daily living habits, health care, or major socioeconomic features measured at the same
time in defined communities in different countries” [direct quote from protocol]241.
By 1985 the project involved a total of 41 different populations in 27 countries across
4 continents, including two UK populations (the cities of Belfast and Glasgow). The
populations comprised men and women in the chosen city/ region aged 35 to 64 years.
Each population was followed for at least 10 years from the mid 1980s to the mid
1990s. The Belfast population was followed from 1983 to 1993, while the Glasgow
population was followed from 1985 to 1994. Routine census data and official
statistics were used to ascertain population denominators and incidence of CVD
events/CVD mortality. In addition, random samples of the populations were surveyed
a number of times over the course of the decade to determine the distribution of risk
factors. Of the many papers since published from the project, several papers
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specifically explore explanations for the time trends in CHD mortality and morbidity
in the different populations13, 14, 22.
One of the key papers analysing trends in CHD mortality, published in 1999, explored
relative contributions to changes in CHD mortality between the mid-1980s and mid-
1990s of trends in case fatality and trends in incidence22. The analysis is based on the
principle that the average annual percentage change in CHD mortality may be
partitioned into the sum of the average annual percentage change in incidence of
major CHD and the average annual percentage change in case fatality. Thus a greater
percentage change in incidence suggests the CHD mortality change is predominantly
influenced by a change in the number of people experiencing major CHD events,
rather than a change in the proportion of major CHD events which are fatal. There
was considerable variation in the change in CHD mortality over the period; while the
majority of populations experienced different degrees of decline, certain populations
experienced an increase (mainly Eastern European populations, Russia and China).
There was also variation in the relative contributions of incidence changes and case
fatality changes between different populations. However, the general tendency was
for a greater change in incidence, compared with case fatality, particularly where a
decline in CHD mortality occurred, implying that the decline in CHD mortality could
be mainly attributed to a decline in incidence over the period (the authors suggest a
two-thirds versus one-third contribution of incidence versus fatality). Among the UK
populations there was no consistent pattern; among men in Glasgow, as described in
section 2.2.2, the average annual relative change in incidence of major CHD was -
1.4% and in case fatality was -1.3%, giving a total decline in CHD mortality of -2.7%,
and suggesting roughly equal contributions of incidence and case fatality trends.
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Among women in Glasgow, the average annual relative change in incidence of major
CHD was +0.2% and case fatality was -2.1%, giving a total decline in CHD mortality
of -1.9%, this time solely influenced by case fatality declines. Among men in Belfast,
the average annual relative change in incidence of major CHD was -4.6% and case
fatality was -1.5%, giving a total decline in CHD mortality of -6.1%, predominantly
influenced by incidence declines. Finally, among women in Belfast, the average
annual relative change in incidence of major CHD was -2.4% and case fatality was -
1.7%, also predominantly influenced by incidence declines. The general picture
though is that both incidence and case fatality rates can be improved, and have been
influential in reducing CHD mortality.
Having considered the relative roles of incidence and case fatality trends, the
investigators then went further to consider the role of risk factors and coronary care in
the incidence and case fatality trends13, 14. The risk factor trends themselves are
reported separately in detail242-245. Using data on 38 populations from 21 countries
with adequate quality data (including Belfast and Glasgow), an ecological analysis
was carried out regressing the average annual change in major CHD incidence
against the average annual changes in different major coronary risks factors for each
population (such that each population was the unit of analysis)246. The percentage of
the variation between the incidence trends in the different population that was
explained by the risk factor trends was then estimated247. A lag period between the
risk factor changes and subsequent incidence rate changes of 4 years was incorporated
in the analysis; this led to a greater proportion of the variation in the trends in major
CHD event rates explained by risk factor trends than with no time lag. The findings
were that cigarette smoking trends alone explained approximately 20% of the
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variation in the incidence trends in men aged 35 to 64 years, while total cholesterol
explained 19% of the variation, and systolic blood pressure explained 6%13. BMI
trends were estimated to explain a large proportion (36%) of the variation in incidence
trends in isolation, but the coefficient of BMI in the corresponding analysis model
was negative indicating counter-intuitively declining CHD risk with increasing BMI.
The negative coefficient was found to have been predominantly influenced by the
declining BMI in five former USSR populations, compared with rising BMI
elsewhere. Excluding these former USSR populations, the total explained variation
by the risk factors combined was 38%, with or without inclusion of BMI. Among
women, the proportions of the variation in trends in incidence explained by the risk
factors were much lower: smoking 0%, total cholesterol 0%, systolic blood pressure
11%, BMI 19% and all risk factors (excluding former USSR populations) 18%. The
variation in the trends was therefore by no means fully explained by the risk factor
changes. The authors cite possible explanations for the unexplained variation as
imprecision in the analyses, modelling limitations (such as inadequate accounting for
lag times or non-linearity of time trends) or the roles of other factors not included in
the analyses. In a companion paper, published at the same time, a similar analysis
was carried out to establish the role of treatment trends in the variation between
populations in the time trends in major CHD event rates, 28-day case fatality and
CHD mortality, based on 31 of the MONICA study populations14. Reflecting the
available evidence at the time, the study, reported substantial and significant increases
between the mid 1980s and mid 1990s in the use of beta blockers, anti-platelet drugs,
thrombolytic drugs and ACE inhibitors in the majority of the populations studied. In
particular, for the two included UK population samples (Glasgow and Belfast),
significant increases in the use of all four treatments occurred (approximately one-
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and-a-half fold increases in the age-standardised proportion of patients given beta-
blockers, a quadrupling in the age-standardised proportion of patients given anti-
platelets and thrombolytics and an increase from no patients receiving ACE inhibitors
in the mid 1980s to roughly one quarter receiving the medication at the time of the MI
in the mid 1990s). The study found that, in isolation, trends in the use of the different
treatments, before or at the time of a major CHD event, could explain the following
percentages of the variation in 28-day case fatality trends between the different
populations (men and women combined): beta-blockers before the major CHD event:
15% and at the time of the event: 18%; anti-platelets before: 24% and during event:
31%; ACE inhibitors before: 38% and during: 32%; coronary artery procedures
before: 29%; thrombolytics during: 35%. The combination of all the treatment trends
(as a score taking account of the combined effects of the treatments) could explain
51% of the variation in the 28-day case fatality trends (61% in men and 41% in
women). In terms of major CHD event rates, 41% of the variation (52% in men,
30% in women) in the time trends between populations could be explained by the
combined treatment trends. Finally, in terms of overall CHD mortality rates, 64% of
the variation (72% in men, 56% in women) in the time trends between populations
could be explained by the combined treatment trends. The influence of treatments
appears greater than that of risk factors on the time trends in incidence of major
CHD events (52% versus 38% of variation explained in men), which the authors
suggest could be due to the treatment changes being particularly large, and that
treatment use may be easier to measure. There is likely to be considerable overlap
between the risk factors and treatment roles, since some of the treatments will work
by reducing the risk factor levels (particularly cholesterol and blood pressure). Thus
the percentages cannot simply be added to give the total variation explained by risk
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factors and treatments. A third paper gives an alternative way of considering the role
of treatments245. The study investigated the role of medication on the decline in blood
pressure (and so indirectly on the trends in CHD) by comparing the shape of the
distribution of blood pressure in the mid-1980s with that in the mid-1990s in the
different world-wide populations. The hypothesis was that the effect of blood
pressure-lowering medication would be realised in a selective depression of the top
end of the population bell curve over time (reflecting the impact of blood pressure-
lowering medication as a high risk as opposed to mass population intervention). The
authors found no significant evidence for such a medication effect (mean blood
pressure changes, pooled across all the populations, were similar in the different blood
pressure centiles), concluding that lifestyle changes rather than medication have had
greater influence on the blood pressure trends, at least over this period. Considering
the UK populations in isolation however gives a different picture. In Glasgow, use of
anti-hypertensive medications increased from 7% to 10% of the study population,
between 1985 and 1994. Over the same period, average systolic blood pressure
declined by -4.5mmHg and diastolic blood pressure declined by -3.6mmHg in men.
The declines were greatest among participants above the 80th blood pressure centiles,
that is, with the highest blood pressure: declines of -6.0mmHg and -4.0mmHg for
systolic and diastolic blood pressure respectively. A similar pattern was seen among
women: systolic blood pressure declined by -6.9mmHg on average and by -7.0mmHg
among women above the 80th centile; diastolic blood pressure declined by -5.9mmHg
on average and by -7.0mmHg above the 80th centile. This suggests a selective
depression of the top end of the bell curve over time which in turn suggests an
influence of medication on the blood pressure trends. In Belfast, use of anti-
hypertensive medication did not increase; at the same time blood pressure levels
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changed little, which neither supports nor refutes an influence of medication in blood
pressure time trends in general.
2.6.1.2 IMPACT Policy model project
The IMPACT project has used aggregate data to examine and model the influence of
different factors on the decline in CHD mortality in England and Wales15, 248 and in
Scotland12 in recent decades, as well as in a number of other countries249-255. The
IMPACT model synthesized data from a range of different sources on risk factor and
treatment trends in the population of interest over a given time period to estimate the
expected total number of CHD deaths prevented or postponed by the trends in the
different factors/treatments. This expected figure is then compared with that actually
observed to give an estimate of the size of the contribution of each factor to the
mortality change. In Scotland, the period under consideration was 1975 to 1994. In
England and Wales, trends over the period 1981 to 2000 were investigated. Different
formulae are employed to assess the impact of the risk factors and treatments. A “best
estimate” of the number of deaths prevented or postponed by a given treatment = no.
eligible patients in latest calendar year × no. patients receiving treatment in latest year
× relative risk reduction × case fatality rate. Several adjustments are made to take
account of treatment use (albeit modest) at the start of the period; treatment
compliance; and double-counting of patients in the various eligible patient groups.
Polypharmacy (the combined effect of multiple treatments in an individual) is also
considered. A “best estimate” of the number of deaths prevented or postponed by
time trends in the risk factors smoking prevalence, blood pressure and cholesterol =
no. of deaths from CHD in the first year × subsequent reduction in the risk factor ×
regression coefficient for change in CHD mortality per unit absolute change in the
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risk factor in the population. A “best estimate” of the number of deaths prevented or
postponed by time trends in the risk factors obesity, diet, physical activity and social
deprivation = no. of deaths attributable to risk factor in the first year of the period –
no. of deaths attributable to risk factor in final year (since suitable data on regression
coefficients were not available for these factors). Since the regression coefficients
and relative risks for the attributable risk calculations came from multiple regression
analyses, they thus represent the (independent) benefit in the presence of other risk
factors. Any decline in mortality unaccounted for by the treatments and risk factors
considered is then attributed to unmeasured factors such as diet and life course effects.
It should be noted that some of the risk factors could lead to an increase rather than
decrease in the number of deaths. Population and patient data came from routine
sources such as Hospital Episode Statistics and The Office for National Statistics (for
the England and Wales analysis) or the Scottish Health Statistics (Scotland analysis).
Estimates for the treatment relative risk reductions came from meta-analyses or multi-
centre randomised controlled trials and estimates of risk factor effects and trends
came largely from MONICA analyses, cross-sectional surveys such as the Health
Survey for England, with some data also from the BRHS.
The IMPACT findings for England and Wales were that, comparing the number of
deaths in 2000 with the number anticipated had the CHD mortality rate remained the
same as in 1981, an observed total of 68 230 fewer deaths occurred, corresponding to
decreases in the CHD mortality rate of 62% in men and 45% in women over this 20
year period15. The IMPACT model predicted that 25 805 deaths were expected to be
prevented by uptake of different treatments. This is 38% of the observed total number
of deaths prevented, indicating a 38% contribution of treatments. An estimated 4779
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deaths (7%) were prevented by immediate treatment for an MI (including
resuscitation, thrombolysis, aspirin, primary angioplasty, beta-blockers and ACE
inhibitors), while 6899 deaths were prevented by secondary prevention after MI or
after revascularisation. 3424 further deaths were prevented by treatments among
patients with chronic angina and 912 with unstable angina, 7760 with heart failure and
1888 with hypertension. A small number (143) were prevented among the disease-
free population due to use of statins for primary prevention. A larger portion, 35 944
(52%) of the deaths prevented, could be accounted for by major risk factor changes.
Declining cigarette smoking had the greatest impact, preventing 29 715 deaths (44%).
Favourable changes in blood pressure and total cholesterol accounted for the
prevention of 5868 and 7900 deaths respectively (close to 10% each). Declining
deprivation had a modest impact, preventing 2126 deaths. Conversely, physical
activity, obesity and diabetes trends all had negative impacts, resulting in increased
rather than reduced numbers of deaths (2662, 2097 and 2888 deaths respectively).
10% of the total 68 230 observed deaths prevented were not accounted for by risk
factor or treatment changes, and were thus attributed to the unmeasured factors. In a
separate paper, the numbers of deaths prevented was used to estimate further the life-
years gained as a result of the time trends in risk factors and treatments256. The
findings were that the changes in treatment would correspond to 194 145 life-years
gained, while the changes in the risk factors would correspond to an additional 731
270 life-years gained, that is, 79% of the total life-years gained. Thus in terms of
longevity, as opposed to mortality, the trends in risk factors have been considerably
more influential than the trends in treatments. A separate analysis was later carried
out, giving an alternative means of interpreting the data, by apportioning the
prevented deaths by risk factor changes into those resulting from primary prevention
81
measures and those resulting from secondary prevention248, that is, comparing those
due to changes in risk factors among the healthy disease-free population with those
due to changes in risk factors among patients with existing CHD. There were 45 370
deaths prevented due to favourable changes in smoking, blood pressure and
cholesterol (by lifestyle changes or medication use). Of these, 36 625 (81%) were
among the disease-free population (so primary prevention) while 8745 (19%) were
among those with CHD (secondary prevention). This implies that of the total 68 230
deaths prevented, 36 625 (54%) can be attributed to primary prevention measures; the
remaining deaths attributed to secondary prevention as a combination of the changes
in risk factors among those with CHD (~13%) or other treatments among those with
CHD (~33%).
In Scotland, looking at trends over an earlier period from 1975 to 1994, a total of
6205 fewer deaths occurred than anticipated in 1994, had rates stayed at the 1975
levels12. Of these, the IMPACT model predicted that 2178 deaths were prevented by
uptake of different treatments (35% of the total number of deaths prevented), while
3425 (56%) were prevented by risk factor changes; the remaining 9% (approximately
600) was attributed to unmeasured factors. In terms of treatment, treatments at the
time of the MI prevented close to 10% of deaths, while secondary prevention after the
MI prevented 6% of deaths, secondary prevention after revascularisation prevented
2%, secondary prevention for angina prevented 5%, secondary prevention for heart
failure prevented 8% and treatment of hypertension prevented 9%. Among the risk
factors, again declining cigarette smoking had the greatest impact, preventing
approximately 36% of deaths. Favourable changes in blood pressure and total
cholesterol accounted for close to 6% each and declining deprivation accounted for
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close to 3%. Physical activity, obesity and diabetes were not considered in this
analysis due to lack of suitable data sources. A separate report from the IMPACT
group suggests that three-quarters of the corresponding life-years gained, were
attributable to risk factor changes, and one-quarter due to treatment changes257.
However, the life-years gained estimates appear to be based on different numbers of
prevented deaths so direct comparison between the estimates of the deaths prevented
and life-years gained in this case is not straightforward.
2.6.1.3 Summary of extent of literature explaining UK CHD trends
Both the MONICA project and IMPACT project are ecological studies involving
analyses based on comparing aggregate characteristics of groups of individuals where
the groups are different cities (WHO MONICA) or different calendar years
(IMPACT). They are thus subject to ecological limitations258. In particular, examples
of an “ecological fallacy” may occur. This is where an association is seen between
two factors A and B at the population level, comparing characteristics of groups of
individuals (suppose A appears to be prevalent in a group if B is prevalent), but this is
not a true association because it is not seen at the individual level, comparing
characteristics of individuals (that is, an individual’s likelihood of having factor B is
independent of whether they have factor A). This situation arises when both A and B
are prevalent in a group, but within the group, the individuals who have factor A are
not the same as the individuals who have factor B. As an illustrative example, in the
BRHS study at the population level, blood group 0 is associated with CHD (towns
with a greater proportion of men in blood group 0 also have a higher incidence of
CHD)259. However, at the individual level, this association is not seen (an individual
with blood group 0 is not at higher CHD risk)259. The IMPACT model makes the
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assumption that individual-level relative risks of risk factors carry across to the
population level. Conversely, the MONICA analysis relies on the assumption that the
regression coefficients found at the population level will apply to individuals.
Moreover, in both studies, different aggregate data sources are combined (some
providing event data, some providing risk factor data). Critchley et al highlight the
potential benefits of such modelling approaches, for example where data on sections
of the population is scarce260. However, if the different aggregate data sources are not
entirely representative of the populations of interest, they may not completely overlap
in terms of the populations covered, risking further false associations. Also the risk
factor/ treatment effect sizes found in the published studies and used to inform the
IMPACT model may not be reflective of the strength of associations in the
population, if the published study or trial populations differ from the population of
interest, or because effect estimates in an (ideal) trial setting may be overestimates of
the likely efficacy in the general population.
At the time the thesis was conceived, no studies in the UK had to my knowledge used
individual level data to explore time trends in CHD mortality or morbidity.
Moreover, there was a lack of research either at an individual level or on an ecological
scale attempting to explain time trends in CHD incidence in the UK, which is the
focus of this thesis. The IMPACT model looked only at CHD mortality, while WHO
MONICA considered trends in CHD incidence but was limited to two UK cities
(Belfast and Glasgow). Further, the nature of the MONICA analyses was such that
the relationship between the trends in CHD and the influencing factors within the
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individual cities was not examined. Instead the role of the factors in explaining the
differences between the various cities in terms of the CHD trends was estimated.
2.6.2 Reasons for time trends in T2DM in the UK
Even fewer studies have to my knowledge explored time trends in T2DM either in the
UK or indeed in other countries (see section 2.7.2 below), perhaps reflecting the more
recent time-frame for the occurrence and description of the T2DM trend, as well as
the lack of data on T2DM morbidity and risk factor levels261. One study in Tayside,
Scotland, sought to ascertain whether the rising T2DM prevalence between 1993 and
2003 was the result of rising incidence or falling mortality rates4. The study found
prevalence to have risen over this period by on average 6.7% per annum adjusting for
age. Meanwhile, a 6.3% per annum age-adjusted increase in incidence occurred, and
mortality fell by 3.7% per annum, adjusting for age. The study then went further to
compare the actual observed rise in prevalence with the expected rise in prevalence
under three different scenarios: 1- assuming incidence to have risen at the observed
rate while mortality remained constant at 1993 levels, 2 – assuming mortality to have
fallen as observed but incidence to have remained constant, and 3 - assuming both
incidence and mortality to have remained constant. The findings were that the
estimated prevalence rise under scenario 1 was close to that observed, while that
under scenario 2 was somewhat lower, implying that rising incidence has had a
greater impact than falling mortality on the changing prevalence rates. That said, the
prevalence rise under scenario 3 (no change in incidence or mortality) was 60% of
that observed, highlighting the interesting point that much of the increase in
prevalence would have occurred anyway, even in the absence of changes in incidence
and mortality, due to incidence being consistently higher than mortality throughout.
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A second study compared time trends in early mortality with time trends in the use of
different medications (glucose regulating drugs, anti-hypertensives, statins) among
T2DM patients in the UK between 1996 and 200625. Based on the observed
concurrent decline in mortality and rise in medication use, and the known
effectiveness of the medications in reducing mortality rates, the authors concluded
that increased medication prescribing may have contributed to the improved survival.
However the study did not formally assess the medication contribution. Although
rising T2DM and rising obesity are often seen as companion public health issues,
going hand in hand43, 262, no studies have directly estimated the possible role of
adiposity trends or trends in other aetiological factors, to the time trends T2DM
prevalence or incidence in the UK.
2.7 Worldwide picture
2.7.1 Describing and explaining time trends in major CHD
In line with the trends in major CHD in the UK, declines in CHD mortality and major
CHD incidence have also been observed in North America252, 254, 263, other countries
in Western Europe249-251, 253, 255, 264, Australasia265, 266 and Japan267. In contrast, in
other regions of the world (Asia10, 11, Eastern Europe268), in predominantly low and
middle-income countries, CHD mortality rates have not been declining, and appear
even to be increasing, leading to a growing CHD healthcare burden. The
unfavourable rising CHD burden (along with other non-communicable diseases) in
these countries ties in closely with the phenomenon of “epidemiological transition”269,
270. The epidemiologic transition defines the development and increased wealth of a
middle or lower-income country which has contributed to improved control of the
spread of infectious diseases, which were previously prevalent. This has positively
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led to a decline in early- and childhood- infectious disease mortality rates. The
resulting increased life-expectancy, along with changing lifestyles, in turn means that
more people live to an age to develop a non-communicable disease such as CHD, and
so the CHD incidence and mortality rates rise, and there is a shift or “transition” from
the burden and priority of communicable diseases to non-communicable diseases.
This transition can be observed both in the overall shift from communicable to non-
communicable diseases, and also within CVD, with a shift from rheumatic heart
disease in childhood to coronary artery diseases in later life270. Indeed, estimates from
the WHO Global Burden of Disease Study suggest a 10% increase in the relative
share of non-communicable diseases, principally CVD, in the disease burden of low-
and-middle income countries between 1990 and 2001271. The extent of transition
differs between countries; countries such as China11 and India10, 272, and parts of
Eastern Europe are currently transitioning and as such are experiencing increased
CHD mortality rates. Some specific countries in Sub-Saharan Africa are yet to
transition and may be faced with a sizeable CHD burden in the future273. It has been
estimated that the number of CHD deaths worldwide may almost double between
1990 and 2020270; CVD is already the leading cause of death worldwide and the third
highest cause of disability274. The growing burden of CHD in other countries re-
emphasizes the potential value of understanding and exploring the reasons for the
decline in CHD mortality in the UK, as a means to inform how to reduce the CHD
burden in other countries.
In terms of understanding and explaining trends, numerous studies have compared
time trends in CHD mortality with time trends in aetiological factors and medication
use, and subsequently hypothesized a relationship between the two275. However,
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fewer have gone further to attempt to quantify the extent to which aetiological factors
and/or medication trends have contributed to the CHD trends. Those that do are
summarised below and in Table 2.1. Most of these studies have focussed on
explaining time trends in CHD mortality; a very limited number have modelled trends
in incidence or survival (CHD morbidity). Furthermore, most rely on synthesis of
different sources, rather than relating individual CHD status to individual levels of
aetiological exposures.
Dominating the list are studies applying the IMPACT model to many different world-
wide populations to explain CHD mortality trends, including Auckland in New
Zealand265, Beijing in China276, Finland253, Ireland250, USA252, 277, Sweden251,
Canada254, Iceland249, and Italy255. In addition to the principal MONICA analyses
involving all the MONICA populations, a few studies have examined CHD trends
within a single MONICA population (in Reykjavik, Iceland278 and in the North
Karelia and Kuopio regions of Finland279), although still involving synthesis of
different data for risk factors and for CHD death rates to compare observed and
expected declines in CHD mortality. In general, where a decline in CHD mortality has
occurred, risk factors have tended to make a larger contribution than treatments. Risk
factors appear to have made the largest contributions, relative to treatments, in the
Nordic countries and in Australia and New Zealand, while the contributions of risk
factors and treatments are approximately 50:50 in the USA, UK, and Ireland. The
relative size of the contribution of each of the individual risk factors appears to vary
between populations.
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Just one study worldwide17 was found to have previously explored the relationship
between time trends in CHD incidence (rather than mortality) and associated factors,
using individual level data to relate an individual’s CHD status to their risk factor
levels or treatment use, thus avoiding the ecological limitations. That is, an analysis
directly comparable with the analyses in this thesis. This US-based study (US Nurses
Health Study) examined the decline in major CHD (fatal CHD or non-fatal MI)
incidence over 14 years between 1980 and 199417. Incidence in 1992-4 was roughly
two-thirds of that in 1980-2 (relative risk from logistic regression of incidence on
time-point = 0.69, adjusted for age). 68% of the decline in incidence could be
explained by combined changes in smoking, diet (particularly a decrease in saturated
fat, an increase in fibre) and post-menopausal hormone use, in the presence of an
adverse secular change in BMI. This figure was derived from the analyses which
revealed that the relative risk of 0.69 was attenuated to 0.90, after adjustment for the
trends in these risk factors (that is, the risk factor levels over the two time-points).
Thus, the proportion of the decline explained by the risk factors (= percentage
attenuation of relative risk) is [(1-0.90)-(1-0.69)]/(1-0.69) = 68%. Decreased smoking
prevalence accounted in isolation for 42% of the decline in CHD (from models
adjusting only for smoking), changes in diet accounted for 52% and an increase in
post-menopausal hormone use accounted for 29%. However the validity of the
observed reduced risk with the use of hormone replacement therapy in this study is
uncertain, in the light of more recent evidence that post-menopausal hormone use
increases CHD risk170-173, as outlined in section 2.5.2.2. Blood pressure, lipid levels,
and diabetes were not considered in these analyses. The main mechanisms through
which diet is seen to increase risk of CHD is by raising cholesterol, blood pressure
and BMI280, 281, thus inclusion of diet arguably captures some of the effects of these
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factors. However, the full role of these factors is unlikely to be ascertained, and the
impact of use of anti-hypertensive medications and lipid-regulating drugs is also not
considered. Finally the study includes women only; the generalisability of the
findings to men is not certain.
2.7.2 Describing and explaining time trends in T2DM
Global prevalence of diabetes (primarily T2DM) is estimated to be rising and is
predicted to continue to rise282-284. Increases have been observed in many countries in
both the developed and developing world. One study projecting global prevalence of
diabetes estimated a prevalence of 2.8% in 2000, corresponding to a total of 171
million people with diabetes worldwide284. The study, based on data from about 40
world-wide populations, further projected the prevalence to almost double to 4.4% by
2030, corresponding to 366 million with diabetes by this time. The greatest increases
in the numbers of people with diabetes were projected to occur in developing
countries. One-and-a-half fold increases in the numbers of people with diabetes were
projected for much of Asia, Sub-Saharan Africa, Latin America and the Caribbean,
and the Middle East, whereas a 50% increase was estimated for the established market
economies. The individual countries with the highest numbers with diabetes in both
2000 and 2030 were projected to be India, followed by China and the US, partially
reflecting the large population sizes of these countries. A similar study, based on
more recent data from 91 countries, estimated current (2010) global prevalence to be
6.4% (285 million diabetic individuals) and suggested an even higher world-wide
prevalence by 2030 than that in the previous study of 7.7%, corresponding to 622
million people with diabetes283. While India, China and the US have the largest
numbers of people with diabetes, the study showed that the Middle Eastern countries
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tended to have the highest prevalence rates (estimated to be over 20% in the United
Arab Emirates by 2030, and over 15% in Kuwait, Bahrain and Saudi Arabia). The
projections in both studies are based primarily on the changing population
demographics (population growth, ageing populations and urbanisation285 being
particularly implicated in the estimated increased prevalence rates). If adiposity or
other aetiological factors are contributing to the rise in T2DM, the projected rates are
likely to be underestimates. Indeed, two projection studies specific to the US
population, where risk factor levels are taken into account in the analyses286-288,
suggest higher numbers of people with diabetes in early 2030 than that reported for
the US in these global projection studies (44.1 million and 37.7 million in the US-
specific studies versus 30.3 and 36.0 million in the global studies).
Studies in several different populations have shown parallel rises in obesity and
T2DM prevalence178, 289, 290, suggesting an association between the two trends,
especially when considered with the PAR for T2DM of obesity178. However, no
studies to my knowledge have formally attempted to quantify the extent to which
rising adiposity levels, or other factors, may have contributed to rising T2DM
prevalence or incidence, reflecting a paucity of data sources75. The two sides of the
afore-mentioned debate in Diabetologia (section 2.3.2) on whether “there really is an
epidemic of diabetes” do attempt to untangle the reasons for the rising prevalence19, 74,
75. The argument in favour of an epidemic considers five possible mechanisms which
could lead to an increase in prevalence: a fall in mortality, demographic changes, a
change in the ratio of diagnosed: undiagnosed cases, an earlier age of onset and finally
an increase in incidence19. A combination of modelling and logical reasoning is used
to determine that only about one quarter of the rise in prevalence can be attributed to
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factors other than rising incidence, leaving around 75% unaccounted for. Much of
this unexplained rise may have occurred even if incidence remained constant (as long
as it exceeds the mortality rate). However, the authors estimate that the required
incidence rate for this to occur, given the mortality and prevalence rates, is too high
and therefore argue that incidence must have increased over time. The converse
argument involves an analysis of data from a pharmaco-epidemiological database in
Denmark74. The analysis showed that while prevalence (of treated T2DM) had
increased rapidly in this population, incidence had remained constant, and instead the
rising prevalence reflected a small decline in mortality (and is therefore not an
epidemic as incidence is not rising). Both sides highlighted the lack of data to
confirm the arguments, and, being a debate, the modelling methods are not detailed
(particularly for the “pro” argument) and so it is difficult to assess the validity and
robustness of the analyses.
2.8 Summary of literature review findings
The available data sources indicate a favourable decline in CHD mortality rates of
almost three quarters from the 1960s to the present in the UK population, as outlined
in section 2.2.1. In contrast an unfavourable increase in T2DM prevalence has been
observed since the 1990s of around 5% per annum (section 2.3.1). The falling CHD
mortality may be seen to reflect either falling incidence of major CHD events or
falling case fatality following such an event. The rising T2DM prevalence may be
seen to reflect either rising T2DM incidence or improved (relative) survival. Reports
on incidence and fatality trends for CHD or T2DM are relatively limited, reflecting a
lack of suitable data sources which have monitored incidence or fatality rates
consistently over a period of time. However, both declines in major CHD incidence
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and declines in major CHD case fatality have been documented, such that it is likely
that both have contributed to the falling mortality rates (section 2.2.2). Meanwhile,
studies of morbidity trends similarly suggest that both rising incidence of T2DM and
improvements in survival rates have concurrently occurred, and so may be
contributing to the prevalence rise (section 2.3.2).
The broad aim of the thesis is to evaluate and try to identify the drivers behind the
trends in incidence of these two conditions. Understanding the reasons for the
incidence trends could help to inform future efforts to reduce CHD and T2DM, both
in the UK and in other countries. This is important because despite the favourable
decline in CHD mortality, reports indicate that CHD remains the leading single cause
of death, both overall and premature, in the UK (section 2.4). Meanwhile, health
economic studies project a considerable and growing health burden of diabetes and its
associated complications. Moreover, CHD and T2DM event rates are rising in many
other countries (section 2.7).
A first step towards evaluating the incidence trends is to try to untangle the true
epidemiological change (reflecting changes in modifiable exposures) from trends that
simply reflect a changing population structure or artefact trends arising from changes
in diagnostic criteria or case ascertainment (section 2.5.1). Possible influences to
consider under these headings are, for major CHD, the change in the definition of MI
in 2000, and changes in ICD coding of cause of death at various time points, which
may influence the numbers of fatal CHD events identified. For T2DM, trends may be
influenced by the change in diagnostic criteria in the late 1990s and possible improved
case ascertainment, driven by public health policy such as QOF. Assuming an
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epidemiological trend is identified, after accounting for population structure change
and diagnostic and ascertainment changes, the next step towards explaining the trends
is to identify candidate factors which could have contributed to the trends, for
inclusion in the analyses. These are modifiable exposures with a likely aetiological
association with CHD or T2DM risk. Their influence will depend on the extent to and
direction in which exposure levels have changed over time in the population. Based
on the epidemiological, aetiological and trial literature, for a decline in major CHD
incidence, factors include primarily cigarette smoking, blood pressure, lipid levels,
adiposity, physical activity, diabetes, dietary factors, alcohol consumption and use of
blood pressure lowering and lipid regulating medications (section 2.5.2). For a rise in
T2DM, factors include adiposity (key), and also physical activity, dietary factors, and
possibly smoking, alcohol consumption and blood pressure (section 2.5.3). Studies
consistently show about a two-fold excess risk of major CHD among patients with
diabetes (section 2.5.4), highlighting the need to consider the trends in incidence of
these two conditions together.
To my knowledge few studies have sought to formally analyse the reasons for the
time trends in major CHD in the UK, or worldwide. The two previous studies of
CHD trends involving UK populations (IMPACT and WHO MONICA) offer
important insights into the trends in CHD mortality and major CHD incidence
respectively but are subject to limitations, particularly the use of population rather
than individual level data (both), the use of exposure effect sizes from external data
sources in the models which may not reflect the true effect in the population
(IMPACT) and the restriction to two UK cities (WHO MONICA) (section 2.6.1). Just
one study worldwide was found which used individual level data to analyse the
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decline in major CHD incidence (Nurse’s Health Study, US); that is, an analysis
directly comparable to those carried out in the thesis, but was limited to women and
excluded key factors such as lipid and blood pressure levels (section 2.7.1). There
appeared to be a lack of studies formally addressing the rise in T2DM, in the UK or
worldwide (sections 2.6.2 and 2.7.2). Thus the analyses in this thesis provide the
opportunity to gain new insights, and address current gaps in the knowledge of CHD
and T2DM time trends, to in turn help address the ongoing CHD and T2DM burdens
in the UK and elsewhere.
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Table 2.1 Studies assessing the contributions of risk factor and treatment trends to CHD trends in different countries
Study and
population Analysis Method
Time
period Outcome
Trend in
outcome
Portion of
trend
explained
by risk
factor
trends
Portion of
trend
explained
by
treatment
trends
Details of
individual
risk factors
contributing
to trend
Details of
individual
risk
factors
counter to
trend
Details of Individual
treatments
Portion of
trend un-
explained
*
WHO
MONICA -
>30
populations
from >20
countries
including
Belfast and
Glasgow14
Ecological analysis
with population as
unit of analysis;
regression of CHD
trend on
contributory factor
trend
mid
1980s
- mid
1990s
CHD
mortality
Varies by
population -
variations in
trends
between
populations
modelled
men 72%,
women
56%
Includes
revascularisation
surgery and
medications before
event and medications
during event
men 27%,
women
44%
(treatments
only
considered)
* IMPACT -Scotland12
Synthesis of
aggregate data
sources; comparing
observed CHD
trend with that
expected given
trends in likely
contributory factors
1975 -
1994
CHD
mortality
Decline; 6205
fewer deaths
than expected
in 1994
56% 35%
Smoking
36%,
Cholesterol
6%, BP 6%,
Deprivation
3%
Includes surgical and
medical treatments
during event, after
event, after
revascularisation, for
angina, for heart failure,
antihypertensives for
prevention
9%
*
IMPACT -
England and
Wales15
Synthesis of
aggregate data
sources; comparing
observed CHD
trend with that
expected given
trends in likely
contributory factors
1981 -
2000
CHD
mortality
Declines of
62% in men
and 45% in
women;
68,230 fewer
deaths than
expected in
2000
52% 38%
Smoking
44%,
Cholesterol
10%, BP
10%,
Deprivation
3%
Diabetes -
5%,
Physical
activity -
4%,
Obesity -
3%
Includes surgical and
medical treatments
during event, after
event, after
revascularisation, for
angina, for heart failure,
statins and
antihypertensives for
prevention
10%
Notes: *Study includes section of UK population; A = only abstract of paper seen; blank cells = no data
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Table 2.1 cntd Studies assessing the contributions of risk factor and treatment trends to CHD trends in different countries
Study and
population Analysis Method
Time
period Outcome
Trend in
outcome
Portion of
trend
explained
by risk
factor
trends
Portion of
trend
explained
by
treatment
trends
Details of
individual
risk factors
contributing
to trend
Details of
individual
risk factors
counter to
trend
Details of Individual
treatments
Portion of
trend un-
explained
IMPACT -
Ireland250
Synthesis of
aggregate data
sources; comparing
observed CHD
trend with that
expected given
trends in likely
contributory factors
1985 -
2000
CHD
mortality
Decline of
47%; 3,763
fewer deaths
than
expected in
2000
48% 44%
Smoking 26%,
Cholesterol
30%, BP 6%,
Physical
inactivity -
4%,
Diabetes -
6%, Obesity
-4%
Includes surgical and
medical treatments
during event, after
event, after
revascularisation, for
angina, for heart failure,
lipid-lowering and
antihypertensives for
prevention
8%
IMPACT -
Finland253
Synthesis of
aggregate data
sources; comparing
observed CHD
trend with that
expected given
trends in likely
contributory factors
1982 -
1997
CHD
mortality
Declines of
56% in men
and 64% in
women; 373
fewer deaths
than
expected in
1997
53% 23%
Smoking 9%,
Cholesterol
37%, BP 8%
Includes surgical and
medical treatments
during event, after
event, after
revascularisation, for
angina, for heart failure,
24%
IMPACT -
Sweden251
Synthesis of
aggregate data
sources; comparing
observed CHD
trend with that
expected given
trends in likely
contributory factors
1986 -
2002
CHD
mortality
Declines of
53% in men
and 52% in
women;
13,180
fewer deaths
than
expected in
2002
55% 36%
Smoking 9%,
Cholesterol
40%, SBP 7%,
Physical
inactivity 6%,
Diabetes -
5%, BMI -
2%
Includes surgical and
medical treatments
during event, after
event, after
revascularisation, for
angina, for heart failure,
lipid-lowering and
antihypertensives for
prevention
9%
Notes: *Study includes section of UK population; A = only abstract of paper seen; blank cells = no data
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Table 2.1 cntd Studies assessing the contributions of risk factor and treatment trends to CHD trends in different countries
Study and
population Analysis Method
Time
period Outcome
Trend in
outcome
Portion of
trend
explained
by risk
factor
trends
Portion of
trend
explained
by
treatment
trends
Details of
individual
risk factors
contributing
to trend
Details of
individual
risk factors
counter to
trend
Details of Individual
treatments
Portion of
trend un-
explained
IMPACT -
Iceland249
Synthesis of
aggregate data
sources; comparing
observed CHD
trend with that
expected given
trends in likely
contributory factors
1981 -
2006
CHD
mortality
Declines of
79% in men
and 82% in
women; 295
fewer deaths
than expected
in 2006
73% 25%
Smoking 22%,
Cholesterol
32%, SBP
22%, Physical
inactivity 5%,
Diabetes -
5%, BMI -
4%
Includes surgical and
medical treatments
during event, after
event, after
revascularisation, for
angina, for heart failure,
lipid-lowering and
antihypertensives for
prevention
2%
IMPACT -
Italy255
Synthesis of
aggregate data
sources; comparing
observed CHD
trend with that
expected given
trends in likely
contributory factors
1980 -
2000
CHD
mortality
42,930 fewer
deaths than
expected in
2000
55% 40%
Smoking 4%,
Cholesterol
23%, SBP
25%, Physical
inactivity 6%,
Diabetes -
2%, BMI -
1%
Includes surgical and
medical treatments
during event, after
event, after
revascularisation, for
angina, for heart failure,
statins and
antihypertensives for
prevention
5%
IMPACT -
Auckland,
New
Zealand265
Synthesis of
aggregate data
sources; comparing
observed CHD
trend with that
expected given
trends in likely
contributory factors
1982 -
1993
CHD
mortality
Decline of
24%; 558
fewer deaths
60% 35%
Smoking 30%,
Cholesterol
12%, DBP 7%
Includes surgical and
medical treatments
during event, after
event, after
revascularisation, for
angina, for heart failure,
antihypertensives for
prevention
5%
Notes: *Study includes section of UK population; A = only abstract of paper seen; blank cells = no data
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Table 2.1 cntd Studies assessing the contributions of risk factor and treatment trends to CHD trends in different countries
Study and
population Analysis Method
Time
period Outcome
Trend in
outcome
Portion of
trend
explained
by risk
factor
trends
Portion of
trend
explained
by
treatment
trends
Details of
individual
risk factors
contributing
to trend
Details of
individual
risk factors
counter to
trend
Details of Individual
treatments
Portion of
trend un-
explained
IMPACT -
USA252
Synthesis of
aggregate data
sources; comparing
observed CHD
trend with that
expected given
trends in likely
contributory factors
1980 -
2000
CHD
mortality
Declines of
50%;
337,658
fewer deaths
than
expected in
2000
44% 47%
Smoking
12%,
Cholesterol
24%, SBP
20%,
Physical
inactivity
5%,
Diabetes -
10%,
Obesity -8%
Includes surgical and
medical treatments
during event, after
event, after
revascularisation, for
angina, for heart failure,
statins and
antihypertensives for
prevention
9%
IMPACT -
Ontario,
Canada254
Synthesis of
aggregate data
sources; comparing
observed CHD
trend with that
expected given
trends in likely
contributory factors
1994 -
2005
CHD
mortality
Decline of
35%; 7585
fewer deaths
than
expected in
2005
48% 43%
Smoking
10%,
Cholesterol
23%, SBP
20%,
Physical
inactivity
4%,
Diabetes -
6%, BMI -
2%
Includes surgical and
medical treatments
during event, after
event, after
revascularisation, for
angina, for heart failure,
lipid-lowering and
antihypertensives for
prevention
9%
IMPACT -
Beijing,
China276
Synthesis of
aggregate data
sources; comparing
observed CHD
trend with that
expected given
trends in likely
contributory factors
1984 -
1999
CHD
mortality
RISE of
50% in men
and 27% in
women;
160 EXTRA
deaths
113% -40%
Smoking
1%,
Cholesterol
77%, BP
0%, BMI
4%, Diabetes
19%
Includes surgical and
medical treatments
during event, after
event, after
revascularisation, for
angina, for heart failure,
antihypertensives for
prevention
27%
Notes: *Study includes section of UK population; A = only abstract of paper seen; blank cells = no data
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Table 2.1 cntd Studies assessing the contributions of risk factor and treatment trends to CHD trends in different countries
Study and
population Analysis Method
Time
period Outcome
Trend in
outcome
Portion of
trend
explained
by risk
factor
trends
Portion of
trend
explained
by
treatment
trends
Details of
individual
risk factors
contributing
to trend
Details of
individual
risk factors
counter to
trend
Details of
Individual
treatments
Portion of
trend un-
explained
A US291
Synthesis of
aggregate data
sources; comparing
observed CHD
trend with that
expected given
trends in likely
contributory factors
1968 -
1976
CHD
mortality Decline >50% 40%
Smoking,
Cholesterol
Treatment in
coronary care
units, for angina
and medications
for hypertension
US263
Synthesis of
aggregate data
sources; comparing
observed CHD
trend with that
expected given
trends in likely
contributory factors
1980 -
1990
CHD
mortality
Decline of
34%;
127,000
fewer deaths
than
expected in
1990
50% 43%
Smoking
6%, LDL
cholesterol
24%, HDL
cholesterol
10%, DBP
14%
Treatment during
event, for angina 7%
Minnesota
Heart
Survey,
Minnesota,
US292
Synthesis of
aggregate data
sources; comparing
observed CHD
trend with that
expected given
trends in likely
contributory factors
1970 -
1984
CHD
mortality
Decline; 212
fewer deaths
than
expected in
1984
6% CABG
94% (only
CABG
considered)
Notes: *Study includes section of UK population; A = only abstract of paper seen; blank cells = no data
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Table 2.1 cntd Studies assessing the contributions of risk factor and treatment trends to CHD trends in different countries
Study and
population Analysis Method
Time
period Outcome
Trend in
outcome
Portion of
trend
explained
by risk
factor
trends
Portion of
trend
explained
by
treatment
trends
Details of
individual
risk factors
contributing
to trend
Details of
individual
risk factors
counter to
trend
Details of
Individual
treatments
Portion of
trend un-
explained
California,
US293
Synthesis of
aggregate data
sources; comparing
observed CHD
trend with that
expected given
trends in likely
contributory factors
1989 -
1997
CHD
mortality
Decline;
33,300 fewer
deaths between
1989 and 1997
than expected
Tobacco
control
program in
1989-1992
WHO
MONICA
North
Karelia and
Kuopio
regions,
Finland279
Synthesis of
aggregate data
sources; comparing
observed CHD
trend with that
expected given
trends in likely
contributory factors
1972 -
1992
CHD
mortality
Decline of 55%
in men and
68% in women
men 80%,
women
72%
Men: smoking
18%,
cholesterol
47%, DBP
27%, Women:
cholesterol
51%, DBP
46%,
Women:
smoking -
16%
men 20%,
women
28%
The
Netherlands
264
Synthesis of
aggregate data
sources; comparing
observed CHD
trend with that
expected given
trends in likely
contributory factors
1978 -
1985
CHD
mortality 23% 67%
Smoking 23%,
Cholesterol
0.4%
Treatment in
coronary care
units, including
revascularisation
and medications;
hypertension
treatment for
prevention
10%
Notes: *Study includes section of UK population; A = only abstract of paper seen; blank cells = no data
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Table 2.1 cntd Studies assessing the contributions of risk factor and treatment trends to CHD trends in different countries
Study and
population Analysis Method
Time
period Outcome
Trend in
outcome
Portion of
trend
explained
by risk
factor
trends
Portion of
trend
explained
by
treatment
trends
Details of
individual risk
factors
contributing to
trend
Details of
individual
risk factors
counter to
trend
Details of
Individual
treatments
Portion of
trend un-
explained
9 Health
Districts,
Italy294
Synthesis of
aggregate data
sources; comparing
observed CHD
trend with that
expected given
trends in likely
contributory factors
1984 -
1987
CHD
mortality
Decline; 10%
in men, 30-59
yrs, 7% in
men, 40-69
yrs, 8% in
women, 30-59
yrs, 10% in
women, 40-69
yrs,
men>50%,
women
>100%
Smoking,
Cholesterol, BP BMI
Auckland,
New
Zealand295
Synthesis of
aggregate data
sources; comparing
observed CHD
trend with that
expected given
trends in likely
contributory factors
1974 -
1981
CHD
mortality
Decline; 126
fewer deaths
than expected
in 1981
40%
Resuscitation
before admit.
hosp 16%,
Coronary Care
Units 5%, Beta
blockers during
event 2%,
Surgery 5%,
antihypertensives
12%
60% (only
treatments
considered)
New
Zealand296
Synthesis of
aggregate data
sources; comparing
observed CHD
trend with that
expected given
trends in likely
contributory factors
1980 -
2004
CHD
mortality Decline
men 73%,
women 87%
Men: Smoking
28%, Cholesterol
26%, SBP 40%,
Women:
Smoking 20%,
Cholesterol 52%,
SBP 47%,
men 23%,
women 13%
Notes: *Study includes section of UK population; A = only abstract of paper seen; blank cells = no data
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Table 2.1 cntd Studies assessing the contributions of risk factor and treatment trends to CHD trends in different countries
Study and
population Analysis Method
Time
period Outcome
Trend in
outcome
Portion of
trend
explained
by risk
factor
trends
Portion of
trend
explained
by
treatment
trends
Details of individual
risk factors
contributing to trend
Details of
individual
risk factors
counter to
trend
Details of
Individual
treatments
Portion of
trend un-
explained
Australia266
Synthesis of
aggregate data
sources;
comparing
observed CHD
trend with that
expected given
trends in likely
contributory
factors
1980 -
1991
CHD
mortality
Decline;
average annual
percentage
changes
ranging from -
3.7 and -10.7,
depending on
age and gender
men
~50%,
women
~25%
Men: Smoking ~8-
31%, Cholesterol ~-4-
9%, BP ~11-31%,
Women: Smoking ~1-
13%, Cholesterol ~1-
35%, BP ~8-29%
men
~50%,
women
~75%
A Australia297
Synthesis of
aggregate data
sources;
comparing
observed CHD
trend with that
expected given
trends in likely
contributory
factors
1968 -
2000
CHD
mortality
Decline of
83%
men 74%,
women
81%
Men: Smoking 16%
(mainly in 1980s),
Cholesterol 22%
(mainly in 1970s),
DBP 36% (whole
period), Women:
Smoking 5% (mainly
in 1980s), Cholesterol
20% (mainly in
1970s), DBP 56%
(whole period)
men 26%,
women
19%
Notes: *Study includes section of UK population; A = only abstract of paper seen; blank cells = no data
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Table 2.1 cntd Studies assessing the contributions of risk factor and treatment trends to CHD trends in different countries
Study and
population
Analysis
Method
Time
period Outcome
Trend in
outcome
Portion
of trend
explained
by risk
factor
trends
Portion
of trend
explained
by
treatment
trends
Details of
individual risk
factors
contributing to
trend
Details of
individual
risk factors
counter to
trend
Details of
Individual
treatments
Portion of trend
un-explained
*
WHO
MONICA -
>30
populations
from >20
countries
including
Belfast and
Glasgow13, 14
Ecological
analysis with
population as
unit of analysis;
regression of
CHD trend on
contributory
factor trend
mid
1980s -
mid
1990s
Major
CHD
incidence
Varies by
population -
variations in
trends
between
populations
modelled
men 38%,
women
18%
men 52%,
women
30%
Men: Smoking
20%,
Cholesterol
19%, SBP 6%
(BMI 36%),
Women:
Smoking 0%,
SBP 11%,
Cholesterol 0%
(BMI 2%)
Includes
revascularisation
surgery and
medications
before event
(and
medications
during event)
? (NOTE
Portions
explained by risk
factors and
treatments
estimated in two
separate studies
so not
independent)
Hunter Region
MONICA
cohort, New
South Wales,
Australia298
Synthesis of
aggregate data
sources;
comparing
observed CHD
trend with that
expected given
trends in likely
contributory
factors
1985 -
1993
Major
CHD
incidence
Declines;
average
annual
decline of
3.3% in men
and 4.3% in
women
men 95%,
women
80%
men 5%,
women
0%
Men: Smoking
39%,
Cholesterol
27%, DBP 30%,
Women:
Smoking 18%,
Cholesterol
32%, DBP 29%
Men Daily
aspirin 5%
Women Daily
aspirin 0%
men 0%, women
20%
Nurses' Health
Study, US17
Individual level
data; percentage
attenuation of
relative risk
1980 -
1994
Major
CHD
incidence
Decline of
31% 68%
Smoking 42%,
Diet 52%, Post-
menopausal
hormone use
29%
BMI -12% 32%
Notes: *Study includes section of UK population; A = only abstract of paper seen; blank cells = no data
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Table 2.1 cntd Studies assessing the contributions of risk factor and treatment trends to CHD trends in different countries
Study and
population
Analysis
Method
Time
period Outcome
Trend in
outcome
Portion of
trend
explained
by risk
factor
trends
Portion of
trend
explained
by
treatment
trends
Details of
individual
risk factors
contributing
to trend
Details of
individual
risk
factors
counter
to trend
Details of
Individual
treatments
Portion of
trend un-
explained
*
WHO
MONICA -
>30
populations
from >20
countries
including
Belfast and
Glasgow14
Ecological
analysis with
population as
unit of
analysis;
regression of
CHD trend on
contributory
factor trend
mid
1980s -
mid
1990s
Major
CHD 28-
day case
fatality
Varies by
population -
variations in
trends between
populations
modelled
men 61%,
women
41%
Includes
revascularisation
surgery and
medications before
event and
medications during
event
men 39%,
women
59%
(treatments
only
considered)
Perth
MONICA
cohort,
Australia16
Individual
level data;
percentage
attenuation of
relative risk
1984 -
2005
12-year
major CHD
case
fatality,
given
survival to
28-days or
1 year
Declines of
40% and 28%
given survival
to 28-days and
1 year
respectively
~100%
Thrombolysis, anti-
platelets, beta-
blockers, ACE
inhibitors, lipid
lowering drugs in
hospital during event
or on discharge,
Revascularisation
within 12 months of
event
Notes: *Study includes section of UK population; A = only abstract of paper seen; blank cells = no data
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Table 2.1 cntd Studies assessing the contributions of risk factor and treatment trends to CHD trends in different countries
Study and
population
Analysis
Method
Time
period Outcome
Trend in
outcome
Portion of
trend
explained
by risk
factor
trends
Portion of
trend
explained
by
treatment
trends
Details of
individual
risk factors
contributing
to trend
Details of
individual
risk factors
counter to
trend
Details of
Individual
treatments
Portion of
trend un-
explained
Hunter
Region
MONICA
cohort, New
South Wales,
Australia298
Synthesis of
aggregate data
sources;
comparing
observed CHD
trend with that
expected given
trends in likely
contributory
factors
1985 -
1993
Major
CHD 28-
day case
fatality in
hospital
Declines;
average annual
decline of
8.9% in men
and 6.9% in
women
men 36%,
women
41%
Men: Aspirin
23% Fibrinolytic
therapy 8% Beta
blockers 3%
ACE inhibitors
3%, Women:
Aspirin 25%
Fibrinolytic
therapy 6% Beta
blockers 3%
ACE inhibitors
4%
men 64%,
women 59%
(treatments
only
considered)
Twin Cities,
Minnesota,
US18
i) Synthesis of
aggregate data
ii) individual
level analysis
1985 -
1990
Major
CHD 28-
day case
fatality
Decline of
26% in men
and 16% in
women
i) synthesis
method:
20% ii)
individual
analysis:
30%
Thrombolytic
therapy during
hospital stay
80%
(thrombolytic
therapy alone
considered)
Notes: *Study includes section of UK population; A = only abstract of paper seen; blank cells = no data
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Chapter 3 Methodology
3.1 Introduction
The chief method employed to address the thesis aims is statistical analysis of pre-
collected data, which come from a combination of different sources. Since the
purpose of this thesis is to address trends in the UK, the data sources are all UK-
based, representative of different sectors of the British population. The principal data
source used is the British Regional Heart Study (BRHS)34, 35, a prospective cohort
study comprising a national sample of British men, who were middle aged when
recruited. A second data source used is The Health Improvement Network (THIN)
database36, comprising national routinely collected data on General Practice
consultations. In addition, certain analyses have been carried out on another
prospective study; the London-based Whitehall II cohort37 of male and female civil
servants. The data sources each have different strengths and thus complement one
another, enabling a fuller picture of trends to be obtained than would be possible from
each dataset in isolation. The data sources are each utilised according to their
respective strengths. Repeating the same analyses in different datasets allows
validation of the results and also enables assessment of the extent to which the same
results apply to different sectors of the population. Sections 3.2, 3.3 and 3.4 introduce
each of the different data sources in turn. The type of data source is described, along
with descriptions of the constituent study participants, the follow-up of the
participants, and assessment of disease outcomes and explanatory factors. Their
suitability for use to address different questions, in relation to their particular
strengths, is discussed. Note that the collection of data for each source, detailed in
sections 3.2.1, 3.2.2, 3.2.4, 3.2.5, 3.3.1, 3.3.2, 3.4.1, 3.4.2, 3.4.4, and 3.4.5, was not
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carried out by myself, the thesis author, but necessarily described here for information
and clarification. The remaining sections detail how the data has been managed and
organised for analyses specific to the thesis, and this data management has been
carried out by me, including sub-studies to explore validity of the data. The statistical
methods used to analyse the datasets are detailed in each of the subsequent results
chapters.
3.2 The British Regional Heart Study
3.2.1 Description of data source
The BRHS is a prospective study of cardiovascular disease in a socially and
geographically representative cohort of middle-aged men in Britain, established in
197834, 35. Two towns were selected from each of 12 metropolitan regions in Britain,
to result in 24 towns in all for study. The choice of towns depended on the town
having a medium sized population (50-100 000) in 1971 and the town being
representative of the region in terms of cardiovascular mortality rates, water quality,
and socio-economic status (according to the Webber classification299). High mobility
towns (new towns and large conurbations) were excluded. The 24 towns selected are
shown in the map of Britain in figure 3.1. Within each of the 24 towns, a General
Practice was selected. Criteria for selecting a practice included its size (practice
population over 7500 and two or more partners), its representativeness of
socioeconomic composition and characteristics of the town population and
willingness to participate. 400 men, aged from 40 and up to 60 years, were then
selected at random, stratified by four 5-year age groups (40-44, 45-49, 50-54 and 55-
59 years), from age-sex registers within each practice, over a recruitment period from
1978 to 1980. Basing the recruitment and selection of study participants within
108
General Practices facilitated the administration and organisation of the study, at a time
when age-sex registers were uncommon (1977), but General Practice lists covered
>95% of the population. The men were invited to attend a local initial health
screening, usually at the Practice premises. A small number of men (<10) in each
town were excluded from the invitation list by the General Practice due to poor
physical or mental health, that prevented the men from attending the screening. The
response rate for those men invited was 78%, resulting in a total of 7735 men
recruited for study (corresponding to approximately 300 from each town).
3.2.2 Description of follow-up
The men have been followed up since baseline (recruitment in 1978-80) until the
present for all-cause mortality through the NHS central registers. In addition, at
regular biennial intervals a standard form (available on the study website at
www.ucl.ac.uk/pcph/research-groups-themes/brhs-pub) has been sent to the General
Practices, to request confirmation of each man's continuing registration, current
address, and any new cardiovascular events and (from 1990 onwards) new diagnoses
of cancer or diabetes that have occurred within the last two years. A man who
removes from the General Practice and re-registers elsewhere is traced to the new
General Practice. The study now includes over 1100 General Practices nationwide, in
addition to the 24 original practices. Follow-up has been maintained for 98% of
surviving men throughout. Follow-up data up to 2007 were available for use during
this thesis. However certain analyses, carried out first, were completed before the
latest follow-up data were available and are therefore based on earlier data.
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At the initial health screening at baseline, a series of anthropometric and physiological
measurements were made, including height, weight, blood pressure,
electrocardiogram (ECG), and lung function. In addition, blood samples were taken
and the men completed a nurse-administered health and lifestyle questionnaire. A
second examination took place at 20-years follow-up in 1998-2000. The same
measurements were made as at baseline, with the addition of measurements of bio-
impedance, waist and hip circumference, triceps and sub-scapular skin-folds. Blood
sample were again taken and the men self-completed a questionnaire. The men have
also completed regular postal questionnaires on health and lifestyle over the course of
the follow-up to date; in 1983-1985 (at 5 years follow-up), in 1992 (12 to 14 years
follow-up), in 1996 (16 to 18 years follow-up), in 2003 (23 to 25 years follow-up),
and in 2005 (25 to 27 years follow-up), at the time of writing. Copies of the
datasheets showing measurements taken at the physical examinations and the
questionnaires are available on the study website. Response rates for each
questionnaire are presented in table 3.1. Postal questionnaire response rates were high,
ranging from 98% at 5 years follow-up to 79% in 2005. 77% attended the 20-year
physical examination. A timeline of the study, showing when relevant data used in the
thesis has been collected for participating men over the course of the follow-up, is
shown in figure 3.2.
3.2.3 Intended use of data source
The intention is to use to the data source to estimate trends in incidence of major
coronary heart disease (CHD) and type 2 diabetes mellitus (T2DM), and to explore
the contribution of concurrent trends in major risk factors and medication use to the
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trends (thesis objectives iii and iv). The data source will also be used to assess the
contribution of trends in T2DM to the trend in major CHD (objective v).
3.2.4 Assessment of disease cases
The disease endpoints chiefly considered in this thesis are major CHD events and new
diagnoses of T2DM. A major CHD event was defined as a fatal or non-fatal
myocardial infarction (MI). Diagnosis of fatal MI in the BRHS was based on deaths
with CHD as the underlying cause, including sudden death of presumed cardiac origin
(international classification of diseases, ninth revision (ICD-9)300, codes 410-414),
ascertained from the NHS central registers. Definite non-fatal MI was ascertained
from the regular review of General Practice records. All new major CHD events
reported by the practices were followed-up with an enquiry form to the General
Practice or hospital consultant to obtain confirmatory evidence that case criteria have
been met. Specifically, the following criteria need to be satisfied (WHO MONICA
study criteria241): chest pain symptoms suggestive of MI, supported by either ECG
changes or specific levels of cardiac enzymes, or both. New diagnoses of diabetes
(with date) were identified from regular reviews of General Practice records from
1990. Further new diabetes diagnoses occurring between 1983-5 and 1990 were
identified from retrospective self-report of a diagnosis of T2DM, with diagnosis date,
in the questionnaire in 1992, confirmed by separate subsequent review of the man’s
General Practice records. Therefore, incident T2DM data with validated diagnosis
dates were available from the time of the 1983-1985 questionnaire onwards (figure
3.2). Any new diagnosis of diabetes was taken to be a diagnosis of T2DM rather
than type 1 as men were aged 45 and over at the start of follow-up for diabetes in
1983-1985.
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3.2.5 Repeated assessment of coronary and diabetic risk factors
Cigarette smoking, weekly alcohol intake and physical activity levels were
ascertained in each of the interview-administered questionnaires and postal
questionnaires using comparable questions each time (figure 3.2). This provided
repeated information over the follow-up on these different coronary risk factors. The
one exception was that physical activity was not included in the questionnaire at 5
years follow-up (1983-5) and the questions on physical activity varied over time,
partially to reflect the changing lifestyles over time as the men entered retirement.
From the information given, men were categorised at each questionnaire time-point as
“current”, “ex” or “never” smokers. Information in previous questionnaires was used
to inform the smoking status in the later questionnaires – for example, if a man
reported being a cigarette smoker in an earlier questionnaire, and then reported being
a non-smoker in a later questionnaire, his smoking status in the later questionnaire
would be defined as “ex smoker”. The men’s alcohol consumption was categorised
as: “never”, “occasionally”, “light”, “moderate” and “heavy”, as outlined
previously301. Answers to questions relating to recreational activities, regular walking
and cycling and sporting activity were combined to give each man a physical activity
score. Men were grouped into six categories based on their score: “inactive”,
“occasional”, “light”, “moderate”, “moderately vigorous” and “vigorous”. This score
has been previously detailed and validated302, by demonstrating the score to be
strongly related to subsequent cardiovascular risk.
Seated systolic blood pressure (SBP) and diastolic blood pressure (DBP) were
measured at the physical examinations at baseline and after 20 years of follow-up
(figure 3.2). Blood pressure was measured at baseline using The London School of
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Hygiene and Tropical Medicine (LSTHM) sphygmomanometer and at 20 years using
the Dinamap 1846SX vital signs monitor (Critikon Inc, Tampa, FL, USA). On both
occasions the mean of two successive readings, adjusted for observer variation, was
used.
Blood samples taken at the two examinations (non-fasting at baseline, fasting at 20
years) were analysed for serum total cholesterol by a modified Liebermann–Burchard
method on a Technicon SMA 12/60 analyser (Technicon Instruments, Tarrytown, NY,
USA) at baseline and with a Hitachi 747 automated analyser (Roche Diagnostics,
Indianapolis, IND, USA) at 20 years. High density lipoprotein (HDL) cholesterol was
measured by the Liebermann–Burchard method or enzymic procedures after
precipitation with magnesium phosphotungstate. Low density lipoprotein (LDL)
cholesterol was not directly measured. Instead, non-HDL cholesterol was computed
as the difference between the total and HDL cholesterol levels, thus mainly
representing LDL cholesterol. Use of non-HDL cholesterol avoids the biases that
may arise when estimating LDL cholesterol values by the Friedewald formula303. In
meta-analyses, the hazard ratio for major CHD incidence per standard deviation
increase in non-HDL has been shown to be comparable to that for directly measured
LDL cholesterol102, supporting use of non-HDL. At baseline and 20 years, body mass
index (BMI) was calculated directly from height and weight measurements taken at
the physical examinations as weight divided by height2. At both time-points, height
(without shoes) was measured to the nearest millimetre using a Harpenden
Stadiometer (Critikon Service Centre, Berkshire, United Kingdom). Weight (in light
clothing and without shoes) was measured to the nearest 0.1kg using an MPS110 field
survey scale (Critikon Service Centre) at baseline304 and using a Soehnle digital
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electronic scale (Critikon Service Centre) at 20 years305. At the times of the other
questionnaires, height was estimated by linear interpolation between the baseline and
20 years measurements, and weight was obtained via self-report in the postal
questionnaires.
In the questionnaires at each time point, each man was asked about his medication
use. In particular, it was possible to identify use of lipid-lowering medications or
blood pressure-lowering medications at each time-point. The questions varied slightly
according to the questionnaire. Some or all of the following items were ascertained:
whether he was regularly receiving lipid-regulating or blood pressure lowering drugs
from a doctor, whether he had used lipid lowering drugs or blood-pressure lowering
drugs in the last 24 hours, and to list all the medications he currently used with
reasons.
3.2.6 Sub-study 1: Investigating comparability between the risk factor
ascertainment methods used at each time point
To ensure as far as possible fair and unbiased estimates of time trends in the risk
factors, which is of particular importance in the analyses for this thesis, the techniques
used to ascertain the risk factor levels at each time point need to be consistent, or if
not, potential differences between the risk factor ascertainment techniques need to be
identified and accounted for. In this section the comparability of the repeated
measurements of each of the risk factors in turn is explored.
As outlined above, the risk factors cigarette smoking and alcohol use were ascertained
via questionnaire only and using broadly consistent questions each time. Moreover
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information in previous questionnaires was used to inform and validate the smoking
status in the later questionnaires. Thus the ascertainment methods for cigarette
smoking and alcohol use are arguably suitably consistent over time.
Physical activity was also measured solely via questionnaire. However in the case of
this risk factor, the questions on physical activity differed between questionnaires, as
outlined above, which may limit comparability between different time-points. Results
related to physical activity trends in the BRHS are thus interpreted with caution
throughout.
A previous study has investigated the consistency between the different blood
pressure measuring equipment (LSHTM sphygmomanometer at baseline versus
Dinamap 1846 at 20 years follow-up)306. This study found significant systematic
overestimation by the Dinamap 1846 of 8mmHg for SBP, but no significant
difference between the two apparatus for DBP. In light of these findings, in all
analyses the 20 year SBP measurements have been adjusted by 8mmHg downwards to
be consistent with the baseline measurements (as in all analyses of BRHS data).
Data were available to investigate the comparability between the different assay
techniques used at baseline and the 20-year examination for total and HDL cholesterol
as a small number of residual baseline samples for total and HDL cholesterol levels
had been re-measured using the assay techniques applied at the 20 year examination.
Using a paired t-test, in 47 subjects, the mean within-person difference in total
cholesterol (re-measured minus baseline) was 0.072 (standard deviation (s.d.) 0.718)
mmol/L, p=0.5. The mean within-person difference in HDL cholesterol (re-measured
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minus baseline) was 0.067 (s.d. 0.552) mmol/L, p=0.4. Since the differences were not
significantly different from zero, and were based on samples stored for almost 20
years, these differences have not been taken into account in the main analyses.
However because comparability between the baseline and 20 year measurements is
particularly important in the analyses in this thesis additional sensitivity analyses have
been conducted using baseline measurements adjusted for the small mean differences
observed.
Height and weight were measured by comparable methods at the physical
examinations at baseline and 20 years. The repeated measurement of height at 20
years enabled validation of the baseline measurements, as well as allowing for
possible height loss with increasing age. A possible source of inconsistency however
between the different BMI measurements is the use of self-reported weight at the
times when a postal questionnaire only was administered, compared with weight
measured by research nurses at the baseline and 20-year examinations. It has been
shown that study subjects, when self-reporting, tend to underestimate their weight307-
310. A comparison between the measured and self-reported weights was made
possible as at the 20-year examination as men self-reported their weight before having
their weight measured. In all, 3837 (70%) of 5516 men alive at 20 years follow-up,
had both self-reported and measured weight at this time-point. A paired t-test
revealed a difference in means of 0.643 (s.d. 3.02) kg; p<0.001, (the self-reported
weight was a mean of 0.643kg lower than the measured value). This figure agrees
closely with previous estimates of differences between self-report and measured
weight in British male populations307-310, lending support to the finding. The self-
reported weights at the other time points were therefore corrected by the mean
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difference between the two weights to improve consistency between the different
corresponding BMI measurements.
3.2.7 Sub-study 2: Deriving physical activity at 5 years follow-up
Physical activity was not ascertained in the questionnaire at 5 years follow-up. In
order to make best use of the data in multivariable analyses involving physical
activity, imputation or “filling in” of the missing physical activity data was
considered. Without physical activity at 5 years follow-up, all risk factor data would
have to be excluded from any multivariable analyses involving physical activity,
leading to considerable loss of information in this complete case analysis. The
physical activity category at 5 years of follow-up was computed as the median of the
category at baseline and the category at the next questionnaire time-point in 1992,
rounded to the nearest integer, with the categories ordered from “inactive” up to
“vigorous.” The effect of imputing this physical activity data is explored when
discussing findings related to this risk factor.
3.2.8 Description of study population
As outlined in section 3.2.1, the BRHS cohort comprised at baseline 7735 men, aged
40 to 60 years, with even numbers of men in each 5-year age-band. The recruitment
methods were designed such that the sample of men would be socially and
demographically representative of the town in which they lived at baseline and, in
turn, given the choice of towns, broadly representative of Britain as a whole. Indeed
the distribution of socio-economic status in the BRHS men reflects closely the
distribution in the general UK population in the 1981 census, the census closest to the
1978-80 baseline recruitment period311. The study sample included men who had
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previous CHD or T2DM diagnoses. Men with these prevalent conditions at baseline
are included or excluded from the analyses as appropriate for each chapter (exclusions
detailed in the relevant results chapter). The majority of men are white; fewer than
1% of men are of other ethnicities. Characteristics of the men at baseline in 1978-
1980 (including socio-demographic characteristics, coronary and diabetic risk factor
levels, and prevalent CHD or T2DM) are presented in table 3.2. At baseline, 30% of
men were from the South of England, as opposed to Northern England (43%),
Midlands and Wales (16%) and Scotland (12%). The most common socio-economic
position (as defined by longest-held occupation at baseline, based upon the Registrar
General’s Social Class Classification) was III skilled manual (43%, e.g. bricklayers),
followed by II intermediate (23%, e.g. teachers and sales managers). 41% of men
were current cigarette smokers, while 11% of men were heavy drinkers and 9% were
physically inactive. One-quarter of men had a history of CHD (including angina
and/or MI), and around half of these men had had a MI (determined from a
combination of ECG evidence and self-report of recall of doctor diagnosis).
Prevalence of (known doctor-diagnosed) diabetes (type 1 or type 2) was 1.3%. A
small proportion (5%) of men reported use of blood pressure lowering medication.
Mean BMI was 25.5kg/m2 and 54% of men were overweight or obese (BMI over
25kg/m2). Mean SBP was 145.2mmHg and mean DBP was 82.2mmHg. Mean total
cholesterol was 6.3mmol/L, mean HDL cholesterol was 1.15mmol/L and mean non-
HDL cholesterol was 5.15mmol/L.
3.2.9 Strengths in relation to intended analyses
A key strength of this data source is the availability of a continuous follow-up over an
extended period for the principal disease endpoints, major CHD and T2DM, alongside
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concurrent repeated measurements of the major coronary and diabetic risk factors.
This makes the BRHS particularly suitable for modelling the role of trends in the
major risk factors in the trends in incidence of major CHD and T2DM. There is a
paucity of similarly suitable data sources (see chapter 2, sections 2.6.1.3 and 2.6.2),
emphasizing the value and uniqueness of the analysis. As outlined above, the risk
factor data has generally either been consistently collected or validation of different
ascertainment techniques has been possible, limiting bias in the estimates of the time
trends in the risk factors and their roles in the trends in major CHD and T2DM. The
social and geographical representativeness of the cohort is a further strength,
supporting generalisability of the findings to the wider British male older population.
Nevertheless this data source has certain limitations in relation to addressing the
objectives of the thesis. First, the data source comprises men only. In order to obtain
a more complete picture of trends in the UK it would be useful to be able to also
examine trends in women. Second, while calculations have shown that the study has
adequate power to detect differences in risk factor levels and cardiovascular risk
within 5-year periods of follow-up34, the cohort is too small for precise estimation of
time trends in major CHD and T2DM incidence rates within different socio-
demographic groups, or to estimate annual major CHD and T2DM incidence rates (as
opposed to rates over several years combined). Also the number of men in the cohort
with T2DM, forming the denominators for estimation of time trends in survival from
major CHD among patients with T2DM (towards objective v), is too few for adequate
power. Thus in order to address the thesis aims as fully as possible two additional
data sources have been employed, each comprising suitable population samples in
which to carry out those analyses which are less feasible using the BRHS data.
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3.3 The Health Improvement Network Database
3.3.1 Description of data source
The THIN database36 is a UK-wide primary care database comprising computerised
anonymised longitudinal patient records retrieved from participating general practices
across the UK. Eligible general practices are those using the Vision (In Practice
Systems, InPS) computer patient record-keeping system for recording patient notes,
including medical diagnoses and symptoms (using the hierarchical Read coding
system312) and prescriptions, test results, immunisations and other health information.
The database is dynamic, in the sense that data is continuously collected and updated,
and patients may join and leave the database at different times. Upon joining THIN
an initial Full Data Collection (FDC) from the General Practice, which includes all
retrospective data, is sent to EPIC, the database providers. Following this, Incremental
Data Collections (IDCs) are made each month by automaton, electronically
downloaded from the General Practice. This method of data collection ensures
minimal disruption to daily practice activities. THIN data collection first began in
November 2002, however the initial FDCs include considerable retrospective data (as
far back as the time when records were first computerised in the practice). That said,
data prior to the early 1990s (particularly mortality data) is less complete and so data
before 1994 has not been used in this thesis. Patient data up to July 2009 were
available in the latest update of the database before the end of the period of research
for the thesis. This update comprises data from 446 General Practices, including 8.2
million patients, contributing a combined total of approximately 51 million patient
years of data. Note that not all practices are present and contribute data in THIN
throughout. Indeed many practices only began use of computerised record systems in
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more recent years and a small number have left THIN after having contributed in
earlier years (see table 3.3). Patients may opt out. However exclusions by patient
choice or otherwise are rare.
3.3.2 Description of follow-up
The data are anonymised at the source general practice, before leaving the practice
computer system. However (encrypted) computer generated identifiers are available
for each patient and each General Practice, enabling different General Practice visits
for the same patient to be linked together such that patients can be followed-up over
time. Each patient may be followed from the latest of the following dates: (i) the date
that the patient registered at a contributing General Practice (ii) the date by which the
practice was fully using their computer system for recording of diagnoses and
prescriptions (termed Acceptable Computer Usage, or ACU), and (iii) the date by
which computerised recording of patient death for the practice had reached an
acceptable level. The need for a date of Acceptable Computer Usage stems from
awareness that when a practice first starts using computerised records in place of
traditional paper records, it takes time for the computer system to be fully adopted by
the practice (for example they may start by recording only certain events or
appointments for each patient). Using data from this initial period, the records would
be likely incomplete leading to biased and incorrect inferences. For each practice, we
have identified the time point at which the practice is first fully using their computer
system based on empirical evaluation of the quantity of each type of record. For a
practice to have acceptable computer usage they would need to have an average of at
least one medical record, two prescriptions and one additional health data (for
example a blood pressure measurement) recorded per patient per year313. The date at
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which recording of deaths in the practice was deemed to have reached an acceptable
level was the start date of the period when the observed number of deaths in the
practice was consistently within 30% of the expected number of deaths for that time
period, given the age-gender distribution of the practice (using the “acceptable
mortality rate date” or “AMR date” as defined by the database providers314).
3.3.3 Intended use of data source
The intention was to use the data source to estimate time trends in incidence of major
CHD and T2DM within different demographic groups (objectives i and ii), and to
explore the relationship between the time trends in T2DM and in major CHD
(objective v).
3.3.4 Identification of cases of major CHD or T2DM
A patient was identified as having had a major CHD event if the general practitioner
(GP) had recorded a Read code in the patient’s records relating to major CHD. All
Read codes that referred to major CHD were identified as follows: An initial list of
all CHD events was obtained using a previously published list of Read codes for all
CHD in The Key Health Statistics (KHS) from General Practice315. Then the list was
narrowed down to those codes referring to major CHD only (specifically acute MI or
to an ECG result corresponding to an MI), with the aid of my Clinical Supervisor. The
Read code dictionary was scanned to identify any extra relevant codes not captured in
the KHS, for example codes added to the Read code dictionary subsequent to
publication of the list. Finally the list was compared with that in the Quality and
Outcomes Framework (QOF) rules for CHD management316 (which describes how
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General Practices will be assessed on CHD management and lists all the Read codes
used to identify CHD patients).
Patients were identified as having T2DM if they had at least one diagnosis in the
medical records with a Read code indicating T2DM or if they had Read codes for
non-specific diabetes and were aged 30 years or over on the date of the first diabetes
diagnosis, and had no codes at any time to indicate T1DM. The inclusion of non-
specific diabetes codes was because many patients did not have a code specifically
indicating T1DM or T2DM. Indeed 20% of the patients included as having T2DM in
the analyses had only non-specific codes. Because of the stipulation of being aged
over 30 years on the first diagnosis date, the majority of patients with these non-
specific codes should have T2DM, and although we cannot rule out the possibility
that some patients will have late onset T1DM (particularly the youngest patients), the
number of misclassified patients is likely to be very small. A list of relevant Read
codes pertaining to diabetes was obtained from scratch using established methods317
by first selecting those Read codes from the chapter C10 (Diabetes mellitus) and
including additionally any other Read codes from other chapters whose descriptions
included words starting with “diab” or including acronyms such as “NIDDM” (non-
insulin dependent diabetes mellitus) or “DKA” (diabetic keto-acidosis) or the word
“insulin”. All codes identified were checked manually that they did in fact refer to the
patient having diabetes, and the resulting code list was checked by a clinician.
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3.3.5 Ascertainment of socio-demographic characteristics
Demographic characteristics available were age (from year of birth information),
gender, and constituent UK country of residence. In addition, the deprivation of the
local area in which the patient resides has been obtained by means of anonymised
linkage of the patient’s postcode. The local area is defined to be an enumeration
district, covering a population of approximately 150 households. Deprivation of the
local area is assessed by computing the Townsend score318 of multiple deprivation for
the local area, using 2001 census data. The Townsend score combines the following
criteria: the percentage of households without access to a car; the percentage of
households not in owner occupied accommodation; the percentage of households in
overcrowded accommodation; the percentage of the economically active population
aged 16-74 who are unemployed. To maintain anonymity, the exact scores are not
available; instead each patient is assigned to a quintile of area deprivation based on
the quintiles of Townsend score for the UK population as a whole. When a patient
moves home, their score is updated in the database to reflect the new area of
residence.
3.3.6 Description of study population
The THIN database comprises General Practices from across the UK, including
Northern Ireland. The number of practices and patients belonging to THIN is
transient and varies each year. Table 3.3 presents the number of General Practices
and patients contributing to THIN and the proportion of the UK population included
in THIN in the latest update (to 2009) by calendar year. The number of General
Practices and patients contributing to THIN increased year on year from 1988 to
2009, with the exception of the most recent year 2009, likely due to delays in
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collecting 2009 data from some practices. The coverage of the UK population also
increased steadily with calendar year, to over 6% in the most recent five years. The
distributions of basic demographic characteristics of patients in THIN, according to
calendar year from 1994, are shown in table 3.4 (data before 1994 is limited). The
mean age of patients contributing data to THIN in each calendar year remained
approximately constant, rising only very gently from 40 to 41 years over the period.
The proportion of patients who were male also remained constant at slightly under
half. While the proportions of patients within each fifth of Townsend score of
deprivation of area of residence remained largely fixed, the proportions of patients
resident in each country of the UK did change. Specifically, with increased calendar
year the proportion of patients from Northern Ireland, Scotland and Wales generally
rose, from a combined proportion of 11% in 1994 to 16% in 2009. According to
population data from the Office for National Statistics, in 2009 49% of the UK
population was male, a proportion corresponding closely to that for patients in THIN.
The same data source gives the proportions of the UK population residing in England,
Wales, Scotland and Northern Ireland in 2009 as 83.8%, 4.9%, 8.4% and 2.9%
respectively. By comparison, in 2009 the proportion of THIN patients residing in
England, Wales, Scotland and Northern Ireland were 83.5%, 6.4%, 6.7% and 3.3%
respectively. Therefore by 2009 Wales and Northern Ireland are slightly
overrepresented in THIN, while Scotland is underrepresented. In earlier calendar
years Northern Ireland was also underrepresented in THIN. Table 3.4 shows that
throughout the period patients were not evenly distributed across the five Townsend
deprivation quintiles; there were fewer people in THIN in the two most deprived
quintiles than the other quintiles. Since the quintiles are based on the distribution of
deprivation in the UK as a whole, this indicates that the THIN database population is
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less deprived than the UK population as a whole. It has been shown that THIN is
nationally representative in terms of CHD prevalence, when compared with QOF
data319 and incidence of CHD is comparable to that in the UK QResearch Primary
Care database320. A further study found data on diabetes in THIN to correspond well
with data in the Health Survey for England6.
3.3.7 Strengths in relation to intended analyses
The key strength is the very large number of patients contributing to the THIN
database, enabling precise estimation of the time trends in major CHD and T2DM
incidence within different demographic groups, and precise estimation of annual
major CHD and T2DM incidence (towards objectives i and ii). The large size is such
that estimates are still precise enough when the population is restricted to just those
patients with T2DM, to explore the relationship between T2DM and major CHD
incidence (objective v). A second advantage is the nationwide scope of the THIN
database, encompassing men and women of all ages, regardless of health status, and
so including those (typically most vulnerable) groups of patients frequently ineligible
to participate in randomised controlled trials and cohort studies. Thus the findings are
widely applicable and generalisable. In these ways the THIN database complements
the BRHS.
The key limitation is the paucity of risk factor data. The nature of this routine
database is such that coronary and diabetic risk factors (smoking, blood pressure
levels, lipid levels, physical activity, adiposity etc) are not necessarily recorded by the
GP, either on a regular basis or at all. Moreover the risk factors remain inconsistently
measured, with variations in recording levels between practices and importantly for
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this thesis, over time, leading to potentially biased trend estimates. Therefore,
inference of the contribution of risk factor changes to disease trends is less feasible
and so analyses using THIN are mainly restricted to describing the major CHD and
T2DM time trends.
3.4 The Whitehall II Study
3.4.1 Description of data source
The opportunity arose to analyse data from a second observational cohort study – the
Whitehall II cohort37. Between 1985 and 1988, all men and women, aged 35-55years,
in 20 civil service departments in London (the target study population) were invited to
participate, by letter, in a screening examination. The response rate, after excluding
those who were ineligible, was 73% (74% among men, 71% among women), resulting
in recruitment of a total of 10308 patients who attended the screening examination
and also completed a baseline questionnaire.
3.4.2 Description of follow-up
Nine follow-up phases, identified as phases 1 to 9 in chronological order have been
completed at the time of writing. At phase 1 (baseline, 1985-8), phase 3 (1991-3),
phase 5 (1997-9), phase 7 (2002-4) and phase 9 (2007-2009) the participants attended
clinical screening examinations, where physical measurements were made and blood
samples taken, and questionnaires were completed. At phase 2 (1989-1990), phase 4
(1995-1996), 6 (2001) and 8 (2006) the participants completed questionnaires only.
The questionnaires in all phases incorporated questions relating to social and
demographic characteristics such as age; health status; work characteristics; social
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networks and type of social supports; and health behaviours such as smoking status
and diet. A summary of the different follow-up phases, along with the corresponding
response rates is given in table 3.5. Data from the screening phases 1, 3, 5 (for the
risk factors) and 1, 3, 5 and 7 (for the events) were made available for the analysis in
this thesis. Participants were also flagged at the National Health Service Central
Registry, which provided information on the date and cause of death.
3.4.3 Intended use of data source
The intention is to use to the data source to carry out analyses comparable to those
carried out in the BRHS – in particular to investigate the contribution of risk factor
changes to the decline in major CHD risk (objective iii). The data will be used to a)
compare and contrast the results for this select professional group based in and around
London against the findings in the national BRHS and so assess the degree of
coherence between the results from the two studies b) extend the analyses to women.
3.4.4 Assessment of major CHD events
Fatal CHD events were identified from flagging with the National Health Service
Central Registry as a record of death with CHD as the underlying cause, including
sudden death of presumed cardiac origin (international classification of diseases, ninth
revision, codes 410-414). Potential new cases of nonfatal MI were ascertained from
questionnaire items on chest pain and the physician’s diagnosis of heart attack in the
questionnaires up to phase 7 (2002-4). Confirmation of each potential nonfatal MI
case according to MONICA criteria was sought, using data from ECGs, markers of
myocardial necrosis, and chest pain history from the patient’s GP-held medical
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records. Only those nonfatal MIs confirmed as such according to the MONICA
criteria were included as events in the analyses.
3.4.5 Repeated assessment of coronary risk factors
At each of the three study phases: baseline (1985-8), phase 3 (1991-3), and phase 5
(1997-9), cigarette smoking status, physical activity levels, elements of diet and
alcohol consumption were ascertained from the lifestyle questionnaires, while fasting
lipid levels, SBP and BMI were obtained from clinical examinations, using consistent
techniques each time321, 322. Total cholesterol was measured in a centrifugal analyser
by enzymic colorimetric methods. HDL cholesterol was determined after precipitation
with dextran sulphate-magnesium chloride321. Non-HDL cholesterol was again
computed as the difference between total and HDL cholesterol. At baseline, 9065
participants (88%) had no HDL cholesterol measurement, but serum apolipoprotein-
A1 was available for almost 80% of participants321. Alcohol consumption in the
previous week was measured as units per week, then categorised as none, within
recommended limit for gender (<21 units for men, <14 units for women), over
recommended limit, and very heavy (>50 units for men and >35 units for women).
Cigarette smoking categories were non-smoker, ex-smoker, and current smoker.
Dietary data available was usual milk consumption (categorised as none, whole milk,
semi-skimmed, skimmed and other), usual bread consumption (white, wholemeal,
granary or wheatmeal, other brown bread, other) and usual fruit and vegetable
consumption (<3 times/week, 3-4 times/week, 5-6 times/week, daily, ≥2 times/day).
Physical activity was measured by self-report of frequency and duration of mild,
moderate and vigorous intensity activities. At Phase 5, the questionnaire was modified
to include 20 items on frequency and duration of different physical activities e.g.
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walking, cycling, sports. Hours per week of moderate and vigorous activity were
computed using these data. Activity levels were then categorised as low, medium or
high with low corresponding to <2 hours per week of moderate activity and <1 hour
of vigorous activity; high corresponding to ≥2.5 hours per week of moderate activity
or >1 hour of vigorous activity; and medium corresponding to levels in between low
and high323.
3.4.6 Sub-study 1: Derivation of HDL cholesterol at baseline
As stated in section 3.4.5, 9065 participants (88%) had no baseline HDL cholesterol
data, however most participants had serum apolipoprotein-A1. Age and gender-
adjusted linear regression of the available baseline HDL data on apolipoprotein-A1
was used to estimate the relationship between the two variables and then predict
baseline HDL for those participants without this measure. Baseline HDL
measurements were available for 1217 (11.8%) of participants (those aged 45-55 at
baseline). There is a strong correlation (0.8) between baseline HDL cholesterol and
baseline Apolipoprotein-A1 for these participants (figure 3.3). Given this correlation,
simple linear regression of baseline HDL cholesterol on baseline Apolipoprotein-A1
(centred at the mean value), adjusting for age and gender, was used to estimate the
relationship between the two measurements. Powers of Apolipoprotein-A1 (squared,
cubed etc.) were added consecutively into the model until no longer significant. The
resulting regression model was used to predict the missing baseline HDL cholesterol
measurements.
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The final regression model took the form:
Variable Coefficient (95% CI) Standard error P-value
a* 0.0123472 (0.0116141, 0.0130803) 0.0003737 <0.001
a2 0.0000329 (0.0000127, 0.0000532) 0.0000103 0.001
a3 -0.000000781 (-0.00000106, -0.000000506) 0.000000140 <0.001
age† -0.0024061 (-0.0064422, 0.00163) 0.0020572 0.242
sex 0.1177088 (0.0896203, 0.1457972) 0.0143168 <0.001
constant term 1.320945 (1.117275, 1.524614) 0.1038109 <0.001
*a = Apolipoprotein-A1, centred at the mean value of 154.4g/L
†age = age at baseline R2 = 0.6704; Root mean squared error = 0.22745.
Note that while squared and cubic terms in Apolipoprotein-A1 were significant, they
were so close to 0 as to make little difference to the HDL cholesterol estimates,
although they are included in the final model. HDL cholesterol measurements in later
phases were not used to predict the earlier measurements as it was felt this could lead
to an artificially induced trend in HDL cholesterol. In all, HDL cholesterol was
predicted in this way for 7,372 of the 9,065 participants missing this variable; the
remaining participants were also missing Apolipoprotein-A1, preventing HDL
cholesterol prediction.
3.4.7 Description of study population
The study population comprised at baseline in 1985-1988 6,895 men (67%) and 3,413
women, aged 35 to 55 years, and predominantly white (89%). Key characteristics
(including socio-demographic characteristics, coronary and diabetic risk factor levels,
and prevalent CHD or T2DM) of the study population at baseline are presented in
table 3.6. 38% of men in Whitehall II belonged to the two most senior employment
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grades at baseline, compared to 11% of women. Half of the 3,413 women in the
Whitehall II cohort instead belonged to the clerical employment grade, ranked as the
most junior. Employment grade is taken to be a marker for socioeconomic position,
with the more senior grades corresponding to a higher socioeconomic status. 16% of
men and 23% of women were current smokers. 22% of men and 42% of women had
low physical activity levels. Mean alcohol consumption was 13 units per week for
men and 6 units per week for women. In terms of diet, the type of milk most
frequently consumed was whole milk (over half of men and women); among breads
wholemeal was favoured (over 40% of men and women); and over half of men and
women consumed fruit and vegetables at least daily. Very few men and women in
this London-based cohort had a history any CHD (2% of men and 1.5% of women),
while <1% of men and women had had an MI before baseline. Mean BMI was
24.6kg/m2 among men and 24.8kg/m2 among women. 40% of men and women were
overweight or obese. Mean SBP was 124.6mmHg among men and 120.1mmHg
among women. Mean total cholesterol levels among men and women were similar at
5.98mmol/L and 5.92mmol/L respectively. However women had higher mean HDL
cholesterol levels and lower non-HDL cholesterol levels. Details of exclusions for
particular analyses are given in the relevant results chapter. The levels of total
cholesterol, HDL cholesterol, non-HDL cholesterol, systolic blood pressure, BMI,
cigarette smoking and history of CHD and MI among men in Whitehall II were more
favourable than in men in the BRHS at baseline. This may partly reflect the slightly
younger age-range and later baseline, but may also be associated with the confined
geographic scope and more favourable socio-economic circumstances of participants
in Whitehall II (no manual workers or unemployed) compared with the BRHS.
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3.4.8 Strengths in relation to intended analyses
As discussed in section 3.4.3, I have obtained access to this second cohort to enable
me to repeat the analysis of the role of risk factors in the decline in major CHD
carried out in the BRHS (objective iii). The value of repeating the analysis using this
additional source of data is firstly the extension of the findings to women since the
cohort comprises both men and women, as opposed to the BRHS study population.
Although THIN comprises both men and women too, the lack of risk factor data
renders THIN unsuitable for these analyses. Secondly, since this type of analysis
(individual level time trends analysis) has not been carried out in the UK population
before (as discussed in chapter 2, section 2.6.1), the repetition of the analyses in a
second data source is important to assess the robustness of the findings. Thirdly, as
the socio-economic circumstances are on average more favourable among participants
in Whitehall II compared with men in the BRHS, the analyses will indicate whether
the findings differ given differing (more favourable) circumstances. While socio-
economic data is available in the BRHS, the study population is too small to enable
reliable, adequately powered subgroup analyses by socio-economic group. Fourthly,
measures of key biochemical risk factors were taken approximately every five to six
years, enabling more precise estimation of trends in risk factors than possible for the
BRHS which currently has only two physical examinations, twenty years apart.
Repeated dietary data is also available, enabling some exploration of the role of diet.
The key limitation of the Whitehall II cohort however is that the London-based cohort
is not geographically representative of Britain, hence the use of the BRHS as the
primary data source for this thesis on national trends.
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Table 3.1 Attrition and questionnaire response rates in the British Regional
Heart Study
Lost to follow-up at time-
point*:
Remaining
participants†:
Response rate:
Time-point Deaths Emigrations,
participants living
overseas, ONS
cancellations, and
those self-
withdrawn from
study
Total
remaining
survivors able
to participate
Total remaining
participants
responding to
questionnaire
(%)
5-years follow-up 1983-1985 290 49 7396 7275 (98%)
12-14 years follow-up 1992 1136 115 6484 5925 (91%)
16-18 years follow-up 1996 1562 177 5996 5263 (88%)
20-years follow-up 1998-2000 2080 139 5516 4252 (77%)‡
23-25 years follow-up 2003 2718 127 4890 3980 (81%)
25-27 years follow-up 2005 3173 81 4481 3540 (79%)
Notes:
Emigrations, participants living overseas, ONS cancellations, and those self-withdrawn from study is
not a cumulative count (unlike the deaths, which increase with time) as some participants withdrawn or
emigrated or overseas at one time-point may be re-enter the study at a later time-point
*Total number lost to follow-up by time-point
†Remaining participants = 7735 – (deaths + emigrations etc), where 7735 is the total number of
participants at baseline
‡The lower response rate at 20-years follow-up compared to both earlier and later years reflects that
only men who attended the physical examination at this time-point were asked to complete the
questionnaire; postal questionnaires at the other time points were sent to all men
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Table 3.2 Key characteristics of the British Regional Heart Study men at baseline
(1978-80)
Men aged 40-49
years, N = 3,736
Men aged 50-60
years, N = 3,999
All men, N =
7735
N (%) N (%) N (%)
Region of Britain
South 1122 (30.0) 1158 (29.0) 2280 (29.5)
Midlands & Wales 614 (16.4) 594 (14.9) 1208 (15.6)
North England 1546 (41.4) 1739 (43.5) 3285 (42.5)
Scotland 454 (12.2) 508 (12.7) 962 (12.4)
Missing 0 0 0
Socio-economic position
I Professional 327 (8.8) 279 (7.0) 606 (7.8)
II Intermediate 869 (23.3) 866 (21.7) 1735 (22.5)
III Skilled non-manual 353 (9.5) 367 (9.2) 720 (9.3)
III Skilled manual 1544 (41.4) 1782 (44.7) 3326 (43.1)
IV Semi-skilled 367 (9.8) 417 (10.5) 784 (10.2)
V Unskilled 155 (4.2) 163 (4.1) 318 (4.1)
Armed forces 116 (3.1) 115 (2.9) 231 (3.0)
Missing 5 10 15
Cigarette smoking
Never 1081 (29.0) 738 (18.5) 1819 (23.6)
Ex-smoker 1163 (31.2) 1552 (38.9) 2715 (35.2)
Current smoker; 1-19 a day 532 (14.3) 656 (16.4) 1188 (15.4)
Current smoker; 20 a day 377 (10.1) 458 (11.5) 835 (10.8)
Current smoker;21-39 a day 405 (10.9) 441 (11.0) 846 (11.0)
Current smoker;40 or more 168 (4.5) 148 (3.7) 316 (4.1)
Missing 10 6 16
Alcohol consumption
None 174 (4.7) 292 (7.3) 466 (6.0)
Occasional 893 (23.9) 952 (23.8) 1845 (23.9)
Light 1193 (31.9) 1351 (33.8) 2544 (32.9)
Moderate 1028 (27.5) 1014 (25.4) 2042 (26.4)
Heavy 446 (11.9) 386 (9.7) 832 (10.8)
Missing 2 4 6
Body mass index, kg/m2
<20 121 (3.2) 148 (3.7) 269 (3.5)
20-24.99 1702 (45.6) 1576 (39.4) 3278 (42.4)
25-29.99 1627 (43.5) 1923 (48.1) 3550 (45.9)
30-39.99 286 (7.7) 347 (8.7) 633 (8.2)
40+ 0 (0) 2 (0.1) 2 (0.03)
Missing 0 3 3
Physical activity
Inactive 288 (7.8) 398 (10.1) 686 (9.0)
Occasional 1039 (28.1) 1306 (33.2) 2345 (30.7)
Light 813 (22.0) 948 (24.1) 1761 (23.1)
Moderate 590 (16.0) 615 (15.6) 1205 (15.8)
Moderately vigorous 663 (17.9) 457 (11.6) 1120 (14.7)
Vigorous 301 (8.1) 212 (5.4) 513 (6.7)
Missing 42 63 105
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Table 3.2 continued. Key characteristics of the British Regional Heart Study men
at baseline (1978-80)
Men aged 40-49
years, N = 3,736
Men aged 50-60
years, N = 3,999
All men, N =
7735
N (%) N (%) N (%)
History of myocardial infarction
No 3404 (91.1) 3379 (84.5) 6783 (87.7)
Yes 332 (8.9) 620 (15.5) 952 (12.3)
Missing 0 0 0
History of coronary heart disease†
No 3003 (80.4) 2788 (69.7) 5791 (74.9)
Yes 733 (19.6) 1211 (30.3) 1944 (25.1)
Missing 0 0 0
History of diabetes mellitus (type 1 or 2)
No 3693 (98.9) 3933 (98.4) 7626 (98.7)
Yes 40 (1.1) 64 (1.6) 104 (1.3)
Missing 3 2 5
Use of blood pressure medication
No 3637 (97.4) 3715 (93.0) 7352 (95.1)
Yes 96 (2.6) 279 (7.0) 375 (4.9)
Missing 3 5 8
Mean (sd) Mean (sd) Mean (sd)
Body mass index, kg/m2 25.4 (3.2) 25.6 (3.3) 25.5 (3.2)
Missing 0 3 3
Systolic blood pressure, mmHg 141.4 (19.2) 148.7 (22.0) 145.2 (21.0)
Missing 4 4 8
Diastolic blood pressure, mmHg 81.6 (12.9) 82.8 (13.5) 82.2 (13.2)
Missing 6 4 10
Total cholesterol, mmol/L 6.29 (1.07) 6.30 (1.02) 6.30 (1.04)
Missing 22 23 45
HDL cholesterol, mmol/L 1.14 (0.26) 1.15 (0.27) 1.15 (0.27)
Missing 149 166 315
Non-HDL cholesterol, mmol/L 5.15 (1.11) 5.15 (1.07) 5.15 (1.09)
Missing 152 168 320
Notes:
*Socio-economic position based on longest-held occupation of men at baseline, using the Registrar
General’s Social Class Classification – I Professionals (e.g. physicians and engineers); II Intermediate
(e.g. teachers and sales managers); III Skilled non-manual (e.g. clerks and shop assistants); III Skilled
manual (e.g. bricklayers); IV Semi-skilled (e.g. postmen); V Unskilled (e.g. porters and general
labourers) and lastly, Armed forces
†History of coronary heart disease includes angina and/or myocardial infarction
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Table 3.3 Total numbers of General Practices and patients contributing data to
THIN and coverage of the UK population by calendar year
Year
No. of practices
contributing
patient data on
30 June of year*
No. of patients
contributing data
on 30 June of
year
Total UK
population (mid-
year counts)‡
% coverage of
UK population†
1988 7 26,539 56,916,448 0.05
1989 10 42,109 57,076,451 0.07
1990 37 226,430 57,237,493 0.40
1991 52 312,084 57,438,658 0.54
1992 62 396,162 57,584,530 0.69
1993 73 488,315 57,713,889 0.85
1994 78 539,833 57,862,145 0.93
1995 84 596,120 58,024,799 1.03
1996 103 788,839 58,164,374 1.36
1997 125 1,037,038 58,314,249 1.78
1998 150 1,241,705 58,474,943 2.12
1999 191 1,620,773 58,684,427 2.76
2000 248 2,140,318 58,886,065 3.63
2001 289 2,528,339 59,113,497 4.28
2002 334 2,981,521 59,318,779 5.03
2003 372 3,317,392 59,552,182 5.57
2004 387 3,461,688 59,841,892 5.78
2005 412 3,693,249 60,235,498 6.13
2006 416 3,828,620 60,584,338 6.32
2007 422 3,947,871 60,985,677 6.47
2008 424 4,047,366 61,398,226 6.59
2009 409 3,950,335 61,791,956 6.39
Notes:
Number of patients contributing data on 30 June is computed by counting the number of patients for
whom 30 June of that year lies between the patient’s “entry date” and “exit date”. A patient’s “entry
date” = maximum of (date of patient registration at practice, date when practice data recording became
at an acceptable level) and a patient’s “exit date” = minimum of (date of death, date of patient transfer
out of practice, date of last data collection from practice). Number of practices contributing patient
data on 30 June is computed by counting the number of practices for which the number of patients
contributing data on 30 June is greater than zero.
*Number of practices in each calendar year is less than the total of 446 practices contributing data to
THIN over the whole period as practices start and stop contributing data at different time-points
‡mid-year count of UK population from Office for National Statistics http://www.statistics.gov.uk
†% coverage of UK population = 100% × no. of patients contributing data on 30 June / mid-year count
of UK population
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Table 3.4 Demographic characteristics of THIN patients by calendar year (every 3rd year selected)
Year
1994 1997 2000 2003 2006 2009
Total patients 539,833 1,037,038 2,140,318 3,317,392 3,828,620 3,950,335
Mean age in years (sd) 39.9 (23.2) 40.3 (23.3) 40 (23.3) 40.2 (23.3) 40.6 (23.4) 41.2 (23.5)
Gender, N (%)
Male 265063 (49.1) 505788 (48.8) 1047591 (48.9) 1619953 (48.8) 1865550 (48.7) 1914186 (48.5)
Female 274770 (50.9) 531236 (51.2) 1092648 (51.1) 1697230 (51.2) 1962722 (51.3) 2035728 (51.5)
Unknown/indeterminate 0 14 79 209 348 421
Townsend score of deprivation of
area of residence, N (%)
1 = least deprived 138927 (28.3) 267160 (28.0) 523291 (26.7) 787181 (26.0) 898738 (25.5) 913603 (25.4)
2 107684 (21.9) 212144 (22.2) 440358 (22.5) 684633 (22.6) 799559 (22.7) 801136 (22.3)
3 92057 (18.7) 184090 (19.3) 403543 (20.6) 632039 (20.8) 741826 (21.0) 755743 (21.0)
4 84765 (17.3) 171188 (17.9) 351530 (17.9) 554852 (18.3) 646327 (18.3) 669169 (18.6)
5 = most deprived 67930 (13.8) 120361 (12.6) 241216 (12.3) 374262 (12.3) 439189 (12.5) 460658 (12.8)
Unknown 48,470 82,095 180,380 284,425 302,981 350,026
Country of UK, N (%)
England 480076 (88.9) 928423 (89.5) 1892113 (88.4) 2827158 (85.2) 3201578 (83.6) 3300359 (83.5)
Northern Ireland 13364 (2.5) 14605 (1.4) 40081 (1.9) 99071 (3.0) 141704 (3.7) 130626 (3.3)
Scotland 18673 (3.5) 45241 (4.4) 103475 (4.8) 221746 (6.7) 259056 (6.8) 265408 (6.7)
Wales 27713 (5.1) 48768 (4.7) 104648 (4.9) 169416 (5.1) 226281 (5.9) 253941 (6.4)
Unknown 7 1 1 1 1 1
Notes: *Area of residence updated in database if patient moves home; Townsend score corresponds to area of residence record closest to calendar year of interest
138
Table 3.5 Follow-up phases for the Whitehall II study and response rates
Phase Dates Type of data collection No of participants Response Rate*
1 1985-1988 Screening + questionnaire 10,308 -
2 1989-1990 Questionnaire 8,132 79%
3 1991-1994 Screening + questionnaire 8,815 86%
4 1995-1996 Questionnaire 8,628 84%
5 1997-1999 Screening + questionnaire 7,870 76%
6 2001 Questionnaire 7,355 71%
7 2002-2004 Screening + questionnaire 6,967 68%
8 2006 Questionnaire 7,173 70%
9 2007-2009 Screening + questionnaire 6,761 66%
Notes:
Reproduced from the Whitehall II cohort website: http://www.ucl.ac.uk/whitehallII/study-phases
*Response rate defined as proportion of Phase 1 responders who participated in the follow-up phase.
Note the difference in definition to that for the British Regional Heart Study, where the response rate
was the proportion of those eligible to participate in the relevant follow-up stage (so excluding those
who died prior to the follow-up stage from the denominator).
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Table 3.6 Key characteristics of the Whitehall II cohort at baseline (1985-1988)
Men, N = 6,895
Women, N =
3,413
All
participants, N
= 10,308
N (%) N (%) N (%)
Employment grade*
Civil Service grades 1-6 (=most
senior) 1015 (14.7) 118 (3.5) 1133 (11.0)
Civil Service grade 7 1632 (23.7) 263 (7.7) 1895 (18.4)
Senior Executive officer 1228 (17.8) 198 (5.8) 1426 (13.8)
Higher Executive officer 1498 (21.7) 478 (14) 1976 (19.2)
Executive officer 881 (12.8) 660 (19.3) 1541 (15.0)
Clerical (=most junior) 641 (9.3) 1696 (49.7) 2337 (22.7)
Missing 0 0 0
Cigarette smoking
Never 3259 (47.7) 1803 (53.2) 5062 (49.5)
Ex-smoker 2482 (36.3) 792 (23.4) 3274 (32.0)
Current smoker 1090 (16.0) 793 (23.4) 1883 (18.4)
Missing 64 25 89
Body mass index, kg/m2
<20 326 (4.7) 284 (8.3) 610 (5.9)
20-24.99 3843 (55.8) 1800 (52.8) 5643 (54.8)
25-29.99 2362 (34.3) 953 (27.9) 3315 (32.2)
30-39.99 347 (5.0) 351 (10.3) 698 (6.8)
40+ 5 (0.1) 23 (0.7) 28 (0.3)
Missing 12 2 14
Physical activity
Low 1455 (22.2) 1311 (41.6) 2766 (28.5)
Medium 643 (9.8) 400 (12.7) 1043 (10.8)
High 4447 (67.9) 1442 (45.7) 5889 (60.7)
Missing 350 260 610
Usual milk consumption
None 201 (2.9) 140 (4.1) 341 (3.3)
Whole milk 4121 (60.0) 1777 (52.4) 5898 (57.5)
Skimmed milk 1339 (19.5) 578 (17.1) 1917 (18.7)
Semi-skimmed milk 1047 (15.3) 766 (22.6) 1813 (17.7)
Other/combination 156 (2.3) 127 (3.7) 283 (2.8)
Missing 31 25 56
Usual bread consumption
White bread 1533 (22.3) 659 (19.5) 2192 (21.4)
Wholemeal 2860 (41.7) 1461 (43.2) 4321 (42.2)
Granary or wheatmeal 1068 (15.6) 511 (15.1) 1579 (15.4)
Other brown bread 186 (2.7) 77 (2.3) 263 (2.6)
Combination 1215 (17.7) 671 (19.9) 1886 (18.4)
Missing 33 34 67
Usual fruit and vegetable
consumption
<3 times per week 882 (12.8) 323 (9.5) 1205 (11.7)
3 or 4 times per week 1062 (15.4) 463 (13.6) 1525 (14.8)
5 or 6 times per week 1124 (16.3) 443 (13) 1567 (15.3)
Daily 2790 (40.6) 1487 (43.7) 4277 (41.6)
≥2 times per day 1018 (14.8) 683 (20.1) 1701 (16.6)
Missing 19 14 33
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Table 3.6 continued Key characteristics of the Whitehall II cohort at baseline
(1985-1988)
Men, N = 6,895
Women, N =
3,413
All
participants, N
= 10,308
N (%) N (%) N (%)
History of myocardial infarction
No 6860 (99.5) 3412 (99.97) 10272 (99.7)
Yes 34 (0.5) 1 (0.03) 35 (0.3)
Missing 1 0 1
History of coronary heart disease†
No 6753 (98.0) 3363 (98.6) 10116 (98.2)
Yes 141 (2.0) 50 (1.5) 191 (1.9)
Missing 1 0 1
Mean (sd) Mean (sd) Mean (sd)
Body mass index, kg/m2 24.6 (3.1) 24.8 (4.3) 24.6 (3.5)
Missing 12 2 14
Systolic blood pressure, mmHg 124.6 (14.1) 120.1 (15.7) 123.1 (14.8)
Missing 14 1 15
Alcohol consumption, units/week 12.8 (14.5) 5.50 (7.7) 10.4 (13.1)
Missing 55 39 94
Total cholesterol, mmol/L 5.98 (1.16) 5.92 (1.18) 5.96 (1.17)
Missing 35 39 74
HDL cholesterol‡, mmol/L 1.28 (0.31) 1.60 (0.37) 1.39 (0.37)
Missing 1,719 779 2,498
Non-HDL cholesterol, mmol/L 4.71 (1.15) 4.31 (1.16) 4.58 (1.17)
Missing 1,722 785 2,507
Notes:
*Employment grade is used as a marker for socio-economic position (more junior grade corresponds to
a lower socio-economic position)
†History of coronary heart disease includes angina and/or myocardial infarction
‡HDL cholesterol data includes imputed values
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Figure 3.1 The 24 towns constituting the British Regional Heart Study
Reproduced with permission from the British Regional Heart Study
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Figure 3.2 Timeline for the British Regional Heart Study, illustrating follow-up of study men and collection of data used in the thesis
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Figure 3.3 HDL cholesterol against Apolipoprotein-A1 for 1,217 participants with
both measurements at baseline in Whitehall II, according to age and gender
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Chapter 4: Estimating recent time trends in incidence of major
coronary heart disease and type 2 diabetes in the UK using data from
The Health Improvement Network and two cohort studies
4.1 Introduction
Chapter 2 highlighted the striking but divergent time trends in coronary heart disease
(CHD) mortality and type 2 diabetes (T2DM) prevalence which have occurred in the
UK in recent decades. The good news is that CHD mortality has been declining since
the 1960s, and the CHD mortality rate is now roughly one-quarter of what it was in
19611. In contrast the time trend in T2DM has been unfavourable; the combined
evidence suggesting T2DM prevalence to have more than doubled since the 1980s2-6.
As outlined in chapter 2, a step towards unpicking and understanding these time
trends is to establish to what extent they reflect trends in incidence of these
conditions. The existing literature suggests that congruous time trends in CHD1, 2, 20-24
and T2DM incidence4, 6, 25, 26 have indeed occurred. However, the data on time trends
in incidence is limited, reflecting the difficulty in measuring incidence. There is a
paucity of data particularly on more contemporary time trends from the 1990s to the
present, and on trends within different socio-demographic groups, to ascertain
whether some groups are experiencing greater changes in incidence than others.
The aim of this chapter is therefore to estimate recent time trends, particularly from
the 1990s to the present, in incidence of major CHD and T2DM in the UK. This
corresponds to objectives i) and ii) of the overall thesis objectives. Overall time
trends, as well as time trends according to different socio-demographic characteristics
(gender, age, UK region and socio-economic background) are described. Data from
the Health Improvement Network (THIN) will primarily be used for the analyses.
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The very large number of patients in this nationally representative database, with data
on demographic characteristics and CHD and T2DM diagnoses, enables precise
estimation of the time trends in CHD and T2DM incidence according to demographic
characteristics. Incidence trends will also be estimated in the smaller British Regional
Heart Study (BRHS) and Whitehall II cohorts (major CHD only for Whitehall II), to
establish concordance between the different data sources. This will help to determine
the extent to which the subsequent analyses in future chapters, using the rich risk
factor data in these two cohorts to attempt to explain the time trends, may be
representative and generalisable to the wider UK population.
The structure of this chapter is as follows: Section 4.2 details methods. Section 4.3
presents results specific to the first objective to estimate time trends in major CHD
incidence, using THIN data. Section 4.4 presents results specific to the second
objective to estimate time trends in T2DM incidence, using THIN data. In section 4.5
the time trends in major CHD and T2DM in the BRHS and Whitehall II cohorts are
presented and compared with the estimates from THIN. The findings are then
discussed in section 4.6.
Objectives
Estimate for men and women in the UK from the 1990s to the present:
1. The time trend in incidence of major CHD
2. The time trend in incidence of T2DM
overall and according to age, gender, socio-economic background and geographic
region
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4.2 Methods
4.2.1 Data sources
As explained in the previous section, the THIN database is principally used for these
analyses, while the time trends will be also estimated in the BRHS (major CHD and
T2DM) and Whitehall II (major CHD only) to assess the comparability between the
data sources.
4.2.2 THIN Study sample
Trends in incidence of major CHD and T2DM were assessed over the 14 year period
from 1 January 1995 to 31 December 2008, reflecting the earliest year that an
adequate number of practices were first contributing data of acceptable completeness
(see chapter 3, section 3.3.2, for details) and the latest complete year that data was
available at the time of analysis. Two cohorts of patients in THIN were followed
retrospectively for incident major CHD or incident T2DM over this time. To be
included in the analyses, men and women had to be registered at a contributing THIN
practice for at least some time between 1995 and 2008 (the time for which they could
be followed-up for incident events). The patients also had to be at least 30 years old or
less than 100 years old for some of that time (incidence of both conditions below the
age of 30 is negligible and too few patients attained over 100 years of age). Patients
were excluded if they were only temporarily registered or in a small number of cases,
where their data was inconsistent (for example, a birth date after a death date). Whole
practices were excluded if they had no data at all on social deprivation.
For the analyses of time trends in incidence of major CHD, patients with evidence of
a history of major CHD prior to follow-up for incident events were excluded. For the
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analyses of time trends in incidence of T2DM, patients with evidence of a history of
any diabetes (T1DM or T2DM or diabetes unspecified) prior to follow-up for incident
events, were excluded. Although patient data has only been fully captured in the
THIN database from the early 1990s, historic data charting patient medical histories is
available for many patients. Therefore it is possible to identify and exclude most
prevalent cases. A previous study showed further that for patients who newly register
at an existing contributing THIN practice, all previous medical history tends to be
added to their records but often with an “event date” as the date of registration (or
close to it), as opposed to the historic date that the diagnosis was made324. In this way
such events may appear as new incident cases rather than prevalent cases. This can be
seen from plots of incidence rates of diagnoses against time from registration, which
show anomalously high incidence rates close to the registration date, if these events
are assumed to have occurred at the given “event date”324. To avoid artificially
inflating incidence rates, therefore, patients were followed for incident events only
from a year after their registration date, and were excluded from analyses if they had a
record of an event before this time (which would most likely be prevalent), or had less
than one years worth of data from their registration date.
For the time trend in major CHD, patients with a history of stable or unstable angina
(but no prior major CHD event) or who developed angina during the follow-up were
retained for analysis. This is because developing angina does not preclude
subsequently having a major CHD event. For the time trend in T2DM, participants
who had a record of T1DM or a record of a complex or non-standard diabetes at any
time before or during the follow-up were excluded. This is because the presence of
another form of diabetes either precludes development of T1DM or, if transient, such
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as gestational diabetes, these patients are likely to differ considerably in terms of their
T2DM risk relative to the rest of the population. Non-standard diabetes cases leading
to exclusion were: gestational diabetes, drug-induced diabetes, malnutrition related
diabetes, secondary diabetes related to e.g. cystic fibrosis. A full list of Read codes
denoting non-standard cases is given in the Appendix A.1. In addition, if the first new
record relating to diabetes during the follow-up implied prevalent diabetes (for
example it related to treatment of existing diabetes), the patient was excluded as a
prevalent case. The flowcharts in figures 4.1 and 4.2 detail the numbers of patients
included and excluded for the analyses of CHD incidence and of T2DM incidence
respectively.
4.2.3 Follow-up
Patients were followed for incident major CHD or T2DM from a start date of the
latest of: 1 January 1995, date practice began providing “acceptable quality” data (see
chapter 3, section 3.3.2, for details – maximum of acceptable computer usage date and
acceptable mortality rate date), date the patient had been registered at the practice for
one year, and date the patient turned 30 years old. Patients were followed until an end
date defined as the earliest of: 31 December 2008, date the patient left the practice,
date the practice left THIN, date of death of the patient. Note that unlike traditional
cohort studies, this analysis therefore involves an “open” cohort in the sense that
patients do not all have the same baseline date but may enter and leave the cohort at
different times.
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4.2.4 Principal outcome as a first major CHD event
A first major CHD event was identified as the first occurring Read code (based on the
associated “event date”) in the patient medical records during the follow-up time
relating to major CHD (see chapter 3, section 3.3.4, for details). Read codes used to
define major CHD are listed in Appendix A.2 along with the frequencies with which
they occurred in each calendar year. Included are codes corresponding to myocardial
infarction (MI), NSTEMI, STEMI and non-specific MI. Unstable angina and non-
specific acute coronary syndrome codes were excluded. The types of codes used vary
over time as more codes are made available or recording preferences change. Trends
in the incidences of different types of codes over time are shown in figure 4.3.
4.2.5 Principal outcome as a first diagnosis of T2DM
A first diagnosis of T2DM was identified principally as the first occurring Read code
(based on the associated “event date”) in the patient medical records during the
follow-up time relating to a T2DM diagnosis (see chapter 3, section 3.3.4, for details).
There were also a number of records related only to diabetes in general, without
specifying type 1 or type 2. As outlined in chapter 3, section 3.3.4, since the
participants were aged at least 30 years, any new non-specific diabetes record was
assumed to refer to T2DM, and included as an incident T2DM case (provided there
were no T1DM records anywhere else in the patient records). Of course we cannot
rule out the possibility that some of these diabetes cases are late onset T1DM,
particularly among the youngest patients, although the number of patients
misclassified in this way is likely to be very small as to have little influence on the
results. Records of insulin-dependent diabetes were also included, provided there
were no other codes to indicate T1DM, as insulin may be indicated for T2DM. The
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prevalences of the different Read codes for the incident T2DM cases in the cohort are
given in Appendix A.3. Trends in the incidences of different types of codes over time
are shown in figure 4.4.
4.2.6 Socio-demographic characteristics
Time trends in incidence of major CHD and T2DM were estimated according to each
of the following socio-demographic characteristics: gender, age, socio-economic
position, and residing country of the UK (England, Wales, Scotland, or Northern
Ireland). Age was grouped into 5-year categories for the purposes of tabulating
incidence rates by age, gender and calendar period, and grouped into 10-year
categories for the purposes of estimating time trends by age-group. The oldest patients
aged 80 and over were combined into a single group to avoid small categories. Socio-
economic position was defined at area level using the Townsend score for social
deprivation of local area of residence, grouped by quintiles (using the postal address
record closest to start of follow-up if more than one record was found) as described in
chapter 3, section 3.3.5.
4.2.7 Statistical methods
The choice of statistical methods used for the analysis was partially a pragmatic
decision to overcome computational limitations. The vast size of the dataset
prevented the patient data, stored separately for each practice, from being combined
into a single dataset. Instead, for each practice in turn, and for each outcome in turn
(an incident major CHD event or a new T2DM diagnosis), the total number of events
and total person-years of follow-up for each combination of: calendar year, age group,
gender, UK country and social deprivation quintile, were computed. The grouped
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data was then combined into a single dataset and a Poisson regression model applied
to this grouped data, regressing the total number of events on calendar year, adjusting
for age and gender, to estimate the yearly change in the incidence of each outcome
over the follow-up period. The log(total person-years) was used as an offset. Squared
and cubic terms in calendar time were added to assess whether the log(incidence rate)
increased linearly with time. Interactions between calendar time and gender, age-
group, deprivation and UK country were added in turn to estimate trends within each
demographic group.
General Practices contribute data to THIN over differing time periods so not all
practices will be present throughout the follow-up period of interest (1995 to 2008), as
illustrated in table 3.3 in chapter 3. Indeed only 72 practices contribute data in every
year of the period. Any variation in major CHD or T2DM incidence rates between
practices could therefore potentially confound the estimates of the time trends in these
outcomes. To account for the potential clustering effect of general practice, random
intercept multi-level Poisson models were used, with the different socio-demographic
patient groups nested in practices.
Graphs of incidence rates against calendar year were also plotted, to visually examine
the pattern of incidence over time. Incidence rates by 5-year age group, 5-year
calendar period and gender were tabulated.
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4.2.8 Analyses using BRHS and Whitehall II data
4.2.8.1 BRHS
The definitions of major CHD and T2DM used in the BRHS are given in chapter 3,
section 3.2.4. To explore the secular time trends in the incidence of major CHD or
T2DM some restructuring of the data was needed. The follow-up for each man was
split into consecutive 5-year periods: 1980 to 1984; 1985 to 1989; 1990 to 1994; 1995
to 1999; 2000 to 2004 and 2005 to 2007. Within each period survival times were
censored at death or end of the period, whichever came sooner, and men were
excluded from the period if they had had an event before the period. The incidence of
major CHD or T2DM in the different periods was then compared, adjusting for age, to
assess secular trends over time. Specifically Cox proportional hazards regression
applied to this split dataset, with calendar time (of start of period) as a covariate, was
used to estimate the yearly change in the hazard of the outcome of interest (major
CHD or T2DM) over the follow-up period. Age was used as the underlying time
scale, with date of birth as a time origin, and age at start of each period as a delayed
entry time to take account of left truncation. Use of an age time scale, as well as
automatically adjusting for age325, permitted calendar time to be entered into the
model as a covariate so that the hazard of the outcome associated with calendar time
could be estimated. Schoenfeld residuals were used to test the proportional hazards
assumption326. The Cox models were stratified by the socio-demographic categories
where this assumption was not met. Interactions between calendar time and country
of Great Britain (England, Wales, Scotland), and socio-economic status (based on
longest occupation held, in seven categories) were added to the Cox model. The
follow-up for each man was then split further into 10-year age-bands, resulting in
separate observations for each period/age-band combination for each man. An
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interaction between age-band (as a categorical variable) and calendar time was added
to the Cox model. Point estimates and 95% confidence intervals (CIs) of the
incidence rate of each outcome within each 5 year period and 5 year age-band were
computed from the doubly split dataset, and tabulated to enable comparison of the
overall levels of incidence in each calendar period and age-band, with that obtained
for men in THIN data. Note that incidence of first major CHD events was assessed
only to 2004 (the most recent complete year of follow-up at time of analysis). As
outlined in chapter 3, section 3.2.4, incident T2DM data with validated diagnosis
dates were available from the 5-year follow-up in 1983-5 but were available only
among survivors (to 1992) before 1990. Therefore T2DM incidence was primarily
assessed in the periods from 1995 to 2007 (latest follow-up date for T2DM at time of
analysis). In line with the analysis of THIN data, men with angina (either at baseline
or during follow up) were retained for the major CHD analysis, unless they also
developed major CHD. Men were included in the analysis of time trends in incidence
of T2DM unless they had died or had a previous diagnosis of T2DM or T1DM before
1995.
To make as full use of the available data on T2DM as possible, and to attempt to
explore trends in T2DM before 1995, the analyses of the time trends in T2DM were
repeated including the period 1985 to 1994, that is to assess trends over the 23 year
period between 1985 and 2007. Since T2DM incident data before 1992 was only
available for survivors to at least 1992, to ensure a fair and unbiased estimate of the
trend in incidence between 1985 and 2007, the analysis was carried out among that
sub-group of men who survived to the end of the follow-up in 2007 only. In this way
the men were treated in the same way throughout the follow-up period thus avoiding
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bias in the estimate of the time trend. The disadvantage of this analysis of survivors is
that it is uncertain how representative the time trend in this sub-group is of the wider
population. To explore this issue, the time trend over just the later period between
1995 and 2007 among this sub-group was also estimated and then compared with the
trend estimated for the full cohort of men in the original analyses to assess how
closely the time trend among the survivors is likely to reflect that of the wider cohort.
4.2.8.2 Whitehall II cohort – incidence of major CHD only
Incident major CHD events (defined as detailed in chapter 3, section 3.4.4) were
ascertained between 1985 and 2004. The same methods were used to estimate time
trends in major CHD hazard as those used for the BRHS men. The follow-up for each
participant was split into consecutive 5-year periods: 1985 to 1989; 1990 to 1994;
1995 to 1999; and 2000 to 2004. Then Cox proportional hazards regression applied to
this split dataset, with calendar time (of start of period) as a covariate, was used to
estimate the yearly change in the hazard of major CHD over the follow-up period,
with censoring and age time-scale as for the BRHS. Interactions between calendar
time and gender, and between calendar time and socio-economic status (based on
Civil Service employment grade, in three categories327) were added to the Cox model,
and, after further splitting of the dataset into 5-year age-bands, an interaction between
calendar time and age-band was also added. Residing location was not considered as
all participants were London-based. Tabulations of incidence rates by age, gender
and calendar period were made as above using the doubly-split dataset.
Again, participants with angina (either at baseline or during follow up) were retained
for analysis, unless they also developed major CHD.
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4.2.9 Secondary analyses to further assess comparability between data sources
A key difference between the analyses of the different data sources, is that the time
trends estimates from regression of THIN data are based on yearly incidence rates,
while (reflecting the smaller sizes of the cohorts), the time trends estimates from the
regression models of BRHS and Whitehall II were necessarily based on 5-yearly
incidence rates. A second difference is that Poisson models were used for the THIN
data (reflecting the necessity to group the data), while Cox’s model was used for the
cohort data (avoids assuming fixed incidence rates with time from start of each
period). Secondary analyses were carried out i) on THIN data, grouping the data into
5-year periods as for the cohorts and ii) on BRHS and Whitehall II data, using Poisson
models, to investigate more closely the comparability between the different data
sources.
4. 3 Results - Time trend in incidence of major coronary heart
disease: The Health Improvement Network
There were 2,927,137 patients aged between 30 and 100 years old eligible for
inclusion in the analyses of incidence of major CHD between 1995 and 2008, from
434 general practices. Exclusions are detailed in the flow chart in figure 4.1. There
were 1,421,694 (49%) men and 1,505,443 women. A total of 36,459 first major CHD
events occurred during 17,236,482 person-years of follow-up between 1 January 1995
and 31 December 2008 corresponding to an overall event rate of 2.12 events per 1000
person years (95% CI 2.09 to 2.14). Among men, 22,834 major CHD events occurred
during 8,268,407 person-years of follow-up, corresponding to an event rate of 2.76
events per 1000 person years (95% CI 2.73 to 2.80). Among women 13,625 major
CHD events occurred during 8,968,075 person-years of follow-up, corresponding to
156
an event rate of 1.52 events per 1000 person years (95% CI 1.49 to 1.55). Table 4.1
presents the major CHD incidence rate for men and women by age and 5-year
calendar period (1995-1999, 2000-2004 and 2005-2008). Among men, declines over
calendar time in the incidence rate within each age group can be seen (looking down
each column). However for the youngest age groups (under 40 years), where
incidence rates are already less than 1 per 1000 person-years in 1995-1999, the
differences between calendar periods are modest. Among women, declines in the
incidence rate over time are seen in age groups above 55 years. Under 55 years, again
where incidence rates are already less than 1 per 1000 person-years in 1995-1999, the
incidence rates appear to have remained relatively constant over time. As expected,
incidence is lower among women throughout and increases with age. Figure 4.5,
which make use of the large number of patients contributing to each calendar year, to
plot yearly incidence rates for men and women respectively, shows further that the
decline is reasonably steady over time, except for a relatively large fall from 1995 to
1996, particularly among men.
Table 4.2 presents incidence rates of major CHD averaged over the first three years
(1995 to 1997) and last three years of the study period (2006-2008), and the absolute
changes in incidence between these two periods, according to demographic groups.
Overall, incidence fell from 3.05 events per 1000 person years (95% CI 2.96 to 3.15)
in 1995-1997 to 1.73 (95% CI 1.70 to 1.76) in 2006-2008, corresponding to an
absolute decline of 1.32 events per 1000 person years (95% CI 1.22 to 1.42). Despite
larger absolute declines among older age groups, the strong positive age gradient in
incidence persisted over the study period. Incidence among men was roughly double
that for women in both 1995 to 1997 and 2006 to 2008 and the absolute decline
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among men was also almost double that for women. A deprivation gradient in
incidence was apparent in both 1995 to 1997 and 2006 to 2008, with incidence rising
with increasing quintile of Townsend score of area deprivation. A reverse gradient
was seen for the absolute decline in incidence, with the greatest absolute decline in the
most deprived quintile. Incidence of major CHD was highest in Scotland and
Northern Ireland in 1995 to 1997, compared to England and Wales, and remained so
in 2006 to 2008. Similar absolute declines in incidence occurred in England, Wales
and Scotland; the absolute decline in Northern Ireland was slightly greater.
From multi-level random intercept Poisson regression (table 4.3), the average annual
percentage decline in the rate of major CHD over the course of the follow-up from
1995 to 2008 was 4.88% (95% CI 4.59 to 5.18), adjusting for age and gender,
corresponding to a total relative decline over 14 years from 1995 to 2008 of 50%
(95% CI 48 to 53). A squared term in calendar year was not significant (p=0.8)
reflecting the apparently steady and reasonably linear decline over time as observed in
figure 4.5. Men experienced a slightly larger average annual age-adjusted relative
decline than women: 4.92% (95% CI 4.55 to 5.29) compared with 4.79% (95% CI
4.30 to 5.27), but this difference was not statistically significant (p=0.8). Thus,
although the larger absolute decline in men suggests incidence to have improved most
in men, the relative declines suggest instead that men and women have benefited
similarly. This reflects the higher incidence rate among men initially. Due to the
similar relative declines, the gender inequality in incidence has persisted. There was
some variation in the trend in major CHD incidence by age (p<0.001 for interaction
between age group and calendar year). The largest declines occurred among the 60-69
and 70-79 year age groups (average annual relative declines of 6.55%, 95% CI 5.97 to
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7.13, and 6.36%, 95% CI 5.82 to 6.89 respectively). Relatively modest relative
declines (between 2.5% and 2.9% per annum) occurred among those over 80 years
and under 50 years, in line with the observed age-gender specific incidence rates in
Table 4.1. The rate of decline in major CHD incidence fell with increasing quintile of
area deprivation (defined using the Townsend score), p=0.007 for deprivation-
calendar year interaction. In order of increasing deprivation from least deprived to
most deprived quintile, the average annual percentage declines in incidence of major
CHD were: 5.51% (95% CI 4.91 to 6.11), 5.15% (95% CI 4.54 to 5.76), 4.98% (95%
CI 4.34 to 5.62), 4.80% (95% CI 4.15 to 5.44), and 3.69% (95% CI 2.93 to 4.45).
This pattern is converse to the trend in absolute declines, as the least deprived
quintiles saw the least absolute declines. This again reflects that the most deprived
areas had higher incidence rates initially. The gradient in the relative declines has led
to persistence in the deprivation inequality in incidence. Incidence of major CHD
appeared to decline slightly faster in Wales and Scotland (average annual age-gender
adjusted relative declines of 5.45%, 95% CI 4.16 to 6.73, and 5.28%, 95% CI 4.11 to
6.44, respectively), than in England (4.90%, 95% CI 4.58 to 5.22) and Northern
Ireland (4.07%, 95% CI 2.22 to 5.89), although these regional differences were not
significant (p=0.5).
4.4 Results - Time trend in incidence of type 2 diabetes: The Health
Improvement Network
There were 2,853,030 patients aged between 30 and 100 years old eligible for
inclusion in the analyses of incidence of T2DM between 1995 and 2008, from 434
general practices. Exclusions are detailed in the flow chart in figure 4.2. There were
1,393,366 (49%) men and 1,459,664 women. A total of 80,896 patients developed
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T2DM during 16,637,711 person-years of follow-up between 1 January 1995 and 31
December 2008 corresponding to an overall incidence rate of 4.86 events per 1000
person years (95% CI 4.83 to 4.90). 44,383 men developed T2DM during 8,030,195
person-years of follow-up, corresponding to an incidence rate of 5.53 events per 1000
person years (95% CI 5.48 to 5.58). 36,513 women developed T2DM during
8,607,516 person-years of follow-up, corresponding to an incidence rate of 4.24
events per 1000 person years (95% CI 4.20 to 4.29). Table 4.4 presents the T2DM
incidence rates for men and women by age and 5-year calendar period (1995-1999,
2000-2004 and 2005-2008). Among both men and women up to the age of 60 years,
incidence of T2DM appears to have risen across all three periods. Among men and
women aged over 60 years, incidence in 2000-2004 was higher than in 1995-1999, but
incidence in 2005-2008 was more or less the same as in 2000-2004. Incidence
increased with age up to 74 years, and was lower in women. As most new cases occur
among the older age groups, the pattern among the older age groups (of an increase in
incidence only initially, followed by relatively constant incidence rates) has greater
influence on the overall time trends, presented in figure 4.6, which plots overall yearly
incidence rates for all men and women respectively, regardless of age. In line with the
incidence rates in the table 4.4, according to the figure 4.6, between 1995 and 1998-
1999 a modest increase in incidence of T2DM was generally seen, among both men
and women. After 1998-1999 incidence appears to have increased at a faster rate until
around 2002. Finally, from about 2002 to the end of the follow-up in 2008, the
incidence rate appeared to remain relatively constant.
Table 4.5 presents incidence rates of T2DM averaged over the first three years (1995
to 1997) and last three years of the study period (2006-2008), and the absolute
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changes in incidence between these two periods, according to demographic groups.
Overall, incidence rose from 3.15 events per 1000 person years (95% CI 3.07 to 3.23)
in 1995-1997 to 5.25 (95% CI 5.19 to 5.31) in 2006-2008, corresponding to an
absolute increase of 2.10 events per 1000 person years (95% CI 2.00 to 2.20), larger
than the absolute decline in major CHD incidence in the same population. Larger
absolute increases occurred among the older age groups, such that incidence remained
higher in the older age groups. A larger absolute increase occurred in men, than in
women, and since incidence was already higher in men in 1995-1997, this resulted in
a greater absolute difference in incidence between men and women in 2006-2008. A
deprivation gradient in incidence was apparent in both 1995-1997 and 2006-2008,
with incidence rising with increasing quintile of Townsend score of area deprivation.
There was no clear trend in the absolute change in incidence by deprivation quintile,
although the most deprived quintile experienced a larger absolute increase in
incidence relative to the other deprivation quintiles. Incidence of T2DM was highest
in Scotland in 1995-1997, compared to England, Wales and Northern Ireland, and
remained so in 2006-2008. Similar absolute increases in incidence occurred in Wales,
Scotland and Northern Ireland; the absolute increase in England was slightly smaller.
From multi-level random intercept Poisson regression (table 4.6), the average annual
percentage increase in the incidence of T2DM over the course of the follow-up from
1995 to 2008 was 3.60% (95% CI 3.83 to 5.18), adjusting for age and gender,
corresponding to a total relative increase over 14 years from 1995 to 2008 of 64% (59
to 69). Squared and cubed terms in calendar year were significant (p<0.001)
reflecting varying rates of change in incidence over the period, as observed in figure
4.6. Men experienced a slightly larger average annual age-adjusted relative increase
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than women: 3.89% (95% CI 3.58 to 4.2) compared with 3.34% (95% CI 3.00 to
3.68), (p=0.02 for interaction between gender and calendar year), in line with the
larger absolute change in incidence in men, and resulting in a widening of the gender
inequality in incidence. The rate of increase in T2DM incidence was greater in
younger age groups (up to 59 years), reflecting the pattern seen in Table 4.4 (p<0.001
for age-calendar year interaction). Average annual relative increases of 5.02% (95%
CI 3.87 to 6.19) and 5.49% (95% CI 4.82 to 6.17) occurred in the 30-39 and 40-49
year age groups. Among those aged 80 years and over, the corresponding figure was
2.51% (95% CI 1.81 to 3.21). Since incidence is lower in younger age groups, this
suggests that the younger age groups may be catching up with the older age groups in
terms of incidence; that is, new cases of T2DM are being increasingly identified at
younger ages. As for the absolute changes, the average annual age-adjusted relative
increase in incidence was highest in the most deprived deprivation quintile: 4.99%
(95% CI 4.40 to 5.58) (p<0.001 for deprivation- calendar year interaction). In the
other deprivation quintiles, the average annual relative increase ranged from 3.12% to
3.86%. This suggests a widening inequality, with T2DM incidence in the most
deprived quintile even higher relative to the other quintiles than previously. In
relative terms, T2DM incidence rose fastest in Northern Ireland (average annual age-
gender adjusted relative increase of 4.84, 95% CI 3.22 to 6.49) and slowest in Wales
(2.65, 95% CI 1.68 to 3.63), although the differences were not significant (p=0.1).
Similar relative increases occurred in England and Scotland of 3.62 (95% CI 3.37 to
3.87) and 3.66 (95% CI 2.69 to 4.63). The higher rate of increase in T2DM incidence
in Northern Ireland has meant that overall T2DM incidence in this constituent country
has gone from being initially lower than in the other constituent countries, to on par
with the other countries by the end of the period.
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4.5 Results – Comparison with British Regional Heart Study and
Whitehall II cohort
4.5.1 Major CHD incidence
4.5.1.1 BRHS overall incidence rates
Of the 7735 men recruited, 981 experienced a definite or possible MI before 1 January
1980 (the start of the follow-up period of interest) and so were excluded from this
analysis. Of the remaining 6754 men, 1240 were recorded as having a first MI over
135,721 person-years of follow-up between 1 January 1980 and 31 December 2004
giving an overall event rate of 9.14 events per 1000 person-years, (95% CI 8.64 to
9.65). Incidence rates by 5-year age group and period (table 4.7) were broadly
consistent with those among men in THIN (for those periods and age-groups covered
by both data sources), except that incidence in THIN was lower in the very oldest age
groups.
4.5.1.2 Whitehall II overall incidence rates
Of 10,308 participants recruited, one had no follow-up data and 35 reported an MI
before baseline and so were excluded from analysis. The remaining 10,272
participants included 6,860 (67%) men and 3,412 women. A total of 382 first major
CHD events occurred during 155,309 person-years of follow-up between 1 January
1985 and 31 December 2004; 307 major CHD events occurred among men during
105,508 person-years of follow-up and 48 major CHD events occurred during 49,800
person-years of follow-up among women. The overall incidence rates were 2.46
events per 1000 person-years (95% CI 2.22 to 2.72) among all participants, 2.91 (95%
CI 2.60 to 3.25) among men and 1.51 (95% CI 1.20 to 1.89) among women. Again,
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incidence rates by gender, and 5-year age group and calendar period (tables 4.8 and
4.9), are consistent with those in THIN.
4.5.1.3 Time trends in major CHD incidence in the different studies
Table 4.10 presents the average annual relative declines in major CHD hazard in the
BRHS and Whitehall II cohorts, estimated from Cox regression analyses, adjusted for
age and gender, overall and according to demographic group. The estimates are
presented alongside the corresponding estimates of the relative declines in major CHD
incidence in THIN for comparison.
There was no evidence of departure from the proportional hazards assumption of the
Cox regression in the BRHS analyses. However, in Cox regression analyses of the
Whitehall II cohort, the proportional hazards assumption was not met for gender so all
models were stratified by gender.
The average annual decline in major CHD hazard in the Whitehall II cohort was
4.24% (95% CI 1.92 to 6.51), adjusting for age and gender, corresponding to a 20-
year fall over 20 years from 1985 to 2004 of 58% (95% CI 32 to 74). This is
consistent with the average annual decline in major CHD incidence of 4.88%
observed in THIN from 1995-2008; the figure of 4.88% is included in the CI for the
Whitehall II figure. Adjusting for age, the hazard rate of major CHD in the BRHS
cohort fell on average by 3.3% (95% CI 2.1 to 4.5, p<0.001) per annum,
corresponding to a fall of 57% (95% CI 42% to 68%) over the 25-year follow-up
period from 1980 to 2004. This is a smaller average annual decline than that observed
in THIN; the CI excludes 4.88%. However, in further analyses of the BRHS,
164
restricting the time period to 1985-2004 (matching that in Whitehall II), the average
annual decline rose to 4.06% (95% CI 2.64 to 5.46), a figure more consistent with that
of Whitehall II and THIN, suggesting that the relative decline in major CHD has been
greater in more recent years.
The estimates of the decline in major CHD hazard in the BRHS and Whitehall II
according to demographic group in Table 4.10 should be interpreted with caution as
the estimates are very imprecise (wide CIs) due to the small numbers within each
group. That said, reassuringly, the overall patterns across demographic groups
observed in THIN are generally replicated in the two cohorts, including the increasing
rates of decline in major CHD with falling deprivation, the slightly smaller rate of
decline in men (Whitehall II), and the faster decline in Wales compared to England
and Scotland (BRHS). The findings for age group are less consistent with THIN.
However due to the ageing of the cohorts, not all age groups are present in the
analyses for the whole time-period (as illustrated in tables 4.7, 4.8 and 4.9), and thus
within each cohort, the time trends by age correspond to different time-periods and so
may not be directly comparable.
Secondary analyses, designed to make the analyses of the different data sources as
comparable as possible, were carried out. In particular, using grouped Poisson
regression for the BRHS and Whitehall II cohorts (instead of Cox regression), and
modelling calendar time in 5-year periods in the THIN regression models (instead of
in years). Further the THIN analyses were restricted to those aged 40 to 70 years to
match the age-range of the cohorts more closely. These alterations made little
difference to the results.
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4.5.2 T2DM incidence
4.5.2.1 BRHS overall incidence rates – all men
6016 of the 7735 men initially recruited in 1978-1980 were included in the present
analyses. The remainder had died (1373, 18%), or had a diagnosis of diabetes, type 1
or type 2, (346, 4%) prior to the start of the follow-up period on 1 January 1995. Of
6016 men, 526 developed T2DM over 62,043 person-years of follow-up between 1
January 1995 and 31 December 2007 giving an overall event rate of 8.48 events per
1000 person-years, (95% CI 7.78 to 9.23). Incidence rates by 5-year age group and
period (table 4.11) were broadly consistent with those among men in THIN.
4.5.2.2 BRHS overall incidence rates – survivors
The analyses were repeated considering incidence of T2DM from 1985 to 2007, but
among only those men who had survived to the end of the follow-up in 2007, to
ensure a fair comparison between time periods given the nature of the data on
incidence of T2DM prior to 1995 (available for survivors only), as detailed in section
4.2.8.1. A total of 3949 men survived to 2007 so were included in the analysis. Of
these men, 524 developed T2DM over 86,489 person-years of follow-up between 1
January 1985 and 31 December 2007 giving an overall event rate of 6.06 events per
1000 person-years, (95% CI 5.56 to 6.60). The incidence rates of T2DM by 5-year
age group and 5-year calendar period are shown in table 4.12. The incidence rates for
the latter three periods 1995-1999, 2000-2004 and 2005-2007 agree closely with those
for the full cohort, and for THIN men.
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4.5.2.3 Time trends in incidence of T2DM in the different studies
Table 4.13 presents the average annual relative increases in T2DM hazard in the
BRHS, among all men and among survivors only, estimated from Cox regression
analyses, adjusted for age, overall and according to demographic group. The
estimates are presented alongside the corresponding estimates in THIN for
comparison. There was some evidence of departure from the proportional hazards
assumption of the Cox regression for constituent country so results are stratified by
country.
Adjusting for age, the hazard rate of T2DM among all men in the BRHS cohort
increased on average by 5.3% (95% CI 2.7 to 8.0, p<0.001) per annum, corresponding
to almost a doubling in the hazard, that is an increase of 96% (95% CI 41% to 173%)
over the 13-year follow-up period from 1995 to 2007. Considering survivors only,
over the extended period from 1985 to 2007, the average annual increase in the hazard
of T2DM, adjusting for age, was 7.69% (95% CI 5.51 to 9.92), corresponding to a
four and a half fold increase over the whole 23-year period. This is a larger relative
increase than for the whole cohort. However, in further analyses of the survivors,
restricted to the same period of 1995 to 2007 as for the whole cohort, the hazard rate
of T2DM increased in this survivor sub-group on average by 5.3% (95% CI 2.3 to 8.4,
p<0.001) per annum. This is very similar to the time trend in T2DM observed over
this period for the whole cohort, indicating that the discrepancy relates to the different
time-periods (with a faster relative increase in the 1980s) rather than a difference
between survivors and the whole cohort. This suggests that the findings on incidence
prior to 1995 in this group of survivors may be extended to the rest of the cohort too.
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The estimate of an average annual increase of 5.3% in the BRHS between 1995 and
2007 is larger than that in THIN from 1995 to 2008 (3.6%). However, the
discrepancy may be explained by the observed “flattening” of the time trend in
incidence in the most recent years, which appears to exert increasing influence on the
overall time trend estimates with every additional year included. In further analyses,
restricting the period by just one year in THIN to 1995-2007 (to match that of the
BRHS analysis), the average annual increase rises to 4.35% (95% CI 4.08 to 4.61).
Restricting further to 1995-2006, the average annual increase is 5.37% (95% CI 5.05
to 5.69), emphasizing the increasing influence of the flattening of the time trend on
the overall trend estimate.
Again, the patterns in the time trend in relation to the different demographic
characteristics are largely consistent across the data sources. All three data sources
show that T2DM incidence increased at a broadly similar rate in the 50-59, 60-69 and
70-79 year old age groups, while the rate of increase in T2DM incidence is greatest in
the most deprived area (THIN) and lowest socio-economic status (BRHS). Wales
experienced the smallest rate of increase in T2DM incidence compared with England
and Scotland according to all three data sources.
Secondary analyses, designed to make the analyses of the different data sources as
comparable as possible, using grouped Poisson regression (BRHS and Whitehall II),
and modelling calendar time in 5-year periods (THIN) made little difference to the
results.
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4.6 Discussion
4.6.1 Summary of main findings
Analysis of data from the THIN primary care database indicates that over the 14 year
period from 1995 to 2008, incidence of major CHD has fallen on average by 4.88%
per annum, adjusting for age and gender. This corresponds to an overall relative
decline of 50%. The fall has been reasonably steady over this period, and represents
an absolute fall in incidence of 1.32 fewer events per 1000 person years. Over the
same period, incidence of T2DM has risen, with an average annual age-gender
adjusted relative increase of 3.60%, corresponding to a total relative increase of 64%
and an absolute increase of 2.10 more events per 1000 person years, thus a larger
absolute change than for major CHD. Unlike the trend in major CHD, the rate of
increase in incidence in T2DM appears to vary considerably over the period; slow
from 1995 to 1998-1999, faster from 1999 to 2003 and then limited beyond 2003.
Overall incidence of both conditions was around 3 events per 1000 person years in
1995. T2DM incidence rose to over 5 events per 1000 person years in 2008, while
major CHD incidence fell to 1.75 events per 1000 person years.
There was some variation in the time trends in incidence of major CHD and of T2DM
by demographic characteristics. For both conditions, there was a deprivation
inequality with more favourable trends (a faster relative decline in major CHD and a
slower relative increase in T2DM) occurring in more affluent areas. Slightly faster
relative changes in both CHD and T2DM occurred among men compared with
women, although the differences were small. In terms of constituent country, the
most favourable trends occurred in Wales (fastest relative fall in incidence of major
CHD and slowest relative increase in incidence of T2DM) while the least favourable
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trends occurred in Northern Ireland (slowest relative fall in incidence of major CHD
and fastest relative increase in incidence of T2DM).
4.6.2 Strengths and limitations of analysis of THIN database
The key strengths of the THIN database analyses, particularly by comparison with the
two cohorts, include the very large sample size and nationwide scope, including men
and women of all ages across the UK, enabling precise estimates of national trends.
There are variations in incidence between different general practices and different
practices contributed data at different time-points. However, multilevel models,
including practice as a random effect, enabled adjustment for this potential
confounding effect of practice on the time trends.
The broad lists of Read codes used to identify major CHD and T2DM ensured as far
as possible that changes in the choices of Read codes used by GPs over time do not
influence the time trend estimates. In terms of the types of Read codes used for major
CHD, codes to identify specifically STEMI and NSTEMI events have been
increasingly used since about 2002 (figure 4.3 and Appendix A.2). However, at the
same time, use of a code for “MI not otherwise specified” and other more general MI
codes has fallen, suggesting that rather than capturing more CHD events not
previously recorded by use of these extra codes post 2002, GPs are using these more
specific codes in place of the more general codes to record the same types of events.
The steady time trend in major CHD incidence supports this. Regarding Read codes
for T2DM, both codes specifically for T2DM, and codes for general diabetes were
assumed to relate to T2DM as patients were aged over 30 years. As for major CHD,
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over time there appears to have been a switch to from non-specific to specific codes,
this time from codes for general diabetes to codes specifically for T2DM (figure 4.4
and Appendix A.3). It is possible that some of the general diabetes codes relate to
T1DM, rather than T2DM. Since the general diabetes codes are used more frequently
in earlier years, this would lead to overestimation of incidence rates particularly in
earlier years and in turn underestimation of the rise in incidence over time. However,
T1DM cases represent a small proportion of all diabetes cases in the population
(~10%)9, and the vast majority of new cases among the over 30s are T2DM.
Therefore, the impact of inclusion of T1DM cases is likely to be minimal. Indeed, the
incidence rates and the time trend in T2DM estimated, correspond closely to those
observed in the BRHS, and to other data sources (once analyses are restricted to the
same time-period).
Individual-level data on socio-economic status is not available. However the area-
level Townsend deprivation score in THIN is arguably a good proxy for individual
socioeconomic status as it is based on areas of only a small number (~150) of
households such that misclassification is unlikely. The comparability between the
results by Townsend deprivation score in THIN and by occupational socio-economic
status in BRHS and Whitehall II supports this.
The THIN database is subject to certain limitations reflecting that the data is routinely
collected and not obtained specifically for research purposes. Patient data in THIN
are accrued only from registration at the practice and when computerised records of
patient visits were available, rather than from birth. Some major CHD events and
T2DM records occurring before the patient registered or patient data was captured on
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computer may be undetected. As a result it is not always possible to ascertain if a
major CHD event or T2DM diagnosis during the follow-up is truly incident.
However, it has been shown that major historical diagnoses (including major CHD or
T2DM) do tend to be recorded at registration; diagnoses recorded close to the
registration date in THIN are most likely records of patient history rather than new
incident events324. Moreover, T2DM, as a chronic condition, generally necessitates
regular monitoring (at least once a year), such that 99.7% of T2DM records in THIN
occur less than one year before the next record, a consistent finding across all calendar
years. Allowing a year after registration before following up patients for incident
events (and excluding patients with an event during that year as prevalent cases), thus
ensures as far as possible that all events captured are new incident cases324. The
chance of including recurrent events is highest in the earlier calendar years, with less
prior patient data, leading to possible overestimation of incidence in early years.
However, incidence of both major CHD and T2DM is broadly comparable to that in
the two cohorts and in other data (see section 4.6.4), thus the impact is likely to be
very modest.
A second potential limitation specific to the analyses of major CHD incidence, is that
fatal CHD events, where a patient dies and cause of death is cited as CHD, may not be
coded as Read codes and so not captured in THIN. The incidence rates in THIN and
the BRHS and Whitehall II are broadly comparable. However, incidence in the oldest
age groups in THIN (over 70 years), among whom a greater proportion of events are
fatal, does appear to be lower than that in the cohorts, suggesting that some fatal
events are missed. To explore the data further, events were broken down into the
proportion fatal (death within 30 days) and non-fatal. Compared with the BRHS over
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the overlapping time-period, the proportions of fatal events in each age group were
indeed lower in THIN. Since studies suggest case fatality rates to also have fallen
over time (see chapter 2, section 2.2.2.2), the impact of missing some fatal events will
likely be underestimation of the decline in major CHD incidence (a greater proportion
of events in the early years will be fatal and so missed, leading to greater
underestimation of incidence in these years and so underestimation of the decline over
time). However the decline observed in THIN was if anything greater than that
observed in the two cohorts, suggesting the impact to be minimal.
4.6.3 Comparisons with the analyses of BRHS and Whitehall II cohort data
The time trend estimates from the BRHS and Whitehall II cohorts, both overall and by
demographic group, were generally consistent with the findings in THIN, when the
differing time-periods covered were taken into account. This is reassuring and
supports the validity and generalisability of the BRHS and Whitehall II analyses in
subsequent chapters to explain the time trends seen.
The time trend estimates from the BRHS and Whitehall II cohorts extend over earlier
calendar years, from the 1980s onwards, showing further that the fall in incidence of
major CHD and rise in incidence of T2DM occurred over this earlier period too.
Comparing the findings for the time trend in major T2DM among the whole BRHS
cohort with the “survivor” cohort over the overlapping time-period 1995 to 2004, the
results were broadly consistent, lending support to use of the findings from the
survivor cohort over the earlier time-period, for which data for the full cohort was not
available, and in the analyses in subsequent chapters.
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The BRHS and Whitehall II cohorts are similar data sources and so share similar
strengths: established dedicated cohort studies with (near) complete and accurate
follow-up for cardiovascular diseases. Indeed follow-up has been maintained for 98%
of surviving men in the BRHS, with similarly high figures for Whitehall II.
Moreover, the methods used to identify participants with major CHD events have
been consistent over the follow-up period in both the BRHS and Whitehall II. The
analysis of time trends in T2DM using the whole BRHS cohort was restricted to that
period when ascertainment methods were also consistent (review of GP records). For
the analysis limited to BRHS “survivors”, over an extended period, the methods of
ascertainment were not consistent (retrospective self-report before 1990 versus later
use of GP records). However, any self-reported T2DM diagnosis in the questionnaire
before 1990 prompted the researchers to go back to the GP records to confirm the
diagnosis and date of diagnosis. Thus any self-reported diagnosis may be taken as a
true doctor-diagnosis, consistent with diagnoses after 1990; that is, the false-positive
rate will be negligible. It is possible that diabetes cases may have been missed where
patients have not reported T2DM (false-negatives). The likely impact of the use of
self-report before 1990 would therefore be to underestimate the incidence of T2DM in
the earliest periods (1985-1989 and 1990-1994). The result of this bias would be
overestimation of the increase in incidence of T2DM over time. That said, the
possible underestimation of diabetes cases and subsequent bias is likely to be small as
previous studies have shown questionnaire self-report of diabetes to agree closely
with medical records, and in particular, have a high specificity (thus corresponding
low false negative rate)328-331.
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The two data sources share the same possible limitation of using cohorts to estimate
time trends (as opposed to repeated cross-sections of a population), that of the ageing
of the cohort over time. Since risk of major CHD increases with age, any residual
confounding by age would have led to underestimation of the favourable decline in
incidence. Adjustment was made for current age at each time-period to take account
of ageing, and although it remains possible that the effects of calendar time and age
have not been fully disentangled, the residual confounding is likely to be minor. The
comparability of the results with THIN supports this.
4.6.4 Comparison with other published data
4.6.4.1 Decline in incidence of major CHD
A previous BRHS analysis reported a consistent decline of 3.5% per annum between
1978 and 200020; a separate analysis of THIN data reported consistent declines by
country of up to 4.6% per annum between 1996 and 200524; the modest variations in
the sizes of the declines in incidence can be accounted for by the different time-
periods covered. Note that the THIN data analyses were published after the initial
drafting of this thesis, and did not consider trends by deprivation.
Referring back to chapter 2, section 2.2.2.1, those studies using other data sources
which considered major CHD incidence trends over time-periods coinciding at least in
part with the time-period covered (1980 to 2008) reported estimates of the average
annual changes ranging from a modest 1.4% decline in men and a 0.2% increase in
women in Glasgow between 1985 and 2004, to a decline of 4.6% among men in
Belfast between 1983 and 1993 (WHO MONICA)22. Separate studies in Scotland
report intermediate sized declines of 3.5% between 1990 and 200021 and 2.7-2.8%
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between 1986 and 20081. However, no studies consider time trends over the exact
same periods as covered here, making direct comparison difficult, as the relative
declines are in part influenced by the initial rate of incidence which varies depending
on the start year. Moreover, all these previous studies were limited to a single city or
region of the UK.
The OXMIS study estimated time trends in major CHD from 1966-7 to 1994-523, that
is over a calendar period predominately prior to calendar periods considered here.
Smaller average annual relative declines in age-standardised incidence of 1.2% in
men and 0.3% in women aged 30 to 69 years in Oxfordshire were observed,
suggesting a smaller rate of decline in earlier years. Although again since the declines
are estimated relative to the incidence rate initially, and incidence in 1966-7 was that
much greater than at the start of the periods considered in the present analyses, the
absolute changes may not be dissimilar.
The similarity of the time trends by gender in the present analyses is in line with
findings from Scotland of similar average annual declines of 2.7% and 2.8% among
men and women respectively between 1986 and 20081. The smaller declines in
women relative to men reported in the WHO MONICA and OXMIS studies could
reflect the earlier time period; the similar trends by gender observed in the present
analysis may suggest therefore that women are now catching up with men in terms of
improving CHD incidence. No studies from other data sources have considered time
trends in incidence by socio-economic status.
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4.6.4.2 Rise in incidence of T2DM
A separate analysis of THIN data reported a trend of 5.2% per annum in T2DM
incidence between 1996 and 20056; this is consistent with the observed trend in the
current analysis of 5.37%, when limited to a similar period 1995-2006. The smaller
increase of 3.6% per annum observed for the whole period from 1995 to 2008 reflects
the “flattening” of the trend in the most recent years, as shown in section 4.4. Notably
in line with the present analysis, a figure in the paper also shows a jump in incidence
in 1999-2000 followed by a tailing off towards the end of the follow-up, although the
authors do not remark on this. The THIN data analyses were published after the
initial drafting of this thesis, and did not consider trends by deprivation or country.
Referring to chapter 2, section 2.3.2.1, three previous studies using other data sources
estimate time trends in diabetes incidence over time-periods coinciding at least in part
with the time-period covered (1985 to 2008)4, 25, 26. The average annual increases in
incidence estimated in these studies were 5.2% and 6.3% among men and women
respectively in the nationwide General Practice Research Database (GPRD )25
between 1996 and 2006; 6.3% in Tayside, Scotland between 1993 and 2004 (DARTS
Clinical Information System data)4; and 4.8% in the GPRD again, over an earlier
period from 1994 to 199826. These estimates are consistent with the findings in the
present analysis, once the “flattening” of the trend beyond 2004 is taken into account.
The two GPRD studies both showed similar trends by gender in line with the present
study findings. No previous studies were found which examine the temporal trend in
T2DM in the most recent years from 2005 onwards so it was not possible to verify the
apparent lack of increase in T2DM in this period. Also no studies considered trends
in major CHD or T2DM incidence according to socio-economic status or country.
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4.6.5 Interpretation of findings
4.6.5.1 Is the decline in major CHD incidence a true epidemiological change in the
population?
The various analyses using the different data sources suggest a fall in the incidence of
major CHD from 1980 to 2008. An important question however is whether this
apparent fall in incidence is a true epidemiological shift in incidence in the
population, that is, fewer people experiencing a major CHD event, reflecting changes
in the risk profile in the population or improved primary preventive treatments. As
discussed in chapter 2, section 2.5.1, the alternative is that the trend is (in some part)
an artefact of changes in factors such as the methods used to identify cases in the
current analysis, case ascertainment (that is, the proportion of all major CHD events
occurring that are known and do not go undiagnosed), changes in diagnostic criteria
and, for fatal CHD events, which may be ascertained from death certificates, changes
in the coding of cause of death.
It was outlined in chapter 3 that for major CHD, within each study the same methods
have been used throughout the follow-up to capture major CHD cases as recorded in
the GP records, and therefore changes in the method used within each study to
identify major CHD events cannot account for the time trend in major CHD events
seen. Given the nature of major CHD events, normally with evident serious
manifestations, case ascertainment (that is, the proportion of all major CHD events
occurring that are known and do not go undiagnosed) is unlikely to be a major issue,
unlike for T2DM which can go undiagnosed. A major change in the diagnosis of MI
occurred in 2000, with the introduction of the measurement of cardiac troponins as the
new reference standard for diagnosing myocardial injury87, compared with the prior
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World Health Organisation (WHO) definition of acute MI of unequivocal
electrocardiogram (ECG) changes and/or unequivocal enzyme changes88, 89. The
likely impact of the introduction of the use of troponins is an increased sensitivity,
with more events classed as major CHD events which might not have been previously
classed as such90-92. This in turn would lead to, if anything, underestimation of the
decline in major CHD incidence, particularly when comparing the periods before and
after 1999, thus does not help to explain the decline observed. The steady trend seen
over the whole period, with no obvious discontinuity around 1999 suggests further
that the diagnostic change has had limited impact. In terms of fatal events, it was
shown above that not all fatal events are captured in THIN, and of those that are, only
a proportion will likely have been identified only from the death certificate, and then
coded as Read codes. Thus any changes in the coding of cause of death on the death
certificates (using the International Classification of Diseases (ICD) coding system) is
unlikely to have much impact. For the BRHS and Whitehall II analyses, ICD coding
changes could have greater influence. As detailed in Chapter 2, section 2.5.1, the main
changes over the period of study (1980 to 2008) were over the period 1984-92 when
direct causes of death could be coded less often, while more secondary causes could
be coded more often, and in 2001 when ICD-9 was replaced by ICD-10. Previous
studies however suggest that both these changes have had minimal impact on CHD
mortality trends332, 333. Janssen et al333 considered the impact of the coding rule
change between 1984 and 1992; a 1% increased mortality rate was observed
immediately after the coding rule change, but it could not be ruled out as being an
outlying estimate and this small discontinuity is unlikely to have had a dramatic
influence on the observed trends, especially since the decline in mortality was greatest
from the 1980s onwards. Griffiths et al332 then considered the impact on the decline in
179
CHD mortality of the most recent (and considerable) ICD-revision in 2001. The
findings were that there was little difference in CHD mortality rates under the
different coding systems (ratio comparing the two rates = 1.005) such that the
influence on the time trends in CHD mortality is likely to be minimal.
Finally, one study suggested that the introduction of the Quality and Outcomes
Framework (QOF) for managing CHD patients in General Practice in 2003 may have
had the impact of GPs reviewing and verifying records, leading to the removal of
incorrect (false positive) CHD codes, since fewer events were found in a more recent
download of GP data compared to an earlier pre-QOF version334. If incidence trends
are computed comparing different data downloads, this could lead to spurious
declines in incidence; however as the same data download of THIN was used for all
calendar years in the present analysis, this observation is unlikely to influence the
present observed CHD incidence trends estimates. Ultimately, this all implies that the
decline observed may be a real epidemiological change, reflecting risk factor trends
and treatment changes, rather than induced by a change in diagnostic criteria.
4.6.5.2 Is the rise in T2DM incidence a true epidemiological change in the
population?
The different data sources showed an increase in incidence of T2DM at least from the
mid 1980s to the early 2000s, although no significant increase in incidence was
observed beyond the early 2000s. The year-on-year analysis of THIN data showed
further an apparent “jump” in incidence around 1999. Again a key question is
whether the pattern in incidence observed reflects true epidemiological changes in the
proportion of the population developing T2DM over calendar time, or whether the
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pattern is in some part an artefact of changes in diagnostic criteria, case ascertainment,
health policy and so forth. Methods employed in the analysis of THIN data for
capturing T2DM diagnoses were consistent throughout the follow-up, and while
methods in the BRHS did differ (self report versus later review of GP records), this is
unlikely to have had a substantial influence on the trends estimates as explained in
section 4.6.3.
Diagnostic criteria for diabetes changed in the late 1990s, with the publishing of new
criteria from the American Diabetes Association in 199793 and then from WHO in
199994. As outlined in chapter 2, section 2.5.1, the key difference in these new
criteria, compared with the existing WHO criteria used before this time95, was the
greater emphasis on the use of fasting glucose (as opposed to previous criteria based
mainly on post-load glucose measurements) along with a reduced diagnostic fasting
glucose threshold to indicate diabetes of 7.0 mmol / l rather than 7.8 mmol/ l
previously. The change in the type of measurements taken, from use of post-load
glucose measurements to fasting glucose has been shown to lead to different patients
being identified as having T2DM, but, the impact of the change in criteria on
prevalence and incidence rates is not fully resolved, with studies having different
conclusions335-339. In studies in the US335, 337, 338 prevalence estimates were lower
using the new criteria, compared to the old, implying if anything, the changing criteria
may lead to underestimation of the rise in T2DM. This was because, in these
populations, it was more common for patients to have above threshold levels of post-
load glucose but not fasting glucose, rather than vice-versa. For example, in the US
NHANES population, of all T2DM cases identified using either criteria, 41% met just
the old post-load criteria compared with 14% meeting just the new fasting glucose
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criteria and 44% meeting both criteria338. This study also estimated prevalence of
T2DM at different time-points using first the existing criteria throughout, and then the
new criteria throughout. It found that whether the new or old criteria were used,
prevalence had increased over time. Conversely, some studies in the UK and
Europe336, 339 suggest that the new diagnostic criteria may have led to an increase in
the number of patients diagnosed with T2DM, who might previously not have been
identified as such, and therefore may explain some of the increase in T2DM incidence
and prevalence over time. This is because in these populations, it was more common
for patients to have above threshold levels of fasting glucose but not post-load
glucose, rather than vice-versa. For example, in the UK, out of all T2DM cases
identified by either criteria, 42% met just the new fasting glucose criteria, while 18%
met just the old post-load glucose criteria and 40% met both, a pattern that persisted
stratifying by ethnic group336.
Recommendations on cardiovascular prevention from the late 1990s97 and the
introduction of QOF for managing diabetes patients in General Practice in 2004 may
have increased awareness of T2DM and so increased T2DM ascertainment. Studies
have investigated the impact of QOF on management of patients with T2DM with
mixed findings340-342, but the impact of QOF on case-ascertainment or incidence is
unclear. Studies estimating case-ascertainment of T2DM in the UK together suggest
that ascertainment stood at around 50% between the 1980s343 and 2000344, but could
have increased to over 80% in 2004-2005345, 346 (post QOF). However as the
estimates at the different time points come from different studies on different sections
of the UK population, a direct comparison may not be fair. Moreover, the 2004-2005
estimate, from a report by the National Diabetes Audit, is calculated from a predicted
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overall diabetes prevalence, based on prevalence observed from surveys carried out
more than 20 years ago and assuming T2DM incidence has remained constant since,
and may appreciably underestimate the extent of undiagnosed disease, if incidence of
T2DM has in fact risen. Morgan et al consider the issue from an alternative
perspective, in their paper on changes in complications of T2DM71. They found that
T2DM patients in 2004 had fewer complications than patients in 1996, and argued
that this could be indicative of improved case-ascertainment, as more T2DM patients
with less severe symptoms may have been identified through routine screening, rather
than as a result of the occurrence of a complication. Incidence of T2DM remained
constant or even appeared to decline after the implementation of QOF, so QOF does
not appear to explain rising T2DM incidence. Instead, the introduction of QOF
appears to have led to a change in coding, with a fall in the use of general diabetes
codes after 2002 (figure 4.4). This is supported by Calvert et al, who also noted a
change over time from general diabetes codes to specific diabetes codes, reflecting the
codes used to define diabetes in QOF rules340.
The change in diagnostic criteria and introduction of cardiovascular prevention
recommendations do coincide with the “jump” in incidence in 1999 so increased
ascertainment arising from the recommendations and/or the changing diagnostic
criteria may help to explain some of the rising incidence at this point. That said,
according to the BRHS analysis, incidence of T2DM has been increasing well before
1999 so the change in diagnostic criteria and cardiovascular recommendations are
unlikely to completely explain the rise in incidence.
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To summarise, before around 1999, there appeared little in the way of changes in
diagnostic criteria or policy that could have influenced incidence rates of T2DM, thus
before 1999 it appears that the increase may be a true epidemiological trend reflecting
changes in the risk profile of the British population. After 1999, the situation is less
clear and it is possible that the true incidence rates in the more recent calendar years
have been influenced to some extent by changing diagnostic criteria and policy
recommendations leading to changes in case-ascertainment. Alternatively, T2DM
incidence may still be increasing at a background steady rate beyond 1999, and the
changes in diagnostic criteria and policy are simply affecting when the new cases are
identified. That is, without the changes, we would still see a steady rise in incidence,
rather than the jump in 1999.
4.6.5.3 Relation to trends in mortality of CHD and prevalence of T2DM
The findings from this chapter suggest that, at least from the 1980s onwards, the
decline in mortality from CHD may be partially explained by a fall in incidence of
major CHD events, that is fewer people experiencing a major CHD event in the first
place. Similarly the rise in prevalence of T2DM, at least from the mid 1980s until the
late 1990s, may be seen to reflect at least in part a rise in incidence of T2DM, that is
an increase in the number of patients developing T2DM. The apparent rise in
incidence beyond 1999 to the early 2000s may also explain the observed rise in
prevalence over this later period, but the extent to which the increase in incidence, and
therefore prevalence, over this time is a true epidemiological increase in the numbers
of patients developing T2DM as opposed to reflections of increased case
ascertainment and diagnostic criteria changes, remains uncertain.
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That is not to say that changes over time in survival, particularly case fatality
following a major CHD event or relative mortality of diabetic patients compared with
the general population, could not also be contributing, if favourable time trends in
these events have also occurred. There is a lack of data on T2DM prevalence trends
beyond 2005 (see chapter 2, section 2.3.1) so it is unknown whether prevalence has
continued to increase in the last five years. It may be that prevalence has also
remained constant in line with the trend in incidence in the most recent years.
Alternatively, if prevalence has continued to increase, a continued rise in prevalence
over this time may instead be more likely to reflect an improvement in relative
mortality.
4.6.5.4 Impact of variations in trends by socio-demographic group
This chapter presents previously little reported trends in incidence of major CHD and
T2DM according to different socio-demographic characteristics. In particular, more
favourable trends occurred in less deprived groups: the rate of decline in major CHD
appeared faster while the rate of increase of T2DM was slower among those in more
professional/ senior employment grades compared with more junior grades or
unskilled occupations and in less deprived areas compared with more deprived areas.
Since incidence of both major CHD and T2DM was initially greater among more
deprived groups, the more favourable trends suggest a widening socio-economic
inequality in terms of T2DM and CHD incidence rates.
The finding of more a favourable trend in incidence of major CHD with increasing
socio-economic position, and a possible resultant widening socio-economic inequality
in incidence, reflects findings from previous studies showing more favourable trends
185
in CHD mortality with increasing socio economic position, both in the BRHS61 and in
other data sources54, 59, 60. Similarly the more favourable trend in incidence of T2DM
with increasing socio-economic position reflects previous study findings showing
more favourable trends in T2DM prevalence with increased socio-economic position
in the BRHS3; few other studies have considered time trends in prevalence by socio-
economic status. This highlights the correspondence between trends in major CHD
incidence and mortality and between trends in T2DM incidence and prevalence.
The apparent similarity in the rate of increase in T2DM and rate of decline of major
CHD by gender has resulted in men remaining at higher risk of both these conditions.
Regarding the trends by constituent country, the least favourable trends in both major
CHD and T2DM incidence (i.e. smallest relative decline in major CHD, and greatest
relative increase in T2DM) occurred in Northern Ireland, while the most favourable
trends occurred in Wales. Given the variations in the absolute incidence rates at the
start of the analyses, the effect of the differing time trends has generally been an
attenuation of the differences in incidence between the different countries.
The least favourable relative changes in incidence of T2DM and major CHD occurred
in the youngest age groups. This is concerning as it is these age groups which will
influence the future prevalence and burden of disease. For major CHD, this reflects
the observed flattening of the decline in CHD mortality in younger groups52-54.
4.6.6 Chapter conclusions/ post-script
In this chapter it has been shown that incidence of major CHD events has declined
since the 1980s among most demographic groups (although some groups have seen
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larger declines than others). It seems likely therefore that a decline in incidence of
major CHD has made an important contribution to the decline in mortality from CHD.
It was also shown that in contrast to the favourable trend in major CHD, incidence of
T2DM has risen, at least between the mid 1980s and early 2000s. Therefore it is
reasonable to suppose that the rise in T2DM incidence has made an important
contribution to the rise in prevalence of T2DM.
In the subsequent results chapters 5, 6, 7, and 8, the reasons for the rise in major CHD
incidence and fall in T2DM incidence will be explored. In particular the roles of
concurrent time trends in risk factors and preventive treatment will be investigated.
This in turn will shed further light on the factors leading to the fall in CHD mortality
and rise in T2DM prevalence, and help to unravel further whether the T2DM
incidence trends are true epidemiological changes or not.
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Table 4.1 Rates of incidence of major CHD per 1000 person-years by age, gender and calendar period: THIN database
Men Age, years
30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80+
Incidence rate per 1000 person-years (95% CI)
1995-
1999 0.12 0.37 0.73 1.65 2.63 4.26 5.64 7.37 9.34 11.46 11.64
(0.08 to 0.19) (0.29 to 0.47) (0.61 to 0.88) (1.46 to 1.86) (2.39 to 2.90) (3.90 to 4.64) (5.20 to 6.11) (6.84 to 7.94) (8.69 to 10.03) (10.63 to 12.37) (10.77 to 12.58)
2000-
2004 0.08 0.32 0.72 1.53 2.38 3.33 4.68 5.80 7.22 8.61 10.29
(0.06 to 0.11) (0.28 to 0.38) (0.64 to 0.80) (1.41 to 1.66) (2.23 to 2.54) (3.14 to 3.52) (4.43 to 4.94) (5.50 to 6.11) (6.85 to 7.61) (8.15 to 9.10) (9.79 to 10.81)
2005-
2008 0.08 0.25 0.66 1.27 1.99 2.58 3.52 3.95 5.13 6.03 8.12
(0.06 to 0.12) (0.20 to 0.30) (0.59 to 0.74) (1.16 to 1.38) (1.85 to 2.14) (2.42 to 2.74) (3.32 to 3.73) (3.71 to 4.20) (4.83 to 5.46) (5.65 to 6.43) (7.69 to 8.57)
Women Age, years
30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80+
Incidence rate per 1000 person-years (95% CI)
1995-
1999 0.04 0.08 0.21 0.29 0.59 1.42 2.00 3.33 4.78 6.06 7.87
(0.02 to 0.08) (0.05 to 0.14) (0.15 to 0.30) (0.21 to 0.38) (0.48 to 0.73) (1.22 to 1.64) (1.75 to 2.27) (3.00 to 3.69) (4.38 to 5.22) (5.57 to 6.59) (7.39 to 8.38)
2000-
2004 0.03 0.06 0.18 0.31 0.57 0.96 1.61 2.49 3.57 4.92 6.51
(0.02 to 0.05) (0.04 to 0.08) (0.15 to 0.23) (0.26 to 0.37) (0.50 to 0.65) (0.87 to 1.07) (1.47 to 1.76) (2.31 to 2.69) (3.34 to 3.81) (4.63 to 5.23) (6.24 to 6.80)
2005-
2008 0.03 0.05 0.14 0.32 0.56 0.70 1.03 1.70 2.45 3.62 5.85
(0.02 to 0.06) (0.04 to 0.08) (0.11 to 0.18) (0.27 to 0.38) (0.49 to 0.64) (0.62 to 0.79) (0.93 to 1.14) (1.55 to 1.86) (2.26 to 2.66) (3.37 to 3.89) (5.59 to 6.12)
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Table 4.2 Major CHD incidence rates in 1995-1997 and 2006-2008 and absolute
changes in incidence between the two periods, overall and by demographic group
Major CHD
incidence rate in
1995-1997, 95% CI
Major CHD
incidence rate in
2006-2008, 95% CI
Absolute change in
incidence, 95% CI
Overall 3.05 (2.96 to 3.15) 1.73 (1.70 to 1.76) -1.32 (-1.42 to -1.22)
By Demographic group
Age, years
30-39 0.14 (0.10 to 0.19) 0.11 (0.10 to 0.14) -0.02 (-0.07 to 0.02)
40-49 0.76 (0.67 to 0.87) 0.58 (0.54 to 0.62) -0.19 (-0.29 to -0.08)
50-59 2.27 (2.09 to 2.47) 1.45 (1.38 to 1.52) -0.82 (-1.02 to -0.62)
60-69 4.87 (4.57 to 5.19) 2.40 (2.30 to 2.50) -2.47 (-2.79 to -2.14)
70-79 8.44 (7.99 to 8.91) 4.01 (3.85 to 4.17) -4.43 (-4.92 to -3.94)
80+ 10.26 (9.60 to 10.97) 6.58 (6.33 to 6.85) -3.68 (-4.41 to -2.95)
Sex
Men 3.98 (3.83 to 4.15) 2.26 (2.21 to 2.32) -1.72 (-1.89 to -1.55)
Women 2.22 (2.11 to 2.34) 1.23 (1.19 to 1.27) -0.99 (-1.11 to -0.87)
Townsend
quintile of area
deprivation
1 (least
deprived) 2.36 (2.21 to 2.52) 1.38 (1.33 to 1.45) -0.97 (-1.14 to -0.81)
2 2.83 (2.65 to 3.03) 1.68 (1.61 to 1.76) -1.15 (-1.35 to -0.94)
3 3.18 (2.97 to 3.42) 1.77 (1.67 to 1.86) -1.42 (-1.66 to -1.17)
4 3.76 (3.50 to 4.02) 2.05 (1.94 to 2.16) -1.71 (-1.99 to -1.43)
5 (most
deprived) 4.01 (3.70 to 4.34) 2.24 (2.13 to 2.36) -1.77 (-2.10 to -1.43)
UK Country
England 3.05 (2.95 to 3.15) 1.70 (1.66 to 1.74) -1.34 (-1.45 to -1.24)
Wales 2.77 (2.41 to 3.20) 1.49 (1.34 to 1.66) -1.28 (-1.70 to -0.86)
Scotland 3.32 (2.84 to 3.88) 2.01 (1.85 to 2.19) -1.31 (-1.85 to -0.77)
Northern
Ireland 3.72 (2.97 to 4.65) 2.13 (1.93 to 2.35) -1.58 (-2.44 to -0.73)
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Table 4.3 Major CHD rate ratio per annum increase in calendar time between
1995 and 2008, and corresponding percentage decline in incidence, overall and
by demographic group
Major CHD Rate ratio
per annum increase in
calendar time, 95% CI
% decline in major
CHD incidence per
annum*, 95% CI
p-
value†
Overall 0.951 (0.948 to 0.954) 4.88 (4.59 to 5.18)
By Demographic group
Age, years
30-39 0.971 (0.947 to 0.996) 2.89 (0.40 to 5.32)
40-49 0.975 (0.964 to 0.986) 2.48 (1.36 to 3.58)
50-59 0.960 (0.952 to 0.967) 4.04 (3.31 to 4.77)
60-69 0.934 (0.929 to 0.940) 6.55 (5.97 to 7.13)
70-79 0.936 (0.931 to 0.942) 6.36 (5.82 to 6.89)
80+ 0.973 (0.966 to 0.979) 2.74 (2.12 to 3.36) <0.001
Sex
Men 0.951 (0.947 to 0.955) 4.92 (4.55 to 5.29)
Women 0.952 (0.947 to 0.957) 4.79 (4.30 to 5.27) 0.8
Townsend quintile of
area deprivation
1 (least deprived) 0.945 (0.939 to 0.951) 5.51 (4.91 to 6.11)
2 0.949 (0.942 to 0.955) 5.15 (4.54 to 5.76)
3 0.950 (0.944 to 0.957) 4.98 (4.34 to 5.62)
4 0.952 (0.946 to 0.959) 4.80 (4.15 to 5.44)
5 (most deprived) 0.963 (0.956 to 0.971) 3.69 (2.93 to 4.45) 0.007
UK Country
England 0.951 (0.948 to 0.954) 4.90 (4.58 to 5.22)
Wales 0.945 (0.933 to 0.958) 5.45 (4.16 to 6.73)
Scotland 0.947 (0.936 to 0.959) 5.28 (4.11 to 6.44)
Northern Ireland 0.959 (0.941 to 0.978) 4.07 (2.22 to 5.89) 0.5
Note: From multilevel Poisson models, adjusted for age and sex, with random intercepts to adjust for
practice variation. *Calculated from rate ratios (RR) as 100*(1-RR). †p-value for interaction between
calendar year and demographic factor, to assess for a difference in the time trends according to each
category of the demographic factor
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Table 4.4 Rates of incidence of T2DM per 1000 person-years by age, gender and calendar period: THIN database
Men Age, years
30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80+
Incidence rate per 1000 person-years (95% CI)
1995-
1999 0.33 0.72 1.53 2.32 3.53 5.06 6.93 7.44 7.94 7.56 5.84
(0.26 to 0.43) (0.60 to 0.86) (1.34 to 1.74) (2.09 to 2.57) (3.24 to 3.84) (4.68 to 5.49) (6.44 to 7.45) (6.90 to 8.01) (7.34 to 8.58) (6.89 to 8.30) (5.24 to 6.51)
2000-
2004 0.65 1.24 2.34 3.88 5.63 7.79 10.45 12.70 12.98 11.61 8.67
(0.57 to 0.73) (1.14 to 1.34) (2.19 to 2.49) (3.68 to 4.08) (5.39 to 5.87) (7.50 to 8.09) (10.07 to 10.84) (12.25 to 13.18) (12.47 to 13.51) (11.07 to 12.18) (8.21 to 9.15)
2005-
2008 0.71 1.47 2.80 4.46 6.66 7.94 10.41 12.49 12.59 11.82 8.46
(0.63 to 0.80) (1.36 to 1.59) (2.65 to 2.96) (4.26 to 4.67) (6.40 to 6.93) (7.65 to 8.24) (10.06 to 10.78) (12.04 to 12.96) (12.09 to 13.12) (11.26 to 12.40) (8.02 to 8.92)
Women
Age, years
30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80+
Incidence rate per 1000 person-years (95% CI)
1995-
1999 0.37 0.59 1.08 1.36 2.37 3.48 4.63 5.52 6.40 6.43 5.19
(0.29 to 0.48) (0.49 to 0.73) (0.92 to 1.26) (1.19 to 1.56) (2.13 to 2.63) (3.16 to 3.83) (4.24 to 5.05) (5.08 to 5.99) (5.92 to 6.91) (5.92 to 6.98) (4.80 to 5.62)
2000-
2004 0.51 0.91 1.53 2.47 3.60 4.98 7.56 8.97 10.07 9.12 7.32
(0.45 to 0.59) (0.83 to 1.01) (1.41 to 1.65) (2.32 to 2.64) (3.41 to 3.80) (4.75 to 5.22) (7.24 to 7.89) (8.61 to 9.36) (9.66 to 10.49) (8.72 to 9.55) (7.03 to 7.63)
2005-
2008 0.47 1.00 1.66 2.84 4.09 5.32 6.97 8.93 10.17 9.44 7.14
(0.40 to 0.54) (0.91 to 1.10) (1.54 to 1.78) (2.68 to 3.01) (3.88 to 4.30) (5.09 to 5.56) (6.68 to 7.26) (8.57 to 9.31) (9.75 to 10.6) (9.01 to 9.89) (6.85 to 7.45)
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Table 4.5 T2DM incidence rates in 1995-1997 and 2006-2008 and absolute
changes in incidence between the two periods, overall and by demographic group
T2DM incidence
rate in 1995-1997
(95% CI)
T2DM incidence
rate in 2006-2008
(95% CI)
Absolute change in
incidence (95% CI)
Overall 3.15 (3.07 to 3.23) 5.25 (5.19 to 5.31) 2.10 (2.00 to 2.20)
By Demographic group
Age, years
30-39 0.46 (0.39 to 0.55) 0.96 (0.90 to 1.01) 0.49 (0.40 to 0.59)
40-49 1.39 (1.26 to 1.54) 2.95 (2.86 to 3.04) 1.55 (1.39 to 1.72)
50-59 3.45 (3.23 to 3.70) 5.99 (5.85 to 6.14) 2.54 (2.26 to 2.81)
60-69 5.84 (5.50 to 6.19) 9.27 (9.07 to 9.48) 3.43 (3.03 to 3.83)
70-79 6.60 (6.20 to 7.02) 10.7 (10.5 to 11.0) 4.13 (3.64 to 4.63)
80+ 5.31 (4.83 to 5.83) 7.46 (7.18 to 7.75) 2.16 (1.59 to 2.73)
Sex
Men 3.44 (3.29 to 3.59) 6.06 (5.97 to 6.16) 2.63 (2.45 to 2.80)
Women 2.82 (2.69 to 2.95) 4.49 (4.41 to 4.57) 1.67 (1.52 to 1.82)
Townsend quintile of area
deprivation
1 (least deprived) 2.39 (2.24 to 2.55) 4.34 (4.24 to 4.45) 1.95 (1.76 to 2.14)
2 2.86 (2.68 to 3.06) 4.79 (4.67 to 4.91) 1.92 (1.69 to 2.15)
3 3.04 (2.83 to 3.27) 5.32 (5.19 to 5.46) 2.28 (2.02 to 2.54)
4 4.08 (3.81 to 4.36) 6.04 (5.88 to 6.20) 1.96 (1.65 to 2.28)
5 (most deprived) 4.14 (3.82 to 4.47) 7.06 (6.85 to 7.28) 2.93 (2.54 to 3.32)
UK Country
England 3.11 (3.01 to 3.21) 5.18 (5.12 to 5.25) 2.08 (1.95 to 2.20)
Wales 3.02 (2.63 to 3.46) 5.46 (5.21 to 5.72) 2.44 (1.96 to 2.93)
Scotland 3.44 (2.95 to 4.01) 5.79 (5.56 to 6.03) 2.35 (1.77 to 2.92)
Northern Ireland 2.83 (2.19 to 3.67) 5.26 (4.93 to 5.60) 2.42 (1.62 to 3.23)
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Table 4.6 T2DM rate ratio per annum increase in calendar time between 1995
and 2008, and corresponding percentage increase in incidence, overall and by
demographic group
T2DM Rate ratio per
annum, 95% CI
% increase in T2DM
incidence per
annum*, 95% CI
p-
value†
Overall 1.036 (1.034 to 1.038) 3.60 (3.37 to 3.83)
By Demographic group
Age, years
30-39 1.050 (1.039 to 1.062) 5.02 (3.87 to 6.19)
40-49 1.055 (1.048 to 1.062) 5.49 (4.82 to 6.17)
50-59 1.043 (1.038 to 1.048) 4.32 (3.83 to 4.81)
60-69 1.029 (1.025 to 1.033) 2.91 (2.49 to 3.33)
70-79 1.034 (1.029 to 1.039) 3.39 (2.93 to 3.86)
80+ 1.025 (1.018 to 1.032) 2.51 (1.81 to 3.21) <0.001
Sex
Men 1.039 (1.036 to 1.042) 3.89 (3.58 to 4.20)
Women 1.033 (1.030 to 1.037) 3.34 (3.00 to 3.68) 0.02
Townsend quintile of
area deprivation
1 (least deprived) 1.034 (1.030 to 1.039) 3.43 (2.96 to 3.91)
2 1.031 (1.026 to 1.036) 3.12 (2.63 to 3.60)
3 1.039 (1.034 to 1.044) 3.86 (3.36 to 4.35)
4 1.035 (1.030 to 1.040) 3.52 (3.02 to 4.03)
5 (most deprived) 1.050 (1.044 to 1.056) 4.99 (4.40 to 5.58) <0.001
UK Country
England 1.036 (1.034 to 1.039) 3.62 (3.37 to 3.87)
Wales 1.027 (1.017 to 1.036) 2.65 (1.68 to 3.63)
Scotland 1.037 (1.027 to 1.046) 3.66 (2.69 to 4.63)
Northern Ireland 1.048 (1.032 to 1.065) 4.84 (3.22 to 6.49) 0.1
Note: From multilevel Poisson models, adjusted for age and sex, with random intercepts to adjust for
practice variation. *Calculated from rate ratios (RR) as 100*(1-RR). †p-value for interaction between
calendar year and demographic factor, to assess for a difference in the time trends according to each
category of the demographic factor
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Table 4.7 Rates of incidence of major CHD per 1000 person-years by age and calendar period: British Regional Heart Study men
Age group, years
40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84
Number of person-years of follow-up
1980-1984 3013.7 8307.8 8199.9 7882.4 5056.8
1985-1989 3050.1 8109.0 7852.4 7321.5 4426.2 114.0
Calendar 1990-1994 2940.4 7751.3 7214.9 6445.9 3704.3 94.4
period 1995-1999 2818.9 7294.8 6551.6 5492.1 2891.3 67.1
2000-2004 2627.0 5956.1 5022.3 3744.7 1627.3
Number of incident major CHD events
1980-1984 7 28 54 58 55
1985-1989 10 55 59 90 64 1
Calendar 1990-1994 21 35 72 74 67 1
period 1995-1999 18 43 56 80 51 4
2000-2004 16 58 63 68 32
Incidence rate per 1000 person-years (95% CI)
1980-1984 2.32
(1.11, 4.87)
3.37
(2.33, 4.88)
6.59
(5.04, 8.60)
7.36
(5.69, 9.52)
10.88
(8.35, 14.17)
1985-1989 3.28
(1.76, 6.09)
6.78
(5.21, 8.83)
7.51
(5.82, 9.70)
12.29
(10.00, 15.11)
14.46
(11.32, 18.47) NA
Calendar
period 1990-1994
7.14
(4.66, 10.95)
4.52
(3.24, 6.29)
9.98
(7.92, 12.57)
11.48
(9.14, 14.42)
18.09
(14.24, 22.98) NA
1995-1999 6.39
(4.02, 10.14)
5.89
(4.37, 7.95)
8.55
(6.58, 11.11)
14.57
(11.70, 18.13)
17.64
(13.41, 23.21)
2000-2004 6.09
(3.73, 9.94)
9.74
(7.53, 12.60)
12.54
(9.80, 16.06)
18.16
(14.32, 23.03)
19.66
(13.91, 27.81)
Notes: NA = not applicable: too few participants in this age group and period for reliable estimation of incidence rate; Trends in incidence over time can be seen by looking
down each age-group column
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Table 4.8 Rates of incidence of major CHD per 1000 person-years by age and calendar period: Whitehall II men
Age group, years
35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74
Number of person years of follow-up
1985-1989 4450.9 5796.5 4006.1 3985.3 1559.6
Calendar period 1990-1994 1202.0 8597.3 8776.0 6503.5 5976.2 1422.6
1995-1999 1092.1 7770.0 7929.1 5797.5 5302.9 1229.8
2000-2004 954.6 6686.5 6527.7 4770.9 4297.8 867.0
Number of incident major CHD events
1985-1989 0 8 7 19 13
Calendar period 1990-1994 0 6 12 21 28 11
1995-1999 3 18 20 22 26 7
2000-2004 2 13 22 25 23 1
Incidence rate per 1000 person-years (95% CI)
1985-1989 0
1.38
(0.69, 2.76)
1.75
(0.83, 3.67)
4.77
(3.04, 7.47)
8.34
(4.84, 14.35)
Calendar period 1990-1994 0
0.70
(0.31, 1.55)
1.37
(0.78, 2.41)
3.23
(2.11, 4.95)
4.69
(3.23, 6.79)
7.73
(4.28, 13.96)
1995-1999 2.75(0.89, 8.52)
2.32
(1.46, 3.68)
2.52
(1.63, 3.91)
3.79
(2.50, 5.76)
4.90
(3.34, 7.20)
5.69
(2.71, 11.94)
2000-2004 2.10(0.52, 8.38)
1.94
(1.13, 3.35)
3.37
(2.22, 5.12)
5.24
(3.54, 7.75)
5.35
(3.56, 8.05)
1.15
(0.16, 8.19)
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Table 4.9 Rates of incidence of major CHD per 1000 person-years by age and calendar period: Whitehall II women
Age group, years
35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74
Number of person-years of follow-up
1985-1989 1752.1 2401.4 2251.6 2603.8 1075.9
Calendar period 1990-1994 459.0 3210.2 3715.7 3522.1 3846.2 927.9
1995-1999 415.1 2850.5 3302.2 2954.8 3167.4 753.8
2000-2004 370.9 2404.5 2672.2 2280.8 2375.8 483.3
Number of incident major CHD events
1985-1989 0 2 0 3 4
Calendar period 1990-1994 1 0 2 10 5 1
1995-1999 0 2 1 8 9 3
2000-2004 0 1 3 5 14 1
Incidence rate per 1000 person-years (95% CI)
1985-1989 0
0.83
(0.21, 3.33) 0
1.15
(0.37, 3.57)
3.72
(1.40, 9.91)
Calendar period 1990-1994
2.18
(0.31, 15.47) 0
0.54
(0.13, 2.15)
2.84
(1.53, 5.28)
1.30
(0.54, 3.12)
1.08
(0.15, 7.65)
1995-1999 0
0.70
(0.18, 2.81)
0.30
(0.04, 2.15)
2.71
(1.35, 5.41)
2.84
(1.48, 5.46)
3.98
(1.28, 12.34)
2000-2004 0.42(0.06, 2.95)
1.12
(0.36, 3.48)
2.19
(0.91, 5.27)
5.89
(3.49, 9.95)
2.07
(0.29, 14.69)
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Table 4.10 Average annual age-gender-adjusted percentage declines in incidence of major CHD between 1980 and 2008 in the different
data sources, overall and according to socio-demographic characteristics
British Regional Heart Study, 1980 to 2004 Whitehall II cohort, 1985 to 2004 The Health Improvement Network, 1995 to 2008
Average annual decline in
hazard (95% CI), %
Average annual decline in
hazard (95% CI), %
Average annual decline in
rate (95% CI), %
Overall 3.30 (2.14, 4.46) Overall 4.24 (1.92, 6.51) Overall 4.88 (4.59 to 5.18)
Age group, years Age group, years Age group, years
40-49 3.75 (-11.9, 17.2) 40-49 -2.10 (-9.22, 4.57) 40-49 2.48 (1.36 to 3.58)
50-59 2.35 (-0.23, 4.86) 50-59 5.60 (2.89, 8.23) 50-59 4.04 (3.31 to 4.77)
60-69 3.57 (2.10, 5.02) 60-69 3.18 (-3.10, 9.07) 60-69 6.55 (5.97 to 7.13)
70-79 3.24 (0.20, 6.19) 70-79 6.36 (5.82 to 6.89)
Gender Gender
Men 4.35 (1.80, 6.84) Men 4.92 (4.55 to 5.29)
Women 3.72 (-1.99, 9.12) Women 4.79 (4.30 to 5.27)
Socio-economic status Employment grade Townsend quintile
I Professional 5.33 (0.37, 10.1) Civil Service grades 1-7 5.16 (1.79, 8.41) 1 (least deprived) 5.51 (4.91 to 6.11)
II Intermediate 3.42 (0.87, 5.91) Executive officer 4.10 (1.11, 7.00) 2 5.15 (4.54 to 5.76)
III Skilled non-manual 4.41 (0.46, 8.20) Clerical 2.46 (-2.62, 7.28) 3 4.98 (4.34 to 5.62)
III Skilled manual 3.32 (1.55, 5.05) 4 4.80 (4.15 to 5.44)
IV Semi-skilled 1.78 (-1.66, 5.11) 5 (most deprived) 3.69 (2.93 to 4.45)
V Unskilled 1.40 (-3.99, 6.51)
[Armed forces 1.36 (-5.45, 7.74)]*
Constituent country Constituent country
England 2.94 (1.65, 4.21) England 4.90 (4.58 to 5.22)
Wales 6.61 (0.42, 12.4) Wales 5.45 (4.16 to 6.73)
Scotland 4.79 (1.58, 7.89) Scotland 5.28 (4.11 to 6.44)
*Socio-economic status in the BRHS listed in decreasing order with the exception of armed forces, which forms a distinct group of mixed status
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Table 4.11 Rates of incidence of T2DM per 1000 person-years by age and calendar period: British Regional Heart Study men
Age group,
years
55-59 60-64 65-69 70-74 75-79 80-84 85-89
Number of person-years of
follow-up
Calendar period 1995-1999 3028.5 7803.1 7327.5 6325.5 3288.8
2000-2004 2799.6 6943.1 6196.6 4780.5 2211.6
2005-2007 2229.3 3599.7 2872.9 1949.8 571.7
Number of incident T2DM
diagnoses
Calendar period 1995-1999 18 54 45 46 20
2000-2004 21 69 70 44 18
2005-2007 26 50 21 18 6
Incidence rate per 1000
person-years (95% CI)
5.94 6.92 6.14 7.27 6.08
Calendar period 1995-1999 (3.74, 9.43) (5.30, 9.04) (4.59, 8.23) (5.45, 9.71) (3.92, 9.43)
7.50 9.94 11.30 9.20 8.14
2000-2004 (4.89, 11.5) (7.85, 12.58) (8.94, 14.28) (6.85, 12.37) (5.13, 12.92)
11.66 13.89 7.31 9.23 10.50
2005-2007 (7.94, 17.13) (10.53, 18.33) (4.77, 11.21) (5.82, 14.65) (4.72, 23.36)
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Table 4.12 Rates of incidence of T2DM per 1000 person-years by age and calendar period: British Regional Heart Study men who have
survived to 2007 (end of follow-up)
Age group, years
45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85-89
Number of person-years of follow-up
1985-1989 2580.7 6598.7 5280.0 3502.2 1441.1
Calendar
period 1990-1994 2628.0 6570.2 5262.5 3484.6 1429.6
1995-1999 2587.1 6427.1 5138.5 3414.4 1392.8
2000-2004 2512.4 6175.2 4907.6 3265.3 1346.6
2005-2007 2147.4 3458.5 2645.9 1685.1 499.2
Number of incident T2DM diagnoses
1985-1989 3 19 9 6 2
Calendar
period 1990-1994 5 21 23 11 4
1995-1999 13 38 34 18 10
2000-2004 17 60 62 36 14
2005-2007 25 49 21 18 6
Incidence rate per 1000 person-years (95% CI)
1985-1989 1.16
(0.37, 3.60)
2.88
(1.84, 4.51)
1.70
(0.89, 3.28)
1.71
(0.77, 3.81)
1.39
(0.35, 5.55)
Calendar
period
1990-1994 1.90
(0.79, 4.57)
3.20
(2.08, 4.90)
4.37
(2.90, 6.58)
3.16
(1.75, 5.70)
2.80
(1.05, 7.46)
1995-1999 5.02
(2.92, 8.65)
5.91
(4.30, 8.13)
6.62
(4.73, 9.26)
5.27
(3.32, 8.37)
7.18
(3.86, 13.34)
2000-2004 6.77
(4.21, 10.88)
9.72
(7.54, 12.51)
12.63
(9.85, 16.2)
11.03
(7.95, 15.28)
10.40
(6.16, 17.55)
2005-2007 11.64
(7.87, 17.23)
14.17
(10.71, 18.75)
7.94
(5.17, 12.17)
10.68
(6.73, 16.95) NA
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Table 4.13 Average annual age-gender-adjusted percentage increases in incidence of T2DM between 1985 and 2008 in the different data
sources, overall and according to socio-demographic characteristics
British Regional Heart Study - all men, 1995 to 2007 British Regional Heart Study - survivors, 1985
to 2007
The Health Improvement Network, 1995 to 2008
Average annual increase
in hazard (95% CI), %
Average annual
increase in hazard
(95% CI), %
Average annual
increase in rate (95%
CI), %
Overall 5.33 (2.70, 8.02) Overall 7.69 (5.51, 9.92) Overall 3.60 (3.37 to 3.83)
Age group, years Age group, years Age group, years
30-39 5.02 (3.87 to 6.19)
40-49 5.49 (4.82 to 6.17)
50-59 6.30 (-1.48, 14.7) 50-59 4.32 (3.83 to 4.81)
60-69 5.83 (1.42, 10.4) 60-69 8.38 (5.37, 11.5) 60-69 2.91 (2.49 to 3.33)
70-79 5.16 (1.81, 8.61) 70-79 7.33 (3.78, 11.0) 70-79 3.39 (2.93 to 3.86)
Gender
Men 3.89 (3.58 to 4.20)
Women 3.34 (3.00 to 3.68)
Socio-economic status Socio-economic status Townsend deprivation quintile
I Professional 5.07 (-2.44, 13.2) I Professional 6.98 (2.47, 11.7) 1 = least deprived 3.43 (2.96 to 3.91)
II Intermediate 2.57 (-2.08, 7.44) II Intermediate 3.98 (0.83, 7.23) 2 3.12 (2.63 to 3.60)
III Skilled non-manual 3.44 (-3.89, 11.3) III Skilled non-manual 7.40 (2.88, 12.1) 3 3.86 (3.36 to 4.35)
III Skilled manual 6.86 (3.01, 10.9) III Skilled manual 9.68 (6.98, 12.5) 4 3.52 (3.02 to 4.03)
IV Semi-skilled 7.70 (0.10, 15.9) IV Semi-skilled 7.76 (3.00, 12.7) 5 = most deprived 4.99 (4.40 to 5.58)
V Unskilled 16.5 (4.97, 29.4) V Unskilled 14.7 (8.52, 21.3)
[Armed forces -5.97 (-17.8, 7.54)]* [Armed forces 4.9 (-3.34, 13.9)]*
Constituent country Constituent country Constituent country
England 4.65 (1.84, 7.53) England 7.36 (5.01, 9.77) England 3.62 (3.37 to 3.87)
Wales -0.74 (-14.3, 14.9) Wales 1.90 (-10.2, 15.7) Wales 2.65 (1.68 to 3.63)
Scotland 6.31 (-0.97, 14.1) Scotland 11.3 (4.75, 18.3) Scotland 3.66 (2.69 to 4.63)
*Socio-economic status in the BRHS listed in decreasing order with the exception of armed forces, which forms a distinct group of mixed status
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Figure 4.1 Flowchart illustrating derivation of THIN cohort for analysis of time
trend in major CHD incidence
Patients permanently registered
with consistent data =
6,944,448
Patients in practices with
postcode level data = 8,002,476
in 434 practices
Exclude 11 practices with no postcode
level data including area deprivation
Exclude patients temporarily registered
or whose birth, death, registration and
transfer dates and status are not all
consistent with each other or who are
neither male nor female
Patients registered for at least
one year and present for some
time between 1995 and 2008 =
4,856,522
Exclude patients not present between
1995 and 2008, with at least one year’s
data after registration (to ensure patient
history captured)
Patients aged between 30 and
100 years = 3,094,893
Exclude patients under 30 at end of
follow-up or over 100 before start
Patients with no prior major
CHD event = 3,037,907
MAJOR CHD INCIDENCE COHORT
1,421,694 men
1,505,443 women
Patients with all demographic
data for analyses = 2,927,137
Exclude 56,986 patients with a record of
a major CHD event prior to start of
follow-up
Exclude patients with incomplete
demographic data
Start: Total patients in practices
contributing data to THIN
between 1995 and 2008 =
8,184,975 in 445 practices
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Figure 4.2 Flowchart illustrating derivation of THIN cohort for analysis of time
trend in T2DM incidence
Patients permanently registered
with consistent data =
6,944,448
Patients in practices with
postcode level data = 8,002,476
in 434 practices
Exclude 11 practices with no postcode
level data including area deprivation
Exclude patients temporarily registered
or whose birth, death, registration and
transfer dates and status are not all
consistent with each other or who are
neither male nor female
Patients registered for at least
one year and present for some
time between 1995 and 2008 =
4,856,522
Exclude patients not present between
1995 and 2008, with at least one year’s
data after registration (to ensure patient
history captured)
Patients aged between 30 and
100 years = 3,094,893
Exclude patients under 30 at end of
follow-up or over 100 before start
Patients with no prior diabetes
diagnosis = 2,960,879
Patients with no T1DM,
gestational diabetes or non-
standard diabetes diagnoses at
any time = 3,076,336
Patients with all demographic
data for analyses = 2,853,030
Start: Total patients in practices
contributing data to THIN
between 1995 and 2008 =
8,184,975 in 445 practices
T2DM INCIDENCE COHORT
1,393,366 men
1,459,664 women
Exclude patients with records any time of:
Medication-induced diabetes 271
Secondary diabetes 52
Diabetes related to malnutrition 46
Other non-standard diabetes 21
Gestational diabetes 4,549
T1DM 13,618
Exclude 115,457 patients with existing
diabetes at start of follow-up
Exclude patients with incomplete
demographic data
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Figure 4.3 Trends over calendar time in use of different types of Read codes for
incident major CHD among patients aged 30 years and over in the THIN
database
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Figure 4.4 Trends over calendar time in use of different types of Read codes for
incident diabetes among patients aged 30 years and over (therefore assumed to
be T2DM) in the THIN database
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Figure 4.5 Time trend in the rate of incidence of major CHD per 1000 person-
years by gender: THIN database
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Figure 4.6 Time trend in the rate of incidence of T2DM per 1000 person-years by
gender: THIN database
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Chapter 5: Analysing the role of trends in aetiological exposures in
the time trend in major coronary heart disease incidence in the
British Regional Heart Study
5.1 Introduction
In chapter 4 it was shown that considerable favourable secular time trends in
incidence of major coronary heart disease (CHD) have occurred in the UK in recent
decades, contributing to an overall decline in CHD mortality rates. In particular in the
British Regional Heart Study (BRHS) cohort, a 57% decline in the incidence of major
CHD over 25 years from 1980 to 2004 was observed, adjusting for age.
Understanding the reasons for the favourable time trend in CHD incidence may help
to inform future efforts to reduce CHD further, both in the UK and in other locations.
As shown in chapter 2, table 2.1, few studies worldwide have been able to examine
the contribution of changes in lifestyle factors or interventions, either individually or
in combination, to time trends in CHD incidence13, 17, 298. The one previous study
incorporating sections of the UK population, was based on aggregate data and thus
subject to limitations of ecological analyses13. It also included only two cities (Belfast
and Glasgow), which may not be representative of the wider UK population, and
focus was on explaining variations in major CHD trends between populations rather
than within populations. The aim of this chapter is therefore to explore the reasons
for the decline in major CHD incidence in the UK population. Specifically, the
principal objectives are to estimate secular trends in established aetiological exposures
and then to quantify the extent to which the decline in incidence of major CHD may
be attributable to the secular trends in these exposures. Data from the representative
BRHS will be used, enabling an individual-level analysis combining individual
aetiological exposure levels with CHD outcomes, to look at trends over 25 years from
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1978 in British men. This corresponds to objective iii)a) of the overall thesis
objectives.
The structure of this chapter is as follows: Section 5.2 details methods specific to this
section, including statistical methods. Section 5.3 presents results related to the first
objective, to estimate secular time trends in major CHD aetiological exposures.
Section 5.4 presents results related to the second objective, to quantify the
contribution of the trends in the aetiological exposures to the decline in incidence of
major CHD. Finally, section 5.5 provides a discussion and interpretation of the
findings of the chapter.
5.2 Methods
5.2.1 Data source
Analyses in this chapter are carried out using the BRHS, described in detail in chapter
3. As outlined in chapter 3, section 3.2.9, the BRHS is particularly suitable for this
analysis as CHD outcomes and risk factors levels have been concurrently monitored
over an extended period. Moreover a marked decline in incidence of major CHD was
demonstrated in the previous chapter 4, and the men recruited to the BRHS cohort are
Objectives
1. To estimate the secular time trends in major CHD aetiological exposures in
British men over 25 years since 1978
2. To quantify the contribution of the trends in the aetiological exposures to
time trends to the decline in incidence of major CHD over this time
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socially and geographically representative of men of the same age across Britain, at
least at recruitment in 1978-80. Follow-up data up to 31 December 2004 was used
for this analysis, as this was the most recent data available when the analysis was
carried out. This enables exploration of time trends over a quarter of a century.
Questionnaire/ examination data up to and including the examination at 20 years
follow-up in 1998-2000 were used.
5.2.2 Principal outcome of a first major CHD event
The principal outcome was a first major CHD event, defined as death with CHD as
the cause or a non-fatal myocardial infarction (MI), over the 25 year period between
baseline (1978-80) and 31 December 2004. Diagnosis methods are outlined in chapter
3, section 3.2.4.
5.2.3 Aetiological exposures
The risk factors considered as potential contributory factors to the CHD trends were
those lifestyle and clinical factors with strong evidence for a potentially causal
association with major CHD identified in chapter 2, section 2.5.2.1, and for which
repeated measurements are available in the BRHS. Specifically, the risk factors
considered were: cigarette smoking, systolic blood pressure (SBP), non-HDL
cholesterol (difference between total cholesterol and HDL cholesterol), HDL
cholesterol, alcohol consumption, physical activity, and BMI. Strong associations
between each of these risk factors and CHD have been established, as outlined in
chapter 2, section 2.5.2.1. Diet and diabetes were also identified as major aetiological
exposures, but repeated data on diet was not available, while the role of diabetes is
considered separately in chapter 9. Methods of ascertainment of each risk factor, and
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categorisations, are detailed in chapter 3, section 3.2.5. Risk factor data over the 20
year period from baseline (1978-80) to the 20-year follow-up examination (1998-
2000) were considered. Cigarette smoking status, alcohol consumption, physical
activity level and BMI data were available at each questionnaire time-point during the
follow-up, that is, at baseline (1978-1980), at 5 years (1983-5), in 1992, in 1996 and
at 20 years (1998-2000). Physical activity data was not collected at 5 years, and was
instead imputed as the “average” of levels at baseline and in 1992 (see chapter 3,
section 3.2.7). SBP, HDL and non-HDL cholesterol measurements were made at the
two physical examinations at baseline and at 20 years.
5.2.4 Statistical methods
As outlined in section 5.1, the main aim of this chapter is to explore and estimate the
secular time trends in the major coronary risk factors and the role that these time
trends have played in the decline in major CHD hazard. Key to addressing this aim is
the availability of repeated risk factor data at the different questionnaire/ examination
time-points in the BRHS. We can compare the risk factor levels in different
questionnaires at different time-points. A crucial point is that when comparing risk
factor levels at different time-points, we are not concerned with within-person
changes. Rather, we compare risk factor levels among men of a certain age at one
time-point with men who reach that same age at a different time point. Figure 5.1
serves to illustrate this, showing the age range of the men at each questionnaire time-
point. Because the age-range of the men at recruitment was wide, spanning twenty
years, from aged 40 to 60 years, there is considerable overlap in age between the
different time-points. Consider for example the youngest men at recruitment who
were 40 years old at say the latter part of the 1978-1980 recruitment period, that is
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recruited in 1980. At the five year follow-up in 1985 they were 45 years old and so
their risk factor and major CHD risk in 1985 may be compared with that at baseline of
other men aged 45 at baseline. Similarly, at the next follow-up date in 1992, they
were aged 52 years. And so on up to the 20 year follow-up in 2000 when, now aged
60, their risk factor data and major CHD risk in 1998-2000 may be compared with
that of the eldest men who were already approaching 60 years at baseline.
Importantly, by comparing men of the same age at the different time-points, rather
than looking at within-man changes, we are able to disentangle the “effect” of
calendar time from the effect of aging. For example, SBP tends to rise with age347
thus looking at within-man changes, any potential secular decline in SBP over
calendar time would likely be masked by the within-man rise with age.
To explore the secular between-time-point risk factor and major CHD trends some
restructuring of the data is needed. The follow-up for each man was split into five
consecutive periods, each of approximately five years, separated by the different
questionnaires/ examination time-points. Specifically the five periods were: period 1
from 1978-80 to 1983-5; period 2 from 1983-5 to 1992; period 3 from 1992 to 1996;
period 4 from 1996 to 1998-2000 and period 5 from 1998-2000 to 2004. Each period
is then treated as if corresponding to a separate individual, such that each of the 7735
men in the BRHS now contribute up to five “pseudo-individuals”, depending on
length of follow-up of each man: if a man dies or is lost to follow-up or experiences a
major CHD event, the man contributes to periods only up to and including the period
in which the death, CHD event or censoring occurs. Thus these men will correspond
to fewer than five new pseudo-individuals and there will be fewer pseudo-individuals
in the later periods. Each of these new pseudo-individuals has a “baseline” as the date
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of the questionnaire at the start of the relevant period, and “baseline” risk factor levels
as the risk factor levels in that questionnaire. Each pseudo-individual is followed-up
for major CHD for approximately five years, to the date of the next questionnaire.
The date of end of follow-up for each pseudo-individual is the minimum of the
following: date of major CHD event, date of non-CHD death, date of loss to follow-
up, date of next questionnaire. For the final period, starting at the latest questionnaire/
examination used in this analysis in 1998-2000, and for which there is no
questionnaire to mark the end of the period, the date of end-of follow-up is the
minimum of: date of major CHD event, date of death, date of loss to follow-up and 31
December 2004. Grouping pseudo-individuals at each period, we obtain five “sub-
cohorts”, each followed-up for approximately five years from “baseline”, at different
calendar periods, which are then compared to assess secular trends over time. From a
data handling point of view, splitting up the data in this way results in one large
dataset, with each row representing a different pseudo-individual, such that each of
the original 7735 men in the BRHS may have up to five rows of data. An illustration
of the dataset is shown below (not actual data):
ID of
man
pseudo-
individual
Pseudo-
baseline
qu’naire
Start date
of follow-
up for
pseudo-
individual
End date of
follow-up
for pseudo-
individual
Outcome
(major
CHD
event) for
pseudo-
individual
Date of
Outcome
Pseudo-
baseline
smoking
Pseudo-
baseline
BMI …
123456 A1 1978-80 01-Jun-79 01-Jun-84 0 current 25.1
123456 A2 1983-85 01-Jun-84 15-Oct-92 0 current 25.3
123456 A3 1992 15-Oct-92 10-Apr-96 0 current 26.0 …
123456 A4 1996 10-Apr-96 01-Jun-99 0 ex 26.2
123456 A5 1998-2000 01-Jun-99 31-Dec-04 0 ex 26.2
123457 B1 1978-80 08-May-80 08-May-85 0 current 28.2
123457 B2 1983-85 08-May-85 15-Oct-92 0 current 28.5 …
123457 B3 1992 15-Oct-92 21-Feb-94 1 21-Feb-94 current 29.0
123458 C1 1978-80 17-Mar-78 17-Mar-83 0 never 27.3
…
123458 C2 1983-85 17-Mar-83 07-Jan-87 0 never 28.2
… … … … … … … … … …
… … … … … … … … … …
211
The first five rows represent five pseudo-individuals derived from the first man (ID
123456), who survived until the very end of the follow-up on 31 December 2004,
without having a major CHD event. The next three rows represent three pseudo-
individuals derived from the second man (ID 123457), who had a major CHD event
on 21 February 1994, after which he no longer contributes to the study. The next two
rows represent two pseudo-individuals derived from a third man (ID 123458) who
died on 7 January 1987, of non-CHD causes, without having a major CHD event.
Simple cross-tabulations of each of the risk factors according to five-year age groups
and questionnaire/ examination time-point were carried out to enable an initial
exploration of how risk factor levels have changed over calendar time in the cohort.
Formal estimates of population-averaged changes over time in each risk factor, per
annum and over the 20-years from baseline (1978-80), were obtained from regression
modelling in this expanded dataset of the each risk factor on calendar time, with use
of generalised estimating equations (GEEs) with robust standard errors to take
account of dependency between repeated measures for each man. For each pseudo-
individual, the variable “calendar time” was computed as the time in years from the
very start of the study, at the first recruitment in 1978, to the date of the start of the
follow-up for each pseudo-individual. The coefficient of calendar time thus
corresponded to the per annum risk factor change, while multiplying the coefficient
by 20 gave an estimate of the 20 year changes. Age at the “baseline” for each pseudo-
individual (that is, at the date of the questionnaire at the start of the period to which
the pseudo-individual belongs) was included as a covariate (along with all significant
powers) to adjust for age and thereby isolate the effect of calendar time from the
effect of cohort aging. Specifically, population-averaged trends in the odds of being a
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current smoker, the odds of being least moderately physically active and the odds of
being a regular drinker over time were obtained from logistic regression with GEEs.
Linear regressions with GEEs were used to give estimates of the population-averaged
age-adjusted mean trends in each of the continuous variables (BMI, SBP, HDL and
non-HDL cholesterol).
The contribution of each risk factor trend to the decline in major CHD hazard was
assessed by comparing Cox proportional hazards regression models of incident major
CHD on “calendar time” in this expanded dataset of pseudo-individuals, with and
without adjustment for the risk factor at the pseudo-baseline for each pseudo-
individual. Age was used as the underlying time scale in these time-dependent Cox
regressions, with date of birth as a time origin, and age at the date of the “baseline”
for each pseudo-individual as a delayed entry time to take account of left truncation.
Use of an age time scale, as well as automatically adjusting for age325, also permitted
calendar time to be entered into the model as a covariate so that the change in the
hazard of major CHD with calendar time could be estimated. Follow-up time and
major CHD incidence were defined using the start and end dates and outcome for
each pseudo-individual defined above. Schoenfeld residuals were used to test the
proportional hazards assumption326. Robust standard errors were used to account for
the dependency between the different pseudo-individuals corresponding to the same
man.
The proportion of the decline in major CHD hazard statistically explained, or
attributable to, the risk factor trend is given by the expression (β0-β1)/β0, where β0 is
the coefficient of calendar time in a Cox regression model with just calendar time as a
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covariate, and β1 is the coefficient of calendar time in a Cox regression model
adjusting additionally for the risk factor(s)348. This is the percentage attenuation of the
calendar time coefficient in the presence of the risk factor(s). Bias-corrected
bootstrap re-sampling was used to give an approximate 95% confidence interval (CI)
for this estimate349. Physical activity, alcohol consumption and cigarette smoking
were entered into models as categorical class variables. BMI, SBP, non-HDL
cholesterol and HDL cholesterol were continuous. As data on SBP, non-HDL
cholesterol and HDL cholesterol were only available at the study baseline in 1978-80
and at 20 years in 1998-2000, to eliminate bias all models incorporating these
variables included only data from the first period (with 1978-80 as the pseudo-
baseline) and the last period (with 1998-2000 as the pseudo-baseline). In the above
expression coefficients of calendar time from these models were compared with the
coefficient from a separate unadjusted model also using this restricted follow-up data.
Squared terms in the continuous risk factor variables were included where significant
(non-HDL cholesterol and SBP).
The above methods to estimate the percentage of the decline in major CHD explained
by the risk factor trends, correspond to those used by Hu et al to investigate the
decline in major CHD in a cohort of women in the US17, as outlined in chapter 2,
section 2.7.1. The chief difference is that Hu et al use logistic regression to compare
the risk of major CHD in different periods, as opposed to the hazard of major CHD
from Cox regression (reflecting that the outcome in the study by Hu et al was
ascertained at intervals rather than continuously). Hu et al note the correspondence
between their pooled logistic regression analysis and time-dependent Cox
regression350. However, use of Cox regression is arguably a more powerful approach,
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as participants are included until the date of their event or exit from the study, rather
than only if they survive to the end of the relevant period (which is the case for
computation of risks in logistic regression which does not take into account person
time).
5.2.5 Participants included in analysis
All study men were included except those who had had a major CHD event before
baseline (n=952). Men who had a major CHD event during follow up were excluded
from the analyses of major CHD incidence after the time of their event. These men
were also excluded after the time of their event from the GEE regression analyses of
changes in risk factors so that the changes in the risk factors estimated from the GEE
analyses corresponded to changes among the disease-free population that may
therefore influence the trend in the hazard of a first major CHD event. Men with
angina (either at baseline or during follow up) were retained for analysis, unless they
also developed a major CHD event. Men missing data on any risk factor in a
questionnaire time-point were excluded from that time-point and the associated
follow-up, but included at other time points. Men missing some risk factor data in all
time-points were excluded from the analyses altogether (n=106).
Table 5.1 shows the numbers of men included in each questionnaire time-point (and
the associated subsequent follow-up period), which corresponds to the numbers of
men with no prior major CHD event and complete risk factor data at that time point.
6,751 men contributed risk factor data at at least one time-point and so could be
included in the main analyses to explain the major CHD time trends. Since follow-up
for major CHD was maintained for >98% of surviving men, the fall in the numbers of
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men contributing over time reflects the loss of those who had a major CHD event,
died or who did not provide risk factor information (by not responding to the
questionnaire or attending the examination), rather than loss to follow-up.
5.3 Results - Time trends in major coronary risk factors
Table 5.2 shows the distribution of the major coronary risk factors at each
questionnaire time-point among the study men, by 5-year age group. The secular time
trends in each risk factor may be seen by looking down each age-group column.
There was a clear decrease over time in the proportion of men who were cigarette
smokers within each age group. Indeed, from logistic regression with GEEs, the age-
adjusted population-averaged odds of being a current cigarette smoker declined by
73% (95% CI 68 to 78, p<0.001) between baseline and the 20-year follow-up. There
was no significant evidence of a change over this time in the proportion of men who
regularly drink, after adjusting for age (p=0.2, from logistic regression with GEEs).
Physical activity levels increased slightly, with the age-adjusted population-averaged
odds of being at least moderately active at 20 years follow-up being 1.91 (95% CI
1.62 to 2.24, p<0.001) times that at baseline. Over the 20-years, age-adjusted mean
BMI increased significantly by 1.89kg/m2 (95% CI 1.61 to 2.18, p<0.001), from linear
regression with GEEs. For example, between baseline and the 1996 questionnaire (an
average time of 17 years into the study), among 55-59 year olds mean BMI increased
from 25.4kg/m2 to 27.2kg/m2. Among 60-64 year olds mean BMI increased from
26.1kg/m2 at 5 years follow-up to 27.3kg/m2 at 20 years follow-up (a period of 15
years). The secular time trends in SBP, HDL and non-HDL cholesterol are not easily
ascertained from the Table 5.2, as these risk factors were only measured at two time
points 20 years apart with non-overlapping age ranges. However, linear regression
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with GEEs gave an estimate of an age-adjusted fall in mean SBP of 7.2mmHg (95%
CI 4.9 to 9.5, p<0.001) over the 20 years. Similarly, from linear regression with
GEEs, it was estimated that mean HDL cholesterol levels increased by 0.15mmol/L
(95% CI 0.12 to 0.19, p<0.001), adjusting for age, and mean non-HDL cholesterol
levels fell by 0.30mmol/L (95% CI 0.18 to 0.41, p<0.001), adjusting for age.
5.4 Results - Analysis of relation of trends in risk factors to trends in
major coronary heart disease incidence
Among the 6,751 men included in the main analysis, adjusting for age, the hazard rate
of major CHD fell by 3.8% (95% CI 2.6 to 5.0, p<0.001) per annum, corresponding to
a fall of 62% (95% CI 48 to 72) over 25 years from baseline. This is very close to the
57% estimate in chapter 4, section 4.5.1.3; the very modest difference reflecting
primarily the exclusion of non-responders (no risk factor data) in later years.
Estimates of the proportions of the decline in the hazard of major CHD over time
attributable to each risk factor time trend, derived using the technique outlined in
section 5.2.4, are presented in table 5.3. The largest single contribution was that of
the fall in cigarette smoking, which in isolation statistically explained 23% (bootstrap
95% CI 15 to 34) of the observed 62% decline in the hazard of major CHD over the
25 years from baseline. The fall in mean SBP explained 13% (bootstrap 95% CI 6 to
54) of the decline in hazard, the rise in mean HDL cholesterol explained 12%
(bootstrap 95% CI 5 to 42) and the fall in mean non-HDL cholesterol explained 10%
(bootstrap 95% CI 4 to 32). Physical activity explained a borderline significant part of
the decline (5%, bootstrap 95% CI 0 to 11). Alcohol consumption had little impact
(1% explained). The rise in mean BMI was adverse (-7% of the decline in major
CHD explained, 95% bootstrap CI -13 to -3), and, in the absence of changes in the
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other risk factors, would have been expected to lead to an increase, rather than a
decline, in the hazard of major CHD over time.
Taken together, the four factors which, singly, accounted for statistically significant
reductions in major CHD hazard (cigarette smoking, SBP, non-HDL cholesterol and
HDL-cholesterol) could explain 46% (bootstrap 95% CI 23 to 164) of the decline.
This figure is less than the sum of the individual contributions reflecting that the risk
factors are not independent from each other. The interpretation of the CI, with an
upper bound greater than 100%, is that the data are consistent (at the 95% confidence
level) with the risk factors explaining at least 23% of the decline in the hazard of
major CHD and at most an even greater decline than that observed. The addition of
physical activity and alcohol intake made little difference to this estimate (44%,
bootstrap 95% CI 22 to 149). There was no evidence of departure from the
proportional hazards assumption of the Cox regression.
The effect of adjustment for the (non-significant) laboratory measurement differences
in blood lipid measurements described in chapter 3, section 3.2.6, would be to reduce
the mean 20 year increase in the HDL cholesterol level from 0.16 mmol/L to 0.10
mmol/L, while leaving the decrease in non-HDL cholesterol levels unchanged at 0.28
mmol/L. On this basis, the contribution of HDL cholesterol to the observed decline in
MI hazard would be reduced from 12% to 7% (bootstrap 95% CI 3 to 29), while that
of non-HDL cholesterol levels would remain unchanged at 10%. The overall
combined contribution of the four major risk factors (smoking, blood pressure, non-
HDL, HDL cholesterol and physical activity) would be reduced from 46% to 43%.
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5.5 Discussion
5.5.1 Summary of main findings
Of the 62% decline in the hazard of major CHD in this cohort of British men over 25
years from 1978-80 to 2004, 46% could be explained by a combination of time trends
in the major coronary risk factors over this time: a fall in the number of cigarette
smokers (most powerful of all), a decrease in the mean SBP among the cohort, an
increase in mean HDL cholesterol and a decrease in mean non-HDL cholesterol.
Physical activity and alcohol consumption had relatively little impact. The rise in
mean BMI was counterproductive and, in the absence of changes in other risk factors,
would have been expected to lead to an increase, rather than a decline, in the
incidence of major CHD.
5.5.2 Comparison with other studies
In terms of the risk factor trends seen, the overall decline in SBP is consistent with
cross-sectional routine data for England reported in the Health Survey for England
1998351 and with SBP trends observed in Glasgow, Scotland (WHO MONICA)245,
(mean fall of 4.5mmHg over an overlapping 10-year period between 1986 and 1995
compared with our figure of 7.6mmHg over 20 years). Data on long-term trends in
cholesterol in the UK is limited, particularly for HDL cholesterol, although a separate
Health Survey for England report on cardiovascular disease and risk factors352
highlighted a significant decline in the prevalence of total cholesterol levels exceeding
5mmol/L between 1994 and 2006. The same report suggested that between 2003 and
2006 the prevalence of HDL cholesterol levels below 1mmol/L had increased in men,
contrary to our findings, which may be explained by the more recent time period,
short (3 year) follow-up and large age–range covering all ages, as opposed to middle
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to older age only. The Office for National Statistics General Household survey
reported a consistent decline in smoking prevalence in Great Britain from 47% among
men aged 50-59 years and 36% among men aged 60 or over in 1978 to 27% among
men aged 50-59 years and 16% among men aged 60 or over in 2000353. Data from the
Health Survey for England73, showed a comparable increase in BMI levels; mean
BMI in men aged 55-64 years increased from 27.1kg/m2 in 1993 to 27.9kg/m2 in
2000. Health Survey for England data also showed the proportion of men and women
meeting government recommended physical activity levels to have risen slightly from
32 to 36% in men in England from 1997 to 2003, the slight increase consistent with
that observed among the BRHS men over that period. The negligible change in
alcohol consumption among the BRHS men reflects national data over a concurrent
period353.
Few studies have looked directly at how time trends in risk factors correspond to time
trends in incidence of major CHD, and just one other study, by Hu et al., in a US
population, used individual data (US Nurses Health Study)17 and may be directly
compared with the chapter findings. In that study, outlined in chapter 2, section 2.7.1,
(which did not measure blood pressure or blood lipids) decreased smoking prevalence
accounted in isolation for 42% of the decline in CHD, changes in diet (particularly a
decrease in saturated fat, an increase in fibre) accounted for 52% and an increase in
post-menopausal hormone use accounted for 29%. In the presence of an adverse
change in BMI, 68% of the decline in incidence could be explained by combined
changes in smoking, diet and post-menopausal hormone use. The larger percentage of
68% of the decline explained by the risk factors may reflect the quality of exposure
assessment, and the influence of diet on a range of risk factors (including blood
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pressure and cholesterol). As outlined in chapter 2, section 2.5.2.2, the protective
effect of hormone replacement therapy is uncertain in the light of more recent
evidence that post-menopausal hormone use increases CHD risk170-173; discounting
hormone replacement therapy would bring the combined percentage explained closer
to our estimate. The WHO MONICA Project, based on aggregate data, suggested
that cigarette smoking, SBP and total cholesterol together explained approximately
38% of the variation in coronary event rates from the mid-1980s to the mid-1990s in
men in 27 different populations, including Belfast and Glasgow13. The individual
contribution of cigarette smoking was 20%, that of total cholesterol was 19% and that
of SBP was 6%, figures broadly consistent with the findings in the present study.
Note that in the WHO MONICA project, a different approach was adopted to that of
Hu et al and that employed in this study; risk factor levels were used to explain
variation between populations rather than variations in MI risk over time within a
single population. The IMPACT project used aggregate data to examine the influence
of different factors on the decline in CHD mortality in England15 and Scotland12 in
recent decades. The IMPACT project found that 52% of the decline in CHD mortality
in England between 1981 and 2000 could be accounted for by major risk factor
changes, with the decline in cigarette smoking accounting for 44% and changes in
blood pressure and total cholesterol accounting for close to 10% each15. Similar
proportions were observed in Scotland, with respect to the CHD mortality decline
between 1975 and 1994 (56% for all major factors, 36% for cigarette smoking and 6%
each for blood pressure and total cholesterol)12. These results correspond well with
the results from the present analysis in showing the relative importance of the risk
factors (in terms of the relative sizes of percentage contributions) to be the same.
None of these studies looked at the contribution of HDL cholesterol.
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This analysis is distinct from studies assessing the more familiar “population
attributable risk fraction” (PARF) of major CHD for given risk factors143, 354. In
studies of PARF, the objective is to assess the degree to which overall risk of major
CHD in a population is attributable to risk factors. In this study the objective is
instead to assess the degree to which the trend over time in major CHD risk in the
population is attributable to risk factor trends; in particular how much of the
favourable decline in major CHD may be attributable to risk factor improvements. As
well as a difference in the interpretation of the findings, the key difference in the
modelling is that overall risk of major CHD in a PARF calculation may be attributed
to a combination of modifiable risk factors, such as adiposity, and static risk factors,
such as genetics, while in contrast, trends over time in major CHD may be attributed
to only modifiable risk factors, which have changed over time in the cohort, thus the
relative contribution of factors may differ. Since the trends in major CHD may be
attributed only to modifiable risk factors, the analysis may arguably be considered to
have more immediate public health implications in terms of identifying ways to
reduce underlying risk of major CHD in a population. For comparison, the
INTERHEART study computed PARFs for (non-fatal) MI for men in Western Europe
as smoking 39%, exercise 38%, alcohol 14%, hypertension 21%, abdominal obesity
69% and lipids (combined) 37%143. Broadly speaking these figures concord with the
present findings, in particular the important roles of smoking, hypertension and lipids.
5.5.3 Strengths and limitations
This cohort is socially and geographically representative of British men of the same
age range, with the exception of ethnic minority groups. The representativeness is
substantiated by the observation in chapter 4, section 4.6.3, that the trends in major
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CHD incidence are consistent with those estimated in THIN and Whitehall II, and
other data sources, while mirroring trends in CHD mortality. Moreover, as detailed in
the previous section 5.5.2, the trends seen in risk factors in this cohort are consistent
with routine data for the UK.
A key strength is the relating of risk factor changes to coronary events within the
same population of individuals, avoiding the limitations of ecological analyses
predominantly used to study time trends258. Comparability between the risk factor
measurements at different time points is also very important in this analysis. As
detailed in chapter 3, sections 3.2.5 and 3.2.6, behavioural risk factor levels have been
recorded frequently and using consistent methods of ascertainment on each occasion.
Adjustment of the 20 year SBP measurements ensured comparability between the two
time-points. In subsidiary analyses adjusting for the non-significant systematic
differences between the baseline and 20-year lipid measurement techniques, the
conclusions did not change.
In this analysis the estimates of the risk factor trends, the major CHD time trend, and
the roles of the risk factors in the CHD time trend, are based on those who provided
risk factor information after baseline (through responding to questionnaires after
baseline and/ or attending the follow-up examination), rather than the whole study
population. The potential for survival or response biases needs consideration. The
most likely impact would be overestimation of the favourable trends observed in both
the risk factors and major CHD incidence, due to the healthy participant effect.
However, the similarity between the major CHD incidence trend estimates in the
BRHS in chapter 4, section 4.5.1.3 (whole cohort) and in the BRHS in this chapter
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(responders with risk factor data) suggests any such bias would be limited. In
addition, to explore the potential response or survivor effects on the risk factor trends
in this cohort, baseline levels of the risk factors among those who attended the 20-
year examination have been compared with levels among non-attendees355. The
differences between the baseline levels were generally small to negligible (mean
differences of 0.1kg/m2, 0mmol/l, 2.4mmHg and 1.2mmHg for BMI, total cholesterol,
SBP and DBP respectively), especially when compared with the overall changes over
time, suggesting that response or survivor effects were unlikely to have had a
dramatic influence on the observed trends (and therefore the contribution to the major
CHD decline). One exception is cigarette smoking; non-attendees were significantly
more likely to be cigarette smokers at baseline than attendees (prevalence of 47%
versus 32%), which may have led to overestimation of the smoking decline (and
therefore contribution to major CHD decline), although again, the difference between
the non-attendees and attendees is still small compared with the change in prevalence
over time.
The limited (two point) data on blood pressure and cholesterol necessitated restriction
of the follow-up time to the first five years and the last five years only to analyse the
contribution of these risk factors. The effect of using this restricted dataset on the
results was investigated by comparing estimates of the contribution of smoking,
alcohol consumption and physical activity computed using this restricted data with the
reported estimates for these risk factors computed from the full dataset. In all cases,
the contributions estimated from the limited dataset (17% for smoking, 0.2% for
alcohol, 2% for physical activity) were slightly smaller than the estimates from the
full dataset. This suggests that use of this limited data may if anything have led to
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underestimation of the contributions of blood pressure and cholesterol, assuming a
similar pattern. Physical activity imputed at Q5 (see chapter 3, section 3.2.7) could
lead to an induced trend in physical activity, however the likely influence on the
physical activity results is small as the observed trend in physical activity was in any
case modest.
Analyses have been based on the assumption that the effects of risk factor levels on
CHD outcomes occur within the time between consecutive questionnaires
(approximately five years). This could lead to underestimation of the effects of a risk
factor trend, if there is a lag time of more than five years before the benefits of a risk
factor change are realised. However, there is evidence that substantial benefits from
smoking cessation, changes in blood lipids and changes in blood pressure are realised
within five years356-358. The effects of regression dilution144, which could influence
both the extent of risk factor changes over time, and the estimates of risk factor
associations with MI risk, have also not been taken into account; this could influence
estimates of risk factor contributions in either direction. Overall statistical power and
precision of the analysis are limited, and bootstrap CIs are therefore wide, although in
the main informative. The cohort comprises older, mainly white, British men;
generalisability of the results of both analyses to other populations (women, younger
men, different ethnic groups or different countries) is uncertain. In chapter 6, trends in
major CHD incidence are analysed in the Whitehall II cohort, comprising men and
women, providing the opportunity to validate the findings in men in the BRHS in this
chapter with an external dataset, as well as to investigate how the results vary for
women.
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5.5.4 Interpretation of findings
In this cohort of older British men, half the decline in major CHD incidence may be
attributed to modest favourable time trends in cigarette smoking, blood lipids (HDL
and non-HDL cholesterol) and blood pressure.
According to the results, an appreciable proportion of the decline in major CHD
incidence remains unexplained. Changing diagnostic criteria for major CHD was
ruled out as a possible explanation for the observed major CHD decline in chapter 4,
section 4.6.5.1. It remains possible that this unexplained decline is also accounted for
by changes in the risk factors evaluated in this analysis (reflecting imprecision in the
analysis leading to underestimation of the risk factor contributions). Alternatively,
although several major cardiovascular risk factors have been considered, trends in
other risk factors, outlined in chapter 2, section 2.5.2.1, could be influential. These
include particularly diabetes (predominantly T2DM) and aspects of diet. Given that
T2DM incidence is rising, and T2DM is associated with an increased risk of major
CHD, T2DM trends will not help to explain the decline in major CHD incidence.
Rather, the rising T2DM will more likely have limited the decline in major CHD, as
for BMI. The relationship between the trends in T2DM and in major CHD is
explored in chapter 9. Diet was not measured longitudinally in this study population
so it was not possible to consider the influence of this factor on the time trends. It is
likely that diet operates on CHD risk at least in part through changing blood pressure
and blood lipid levels, and through BMI. However it may also have some independent
influence. In the Whitehall II cohort certain aspects of diet were measured at repeated
intervals, therefore enabling exploration of the role of diet when the analyses are
carried out on this cohort in chapter 6.
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The unexplained portion of the decline could also reflect other risk factors such as
psychosocial factors, and stress122-126, provided favourable time trends in these factors
have occurred. Life course influences134-139 could be important too, if birth cohort
effects are operating. Previous studies suggest that period, rather than cohort effects
dominate the CHD trends52, 145-147, which would suggest limited impact of early life/
life course influences, however further research is needed to confirm this. Increasing
availability of early treatment, particularly revascularization, for angina (especially
unstable angina) may play a role, although in chapter 2, section 2.5.2.2, it was noted
that the evidence for revascularisation as a primary prevention measure for a major
CHD event is weaker than for the effectiveness of revascularisation as secondary
prevention168. Moreover, the relative low occurrence in the population of
revascularisations as primary prevention suggests that the impact of revascularisations
may be modest at best. Indeed data from the Minnesota Heart Survey suggest
increased numbers of coronary artery bypass grafts (CABGs) in the Minnesota
population explained a modest 6% of the decline in CHD mortality over 14 years292;
since this includes CABGs following a major CHD event, the figure for explaining
CHD incidence trends is likely to be lower. Increasing use of evidence-based
medications (primarily statins152-155 and anti-hypertensive drugs156-160, as outlined in
chapter 2, section 2.5.2.2) may be likely to influence major CHD incidence primarily
through changing blood pressure and blood lipid levels in primary prevention at
least153, 160. The analyses presented here do not distinguish between improvements in
blood pressure and blood lipids due to lifestyle changes and those due to medication
use. In chapter 7, the role of increasing use of evidence-based medications in the
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favourable trends in these risk factors (and by extension, in the CHD decline) will be
explored.
The rise in population BMI during the past 25 years in the UK has almost certainly
reduced the scale of the decline in CHD that has occurred, though its effects have
been outweighed by the favourable changes in cigarette smoking, blood lipids and
blood pressure. The potential for further reductions in CHD in the UK population
through cigarette smoking is constrained by the already low remaining cigarette
smoking prevalence. However, the changes in blood pressure and particularly in
blood lipids that have so far occurred are modest. Population-wide changes in these
factors, particularly through population-wide dietary changes, still have considerable
potential for further reductions in CHD risk.
5.5.5 Chapter conclusions/ postscript
The key finding of this chapter is that approximately half of the 25-year decline in
major CHD among older British men may be explained by favourable time trends in
smoking prevalence, SBP and HDL and non-HDL cholesterol. Questions remain.
First, does the “unexplained” portion of the decline reflect imprecision in the analysis
or other unmeasured contributing factors? Second, have risk factor trends contributed
to a decline in major CHD in women in a similar way? In chapter 6, analogous
analyses are carried out in the Whitehall II cohort of London-based men and women
of a similar age. This will provide the opportunity to compare results for women and
to verify the findings in men, as a step towards establishing whether the results for the
BRHS cohort are due to imprecision or chance, or a true finding. The Whitehall II
cohort will be particularly useful for verifying the roles of blood pressure and lipids
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which are measured more frequently in this cohort than in the BRHS. Moreover, the
role of diet will be explored. A further consideration is the role of preventative
medications, particularly anti-hypertensive drugs and statins. Chapter 7 explores the
extent to which the favourable trends in blood pressure and blood lipids may be
explained by increased medication use, and so by extension, how medication use may
have contributed to the major CHD incidence decline.
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Table 5.1 Men included in the analyses by age and questionnaire time-point
Surviving men with no history of MI prior to questionnaire time-point
Age group, years
40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 All men
Baseline (1978-80) 1,708 1,696 1,676 1,703 6,783*
5 years (1983-85) 1,639 1,633 1,594 1,569 6,435
13 years (1992) 399 1,474 1,382 1,255 827 5,337
17 years (1996) 660 1,369 1,227 1,045 468 4,769
20 years (1998-2000) 1,199 1,122 917 643 3,881
Men with additionally complete data on smoking, physical activity, alcohol and BMI (included in main time trend analysis)†
Age group, years
40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 All men
Baseline (1978-80) 1,689 1,667 1,653 1,668 6,677
5 years (1983-85) 1,537 1,511 1,456 1,403 5,907
13 years (1992) 353 1,298 1,166 992 641 4,450
17 years (1996) 560 1,170 990 785 341 3,846
20 years (1998-2000) 1,071 1,002 770 533 3,376
Men with additionally complete data on SBP, total cholesterol, HDL cholesterol (included in the time trend analysis restricted to first + last 5 yrs of follow-up)‡
Age group, years
40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 All men
Baseline (1978-80) 1,625 1,594 1,585 1,599 6,403
20 years (1998-2000) 1,015 946 723 498 3,182
*The number 6,783 is slightly greater than the 6,754 men in the analyses in chapter 4 as the present analysis begins from study entry in 1978, while the analysis in chapter 4
began in 1980 and thus excludes those men with a major CHD event between 1978 and 1980. †Total number of men in main time trend analysis (number of men with
complete data on smoking, physical activity, alcohol and BMI in at least one time-point = 6,751. This is greater than the number of men in any one time-point as different
men may have complete data in different time-points. ‡Total number of men in time trend analysis restricted to first+last 5 years of follow-up (number of men with complete
data on smoking, physical activity, alcohol and BMI and SBP and lipids in at least one time-point = 6,544. Note: Only men contributing to 2+ time-points could contribute to
the GEE analyses of risk factor trends so total men contributing may be slightly lower for these analyses (data at two or more time-points are needed for GEE modelling).
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Table 5.2 Smoking, alcohol consumption, physical activity, BMI, SBP, HDL cholesterol, non-HDL cholesterol by age group and follow-
up time
Age group, years
40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79
No. of current smokers (%)
Questionnaire time-
point (follow-up) 1978-80 (baseline) 626 (36.7) 703 (41.6) 731 (43.7) 687 (40.4)
1983-85 (5 years) 479 (29.6) 535 (33.2) 533 (33.9) 460 (29.9)
1992 (~13 years) 88 (22.2) 279 (19.0) 280 (20.3) 236 (18.9) 131 (15.9)
1996 (~17 years) 104 (15.9) 206 (15.3) 196 (16.2) 149 (14.4) 51 (11.1)
1998-2000 (20 years) 157 (13.1) 151 (13.5) 116 (12.7) 57 (8.9)
No. of regular drinkers (%)
Questionnaire time-
point (follow-up) 1978-80 (baseline) 1229 (72.0) 1213 (71.6) 1162 (69.4) 1173 (69.0)
1983-85 (5 years) 1049 (64.9) 1023 (63.1) 885 (56.3) 908 (59.2)
1992 (~13 years) 250 (65.8) 904 (64.1) 742 (57.1) 667 (55.6) 437 (55.6)
1996 (~17 years) 424 (67.1) 885 (67.4) 697 (59.5) 577 (58.6) 250 (55.8)
1998-2000 (20 years) 789 (67.0) 723 (65.5) 516 (57.8) 359 (57.5)
No. of men with at least moderate physical activity* (%)
Questionnaire time-
point (follow-up) 1978-80 (baseline) 768 (45.4) 675 (40.3) 583 (35.2) 555 (33.2)
1983-85 (5 years) - - - - - - - - - - - - - - - -
1992 (~13 years) 169 (43.3) 659 (45.8) 587 (44.2) 500 (44.4) 297 (39.5)
1996 (~17 years) 268 (42.4) 548 (41.7) 482 (42.1) 325 (35.2) 126 (30.6)
1998-2000 (20 years) 590 (50.7) 556 (50.9) 405 (46.1) 228 (37.4)
Mean Body mass index, kg/m2 (sd)
Questionnaire time-
point (follow-up) 1978-80 (baseline) 25.27 (3.13) 25.43 (3.13) 25.57 (3.20) 25.49 (3.24)
1983-85 (5 years) 26.05 (3.30) 26.09 (3.16) 26.19 (3.20) 26.10 (3.21)
1992 (~13 years) 26.88 (3.64) 26.74 (3.51) 26.53 (3.25) 26.52 (3.28) 26.24 (3.31)
1996 (~17 years) 27.21 (3.48) 27.05 (3.85) 26.93 (3.46) 26.53 (3.55) 26.06 (3.33)
1998-2000 (20 years) 27.27 (3.81) 27.09 (3.69) 26.79 (3.68) 26.22 (3.54)
* Corresponds to men judged to have moderate, moderately vigorous or vigorous activity levels (as opposed to inactive, occasional or light)
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Table 5.2 continued Smoking, alcohol consumption, physical activity, BMI, SBP, HDL cholesterol, non-HDL cholesterol by age group
and follow-up time
Age group, years
40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79
Mean Systolic blood pressure, mmHg (sd)
Questionnaire time-
point (follow-up) 1978-80 (baseline) 138.7 (17.2) 141.9 (19.5) 144.5 (19.7) 148.1 (21.6)
1983-85 (5 years) - - - - - - - - - - - - - - - -
1992 (~13 years) - - - - - - - - - - - - - - - -
1996 (~17 years) - - - - - - - - - - - - - - - -
1998-2000 (20 years) 144.5 (22.8) 148.1 (23.4) 151.7 (24.1) 155.5 (26.1)
Mean HDL cholesterol, mmol/L (sd)
Questionnaire time-
point (follow-up) 1978-80 (baseline) 1.16 (0.24) 1.14 (0.24) 1.15 (0.26) 1.17 (0.26)
1983-85 (5 years) - - - - - - - - - - - - - - - -
1992 (~13 years) - - - - - - - - - - - - - - - -
1996 (~17 years) - - - - - - - - - - - - - - - -
1998-2000 (20 years) 1.33 (0.34) 1.30 (0.33) 1.31 (0.33) 1.37 (0.35)
Mean non-HDL cholesterol, mmol/L (sd)
Questionnaire time-
point (follow-up) 1978-80 (baseline) 5.07 (1.06) 5.19 (1.06) 5.11 (1.00) 5.18 (1.02)
1983-85 (5 years) - - - - - - - - - - - - - - - -
1992 (~13 years) - - - - - - - - - - - - - - - -
1996 (~17 years) - - - - - - - - - - - - - - - -
1998-2000 (20 years) 4.73 (1.07) 4.76 (1.07) 4.63 (1.05) 4.49 (1.13)
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Table 5.3 Fall in the hazard of a first major CHD event per annum and over 25
years. Percentage of this fall explained by the risk factors from Cox regression
analyses with time-dependent covariates
Cox
model Risk factors adjusted for
Coefficient
for calendar
time, β
Fall in hazard of
major CHD per
annum, % (95%
CI)
p-value
Corresponding fall
in hazard over 25
years, %*
% of the observed
decline in hazard
explained by the risk
factor(s)†, (95% CI)
A No adjustment -0.0385 3.78 (2.6, 5.0) <0.001 61.8
Individual risk factors -
compared with model A
B Smoking (current/ex/never) -0.0297 2.93 (1.7, 4.1) <0.001 52.4 22.9 (15.2, 34.0)
C Physical activity
(inactive/occasional/light/moderate/
moderately vigorous/vigorous)
-0.0365 3.59 (2.4, 4.8) <0.001 59.9 5.2 (0.3, 10.7)
D Alcohol consumption
(never/occasional/light/moderate/he
avy)
-0.0381 3.74 (2.5, 4.9) <0.001 61.4 1.1 (-1.8, 4.5)
E BMI, kg/m2 (continuous) -0.0413 4.04 (2.8, 5.2) <0.001 64.4 -7.1 (-13.0, -3.1)
A2
No adjustment, restricted follow-
up (first five years and last five
years only)§
-0.0492 4.80 (1.4, 8.1) 0.007 70.8
Individual risk factors -
compared with model A2
F HDL cholesterol, mmol/L
(continuous) -0.0432 4.22 (0.8, 7.6) 0.02 66.0 12.3 (5.1, 42.3)
G Non-HDL cholesterol, mmol/L
(continuous) -0.0445 4.36 (0.9, 7.7) 0.01 67.2 9.5 (4.2, 31.5)
H SBP, mmHg (continuous) -0.0426 4.17 (0.7, 7.5) 0.02 65.5 13.4 (5.5, 53.9)
Combinations of risk factors -
compared with model A2
J Smoking, HDL cholesterol, non-
HDL cholesterol, SBP -0.0265 2.62 (-1.0, 6.1) 0.2 48.5 46.1 (22.9, 163.6)
K Smoking, HDL cholesterol, non-
HDL cholesterol, SBP, physical
activity, alcohol
-0.0275 2.71 (-0.9, 6.2) 0.1 49.7 44.1 (21.7, 149.1)
* Corresponding fall in hazard over 25 years =100% × [1- exp(β × 25)]
† For smoking, alcohol, physical activity and BMI, % of the observed decline in hazard over 25 years
explained by the risk factor = 100% × (β0 – β1)/ β0 where β0 is the coefficient for calendar time in the
model only adjusting for age (model A) and β1 is the coefficient for calendar time in the model
adjusting additionally for the risk factor. For SBP, HDL cholesterol and non-HDL cholesterol and all
risk factors combined, β0 is the coefficient for calendar time in the restricted model only adjusting for
age (model A2) and β1 is the coefficient in the model adjusting additionally for the risk factor(s).
§ Separate unadjusted model using restricted follow-up data to enable a valid comparison with models
incorporating blood pressure and cholesterol as data on these variables were only available at limited
time-points
233
Figure 5.1 Mean age and age range of men in the British Regional Heart Study
over the course of the follow-up
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Chapter 6: Analysing the role of trends in aetiological exposures in
the time trend in major coronary heart disease incidence in the
Whitehall II cohort
6.1 Introduction
In the previous chapter 5, it was shown that 46% of the decline in incidence of major
CHD in the British Regional Heart Study (BRHS) cohort of middle-aged British men
could be attributed to favourable time trends in cigarette smoking, systolic blood
pressure (SBP) and both non-HDL and HDL cholesterol. However important
questions remain. It is unknown whether similar patterns are present in British
women. Moreover, a similar analysis has not been previously carried out in the UK,
probably reflecting the paucity of studies with the necessary repeated data on CHD
incidence and risk factors. Thus the findings in the previous chapter need validation,
in particular the role of lipids and SBP, as data on these factors was infrequently
ascertained in the BRHS cohort. The aim of this chapter is therefore to estimate the
contribution of risk factor changes to recent trends in the incidence of major CHD in
the Whitehall II cohort of British men and women. The Whitehall II cohort comprises
men and women similar in age to the BRHS men, and followed-up over an
overlapping time-period. Regular clinical measurements are available in the
Whitehall II cohort (at three separate time-points as opposed to the two examinations
in the BRHS). Thus, the Whitehall II cohort should be suitable for addressing the
above issues raised, that is, validation of the BRHS findings, as well as analysing
trends in British women. The main drawback is the confinement of the Whitehall II
cohort to one single regional geographic location (London), such that the findings
from Whitehall II may not be representative of Britain as a whole, hence the use of the
nationally representative BRHS cohort primarily. That said, the comparability
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between the estimates of the decline in major CHD incidence from the BRHS and
Whitehall II, when restricted to the same time-period (as shown in chapter 4, section
4.5.1.3), suggests that the findings from Whitehall II may be more widely applicable.
The structure of this chapter is as follows: Section 6.2 details methods specific to this
section, including statistical methods. Results are given in section 6.3 and section 6.4.
Section 6.5 provides a discussion and interpretation of the findings of the chapter.
6.2 Methods
6.2.1 Data source
The Whitehall II study was detailed in chapter 3, section 3.4. To recap, the cohort
comprises 10,308 men and women recruited between 1985-1988, aged 35-55 years,
from London civil service departments. Risk factor measurements (including physical
measurements and blood assays) were available at three phases during the follow-up
for this analysis: at phase 1 (baseline, 1985-8), phase 3 (1991-3), and phase 5 (1997-
Objective
To estimate the secular time trends in major coronary risk factors (smoking,
blood pressure, lipid levels, body mass index, physical activity, alcohol
consumption and ietary factors) and the contribution of the risk factor time
trends to the decline in incidence of major CHD over 20 years among men and
women in the Whitehall II cohort.
a) For the whole cohort
b) According to gender
c) According to employment grade
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9). The men and women were followed for incident major CHD up to phase 7 (2002-
4).
6.2.2 Principal outcome of a first major CHD event
The principal outcome was a first major CHD event, defined as a fatal CHD or non-
fatal MI, between baseline (1985-1988) and 2002-4 (end of phase 7), (mean follow-up
of 15.4 (SD 4.2) and 9.0 (SD 4.5) years for patients who were censored, and who
experienced the outcome respectively). As outlined in chapter 3, section 3.4.4, fatal
CHD was identified from flagging with the National Health Service Central Registry.
Nonfatal MIs were ascertained from self-report in the questionnaires up to phase 7,
with subsequent confirmation according to the MONICA criteria.
6.2.3 Coronary risk factors
In line with the analysis in chapter 5, the following risk factors were considered:
Cigarette smoking, alcohol consumption, physical activity, body mass index (BMI),
HDL cholesterol and non-HDL cholesterol, and systolic blood pressure. In addition
data on some elements of diet were available; in particular, frequency of fruit and
vegetable consumption, type of milk regularly consumed and type of bread regularly
consumed. Methods of ascertainment of each risk factor and categorisations are
detailed in chapter 3, section 3.4.5. Data on all risk factors was available at all three
phases 1, 3 and 5 (although for some participants, HDL cholesterol at phase 1 was an
estimate, based on apolipoprotein levels, as described in chapter 3, section 3.4.6).
Thus risk factor trends over an approximately 12 year period from 1985-1988 to
1997-1999 could be estimated.
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6.2.4 Statistical methods
Cox regression was used initially to estimate associations between each risk factor at
phase 1 and subsequent hazard of major CHD over the whole follow-up to 2004 (that
is, ignoring initially the secular trends). This initial Cox regression was carried out to
confirm whether associations between the risk factors and major CHD did indeed
exist to justify inclusion in the main analyses prior to computing attributable
proportions, particularly for the dietary factors for which associations with CHD are
less well established. All risk factors except type of milk were significantly
associated (positively or negatively) with hazard of major CHD. Therefore milk was
not included in the main analyses.
The statistical methods used to estimate both time trends in the coronary risk factors
and the proportion of the decline in incidence of major CHD explained by each risk
factor are the same as those used in chapter 5 for the BRHS cohort (see section 5.2.4).
That is, as in chapter 5, the follow-up for each participant was split into consecutive
periods, each of approximately five years, separated by the different examination
phases: a first period from phase 1 to phase 3; a second from phase 3 to phase 5 and a
third from phase 5 to phase 7. Each period is treated as if corresponding to a separate
individual, and forms a separate row of data. Each of these “pseudo-individuals” has
a “baseline” as the date of the examination at the start of the relevant period, and
“baseline” risk factor levels as the risk factor levels at that examination. Each pseudo-
individual is followed-up for major CHD from their baseline to the minimum of: date
of major CHD event, date of death, date of loss to follow-up, date of next phase. The
major CHD incidence and risk factor levels between pseudo-individuals in different
periods are then compared to assess secular trends over time. In particular, age-
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adjusted secular time trends among men and women from phases 1 to 5 in the risk
factors were estimated from regression of the risk factor on calendar time (of start of
period), in this split dataset, adjusted for age and stratified by gender and using
generalised estimating equations (GEEs) with robust standard errors to take account
of dependency between repeated measures for each participant. Logistic models were
fitted for percentage change in prevalence of being a current cigarette smoker, having
at least medium physical activity levels, consuming alcohol over recommend limit,
usually eating white bread, and usually eating fruit and vegetables at least twice daily;
and linear models for time trend in mean BMI, SBP, HDL and non-HDL cholesterol.
Cox regression on this split dataset, was used to estimate the time trend in the hazard
of major CHD, again using robust standard errors to account for dependency between
repeated observations for each participant. Age was used as the underlying time
scale. The extent to which the secular time trends in each of the risk factors
statistically explained the trend in hazard of major CHD were again estimated by the
expression (β0-β1)/β0, where β0 is the coefficient of calendar time in a Cox regression
model with just calendar time as a covariate, and β1 is the coefficient of calendar time
in a Cox regression model adjusting additionally for the risk factor(s)348. Bias-
corrected bootstrap resampling gave an approximate 95% confidence interval (CI) for
this estimate. Squared terms in the continuous risk factors (BMI, SBP and HDL and
non-HDL cholesterol) were added to the models to test for non-linearity; squared-
terms for HDL and non-HDL cholesterol were significant and so retained in the final
models. The Cox regression analyses were first and foremost applied to men and
women combined, adjusting for gender. Further analyses were carried out to estimate
risk factor contributions to the decline in major CHD in men and women separately,
however these analyses should be considered exploratory, as a means to investigate
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whether there are potentially differences between men and women, as power for these
stratified analyses is low (low numbers of events, particularly for women).
Additional analyses were carried out among all participants stratified by employment
grade categorised as high (civil service grades 1 to 7), medium (civil service
executives, including senior and higher) and low (clerical). Since this London-based
cohort may not be representative of Britain as a whole, particularly in terms of socio-
economic distribution (since the cohort are of a higher on average socio-economic
position), one might hypothesize that the results for participants in the lower socio-
economic groups reflect more closely the national picture. These further stratified
analyses enable exploration of this hypothesis. These analyses were carried out on the
participants as a whole, not simultaneously stratified by gender too, as the double
stratification would have led to low numbers in each group and therefore very
imprecise results. Again, these stratified analyses should be considered exploratory.
6.2.5 Participants included in analysis
Participants who had had an MI before baseline (phase 1) were excluded. Participants
who had an MI during follow up were excluded from analyses of incidence of major
CHD and risk factor trends after the time of their event. Participants who developed
angina (either at baseline or during follow up) were retained for analysis, unless they
also had an MI. Participants missing data on one or more risk factors in a particular
phase were excluded from that phase and the associated follow-up, but included in
other phases. Participants missing data in all phases were excluded from analyses
altogether. Numbers of participants included in each phase are given in table 6.1.
240
6.3 Results – Time trends in the major coronary risk factors in
Whitehall II
Of 10,308 participants recruited, one had no follow-up data, 35 reported having had
an MI before baseline (prevalent cases), and 819 had missing data on ≥1 risk factor at
all phases and were excluded from analysis. The remaining 9,453 participants
included 6,379 (67%) men and 3,074 women. Risk factor levels by age and phase are
presented in table 6.2 for men and table 6.3 for women. Considering first the
favourable risk factor time trends, the proportion of men and women who were
cigarette smokers declined between 1985-8 and 1997-9, although the decline was
significant only among women. In men, the percentage change over the 12 years in
the age-adjusted odds of being a current cigarette smoker was -9.2% (95% CI -20 to
3.6, p=0.2) (table 6.4). The corresponding figure among women was -37% (95% CI -
45 to -27, p<0.001). Mean SBP fell in both sexes with a slightly larger decline
observed in women. Age-adjusted changes in mean SBP over the period were -
4.2mmHg (95% CI -5.0 to -3.4, p<0.001) and -6.2mmHg (95% CI -7.5 to -4.9,
p<0.001) among men and women respectively. Average non-HDL cholesterol and
HDL cholesterol levels also changed favourably. Age-adjusted mean HDL
cholesterol levels rose by 0.13mmol/L (95% CI 0.11 to 0.15, p<0.001) and non-HDL
cholesterol levels changed by -0.40mmol/L (95% CI -0.46 to -0.33, p<0.001) among
men. Among women the corresponding figures were 0.08mmol.L (95% CI 0.04 to
0.11, p<0.001) for HDL cholesterol and -0.56 (95% CI -0.65 to -0.47, p<0.001) for
non-HDL cholesterol, thus a slightly smaller rise in HDL than in men but a
comparable fall in non-HDL. Fruit and vegetable consumption also changed
favourably, with significant one-and-a-half-fold age-adjusted increases in the odds of
consuming fruit and vegetables at least twice daily, among both men and women.
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Certain risk factors did not change favourably over the period, either remaining
relatively constant over the period or changing unfavourably. In particular, over the
period, adjusting for age, mean BMI increased significantly, by 1.16kg/m2 (95% CI
0.99 to 1.33, p<0.001) in men and by 0.78kg/m2 (95% CI 0.41 to 1.15, p<0.001) in
women. Alcohol consumption increased by an average of 6.0 units per week (95% CI
5.2 to 6.8, p<0.001) among men and by 3.2 units per week (95% CI 2.6 to 3.9) among
women, adjusting for age. Correspondingly, adjusting for age, the proportion of men
and women who reported alcohol consumption over the recommended limit also
increased significantly (6% percentage increase in men and 8% in percentage increase
in prevalence in women). Physical activity levels decreased significantly in men; there
was a 12% (95% CI 8.8 to 15) reduction in the proportion of men with at least
moderate physical activity levels, adjusting for age. There was no significant change
in physical activity levels among women (p=0.2 for the age-adjusted trend over time
in odds of having at least moderate physical activity levels). Bread consumption did
not alter substantially, with little change in the proportions of men and women
reporting consumption of predominantly white bread, as opposed to other bread types.
6.4 Results - Analysis of relation of trends in risk factors to trends in
major coronary heart disease incidence
Among this group of participants with available risk factor data, the observed decline
in major CHD hazard was 6.51% (95% CI 3.22 to 9.68) per annum, adjusting for age
and gender, or 74% (95% CI 48 to 87) over 20 years (table 6.5), higher than the 58%
observed for the whole cohort. Estimates of the proportions of this decline in the
hazard of a first major CHD event over time among all participants attributable to
each risk factor change are presented in table 6.5. Four risk factor trends contributed
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in isolation to the 74% decline in hazard of major CHD among all participants.
Percentage contributions of these risk factors in order of size were: declining non-
HDL cholesterol 34% (bootstrap 95% CI 20 to 76), rising HDL cholesterol 17%
(bootstrap 95% CI 10 to 32), declining SBP 13% (bootstrap 95% CI 7 to 24), and
declining cigarette smoking 6% (bootstrap 95% CI 2 to 14). Together they explained
a total of 54% (95% bootstrap CI 34 to 105) of the decline (as before the upper bound
of the CI indicates that the data are consistent at the 95% confidence level with the
risk factors explaining a greater decline than that observed). The contribution of
increased fruit and vegetable consumption did not reach statistical significance (7%,
bootstrap 95% CI -1 to 20), the combined contribution with the four other risk factors
being 56% (bootstrap 95% CI 34 to 112). Trends in physical activity, alcohol
consumption and bread consumption had no notable impact. The rise in mean BMI
was adverse, explaining -11% (bootstrap 95% CI -23 to -5) of the decline in major
CHD hazard in isolation. The proportion of the decline explained by the risk factors
combined reduced from 56% to 48% (bootstrap 95% CI 27 to 96) with additional
adjustment for the adverse trend in BMI. This suggests that increasing BMI limited
the scale of the CHD decline.
In chapter 4, section 4.5.1.3, it was shown that men and women in the cohort
experienced similar declines in the hazard of major CHD. In this subgroup of
participants with risk factor data, the declines, although larger than for the whole
cohort, remained similar among men and women (73% and 82% respectively). The
relative contributions of each of the risk factors to the CHD declines within each
gender were broadly similar to each other and to that in the combined analysis (table
6.6). Exceptions were that among women, there was a smaller contribution from
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HDL cholesterol compared with SBP and the proportion explained by cigarette
smoking was not significant (although the point estimate was larger than for men).
Further, among women, a negative impact of BMI was not as apparent. The
percentage contribution of the five risk factors: HDL and non-HDL cholesterol, SBP,
cigarette smoking and fruit and vegetable consumption, combined was similar among
men and women (54%, bootstrap 95% CI 30 to 126, and 59%, 95% bootstrap CI 19 to
221 respectively).
The analysis stratifying by baseline employment grade, categorised as high (civil
service grades 1 to 7), medium (civil service executives, including senior and higher)
and low (clerical), is shown in table 6.7. The percentage decline in incidence of major
CHD over 20 years among participants in the lowest employment grades was smallest
(60.9%, 95% CI -60.5 to 90.5), followed by a marginally larger decline among those
in the highest employment grades (66.6%, 95% CI 0.3 to 88.8), and with the largest
decline occurring in those of intermediate employment grades (79.9%, 95% CI 51.3 to
91.7). The differences in the percentage decline in incidence of major CHD over 20
years in each employment grade were not significant (p=0.6). The relative
contributions of the risk factors to the major CHD trends were similar for medium and
high employment grades, with non-HDL cholesterol the greatest contributor, followed
by HDL, SBP and a small contribution from smoking (table 6.7). For the low
employment grade, the relative contributions differed somewhat. Non-HDL remained
the greatest contributor, however smoking and SBP appeared to be more influential;
smoking making a contribution comparable to that of HDL and SBP making a larger
contribution than HDL.
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There was no strong evidence of departure from the proportional hazards assumption
of the Cox regressions tested using Schoenfeld residuals.
6.5 Discussion
6.5.1 Summary of main findings
Over half of the 74% decline in major CHD incidence over 20 years among
participants with risk factor data (men and women combined) in the Whitehall II
cohort could be attributed to a combination of favourable time trends in major risk
factors, particularly non-HDL cholesterol, HDL cholesterol, SBP, and cigarette
smoking. A borderline significant association of the CHD decline with increased fruit
and vegetable consumption was also observed. Bread consumption, physical activity
and alcohol consumption did not help to explain the decline in major CHD. Rising
adiposity had an adverse impact, such that had other favourable risk factor trends not
occurred, the unfavourable trend in BMI may have led to an increase in major CHD
incidence over the follow-up.
6.5.2 Comparison between men and women in Whitehall II
In chapter 4, section 4.5.1.3, it was shown that over 20 years between 1985 and 2004
similar declines in hazard of major CHD occurred in men and women. In this chapter,
results reveal that coronary risk factor time trends have had broadly comparable
influences on the declines in men and women. In particular, the four major risk
factors (non-HDL and HDL cholesterol, SBP and cigarette smoking) combined could
explain a similar proportion (about half) of the declines in both men and women.
While the estimated size of the potential contribution associated with each of the risk
factors individually differed for men and women, the relative impact associated with
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each risk factor was broadly comparable, with the exception that SBP was more
influential than HDL cholesterol among women, while the reverse was true among
men. The broad similarity in the potential influences of the risk factor trends on the
CHD decline between men and women fits with previous research suggesting the
associations of these particular risk factors with CHD to be similar among men and
women100, 103, 359. The differences in the relative importance of SBP and HDL
cholesterol likely reflect differing time trends in the risk factors: the observed greater
decline in age-adjusted average SBP among women compared with men (fall of
6.2mmHg versus 4.2mmHg over 12 years), and the greater rise in age-adjusted
average HDL among men compared with women (rise of 0.13mmol/L versus
0.08mmol/L over 12 years), rather than different strengths of association of the risk
factors. There is a lack of national data on trends over this period in lipids so it is
difficult to assess whether the differences in the trends in HDL between men and
women observed in this cohort have also occurred in the British population as a
whole. However Health Survey for England data360 on mean SBP levels between
1993 and 1998, a period overlapping the phase 2 and phase 3 Whitehall II
measurements, show SBP to have declined by 1 to 2mmHg more in women over this
time compared with men, among participants of a similar age as those in Whitehall II
at phases 2 and 3, in line with our findings. Specifically, declines between 1993 and
1998 in mean SBP were: 2mmHg and 2mmHg (men, aged 45-54 and 55-64 years
respectively) and 3mmHg and 4mmHg (women, aged 45-54 and 55-64years
respectively). Although rising adiposity was associated with an adverse impact on the
trend in major CHD among men, this was not observed among women. This finding
is somewhat counterintuitive given the similar influence of BMI in men and women361
and the estimates of the trends in BMI; although women experienced a smaller age-
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adjusted rise in mean BMI over the period, this rise was nevertheless significant and
not unsubstantial (0.8kg/m2 compared with 1.2kg/m2 among men). Limitations in the
analyses (detailed below), particularly the lack of power in the analyses for women,
may explain the apparent limited influence of the rise in BMI in women.
6.5.3 Comparison between employment grade in Whitehall II
In chapter 4, section 4.5.1.3, a gradient in the trend in major CHD incidence by
employment grade was observed, whereby the largest decline occurred among those
in the most senior employment grades, while the smallest decline occurred in the most
junior employments grades. This is in line with the deprivation gradients observed in
THIN and BRHS. Due to smaller numbers of participants in the analyses in this
chapter, the gradient did not persist, suggesting the influence of responder bias on the
results. However, the analyses of the contributions of the risk factors do reveal some
differences between the employment grades. For medium and high employment
grades non-HDL cholesterol was the greatest contributor, followed by HDL, SBP and
a small contribution from smoking. In contrast, for the low employment grade,
smoking and SBP appeared to be more influential; particularly relative to HDL.
While these results stratified by employment grade should be interpreted with caution
due to the low numbers, leading to imprecise estimates, it is interesting to note that the
results for the most junior employment grade reflect more closely the findings of the
relative risk factor contributions in the BRHS (greater influence of smoking and SBP).
This fits with the fact that the Whitehall II cohort as a whole is less deprived relative
to the BRHS (which is more closely representative of the general population). This is
because the recruitment sampling frame of men and women employed in London civil
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service offices automatically led to the absence of manual labourers and unemployed
individuals in the Whitehall II cohort.
6.5.4 Comparison of men in Whitehall II with the BRHS findings
The Whitehall II cohort comprises men of an overlapping age-range to the men in the
BRHS, followed over a similar calendar period. The men in Whitehall II were aged
35-55 at recruitment in 1985-88. In comparison men in the BRHS were aged 40-60 at
recruitment in 1978-80, and so were aged 45-70 in 1985-88. The considerable overlap
in age suggests that useful comparison may be drawn between the analyses of the two
cohorts. In chapter 4, 4.5.1.3, it was observed that the decline in incidence of major
CHD among men in Whitehall II was comparable to that found in the BRHS over the
same period (4.24% per annum versus 4.06% per annum). The results of the analysis
of the Whitehall II men in this chapter, assessing the contribution of risk factor trends
to the CHD decline, are also largely consistent with the analogous analysis of the
BRHS men in chapter 5. A similar proportion of the decline in major CHD could be
attributed to changes in cardiovascular risk factors among men in both cohorts (53%
versus 46% in the BRHS). The same four risk factors were important in both cohorts
(cigarette smoking, SBP and non-HDL and HDL cholesterol), and the same risk
factors that had little impact (alcohol consumption and physical activity) or were
counterproductive (BMI). However, there are certain differences between the
findings from the two cohorts. The relative impacts of the four key risk factors
differed, with non-HDL cholesterol and HDL cholesterol explaining the largest
portion of the decline in major CHD in the present cohort, compared with cigarette
smoking having the greatest influence in the BRHS. Indeed these four risk factors, in
order of size of contribution, are essentially reversed (to recap, contributions of
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smoking, SBP, HDL cholesterol and non-HDL cholesterol in the BRHS were 23%,
13%, 12% and 10% respectively; corresponding figures for the Whitehall II men are
5%, 11%, 19%, 34%). The differences in the percentage contributions could be the
result of limitations or imprecision in either or both analyses, for example the limited
two-point cholesterol data in the BRHS analysis may possibly have led to
underestimation of the contribution of lipids in the BRHS. Other possible
explanations could be the earlier start-date for the BRHS (seven years prior to
Whitehall II) and the despite the overlap in age, the BRHS men are on average 10
years older in the same calendar year. That said, adjustment was made for age, and
trends within each age-group were similar, and the time trends in the BRHS before
and after the start-date for Whitehall II (1985) were consistent, thus the differences in
age and start-date are unlikely to explain the variations in the relative roles of the risk
factors. However, one could plausibly reason that the differences in the findings are
reflections of differences in the population demographics of the cohorts other than
age, in particular, the higher average socioeconomic status in the Whitehall II
London-based cohort compared with the nationwide BRHS cohort, as described
above. Tied to the higher socio-economic status of the cohort, the reduced impact of
quitting smoking in Whitehall II men may be explained by an already lower
prevalence of smokers at a later baseline (23% among men in Whitehall II compared
with about 40% among men in the BRHS) and therefore less potential for a decline in
prevalence over time (smoking prevalence declined by three-quarters among BRHS
men over 20 years while among men in Whitehall II, there was only a non-significant
decline of 9% over 12 years). The trend in and contribution of non-HDL cholesterol
was smaller in the BRHS, (non-HDL cholesterol fell by 0.4mmol/L over 12 years in
Whitehall II men, compared to 0.35mmol/L over 20 years in the BRHS). This
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difference possibly reflects greater take-up of effective lipid lowering medication in
Whitehall II362 , which may again be associated with socio-economic status or
possibly reflect better access to medical care in London as opposed to other UK
regions. The contribution of SBP to the CHD decline was very similar in both cohorts,
reflecting comparable declines over time in mean SBP levels (4.2mmHg over 12 years
in Whitehall II men versus 7.2mmHg over 20 years in the BRHS). The contribution
of HDL cholesterol was also broadly consistent in both cohorts, with a slightly faster
rate of increase in HDL cholesterol occurring in the Whitehall II men (0.13mmol/L
over 12 years compared with 0.15mmol/L over 20 years in the BRHS), leading to a
slightly larger proportion of the CHD decline explained. Elements of diet associated
with major CHD risk (frequency of consumption of fruit and vegetables, and type of
bread predominantly consumed) were available for inclusion in the Whitehall II
analysis, but not captured in the BRHS. While bread consumption did not influence
the CHD trend, there was some suggestion that increasing fruit and vegetable
consumption may have made a contribution when considered in isolation. However,
when considered in conjunction with the other major risk factors, fruit and vegetable
consumption had little added independent contribution; it is likely that the effect of
fruit and vegetable consumption is largely mediated by factors such as HDL
cholesterol. Note finally that the BRHS findings correspond more closely to findings
from the IMPACT model15 on the role of risk factors on the decline in CHD mortality,
which also addresses trends among the whole British population, rather than in a
single location.
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6.5.5 Strengths and limitations
Multiple repeated measurements of risk factors, using consistent techniques on each
occasion, are a key strength of this analysis. In particular, lipid and blood pressure
measurements were available at three time-points, instead of the two measurements in
the BRHS. Also, additional repeated data on elements of diet was available in
Whitehall II. As for the corresponding analysis of BRHS data in chapter 5, risk factor
trends to coronary events at an individual-level, thus avoiding the limitation of
ecological analyses predominantly used to study time trends. A similar “lag” between
the risk factor ascertainment and a major CHD event was allowed for as that in the
BRHS analysis as risk factor levels were related to major CHD events up to five years
ahead, based on the interval between clinic phases. Further, this is apparently the first
such individual-level study of major CHD trends following both men and women,
enabling extension of the analysis to women. That said, women in Whitehall II
experienced few events leading to imprecision in the analysis (in particular some of
the bootstrap CIs for the “percentage explained” estimates were unstable and very
wide). Unstable bootstrap CIs tended to occur when the percentage explained
estimate was large and/ or multiple risk factors were included in the models.
Consequently the findings particularly for women need to be interpreted with some
caution, although in the least the point estimates give an indication of how similar or
dissimilar the results are to those for men. In the same vein, the analyses stratified by
employment grade should be seen as exploratory and interpreted with caution – a
consequence of the low power of each grade-specific analysis was lack of
convergence of the interactions to estimate bootstrap CIs for the percentage
contributions of the risk factors and so CIs could not be given.
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As for the BRHS analysisin chapter 5, the analyses in this chapter were necessarily
based on participants who re-attended after baseline, and provided complete risk
factor data at one phase at least. The potential for survival or response biases needs
consideration. Again, the most likely impact would be overestimation of the
favourable trends observed in both the risk factors and major CHD incidence, due to
the healthy participant effect. Unlike the BRHS, the estimate of the major CHD
incidence decline in chapter 4 (whole Whitehall II cohort – see section 4.5.1.3) did
differ from the estimate in this chapter (responders with risk factor data) – 58% versus
74%. This indicates some such bias, whereby the decline among responders is larger
than that of non-responders. This is likely to reflect that a greater proportion of the
Whitehall II cohort were missing risk factor information and so were excluded from
this analysis than in the BRHS. We could arguably expect similar overestimation of
the favourable risk factor trends, and so the percentage explained by each risk factor
may still be reflective of the cohort as a whole. The comparability of the Whitehall II
findings with that of the BRHS, particularly when broken down by employment
grade, in terms of the relative contributions of the risk factors, supports this.
Any measurement imprecision of the risk factors, particularly likely for the dietary
factors, physical activity and alcohol consumption, may have led to underestimation
of the contribution to the CHD decline. Limited elements of diet were available (fruit
and vegetables, milk, bread consumption). Had more aspects of diet been considered,
diet as a whole may have had greater influence.
A limitation specific to this analysis of Whitehall II data is that HDL cholesterol
values at baseline were derived from serum apolipoprotein-A1 for a subgroup of the
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participants. The likely impact is underestimation of the variance associated with the
baseline HDL measurements but without biasing the estimate of the contribution of
HDL to the decline in major CHD. A further limitation specific to the Whitehall II
analysis is the restricted London-based sampling frame and such that the Whitehall II
cohort is not representative/ reflective of Britain as a whole in terms of socio-
economic status. The lack of representativeness may help to explain the differences
between the findings for Whitehall II and the BRHS in terms of the relative risk factor
contributions.
6.5.6 Interpretation of findings
The results have shown that approximately half of the decline over 20 years in major
CHD incidence among both men and women in the Whitehall II cohort may be
attributed to concurrent time trends in the major coronary risk factors (specifically,
non-HDL and HDL cholesterol, SBP and cigarette smoking), findings broadly
consistent with the findings in the BRHS. Thus the results of the Whitehall II analysis
in this chapter lend support to and help to validate the findings in the BRHS in chapter
5, including the novel finding of the role of HDL cholesterol (a risk factor not
included in any previous time trends analyses of CHD, incidence or mortality). This
strengthens the conclusions of the previous chapter; firstly that major coronary risk
factors have made a substantial contribution to the decline in incidence of major CHD
in men in Britain and secondly, that there remains a portion of the decline in major
CHD not explained by the risk factors. The correspondence of the results for men
from the two distinct cohorts suggests that the “unexplained portion” is not connected
to limitations unique to each analysis, such as the limited two-point data on SBP and
lipids in the BRHS analysis and the estimated baseline HDL cholesterol in the
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Whitehall II analysis. The “unexplained portion” could reflect however
methodological limitations common to both analyses, for example measurement
imprecision, particularly for the factors assessed by questionnaire, which may have
led to underestimation of the risk factor contributions. Otherwise some of the
“unexplained portion” may reflect the influence of other factors as outlined in chapter
5, section 5.5.4, (psycho social factors, life course influences, and preventive
treatments). Diet trends were also cited as a possible explanation for the unexplained
portion of the decline in major CHD incidence in the BRHS. Elements of diet (fruit
and vegetable consumption, bread consumption) were considered in the Whitehall II
analysis. These dietary factors appeared to have little independent influence on the
CHD incidence trends. However, other aspects of diet not considered may have made
a contribution.
A further result common to both cohorts was the negative estimated impact of BMI on
the CHD decline; both studies suggesting that rising BMI has reduced the scale of the
decline in BMI. While the negative contribution of rising mean BMI over recent
decades appears to have been outweighed by the favourable trends in other vascular
risk factors, continued increases in BMI may further reduce or even reverse the
decline in CHD incidence. The rising BMI in the UK and in other countries needs
therefore urgent attention.
While there are evident similarities between the results for the two cohorts, certain
differences were observed, in terms of the relative impact of each of the major risk
factors. In particular a greater decline in non-HDL cholesterol was observed in
Whitehall II corresponding to a greater role in the decline in major CHD, and a
254
greater decline in, and so greater role of, smoking prevalence in the BRHS. As
discussed in section 6.5.4 these differences are plausible in the light of the differences
in the demographics of the populations from which the two cohorts were derived. It
suggests inequalities in healthcare access/health education according to socio-
economic status, with certain less deprived groups (like the Whitehall II cohort)
experiencing greater (non-HDL cholesterol) or earlier (smoking) health improvements
than the general British population, which is of concern. However at the same time,
the Whitehall II study is informative in showing health gain in the real world given
favourable circumstances. The trends in this group may represent achievable goals for
population-wide prevention of CHD, highlighting what can be achieved and
emphasizing the value of measures to reduce exposure to these risk factors in the
population.
Contrasting the results for men and women in Whitehall II, the risk factor reductions
were of broadly comparable importance for men and women. The findings suggest
that similar influences have operated to achieve declines in incidence of major CHD
among both men and women, such that similar prevention strategies may be
appropriate for both genders. However further research is needed to validate these
findings, as the low power for the gender specific analyses warrants a need for caution
in interpreting the results.
6.5.7 Chapter conclusions/ postscript
In chapter 5 and in this chapter 6, the factors that have influenced the decline in the
incidence of major CHD have been explored. The key findings are that the major
coronary risk factors appear to go at least half way towards explaining the decline in
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incidence of major CHD in both men and women, with the findings for men evaluated
in two separate cohorts. In particular, in addition to smoking, the favourable trends in
SBP, and in non-HDL and HDL cholesterol, may explain a non trivial portion of the
major CHD incidence decline. In the next chapter 7, the role of increased use of
evidence-based medications (anti-hypertensive drugs and lipid-regulating drugs) in
the favourable blood pressure and blood lipid changes is explored. Given that
evidence-based medications are likely to influence major CHD risk primarily through
changing blood pressure and blood lipid levels, the analyses by extension, may also
indicate to what extent medication use may have contributed to the major CHD
incidence decline.
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Table 6.1 Numbers of participants contributing data in each study phase by age group (participants with complete risk factor data and
no prior MI)
Men
Age, years
34-39 40-44 45-49 50-54 55-59 60-64 65-68 All
Study Phase 1 (1985-8) 1,333 1,354 928 1,048 129 0 0 4,792
3 (1991-3) 100 1,537 1,401 1,015 1,029 143 0 5,225
5 (1997-9) 0 9 783 964 614 653 180 3,203
Women
Age, years
34-39 40-44 45-49 50-54 55-59 60-64 65-68 All
Study Phase 1 (1985-8) 547 562 532 629 99 0 0 2,369
3 (1991-3) 45 549 582 487 575 76 0 2,314
5 (1997-9) 0 2 291 336 288 289 79 1,285
All participants
Age, years
34-39 40-44 45-49 50-54 55-59 60-64 65-68 All
Study Phase 1 (1985-8) 1,880 1,916 1460 1677 228 0 0 7,161
3 (1991-3) 145 2,086 1983 1502 1604 219 0 7,539
5 (1997-9) 0 11 1074 1300 902 942 259 4,488
Note: Overall number of participants contributing to analyses for at least one phase = 9,453. The numbers of participants contributing data to each particular phase is lower
because different participants may be missing risk factor data at (and so excluded from) different phases
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Table 6.2 Distribution of major coronary risk factors by age and study phase:
men
Age, years
34-39 40-44 45-49 50-54 55-59 60-64 65-68
Number of participants
Phase 1 – 1985-8 1333 1354 928 1048 129
Phase 3 – 1991-4 100 1537 1401 1015 1029 143
Phase 5 – 1997-9 9 783 964 614 653 180
Number of current smokers (%)
Phase 1 – 1985-8 235 (17.6) 226 (16.7) 145 (15.6) 139 (13.3) 21 (16.3)
Phase 3 – 1991-4 11 (11.0) 224 (14.6) 192 (13.7) 117 (11.5) 92 (8.9) 13 (9.1)
Phase 5 – 1997-9 NA* 77 (9.8) 92 (9.5) 60 (9.8) 39 (6.0) 12 (6.7)
Number at least moderately physically active (%)
Phase 1 – 1985-8 1056 (79.2) 1068 (78.9) 719 (77.5) 794 (75.8) 86 (66.7)
Phase 3 – 1991-4 73 (73.0) 1099 (71.5) 993 (70.9) 699 (68.9) 749 (72.8) 113 (79.0)
Phase 5 – 1997-9 NA* 518 (66.2) 652 (67.6) 439 (71.5) 494 (75.7) 135 (75)
Number consuming over recommended limit of alcohol (%)
Phase 1 – 1985-8 299 (22.4) 274 (20.2) 173 (18.6) 146 (13.9) 19 (14.7)
Phase 3 – 1991-4 20 (20.0) 307 (20.0) 295 (21.1) 176 (17.3) 134 (13.0) 18 (12.6)
Phase 5 – 1997-9 NA* 229 (29.2) 284 (29.5) 178 (29.0) 156 (23.9) 28 (15.6)
Number with white bread as usual bread type consumed (%)
Phase 1 – 1985-8 1061 (79.6) 1038 (76.7) 712 (76.7) 796 (76.0) 96 (74.4)
Phase 3 – 1991-4 77 (77.0) 1178 (76.6) 1058 (75.5) 770 (75.9) 800 (77.7) 123 (86.0)
Phase 5 – 1997-9 NA* 582 (74.3) 723 (75.0) 462 (75.2) 513 (78.6) 136 (75.6)
Number consuming fruit or vegetables at least twice daily (%)
Phase 1 – 1985-8 212 (15.9) 206 (15.2) 134 (14.4) 136 (13.0) 21 (16.3)
Phase 3 – 1991-4 16 (16.0) 278 (18.1) 274 (19.6) 185 (18.2) 200 (19.4) 28 (19.6)
Phase 5 – 1997-9 NA* 246 (31.4) 356 (36.9) 204 (33.2) 258 (39.5) 75 (41.7)
Mean BMI, kg/m2 (sd)
Phase 1 – 1985-8 24.1 (3.2) 24.5 (3.0) 24.8 (2.9) 25.1 (2.8) 25.2 (3.2)
Phase 3 – 1991-4 24.2 (3.2) 24.8 (3.3) 25.1 (3.3) 25.3 (3.0) 25.3 (2.9) 24.8 (2.9)
Phase 5 – 1997-9 NA* 25.7 (3.7) 26.2 (3.5) 26.1 (3.4) 25.9 (3.2) 25.5 (3.0)
Mean SBP, mmHg (sd)
Phase 1 – 1985-8 123.3 (12.9) 124.0 (13.5) 124.8 (13.8) 126.0 (15.0) 127.3 (16.5)
Phase 3 – 1991-4 120.2 (13.1) 119.8 (12.2) 120.8 (12.3) 122.6 (13.4) 125.2 (14.2) 126.4 (16.4)
Phase 5 – 1997-9 NA* 119.6 (14.2) 123.4 (15.4) 125.9 (16.5) 127.0 (16.8) 130.5 (18.6)
Mean non-HDL cholesterol, mmol/L (sd)
Phase 1 – 1985-8 4.42 (1.1) 4.69 (1.1) 4.86 (1.1) 4.92 (1.1) 5.07 (1.1)
Phase 3 – 1991-4 4.70 (1.2) 4.93 (1.2) 5.16 (1.2) 5.22 (1.1) 5.32 (1.1) 5.38 (1.1)
Phase 5 – 1997-9 NA* 4.35 (1.1) 4.57 (1.1) 4.55 (1.1) 4.57 (1.0) 4.53 (1.0)
Mean HDL cholesterol, mmol/L (sd)
Phase 1 – 1985-8 1.29 (0.3) 1.30 (0.3) 1.27 (0.3) 1.27 (0.3) 1.23 (0.3)
Phase 3 – 1991-4 1.35 (0.3) 1.31 (0.3) 1.32 (0.4) 1.32 (0.4) 1.34 (0.4) 1.35 (0.4)
Phase 5 – 1997-9 NA* 1.36 (0.3) 1.39 (0.3) 1.38 (0.4) 1.41 (0.3) 1.36 (0.3)
*Too few participants (n=9) to estimate risk factor levels for men aged 40-44 years in phase 5
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Table 6.3 Distribution of major coronary risk factors by age and study phase:
women
Age,
years
34-39 40-44 45-49 50-54 55-59 60-64 65-68
Number of
participants
Phase 1 – 1985-8 547 562 532 629 99
Phase 3 – 1991-4 45 549 582 487 575 76
Phase 5 – 1997-9 2 291 336 288 289 79
Number of current smokers (%)
Phase 1 – 1985-8 106 (19.4) 138 (24.6) 128 (24.1) 158 (25.1) 26 (26.3)
Phase 3 – 1991-4 12 (26.7) 65 (11.8) 100 (17.2) 87 (17.9) 104 (18.1) 9 (11.8)
Phase 5 – 1997-9 NA* 31 (10.7) 50 (14.9) 40 (13.9) 37 (12.8) 8 (10.1)
Number at least moderately physically active (%)
Phase 1 – 1985-8 363 (66.4) 338 (60.1) 297 (55.8) 332 (52.8) 52 (52.5)
Phase 3 – 1991-4 30 (66.7) 322 (58.7) 310 (53.3) 221 (45.4) 257 (44.7) 34 (44.7)
Phase 5 – 1997-9 NA* 137 (47.1) 174 (51.8) 134 (46.5) 145 (50.2) 40 (50.6)
Number consuming over recommended limit of alcohol (%)
Phase 1 – 1985-8 72 (13.2) 59 (10.5) 41 (7.7) 45 (7.2) 7 (7.1)
Phase 3 – 1991-4 6 (13.3) 67 (12.2) 60 (10.3) 36 (7.4) 38 (6.6) 4 (5.3)
Phase 5 – 1997-9 NA* 51 (17.5) 56 (16.7) 47 (16.3) 29 (10.0) 13 (16.5)
Number with white bread as usual bread type consumed (%)
Phase 1 – 1985-8 463 (84.6) 457 (81.3) 419 (78.8) 494 (78.5) 82 (82.8)
Phase 3 – 1991-4 37 (82.2) 447 (81.4) 475 (81.6) 371 (76.2) 448 (77.9) 60 (78.9)
Phase 5 – 1997-9 NA* 235 (80.8) 270 (80.4) 223 (77.4) 221 (76.5) 65 (82.3)
Number consuming fruit or vegetables at least twice daily (%)
Phase 1 – 1985-8 120 (21.9) 127 (22.6) 89 (16.7) 131 (20.8) 25 (25.3)
Phase 3 – 1991-4 14 (31.1) 164 (29.9) 171 (29.4) 108 (22.2) 139 (24.2) 18 (23.7)
Phase 5 – 1997-9 NA* 134 (46.0) 171 (50.9) 136 (47.2) 140 (48.4) 32 (40.5)
Mean BMI, kg/m2 (sd)
Phase 1 – 1985-8 23.7 (4.1) 24.1 (4.0) 25.0 (4.1) 25.7 (4.3) 26.4 (6.1)
Phase 3 – 1991-4 24.9 (4.8) 24.8 (4.7) 25.6 (4.8) 25.8 (4.4) 26.4 (4.4) 26.4 (5.3)
Phase 5 – 1997-9 NA* 25.9 (5.1) 26.3 (4.9) 27.0 (5.0) 26.7 (5.0) 26.0 (3.8)
Mean SBP, mmHg (sd)
Phase 1 – 1985-8 114.7 (13.2) 117.5 (13.8) 122.1 (16.4) 124.5 (16.3) 128.5 (18.0)
Phase 3 – 1991-4 114.1 (11.3) 113.5 (13.1) 115.6 (12.8) 119.5 (14.0) 122.2 (14.4) 124.4 (14.9)
Phase 5 – 1997-9 NA* 115.3 (14.8) 120.5 (16.2) 123.4 (17.3) 127.2 (17.8) 129.2 (21.0)
Mean non-HDL cholesterol, mmol/L (sd)
Phase 1 – 1985-8 3.80 (0.9) 3.93 (1.0) 4.33 (1.0) 4.91 (1.2) 5.18 (1.2)
Phase 3 – 1991-4 4.36 (1.2) 4.33 (1.1) 4.56 (1.1) 4.99 (1.2) 5.38 (1.3) 5.88 (1.4)
Phase 5 – 1997-9 NA* 4.00 (1.1) 4.29 (1.0) 4.48 (1.2) 4.66 (1.1) 4.88 (1.1)
Mean HDL cholesterol, mmol/L (sd)
Phase 1 – 1985-8 1.59 (0.4) 1.59 (0.4) 1.59 (0.4) 1.64 (0.4) 1.70 (0.4)
Phase 3 – 1991-4 1.59 (0.4) 1.66 (0.4) 1.70 (0.4) 1.71 (0.4) 1.68 (0.5) 1.62 (0.4)
Phase 5 – 1997-9 NA* 1.69 (0.4) 1.69 (0.4) 1.67 (0.4) 1.66 (0.4) 1.63 (0.5)
*Too few participants (n=2) to estimate risk factor levels for women aged 40-44 years in phase 5
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Table 6.4 Age-adjusted population-averaged time trends in coronary risk factors among men and women over 12 years from 1985-8
(baseline) to 1997-9 (phase 5)
Men Women
Risk factor
Change in mean
levels per annum
(95% CI)
p-
value
Change over 12
years (95% CI)
Change in mean
levels per annum
(95% CI)
p-
value
Change over 12
years (95% CI)
BMI, kg/m2 0.10 (0.08, 0.11) <0.001 1.16 (0.99, 1.33) 0.07 (0.03, 0.10) <0.001 0.78 (0.41, 1.15)
SBP, mmHg -0.35 (-0.42, -0.28) <0.001 -4.19 (-5.02, -3.35) -0.52 (-0.63, -0.41) <0.001 -6.21 (-7.52, -4.90)
Non-HDL cholesterol, mmol/L -0.033 (-0.038, -0.028) <0.001 -0.40 (-0.46, -0.33) -0.047 (-0.054, -0.039) <0.001 -0.56 (-0.65, -0.47)
HDL cholesterol, mmol/L 0.011 (0.009, 0.012) <0.001 0.13 (0.11, 0.15) 0.006 (0.004, 0.009) <0.001 0.08 (0.04, 0.11)
Risk factor
% change in odds
per annum (95%
CI)
p-
value
% change over 12
years (95% CI)
% change in odds
per annum (95%
CI)
p-
value
% change over
12 years (95%
CI)
Current smoker -0.80 (-1.89, 0.30) 0.2 -9.2 (-20.4, 3.6) -3.78 (-4.94, -2.62) <0.001 -37.1 (-45.5, -27.2)
At least moderate physical activity -1.06 (-1.35, -0.76) <0.001 -12.0 (-15.1, -8.8) -0.48 (-1.16, 0.21) 0.2 -5.6 (-13.1, 2.5)
Consume alcohol over recommended limit 6.12 (5.15, 7.10) <0.001 104 (82.8, 128) 7.96 (5.79, 10.17) <0.001 151 (96.5, 220)
White bread as usual bread type -0.26 (-0.53, 0.01) 0.06 -3.1 (-6.2, 0.1) 0.12 (-0.24, 0.47) 0.5 1.4 (-2.8, 5.8)
Consume fruit and vegetables ≥2 daily 7.99 (7.01, 8.98) <0.001 151 (125, 180) 8.73 (7.56, 9.92) <0.001 173 (140, 211)
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Table 6.5 Fall in hazard of a first major CHD event among all participants in Whitehall II between 1985 and 2004 and percentage of this
fall explained by risk factor time trends
Model Risk factors adjusted for in addition to age and gender β-coefficient forcalendar time
Fall in hazard per
annum, % (95% CI)
p-
value
Corresponding
fall in hazard
over 20 years, %
% of the observed decline
in hazard over 20 years
explained by the risk
factor(s), (95% CI)*
A No adjustment -0.0673 6.51 (3.22, 9.68) <0.001 74.0
Effect of individual risk factors in isolation
B Smoking (current/ex/never) -0.0633 6.13 (2.82, 9.33) <0.001 71.8 5.9 (2.3, 13.6)
C Physical activity (low/medium/high) -0.0673 6.51 (3.20, 9.70) <0.001 74.0 0.1 (-4.5, 5.3)
D Alcohol units per week (none/within limit/over limit/heavy) -0.0666 6.44 (3.13, 9.65) <0.001 73.6 1.0 (-6.1, 8.3)
E Usual bread consumption (white/wholemeal/granary orwheatmeal/other brown bread/combination) -0.0677 6.55 (3.26, 9.72) <0.001 74.2 -0.6 (-3.3, 0.3)
F Usual fruit and vegetable consumption (<3 per week/3-4 perweek/5-6 per week/daily/>1 per day) -0.06266 6.07 (2.72, 9.31) <0.001 71.4 6.8 (-1.1, 19.9)
G BMI, kg/m2 (continuous) -0.0745 7.18 (3.94, 10.32) <0.001 77.5 -10.8 (-23.2, -4.6)
H SBP, mmHg (continuous) -0.0586 5.70 (2.41, 8.87) 0.001 69.1 12.8 (7.4, 24.4)
I HDL cholesterol, mmol/L (continuous) -0.0561 5.45 (2.13, 8.67) 0.001 67.4 16.6 (9.9, 32.3)
J Non-HDL cholesterol, mmol/L (continuous) -0.0441 4.32 (0.79, 7.72) 0.02 58.6 34.4 (20.4, 75.7)
Effect of combinations of risk factors
K Smoking, non-HDL cholesterol, HDL cholesterol, SBP -0.0309 3.05 (-0.47, 6.44) 0.09 46.2 54.0 (34.4, 105)
L Smoking, non-HDL cholesterol, HDL cholesterol, SBP,usual fruit and vegetable consumption -0.0297 2.92 (-0.64, 6.36) 0.1 44.8 55.9 (34.3, 112)
M Smoking, non-HDL cholesterol, HDL cholesterol, SBP,usual fruit and vegetable consumption, BMI -0.0350 3.44 (-0.15, 6.91) 0.06 50.4 47.9 (26.6, 95.5)
*% of the observed fall in hazard rate explained by risk factor = 100% × (β0- β1)/ β0, where β0 is the coefficient of calendar time in the Cox regression model which only
included calendar time (Model A), and β1 is the coefficient of calendar time in the Cox regression model adjusting additionally for the risk factor(s)
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Table 6.6 Fall in hazard of a first major CHD event among men and women in Whitehall II between 1985 and 2004 and percentage of
the fall explained by risk factor time trends, separate results for each gender
Men Women
Model Risk factors adjusted for in addition to age
Fall in hazard
per annum, %
(95% CI)
p-
value
% of the observed
decline in hazard
explained by the
risk factor(s),
(95% CI)*
Fall in hazard per
annum, % (95% CI)
p-
value
% of the observed
decline in hazard
explained by the
risk factor(s),
(95% CI)*
A No adjustment 6.26 (2.66, 9.73) 0.001 8.12 (-0.25, 15.80) 0.06
Effect of adjustment for individual risk factors in isolation
B Smoking (current/ex/never) 5.96 (2.34, 9.45) 0.001 4.8 (1.4, 13) 7.51 (-0.96, 15.27) 0.08 7.9 (-3.3, 43.9)
C Physical activity (low/medium/high) 6.31 (2.70, 9.79) 0.001 -0.9 (-6.9, 4.7) 7.78 (-0.75, 15.58) 0.07 4.5 (-3.1, 60.7)
D Alcohol units per week (none/within limit/over limit/heavy) 6.25 (2.62, 9.75) 0.001 0.1 (-9.2, 9.3) 7.84 (-0.64, 15.60) 0.07 3.7 (-10.2, 32.6)
E Usual bread consumption (white/wholemeal/granary or
wheatmeal/other brown bread/combination) 6.29 (2.69, 9.75) 0.001 -0.5 (-3.8, 0.6) 8.16 (-0.26, 15.86) 0.06 -0.4 (-9.1, 6.4)
F Usual fruit and vegetable consumption (<3 per week/3-4 per
week/5-6 per week/daily/>1 per day) 5.87 (2.20, 9.40) 0.002 6.3 (-2.2, 23.1) 7.29 (-1.32, 15.18) 0.1 10.6 (-23.1, 57.3)
G BMI, kg/m2 (continuous) 7.32 (3.73, 10.77) <0.001 -17.6 (-41.1, -8.2) 8.22 (-0.06, 15.81) 0.05 -1.2 (-28.0, 14.2)
H SBP, mmHg (continuous) 5.58 (1.98, 9.05) 0.003 11.1 (5.7, 25.5) 6.67 (-1.73, 14.37) 0.1 18.5 (6.8, 69.8)
I HDL cholesterol, mmol/L (continuous) 5.10 (1.43, 8.62) 0.007 19.1 (10.2, 39.0) 7.48 (-0.91, 15.17) 0.08 8.3 (1.0, 44.4)
J Non-HDL cholesterol, mmol/L (continuous) 4.19 (0.32, 7.91) 0.03 33.8 (18.2, 87.4) 5.52 (-3.47, 13.73) 0.2 33.0 (10.8, 214)
Effect of adjustment for combinations of risk factors
K
Smoking, non-HDL cholesterol, HDL cholesterol, SBP 2.99 (-0.88, 6.71) 0.1 53.0 (30.7, 123) 3.66 (-5.35, 11.89) 0.4 56.0 (21.5, 269)
L Smoking, non-HDL cholesterol, HDL cholesterol, SBP, usual
fruit and vegetable consumption 2.90 (-1.02, 6.67) 0.1 54.4 (29.8, 126) 3.38 (-5.66, 11.65) 0.5 59.4 (19.2, 221)
M Smoking, non-HDL cholesterol, HDL cholesterol, SBP, usual
fruit and vegetable consumption, BMI 3.48 (-0.49, 7.30) 0.09 45.1 (21.7, 119) 3.76 (-5.27, 12.02) 0.4 54.7 (11.2, 210)
* % of the observed fall in hazard rate explained by risk factor = 100% × (β0- β1)/ β0, where β0 is the coefficient of calendar time in the Cox regression model which only
included calendar time (Model A), and β1 is the coefficient of calendar time in the Cox regression model adjusting additionally for the risk factor(s)
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Table 6.7 Fall in hazard of a first major CHD event among all participants in Whitehall II between 1985 and 2004 and percentage of this
fall explained by risk factor time trends, separate results for each employment grade
Employment grade
High (civil service grades 1 to 7)
Medium (civil service executives, including
senior) Low (clerical)
Model Risk factors adjusted for in addition to age and gender
Fall in hazard per
annum, % (95%
CI)
p-
value
% of decline in
hazard
explained by
risk factor(s),
(95% CI)*
Fall in hazard per
annum, % (95%
CI)
p-
value
% of decline in
hazard
explained by
risk factor(s),
(95% CI)*
Fall in hazard per
annum, % (95%
CI)
p-
value
% of decline in
hazard
explained by
risk factor(s),
(95% CI)*
A No adjustment 4.88 (-1.54, 10.89) 0.133 7.91 (3.49, 12.14) 0.001 4.53 (-3.85, 12.22) 0.28
Effect of individual risk factors in isolation
B Smoking (current/ex/never) 4.71 (-1.73, 10.75) 0.148 3.4 7.61 (3.16, 11.86) 0.001 4.0 3.97 (-4.54, 11.78) 0.35 12.6
C Physical activity (low/medium/high) 4.73 (-1.69, 10.76) 0.145 3.0 8.08 (3.63, 12.33) <0.001 -2.2 4.14 (-4.31, 11.9) 0.326 8.7
D Alcohol units per week (none/within limit/overlimit/heavy) 5.07 (-1.38, 11.11) 0.121 -4.0 7.83 (3.35, 12.09) 0.001 1.1 4.46 (-3.96, 12.2) 0.29 1.4
E Usual bread consumption (white/wholemeal/granary orwheatmeal/other brown bread/combination) 4.85 (-1.57, 10.87) 0.136 0.6 7.93 (3.51, 12.15) 0.001 -0.2 4.6 (-3.78, 12.3) 0.273 -1.6
F Usual fruit and vegetable consumption (<3 per week/3-4per week/5-6 per week/daily/>1 per day) 5.06 (-1.44, 11.14) 0.124 -3.8 7.45 (2.93, 11.76) 0.001 6.1 3.72 (-4.83, 11.56) 0.383 18.2
G BMI, kg/m2 (continuous) 5.78 (-0.64, 11.79) 0.077 -19.1 8.34 (3.96, 12.52) <0.001 -5.7 5.66 (-2.56, 13.22) 0.172 -25.7
H Systolic blood pressure, mmHg (continuous) 4.56 (-1.86, 10.57) 0.16 6.7 6.96 (2.54, 11.18) 0.002 12.5 3.11 (-5.27, 10.82) 0.455 31.7
I HDL cholesterol, mmol/L (continuous) 3.8 (-2.66, 9.85) 0.243 22.6 6.75 (2.24, 11.05) 0.004 15.2 3.86 (-4.54, 11.59) 0.357 14.9
J Non-HDL cholesterol, mmol/L (continuous) 2.32 (-4.54, 8.74) 0.497 53.0 5.83 (1.01, 10.41) 0.018 27.2 2.59 (-6.31, 10.75) 0.556 43.3
Effect of combinations of risk factors
K Smoking, non-HDL cholesterol, HDL cholesterol, systolicblood pressure 1.76 (-5.04, 8.12) 0.602 64.4 4.36 (-0.47, 8.95) 0.076 46.0 0.24 (-8.77, 8.51) 0.956 94.7
L Smoking, non-HDL cholesterol, HDL cholesterol, systolicblood pressure, usual fruit and vegetable consumption 2.19 (-4.67, 8.6) 0.523 55.8 4.14 (-0.74, 8.79) 0.095 48.7 -0.5 (-9.59, 7.83) 0.91 110.7
M
Smoking, non-HDL cholesterol, HDL cholesterol, systolic
blood pressure, usual fruit and vegetable consumption,
BMI
2.26 (-4.75, 8.8) 0.518 54.3 4.33 (-0.62, 9.03) 0.085 46.3 1.05 (-7.98, 9.32) 0.813 77.2
* % of the observed fall in hazard rate explained by risk factor = 100% × (β0- β1)/ β0, where β0 is the coefficient of calendar time in the Cox regression model which only
included calendar time (Model A), and β1 is the coefficient of calendar time in the Cox regression model adjusting additionally for the risk factor(s)
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Chapter 7: Assessing the role of medication in the time trends in the
major coronary aetiological exposures in the British Regional Heart
Study
7.1 Introduction
In chapters 5 and 6 it was shown that a substantial portion of the decline in major CHD
incidence in Britain in recent decades may be attributed to concurrent favourable trends in
the major aetiological exposures. Among other factors, favourable trends in blood
pressure (BP), HDL cholesterol and non-HDL cholesterol have made appreciable
contributions. The reasons for the favourable changes in BP and blood lipids however
have not been examined. The trends may reflect favourable changes in the underlying
determinants of BP or blood lipids in the population; for BP, adiposity, alcohol intake,
physical activity, and dietary factors (particularly salt intake) are known modifiable
determinants363 while for total and LDL cholesterol dietary saturated fat intake, adiposity
and physical activity are important364. Alternatively, the trends in these risk factors may
reflect the increasingly widespread use365 of specific medications to lower BP (including
particularly ACE inhibitors, beta blockers, calcium channel blockers, diuretics)156-160 and
to lower total and LDL-cholesterol (particularly statins)152-155.
The evidence suggest that blood pressure lowering medications influence major CHD risk
primarily through changing blood pressure160, and lipid-regulating medications prevent
major CHD events primarily through changing blood lipid levels (principally LDL
levels)153. Therefore understanding the contributions of medication-related and non-
medication-related factors to the changes in BP and blood lipids which have occurred
during recent decades could help to inform efforts to bring about further reductions in the
risk of CHD.
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The aim of this chapter is therefore to assess the role of medication in changes in systolic
BP (SBP), diastolic BP (DBP), non-HDL cholesterol and HDL cholesterol which have
occurred. This corresponds to objective iii) b) of the overall thesis objectives.
In particular, the analyses will explore the extent to which increased uptake of blood
pressure lowering medications365 (including particularly angiotensin-converting enzyme
inhibitors, β-blockers, calcium channel blockers and diuretics) may have contributed to
blood pressure changes, and the extent to which increased uptake of lipid-regulating
medications365 (particularly statins) may have contributed to the changes in lipid levels.
The British Regional Heart Study is used for this analysis, to explore the BP and lipid
trends in older British men between 1978 and 2000.
The structure of this chapter is as follows: Section 7.2 details methods specific to this
chapter, including statistical methods. Results are given in section 7.3. Finally, section
7.4 provides a discussion and interpretation of the findings of the chapter.
Objective
To estimate the contribution of increased uptake of medication to the trends in
blood pressure and cholesterol in the BRHS
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7.2 Methods
7.2.1 Data source
Analyses in this chapter are carried out using the BRHS. Marked favourable trends in
blood pressure and blood lipids were demonstrated in chapter 5 to be associated with the
decline in major CHD incidence in this cohort. Medication use was ascertained
repeatedly, at each of the questionnaires.
7.2.2 Coronary risk factors as the principal outcomes
The main outcomes were systolic blood pressure (SBP), diastolic blood pressure (DBP),
HDL cholesterol and non-HDL cholesterol, measured at physical examinations at
baseline (1978 to 1980) and after 20 years (1998 to 2000).
7.2.3 Medication use
From questions about medication use in every questionnaire between baseline and 20
years (that is, in 1978-80, in 1983-5, in 1992 and in 1996), current use of drugs to lower
blood pressure and current use of drugs to regulate lipid levels at each time-point was
determined. The information at each time-point was then combined to produce an
indicator for blood pressure-lowering drug use at any time between baseline and 20 years,
and a similar indicator for lipid-regulating drug use at any time between baseline and 20
years.
7.2.4 Potential confounding variables: factors associated with dyslipidemia and
hypertension
Potential factors that may increase risk of high SBP and DBP considered in this analysis
were BMI, physical inactivity and alcohol intake as these factors have been found to be
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associated with blood pressure levels363. For high non-HDL cholesterol factors
considered were BMI and physical inactivity, again factors previously shown to be
associated with non-HDL or LDL cholesterol levels364. For low HDL cholesterol, BMI,
physical inactivity, alcohol use and smoking status were considered as all four factors
have been shown to be associated with HDL cholesterol levels364. Differences between
medication users and non-medication users in the overall levels of these lifestyle factors,
as well as in temporal changes in these factors could potentially confound estimates of the
modifying effect of medication use on trends in blood pressure and cholesterol.
Therefore, recorded levels of each factor at both baseline and the 20-year follow-up,
categorised as outlined in chapter 3, section 3.2.5, were used in analyses.
7.2.5 Statistical methods
Again the dataset was split such that measurements at baseline and 20 years formed two
separate rows of data for each man. Age-adjusted changes in each of the four outcomes
were estimated from linear regression of the outcome on a time variable (taking the value
0 at baseline, and value 20 at 20 years), adjusting for age. Generalised estimating
equations with robust standard errors were used in the regressions to take account of the
repeated measures of each outcome (one at baseline and a second at 20 years) for each
man. An interaction term of time with an indicator for medication use at any time
between baseline and 20 years was added to the model to estimate the trend in the
outcome according to whether a man had received medication or not. Predicted BP and
cholesterol levels for a 60 year old man at baseline and at 20 years were estimated from
the regression models. Multivariable models, adjusting additionally for the current levels
at both time points of the risk factors for each outcome (BMI as a continuous variable and
physical activity, smoking status and alcohol intake categorised as described above) ,
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were used to take account of possible differences in these factors between the men
receiving and not receiving medication.
7.2.6 Participants included in analysis
In this analysis, only those men who were alive at the 20 year follow-up and attended the
20-year physical examination were included. In contrast to the analyses in chapter 5, men
were included regardless of previous MI. However analyses were also repeated
separately among men who did and did not experience an MI before or during the 20 year
follow-up to correspond to the study sample in chapter 5. Further, as sensitivity analyses,
the analyses were repeated among men who did not have any previous cardiovascular
disease (MI, other CHD or stroke) as all forms of cardiovascular disease are known to
affect blood pressure and cholesterol levels (in particular, blood pressure and lipid levels
may fall as a result of an MI or stroke103).
7.3 Results – Examining the role of medication in the risk factor changes
Of 7735 men who entered the study, 4252 surviving men were re-examined at 20 years.
Of these men, 21 (0.5%) were missing a valid blood pressure measurement at baseline
and/or 20 years, leaving 4231 men for inclusion in analyses of trends in SBP and DBP.
386 men (9%) were missing a valid lipid measurement at baseline and/or 20 years and a
further 4 men (0.09%) were missing records of lipid-regulating medication use, leaving
3862 men for inclusion in analyses of trends in non-HDL and HDL cholesterol. 1561
(37%) out of 4231 men reported use of blood pressure-lowering drugs at some point over
the 20 years; the proportion increased from 3.0% at baseline (1978-1980) to 33% at 20
years follow-up (1998-2000). 302 (7.8%) out of 3862 men reported use of lipid-regulating
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drugs at some point over the 20 years; none reported use at baseline, compared with 7.4%
at 20 years.
Adjusting for age, mean SBP changed by -7.6mmHg; 95% confidence interval (CI) -9.7
to -5.4, p<0.001, while mean DBP changed by +3.3mmHg (95% CI +2.2 to +4.5,
p<0.001) over 20 years (table 7.1). The trends in SBP and DBP varied according to blood
pressure-lowering drug use: Mean changes in SBP were -12.3mmHg (95% CI -14.7 to -
9.9) among medication users and -1.6mmHg (95% CI -3.7 to +0.5) among men not on
medication (p<0.001 for medication-time interaction). Mean changes in DBP were -
1.2mmHg (95% CI -2.5 to +0.07) among medication users and +7.7mmHg (95% CI +6.6
to +8.8) among men not on medication (p<0.001 for medication-time interaction).
Adjusting for age, mean non-HDL cholesterol changed by -0.35mmol/L (95% CI -0.46 to
-0.24, p<0.001). The change among medication users was -1.78mmol/L (95% CI -1.96 to
-1.60), compared with a change of -0.24mmol/L (95% CI -0.35 to -0.13) among men not
on medication (p<0.001 for medication-time interaction). Mean HDL cholesterol
changed by +0.16mmol/L (95% CI +0.13 to +0.19, p<0.001). There was no evidence that
the trend in HDL cholesterol varied according to lipid-regulating drug use. HDL
cholesterol changed by +0.18 (95% CI +0.14 to +0.23) among medication users and by
+0.16 (95% CI +0.13 to +0.19) among men not on medication (p=0.15 for medication-
time interaction).
The results suggest that had none of the men using blood pressure-lowering medication
been present, we would have expected an overall average decline in SBP among all men
of 1.61mmHg (the change among men not on medication). Given that the actual average
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decline observed was 7.56mmHg, this suggests that (7.56-1.61)/7.56 = 79% of the overall
cohort-wide decline in SBP may be attributed to the greater changes occurring among that
select (high-risk) group of medication users, over and above the changes occurring among
men not on medication. Similarly, 29% of the decline in non-HDL cholesterol and none
of the increase HDL cholesterol may be attributed to greater changes occurring only
among lipid-regulating drug users, over and above the background changes occurring in
men not on medication.
With additional adjustment for measured confounders (BMI, alcohol use and physical
activity for SBP and DBP; BMI and physical activity for non-HDL cholesterol; BMI,
physical activity, smoking and alcohol use for HDL cholesterol) the favourable trends in
SBP, non-HDL cholesterol and HDL cholesterol became slightly stronger and the
unfavourable trend in DBP became weaker, but the interactions between medication use
and time were essentially unchanged (table 7.2), reflecting the little variation in the
absolute levels and temporal changes in these behavioural factors according to BP-
lowering medication use (table 7.3) and lipid-regulating medication use (table 7.4). In
sensitivity analyses adjusted for the (non-significant) systematic differences in lipid
measurements between the baseline and 20-year assay techniques described in the chapter
3, section 3.2.6, the trends in non-HDL cholesterol were unchanged and, while the
increase in HDL became slightly weaker, it remained significant and there remained no
difference according to medication use (table 7.5).
Analogous results among that subgroup of men with no prior MI before the 20-year
follow-up (to correspond with the sample of men included in the previous analysis to
explain the decline in MI) are shown in table 7.6. The 20-year trends and predicted levels
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for a 60-year old for each risk factor, overall and according to medication use, were all
very similar to the results for the whole cohort, and therefore in particular, the differences
and similarities between those who did and did not report medication use, persisted.
Indeed, combining the trends estimates as above, among this sub-cohort, 75% of the
overall cohort-wide decline in SBP may be attributed to the greater changes occurring
among that select (high-risk) group of medication users, over and above the changes
occurring among men not on medication. 30% of the decline in non-HDL cholesterol and
none of the increase HDL cholesterol may be attributed to greater changes occurring only
among lipid-regulating drug users, over and above the background changes occurring in
men not on medication. Excluding further men who did not have any previous CHD (that
is, angina or MI) or stroke before the 20-years, the results did not alter appreciably (data
not shown).
7.4 Discussion
7.4.1 Summary of main findings
Over a 20-year period between 1978-1980 and 1998-2000, a significant favourable
increase of 14% in average HDL cholesterol, and significant but more modest favourable
falls of 5% and 7% in SBP and non-HDL cholesterol respectively, were observed in this
survivor cohort of British men. Most (80%) of the fall in SBP and a smaller proportion
(33%) of the fall in non-HDL cholesterol could be attributed to larger decreases in
medication users over and above the decreases among men not on medication. The
favourable increase in HDL cholesterol however was independent of medication use.
DBP did not change favourably over the 20 years.
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The results were similar for men with and without a major CHD event or CVD event
before or during the 20-year follow-up.
7.4.2 Comparison with other studies
In terms of the risk factor trends seen, as discussed in chapter 5, section 5.5.2, the overall
decline in SBP is consistent with cross-sectional routine data for England reported in the
Health Survey for England 1998351 and with SBP trends observed in Glasgow, Scotland
(WHO MONICA, (mean fall of 4.5mmHg over an overlapping 10-year period between
1986 and 1995 compared with our figure of 7.6mmHg over 20 years)245. However modest
declines in DBP were also reported in these two studies, in contrast to our observed
increase. The limited data on national trends in cholesterol in the UK352 is consistent with
the trends seen here (see chapter 5, section 5.5.2).
There is little data on blood pressure and cholesterol temporal trends according to
medication use and few studies have formally investigated the impact of medication use
on secular trends in blood pressure and cholesterol. A report from the Minnesota Heart
Survey compared the trend in total cholesterol from 1980 to 2002 among the entire
population with the trend among that subgroup not using lipid-regulating medication366.
The trends were fairly similar until the last few study years, when the general population
showed a steeper decline in total cholesterol compared with the subgroup not using
medication, suggesting that lipid-regulating drug use may be partially responsible for the
overall population-wide trend in total cholesterol at least in later years. A separate recent
study in the US population found that one-quarter of an observed 0.34mmol/L mean fall
in total cholesterol between 1980 and 2000 could be attributed to statin use367, broadly
consistent with the present findings of one third of the (smaller) decline in non-HDL
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cholesterol the UK over the same period associated with users of medication. A study in
Finland observed declines in total cholesterol of 0.86mmol/L in men and 0.97mmol/L in
women between 1982 and 2007368. Expected declines given dietary and medication
trends over the same period were estimated, and compared with the observed declines to
estimate the contribution of diet and medication use to the total cholesterol declines. The
results were that the majority of the total cholesterol decline (65% in men and 60% in
women) could be attributed to changes in dietary fat quality and cholesterol intake, while
lipid-regulating medication explained 16% in men and 7% in women. The conclusions
are consistent with the present study in that other factors (diet) may have been more
important than use of lipid-regulating medications in the favourable lipid trends.
However, the contribution of lipid-regulating medications is even smaller than that
estimated in the present analysis. Since uptake of lipid-regulating drugs was greater in
the Finnish population (up to 30% among older adults), reflecting the more recent time-
period, differences in uptake cannot explain this. The difference could instead reflect the
limitations of the ecological analysis in the Finnish study, or that total cholesterol instead
of non-HDL was considered or that concerted efforts have been made to reduce dietary
intake of cholesterol in Finland369, 370 which was initially very high, more so than in the
UK, leading to overall greater lipid changes and a greater impact of diet in the Finnish
population. As discussed in chapter 2, section 2.6.1.1, the WHO MONICA project
investigated the role of medication on time trends in blood pressure by comparing the
shape of the distribution of blood pressure in the mid-1980s with that in the mid-1990s in
different world-wide populations245. The hypothesis was that the effect of blood
pressure-lowering medication would be realised in a selective depression of the top end of
the population bell curve over time (reflecting the impact of blood pressure-lowering
medication as a high risk as opposed to mass population intervention). The study found
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no significant evidence for such a medication effect for the overall analysis of all
populations combined (mean blood pressure changes, pooled across all the populations,
were similar in the different blood pressure centiles) but may have been limited by this
indirect ecological approach. Considering the UK populations in isolation however gives
a different picture. In Glasgow, use of anti-hypertensive medications increased from 7%
to 10% of the study population, between 1985 and 1994. Over the same period, average
systolic blood pressure declined by -4.5mmHg and diastolic blood pressure declined by -
3.6mmHg in men. The declines were greatest among participants above the 80th blood
pressure centiles, that is, with the highest blood pressure: declines of -6.0mmHg and -
4.0mmHg for systolic and diastolic blood pressure respectively. A similar pattern was
seen among women: systolic blood pressure declined by -6.9mmHg on average and by -
7.0mmHg among women above the 80th centile; diastolic blood pressure declined by -
5.9mmHg on average and by -7.0mmHg above the 80th centile. This suggests a selective
depression of the top end of the bell curve over time which in turn suggests an influence
of medication on the blood pressure trends, in line with the present BRHS findings for
Great Britain as a whole. In Belfast, use of anti-hypertensive medication did not increase;
at the same time blood pressure levels changed little, which neither supports nor refutes
an influence of medication in blood pressure time trends in general.
7.4.3 Strengths and Limitations
This study provided data on long-term changes in BP and cholesterol in a socially and
geographically representative sample of older British men. Cross-calibration of BP and
lipid measurement techniques used at 20 years with those at baseline ensured
comparability between the two time-points (as outlined in chapter 3, section 3.2.6).
Further, in subsidiary analyses adjusting for the non-significant systematic differences
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between the baseline and 20-year lipid measurement techniques, the conclusions did not
change.
The ascertainment of medication use needs consideration. Questions on medication use
in repeated questionnaires over the 20-year follow-up helped to ensure all users of
relevant medications over this period were identified, particularly by asking in the
questionnaires not only about specific medications but to list all prescriptions.
Comparison data on population-wide prevalence of medication use is limited, particularly
in earlier years. Findings from routine prescription records showed that in 1998, among
men aged 65-to-74 years, the prevalence of prescribing of lipid-regulating medication was
7.8%315, a figure which agrees closely with our data (7.7% in 1998-2000), which helps to
validate our self-reported medication measure. Corresponding figures for blood pressure
medication from this report could not be compared as patients may be prescribed more
than one type of blood pressure medication, leading to larger prescription numbers.
However a population-based study found self-report of antihypertensive medication use
to agree reasonably closely with prescription data371. Moreover, self-report may arguably
be a better reflection of medication compliance than prescription records.
The analyses were necessarily based on those surviving men who attended the 20-year
follow-up re-examination. This potential for survival and response biases needs
consideration. The most likely impact would be overestimation of the favourable trends
observed (healthy participant effect). Importantly, the healthy participant effect is
unlikely to explain the differential trends according to medication use and thus the role of
medication, which is the key finding (since both groups may be similarly influenced by
the healthy participant effect, such that the difference between the groups is unlikely to be
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affected). Also, as discussed in chapter 5, section 5.5.3, baseline levels of blood pressure
and cholesterol among those who survived to attend the 20-year examination have been
shown to be similar to levels among non-attendees355, especially when compared with the
overall changes over time, suggesting that a healthy participant effect was unlikely to
have had a dramatic influence on the observed trends.
As might be expected, baseline levels of SBP, DBP, and non-HDL cholesterol were much
higher in those men who reported subsequent medication use (table 7.1), thus there was
arguably greater potential for a decline in these groups. Nevertheless, in separate
analyses, including baseline levels of the outcome as a covariate to adjust for regression
to the mean372, the changes in SBP, DBP and non-HDL cholesterol in the medication
users remained significantly greater than the changes in men not using medication while
there remained no significant difference in the HDL cholesterol trends.
A limitation is that only 8% of men were on lipid-regulating medications, raising issues
of low statistical power (wide CIs). The cohort comprises older British men, for whom
prevalence of medication use is higher than for younger men and women and therefore
generalisability of these results to other populations is uncertain. In particular, if
prevalence of medication use is lower in another population, the percentage of the BP and
cholesterol trends attributable to added changes among medication users will be lower.
7.4.4 Interpretation of findings
The marked increase in levels of the protective factor HDL-cholesterol, which rose by
about 14% between 1980 and 2000, was independent of medication use. The trend is
likely to reflect secular changes in the determinants of HDL-cholesterol, in particular the
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decline in cigarette smoking prevalence among the study population, since cigarette
smoking is associated with markedly reduced HDL-cholesterol levels373 and smoking
cessation has been shown to raise HDL-cholesterol levels374. Other possible factors
include diet and vitamin C supplementation364, 375. Of the more modest overall 7%
decline in non-HDL cholesterol, approximately one-third of the decline could be
accounted for by the decline occurring in users of lipid-regulating medications. The
remaining population wide decline in non-HDL cholesterol may reflect the
contemporaneous fall in the dietary consumption of saturated fat; household purchase
data suggest that daily total and saturated fat intake fell in the UK from 47g to 29g
between 1980 and 2000376. However dietary data was not available to directly examine
the role of dietary factors in the BRHS. The overall 5% decline in population SBP in this
survivor cohort was largely accounted for by changes among users of blood pressure-
lowering medication, reflecting the high prevalence of blood pressure- lowering
medication use in this cohort of older British men. No material decline in SBP occurred
among men not receiving blood pressure-lowering medication, while DBP increased
which was unexpected and merits further study. The much stronger favourable declines in
non-HDL cholesterol and SBP among medication users, compared with men not using
medication, could be attributed entirely to the medication itself or could also partly reflect
more favourable life-style changes or a differing risk-profile among medication users
compared with men not using medication. The persistence of differential trends according
to medication use even after adjustment for concurrent changes in major potential
confounders (smoking status, alcohol use, BMI and physical inactivity), and in sensitivity
analyses excluding men with previous MI, suggests that it is most likely the treatment
itself that is bringing about the changes in medication users. Indeed in further sensitivity
analyses, excluding men with any previous cardiovascular morbidity (MI or other CHD
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or stroke), the differential trends remained (data not shown). However a limitation is that
diet was not measured in this analysis. Medication users may also have made more
favourable changes to their diet than those not using medication which may explain some
part of the differential trends. That said, while it is recognised that lipid-regulating
medications act principally on non-HDL cholesterol rather than HDL, we might expect
diet to have more similar influences on both lipid types. Thus if diet did differ
substantially between the two medication groups we might have expected differences in
the trends in HDL between the two groups as well, which we did not see.
The results of the present study confirm that the use of medication to lower BP was
widespread before 2000, and suggest that use of anti-hypertensive drugs may explain
much of the fall in SBP. Since in chapter 5 (section 5.4) it was estimated that falling SBP
levels could explain 13% of the decline in major CHD incidence in the BRHS, it might be
inferred that the contribution of increased use of anti-hypertensive drugs to the CHD
decline is close to this figure. This assumes however that the effect of anti-hypertensive
drugs on CHD risk is only through lowering BP; the contribution of these drugs to the
CHD decline may be greater if anti-hypertensive drugs have a broader effect on CHD
risk. That said, studies suggest that the effect of anti-hypertensive drugs is predominantly
through moderating BP levels160.
Around one third of the decline in non-HDL cholesterol could be attributed to use of
lipid-regulating drugs. Since in chapter 5 (section 5.4), it was estimated that falling non-
HDL cholesterol levels could explain 10% of the decline in major CHD incidence, it
might be inferred that the contribution of increased use of lipid-regulating drugs to the
CHD decline is modest, at around 3%. This again assumes that the effect of lipid-
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regulating drugs on CHD risk is only through lowering non-HDL cholesterol; the
contribution of these drugs to the CHD decline may be greater if the drugs have a broader
effect on CHD risk. Again, studies suggest however that the effect of lipid-regulating
drugs is predominantly through moderating cholesterol levels.153
The modest impact of lipid-regulating drugs reflects in part the low uptake of these drugs
during the period of study. Since 2000, further population-wide declines in blood
cholesterol and BP have occurred352. At least part of these changes are likely to reflect
further increases in the prevalence of lipid lowering and BP-lowering drugs since 2000377.
7.4.5 Chapter conclusions/ postscript
The key finding of this chapter is that the changes in SBP in this cohort appear to be
largely confined to medication users, while the change in non-HDL cholesterol probably
reflects a combination of medication and lifestyle and the change in HDL cholesterol
likely reflects predominantly lifestyle factors. The implication is that use of anti-
hypertensive drugs may have made an appreciable contribution to the decline in major
CHD incidence. The contribution of lipid-regulating drugs is much more modest but the
effects of lipid-regulating drugs may be yet to be realised due to low uptake during the
period of study.
Together, chapters 5, 6 and 7 have explored the reasons for the favourable decline in
major CHD incidence in Britain in recent decades. In the next chapter 8, the factors
influencing the unfavourable parallel rise in T2DM incidence are investigated.
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Table 7.1 Mean age-adjusted changes over 20 years from 1978-80 to 1998-2000 in SBP, DBP, HDL cholesterol and non-HDL cholesterol
and predicted levels for a 60-year old in 1978-80 and in 1998-2000, overall and according to medication use between the two time-points
N
Predicted level for 60
year old in 1978-80
(95% CI)
Mean age-adjusted
change over 20 years
(95%CI) P
Predicted level for 60
year old in 1998-2000
(95% CI)
SBP, mmHg
All men 4231 150.4 (149.1, 151.7) -7.56 (-9.69, -5.43) <0.001 142.9 (141.8, 143.9)
Men using BP-lowering medication 1561 158.3 (156.8, 159.7) -12.30 (-14.69, -9.92) <0.001 146.0 (144.4, 147.5)
Men not using BP-lowering medication 2670 144.1 (142.7, 145.4) -1.61 (-3.71, 0.49) 0.13 142.4 (141.3, 143.6)
p-value for interaction <0.001
DBP, mmHg
All men 4231 81.6 (80.9, 82.3) 3.31 (2.18, 4.45) <0.001 84.9 (84.4, 85.5)
Men using BP-lowering medication 1561 86.9 (86.0, 87.8) -1.22 (-2.51, 0.07) 0.06 85.7 (84.9, 86.4)
Men not using BP-lowering medication 2670 77.6 (76.9, 78.3) 7.68 (6.57, 8.79) <0.001 85.3 (84.7, 85.9)
p-value for interaction <0.001
HDL cholesterol, mmol/L
All men 3862 1.16 (1.14, 1.18) 0.16 (0.13, 0.19) <0.001 1.32 (1.30, 1.34)
Men using lipid-regulating medication 302 1.12 (1.09, 1.16) 0.18 (0.14, 0.23) <0.001 1.30 (1.27, 1.34)
Men not using lipid-regulating medication 3560 1.16 (1.14, 1.18) 0.16 (0.13, 0.19) <0.001 1.32 (1.30, 1.34)
p-value for interaction 0.15
Non-HDL cholesterol, mmol/L
All men 3862 5.08 (5.01, 5.14) -0.35 (-0.46, -0.24) <0.001 4.73 (4.67, 4.78)
Men using lipid-regulating medication 302 6.01 (5.87, 6.15) -1.78 (-1.96, -1.60) <0.001 4.23 (4.10, 4.35)
Men not using lipid-regulating medication 3560 5.00 (4.94, 5.07) -0.24 (-0.35, -0.13) <0.001 4.76 (4.70, 4.82)
p-value for interaction <0.001
Note: Mean changes, associated p-values and predicted levels from linear regression models with generalised estimating equations and robust standard errors
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Table 7.2 Mean changes over 20 years from 1978-80 to 1998-2000 in SBP, DBP,
HDL cholesterol and non-HDL cholesterol, overall and according to medication
use between the two time-points, adjusting for age and risk factors for
hypertension or hypercholesterolemia
N
Mean age- and risk-
factor adjusted*
change over 20 years
(95%CI) p
SBP, mmHg
All men 4229 -9.00 (-11.14, -6.86) <0.001
Men using BP-lowering medication 1561 -13.39 (-15.81, -10.98) <0.001
Men not using BP-lowering medication 2668 -3.21 (-5.33, -1.09) 0.003
p-value for interaction <0.001
DBP, mmHg
All men 4229 1.98 (0.84, 3.11) 0.001
Men using BP-lowering medication 1561 -2.43 (-3.73, -1.13) <0.001
Men not using BP-lowering medication 2668 6.20 (5.08, 7.32) <0.001
p-value for interaction <0.001
HDL cholesterol, mmol/L
All men 3858 0.18 (0.15, 0.21) <0.001
Men using lipid-regulating medication 302 0.21 (0.17, 0.25) <0.001
Men not using lipid-regulating medication 3556 0.18 (0.15, 0.21) <0.001
p-value for interaction 0.11
non-HDL cholesterol, mmol/L
All men 3860 -0.40 (-0.51, -0.29) <0.001
Men using lipid-regulating medication 302 -1.84 (-2.02, -1.66) <0.001
Men not using lipid-regulating medication 3558 -0.29 (-0.40, -0.18) <0.001
p-value for interaction <0.001
*Confounders adjusted for:
SBP, DBP: BMI, alcohol use, physical activity; non-HDL cholesterol: BMI, physical activity;
HDL cholesterol: BMI, smoking, alcohol use, physical activity
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Table 7.3 Baseline level, 20-year level, and change in risk factors for high SBP or
DBP according to blood pressure lowering medication use between baseline and
20-years
Blood pressure lowering medication use
No (n=2670) Yes (n=1561)
Total non-
missing Mean (sd)
Total non-
missing Mean (sd)
Age, years
Baseline 2670 48.3 (5.51) 1561 49.8 (5.39)
20 year follow-up 2670 68.3 (5.51) 1561 69.8 (5.39)
Body mass index, kg/m2
Baseline 2670 25.1 (2.89) 1561 26.1 (3.07)
20 year follow-up 2660 26.5 (3.57) 1552 27.7 (3.88)
Change 2660 +1.44 (2.34) 1552 +1.65 (2.61)
Total non-
missing N (%)
Total non-
missing N (%)
Alcohol use
Baseline 2669 1560
none 123 (4.6) 89 (5.7)
occasional 665 (24.8) 376 (24.1)
light 981 (36.8) 550 (35.3)
moderate 678 (25.4) 383 (24.6)
heavy 225 (8.4) 162 (10.4)
20 year follow-up 2613 1525
none 263 (10.1) 166 (10.9)
occasional 670 (25.6) 446 (29.3)
light 1170 (44.8) 648 (42.5)
moderate 430 (16.5) 220 (14.4)
heavy 80 (3.1) 45 (2.9)
Change 2612 1524
reduced alcohol use 985 (37.7) 644 (42.3)
no change 1205 (46.1) 651 (42.7)
increased alcohol use 422 (16.2) 229 (15.0)
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Table 7.3 continued Baseline level, 20-year level, and change in risk factors for
high SBP or DBP according to blood pressure lowering medication use between
baseline and 20-years
Blood pressure lowering medication use
No (n=2670) Yes (n=1561)
Total non-
missing N (%)
Total non-
missing N (%)
Physical activity
Baseline 2640 1543
vigorous 242 (9.2) 109 (7.1)
moderately vigorous 502 (19.0) 231 (15.0)
moderate 474 (18.0) 238 (15.4)
light 568 (21.5) 339 (22.0)
occasional 703 (26.6) 505 (32.7)
inactive 151 (5.7) 121 (7.8)
20 year follow-up 2579 1497
vigorous 420 (16.3) 199 (13.3)
moderately vigorous 493 (19.1) 192 (12.8)
moderate 399 (15.5) 189 (12.6)
light 481 (18.7) 279 (18.6)
occasional 561 (21.8) 394 (26.3)
inactive 225 (8.7) 244 (16.3)
Change 2551 1479
more active 1014 (39.8) 526 (35.6)
no change 688 (27.0) 399 (27.0)
less active 849 (33.3) 554 (37.4)
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Table 7.4 Baseline level, 20-year level and change in risk factors for low HDL
cholesterol, or high non-HDL cholesterol according to lipid-regulating
medication use between baseline and 20-years
Lipid-regulating medication use
No (n=3560) Yes (n=302)
Total non-
missing Mean (sd)
Total non-
missing Mean (sd)
Age, years
Baseline 3560 49.0 (5.52) 302 48.0 (5.25)
20 year follow-up 3560 69.0 (5.52) 302 68.0 (5.25)
Body mass index, kg/m2
Baseline 3560 25.3 (2.93) 302 25.9 (3.10)
20 year follow-up 3544 26.8 (3.62) 299 27.6 (3.76)
Change 3544 +1.47 (2.37) 299 +1.68 (2.38)
Total non-
missing N (%)
Total non-
missing N (%)
Smoking status
Baseline 3555 302
smoker 1133 (31.9) 118 (39.1)
non-smoker 2422 (68.1) 184 (60.9)
20 year follow-up 3551 302
smoker 455 (12.8) 29 (9.6)
non-smoker 3096 (87.2) 273 (90.4)
Change 3548 302
gave up smoking 718 (20.2) 91 (30.1)
no change 2786 (78.5) 209 (69.2)
took up smoking 44 (1.3) 2 (0.7)
Alcohol use
Baseline 3558 302
none 168 (4.7) 16 (5.3)
occasional 883 (24.8) 65 (21.5)
light 1305 (36.7) 105 (34.8)
moderate 883 (24.8) 79 (26.2)
heavy 319 (9.0) 37 (12.2)
20 year follow-up 3484 297
none 351 (10.1) 22 (7.4)
occasional 949 (27.2) 79 (26.6)
light 1532 (44.0) 129 (43.4)
moderate 549 (15.8) 57 (19.2)
heavy 103 (3.0) 10 (3.4)
Change 3482 297
reduced alcohol use 1363 (39.1) 128 (43.1)
no change 1563 (44.9) 117 (39.4)
increased alcohol use 556 (16.0) 52 (17.5)
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Table 7.4 continued Baseline level, 20-year level and change in risk factors for low
HDL cholesterol, or high non-HDL cholesterol according to lipid-regulating
medication use between baseline and 20-years
Lipid-regulating medication use
No (n=3560) Yes (n=302)
Total non-
missing N (%)
Total non-
missing N (%)
Physical activity
Baseline 3522 300
vigorous 299 (8.5) 20 (6.7)
moderately vigorous 625 (17.8) 52 (17.3)
moderate 622 (17.7) 43 (14.3)
light 760 (21.6) 63 (21.0)
occasional 998 (28.3) 93 (31.0)
inactive 218 (6.2) 29 (9.7)
20 year follow-up 3429 294
vigorous 521 (15.2) 53 (18.0)
moderately vigorous 585 (17.1) 45 (15.3)
moderate 506 (14.8) 39 (13.3)
light 642 (18.7) 49 (16.7)
occasional 812 (23.7) 62 (21.1)
inactive 363 (10.6) 46 (15.7)
Change 3393 292
more active 1280 (37.7) 125 (42.8)
no change 933 (27.5) 69 (23.6)
less active 1180 (34.8) 98 (33.6)
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Table 7.5 Mean changes over 20 years from 1978-80 to 1998-2000 in HDL cholesterol and non-HDL cholesterol and predicted levels for a
60-year old in 1978-80 and in 1998-2000, overall and according to medication use between the two time-points, adjusting for the non-
significant systematic differences between the baseline and 20-year assay techniques
Adjusting for age only Adjusting additionally for risk factors*
N
Predicted level for
60 year old in
1978-80 (95% CI)
Mean change over 20
years (95%CI) p
Predicted level for
60 year old in
1998-2000 (95%
CI) N
Mean change over 20
years (95%CI) p
HDL cholesterol, mmol/L
All men 3862 1.22 (1.20, 1.24) 0.09 (0.06, 0.13) <0.001 1.32 (1.30, 1.33) 3858 0.12 (0.09, 0.15) <0.001
Men using lipid-
regulating medication 302 1.19 (1.16, 1.22) 0.12 (0.07, 0.16) <0.001 1.30 (1.27, 1.34) 302 0.14 (0.10, 0.18) <0.001
Men not using lipid-
regulating medication 3560 1.23 (1.21, 1.25) 0.09 (0.06, 0.12) <0.001 1.32 (1.30, 1.34) 3556 0.12 (0.09, 0.15) <0.001
p-value for interaction 0.15 p-value for interaction 0.11
non-HDL cholesterol, mmol/L
All men 3862 5.08 (5.02, 5.15) -0.36 (-0.47, -0.25) <0.001 4.73 (4.67, 4.78) 3860 -0.41 (-0.52, -0.29) <0.001
Men using lipid-
regulating medication 302 6.01 (5.87, 6.15) -1.79 (-1.97, -1.61) <0.001 4.23 (4.10, 4.35) 302 -1.85 (-2.03, -1.66) <0.001
Men not using lipid-
regulating medication 3560 5.01 (4.94, 5.08) -0.25 (-0.36, -0.14) <0.001 4.76 (4.70, 4.82) 3558 -0.30 (-0.41, -0.19) <0.001
p-value for interaction <0.001 p-value for interaction <0.001
*Confounders adjusted for: non-HDL cholesterol: BMI, physical activity; HDL cholesterol: BMI, smoking, alcohol use, physical activity
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Table 7.6 Mean age-adjusted changes over 20 years from 1978-80 to 1998-2000 in SBP, DBP, HDL cholesterol and non-HDL cholesterol
and predicted levels for a 60-year old in 1978-80 and in 1998-2000, overall and according to medication use between the two time-points,
among men who did not experience an MI before the 1998-2000 examination.
Adjusting for age only Adjusting additionally for confounders*
N
Predicted level for
60 year old in 1978-
80 (95% CI)
Mean change over
20 years (95%CI) p
Predicted level for
60 year old in 1998-
2000 (95% CI) N
Mean change over 20
years (95%CI) p
SBP, mmHg
All men 3722 150.3 (148.9, 151.8) -7.18 (-9.45, -4.90) <0.001 143.2 (142.0, 144.3) 3720 -8.86 (-11.16, -6.57) <0.001
Men using BP-lowering medication 1279 158.8 (157.2, 160.4) -11.12 (-13.68, -8.55) <0.001 147.7 (146.0, 149.3) 1279 -12.39 (-14.99, -9.79) <0.001
Men not using BP-lowering medication 2443 144.0 (142.6, 145.5) -1.77 (-4.00, 0.46) 0.1 142.3 (141.1, 143.5) 2441 -3.47 (-5.73, -1.22) 0.003
p-value for interaction <0.001 p-value for interaction <0.001
DBP, mmHg
All men 3722 81.3 (80.5, 82.1) 3.90 (2.69, 5.11) <0.001 85.2 (84.6, 85.8) 3720 2.47 (1.26, 3.68) <0.001
Men using BP-lowering medication 1279 86.9 (85.9, 87.8) -0.46 (-1.84, 0.92) 0.5 86.4 (85.6, 87.2) 1279 -1.77 (-3.16, -0.38) 0.012
Men not using BP-lowering medication 2443 77.4 (76.6, 78.2) 7.94 (6.77, 9.11) <0.001 85.3 (84.7, 85.9) 2441 6.44 (5.25, 7.62) <0.001
p-value for interaction <0.001 p-value for interaction <0.001
HDL cholesterol, mmol/L
All men 3404 1.16 (1.14, 1.18) 0.15 (0.12, 0.19) <0.001 1.32 (1.30, 1.34) 3400 0.18 (0.15, 0.21) <0.001
Men using lipid-regulating medication 228 1.14 (1.11, 1.18) 0.17 (0.12, 0.22) <0.001 1.31 (1.27, 1.35) 228 0.19 (0.14, 0.24) <0.001
Men not using lipid medication 3176 1.16 (1.14, 1.19) 0.15 (0.12, 0.19) <0.001 1.32 (1.30, 1.34) 3172 0.18 (0.15, 0.21) <0.001
p-value for interaction 0.5 p-value for interaction 0.6
non-HDL cholesterol, mmol/L
All men 3404 5.04 (4.97, 5.11) -0.30 (-0.41, -0.18) <0.001 4.75 (4.69, 4.81) 3402 -0.36 (-0.48, -0.24) <0.001
Men using lipid-regulating medication 228 6.00 (5.84, 6.16) -1.69 (-1.90, -1.48) <0.001 4.31 (4.16, 4.46) 228 -1.76 (-1.97, -1.54) <0.001
Men not using lipid medication 3176 4.98 (4.91, 5.05) -0.21 (-0.32, -0.09) <0.001 4.77 (4.71, 4.83) 3174 -0.27 (-0.39, -0.15) <0.001
p-value for interaction <0.001 p-value for interaction <0.001
*Confounders: SBP, DBP: BMI, alcohol use, physical activity; Non-HDL: BMI, physical activity; HDL: BMI, smoking status, alcohol use, physical activity
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Chapter 8: Analysing the trend in type 2 diabetes incidence in the
British Regional Heart Study
8.1 Introduction
In chapter 4 it was shown that incidence of T2DM has risen, at least as far as the early
2000s, in the UK. In particular, according to data from the British Regional Heart
Study (BRHS), an average annual increase of roughly 5-7% occurred between 1985
and 2007, in line with estimates from THIN and from other data sources.
Understanding the reasons for this unfavourable trend may help to inform efforts to
curb future T2DM increases, both in the UK and in other locations. The rise in
T2DM is thought to result from the marked rises in population adiposity which have
also occurred, given the established strong association between adiposity and
T2DM43, 175-181, 185, 186, 378, 379 identified in numerous studies, including in the
BRHS185, 378, 379. Analysis of BRHS data in chapter 5 suggested that body mass index
(BMI) among British men increased on average by 1.9kg/m2 over 20 years from 1979
to 1999, and a separate report from the Health Survey for England showed that the
prevalence of overweight and obesity in England had increased from 58% of men and
51% of women in 1994 to 68% and 71% in 2006 respectively352. However, few
attempts have been made to quantify the contribution of trends in adiposity to the
observed time trend in T2DM, partly reflecting the paucity of studies that have
simultaneously monitored both T2DM and adiposity levels in the same population
over an extended period. Can the rise in T2DM in the UK be fully accounted for by
rising adiposity levels, as speculated, or are other factors also playing a role? The aim
of this chapter is to address this question by quantifying the contribution of increasing
population adiposity levels to the time trend in incidence the incidence of doctor-
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diagnosed T2DM in British men over 24 years between 1984 and 2007, using data
from the BRHS. Similar modelling methods will be applied to those used in chapters
5 and 6, when explaining the trend in incidence of major CHD. This corresponds to
objective iv) of the overall thesis objectives.
The structure of this chapter is as follows: Section 8.2 details the methods employed
to address the objective. Results of the analyses are presented in section 8.3 and
finally a discussion and interpretation of the findings are given in section 8.4.
8.2 Methods
8.2.1 Data Source
Follow-up data from five years into the study in 1983-5 until 2007 for men in the
BRHS was used for this analysis, as incident T2DM data with validated diagnosis
dates were available from the 5-year follow-up onwards (see chapter 3, section 3.2.4
for details). The end-date of end of 2007 reflects the date the analyses were carried
out. Questionnaire/ examination data up to and including the examination at 20 years
follow-up in 1998-2000 were used. As for the major CHD trends analysis, the BRHS
is particularly suitable for this analysis as T2DM incidence and risk factors levels
have been concurrently monitored over an extended period. Moreover a marked rise
in incidence of T2DM was demonstrated in chapter 4 (section 4.5.2), and the men
Objective
Estimate the contribution of the time trend in BMI to the rise in incidence of
T2DM in the BRHS
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recruited to the BRHS cohort are socially and geographically representative of men of
the same age across Britain.
8.2.2 Principal outcome as a first diagnosis of T2DM
The principal outcome was a first diagnosis of T2DM. Details of methods to
ascertain new T2DM cases in the BRHS are given in chapter 3, section 3.2.4. T2DM
incidence was compared in three consecutive follow-up periods of approximately 8
years each in length, separated by intermittent questionnaires/examination sessions:
period 1 from 1983-1985 to 1992; period 2 from 1992 to 1998-2000; and period 3
from 1998-2000 to 2007 (figure 8.1). For ease of presentation, where questionnaires
or examinations were completed over a 2.5-year period, in 1983-5, and 1998-2000,
the central year (1984, 1999) will be used hereon to refer to these. Thus the three
periods are: period 1 from 1984 to 1992; period 2 from 1992 to 1999 and period 3
from 1999 to 2007.
8.2.3 BMI as the key explanatory factor
The principal exposure was BMI recorded in the questionnaire/examination at the
start of each period, that is in 1984, in 1992 and in 1999 (measurement techniques
detailed in chapter 3, section 3.2.5). The influence of prior BMI levels recorded at
recruitment in 1978-80 was also considered.
8.2.4 Confounding factors
Factors which could potentially confound the relationship between BMI and T2DM,
and/or the relationship between calendar time and T2DM, could as a result also
influence the estimated contribution of the BMI trend to the rise in T2DM. Analyses
290
adjusting for such factors (where data was available) were therefore carried out.
Specifically, factors considered were: cigarette smoking,199 physical activity188, 378 and
alcohol consumption200. Diet is likely to be an important confounding factor189-198,
however as it was not measured at repeated intervals in the BRHS, the influence of
diet could not be directly assessed. Blood pressure201, 202 may play a role but was only
measured once between 1984 and 2007 (the follow-up period for T2DM) and
therefore could not be accounted for in the analysis.
8.2.5 Participants included in analysis
All men who had a diagnosis of diabetes prior to the start of the follow-up in 1984
(identified from self-report in the questionnaires at baseline and in 1984) were
excluded. Since diabetes diagnoses before 1990 were identified using the 1992
questionnaire data (see chapter 3, section 3.2.4), diabetes diagnoses were only
available between 1984 and 1990 for men who had survived to 1992. To ensure a fair
comparison between the time periods, the analyses were therefore restricted to
estimate incidence of T2DM in each period among men who were still alive at the end
of the particular period. Men who had a diagnosis of diabetes during the study
follow-up, from 1984 onwards, contributed to all analyses only up to the time of the
diagnosis, and were excluded from analyses thereafter. Men who had a diagnosis
within one year of the start of each period of follow-up were also excluded to limit
reverse causality380 whereby the BMI level at the start of the period is the result of
development of diabetes before the BMI measurement (since a diagnosis of diabetes
may occur some time after the patient first develops the disease). At the same time,
follow-up for T2DM in each time period among the retained men was started from
one year after the start of the period. Thus note that when incidence of T2DM in the
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three periods is discussed, period 1 from 1984 to 1992 actually corresponds to
incidence between 1985 and 1992; period 2 from 1992 to 1999 corresponds to 1993 to
1999 and period 3 from 1999 to 2007 corresponds to 2000 to 2007.
8.2.6 Statistical methods
As in chapters 5 and 6, analysis entailed splitting the follow-up time for each man into
separate periods, in this case the three periods defined above: period 1 from 1984 to
1992; period 2 from 1992 to 1999 and period 3 from 1999 to 2007. Using the
repeated measurements of BMI at the start of each of the three time-periods as well as
at baseline, estimates of the population-averaged annual age-adjusted changes in BMI,
over the whole length of the follow-up and between each consecutive time-period,
were obtained from linear regression on this split dataset of BMI on calendar time,
including age as a covariate. Generalised estimating equations with robust standard
errors were used to account for the dependency between repeated measures of BMI
from the same individual. The contribution of increasing BMI to the trend in
incidence of T2DM was estimated by comparing Cox models regressing incident
T2DM on indicators for each time period, with and without additional adjustment for
the BMI measures at the start of each period (as a continuous variable with all
significant powers). The proportion of the trend in T2DM hazard from period 1 (start
of follow-up) to period 3 (end of follow-up) that could be statistically explained by
increasing BMI was estimated by the expression: (β0- β1)/ β0, where β0 is the
coefficient of the indicator for the period 3 in the Cox regression model which only
included time period, and β1 is the coefficient of the indicator for the period 3 in the
Cox regression model adjusting additionally for BMI348. A 95% confidence interval
(CI) for this estimate was obtained using bias-corrected bootstrap resampling349.
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Similarly, period 3 was compared with period 2, and period 2 was compared with
period 1, to determine whether the percentage explained was constant over time. In
each model, age was used as the underlying time scale, with date of birth as a time-
origin and age at time of questionnaire (plus one year to limit reverse causality) as the
delayed entry time to take account of left truncation, thereby automatically adjusting
for age and permitting time period to be entered into the model. Survival times were
censored at the end of each period. Schoenfeld residuals were used to test the
proportional hazards assumption of the Cox regression. To explore the possible
impact of not just current BMI but earlier BMI as well, additional analysis models
were constructed, incorporating an earlier “lagged” measurement, approximately 5-8
years prior to the current measurement. In particular, BMI measured at the physical
examination at baseline (1978-80) was used to predict diabetes in period 1 (1984 to
1992); BMI in 1984 was used for period 2 (1992 to 1999); and BMI in 1992 was used
for period 3 (1999 to 2007). Models were also considered with BMI categorised as
underweight (<18.5kg/m2), normal weight (18.5-25kg/m2), overweight (25-30kg/m2)
and obese (>30kg/m2), and excluding those aged over 65 years (as BMI may predict
T2DM risk less well in older men381). Additional analyses were carried out adjusting
the Cox models for the repeated measures of the potential confounding factors at the
start of each period, listed in section 8.2.4.
8.3 Results
6451 of the 7735 men initially recruited in 1978-1980 were included in the present
analyses. The remainder had died before the end of the first follow-up period in 1992
(1152, 14.9%), or had a diagnosis of diabetes (123, 1.6%) before the start of follow-
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up for diabetes in 1984, or had a diagnosis of diabetes within one year of the BMI
measurement for a particular time period (9, 0.1%).
8.3.1 Comparison of incidence of T2DM in the three separate time-periods
The incidence rate of T2DM increased substantially from each time-period to the
next, both within 5-year age groups and overall (table 8.1 and figure 8.1). The hazard
of T2DM was more than two fold greater in the most recent period 1999-2007 than in
the earliest period 1984-1992 (age-adjusted hazard ratio 2.33, 95% CI 1.75 to 3.10).
Between the periods 1984-1992 and 1992-1999 the risk of T2DM increased by about
a half (age-adjusted hazard ratio 1.59, 95% CI 1.23 to 2.05). A similar increase was
observed between the periods 1992-1999 and 1999-2007 (age-adjusted hazard ratio
1.47, 95% CI 1.17 to 1.84). There was no evidence of departure from the proportional
hazards assumption of the Cox regression.
8.3.2 Time trend in mean BMI
The average annual age-adjusted increase in mean population BMI between 1984 and
1999 (that is, during the follow-up for T2DM) was 0.074kg/m2, (95% CI 0.058 to
0.09), corresponding to a total increase over the 15 years of 1.42kg/m2 (95% CI 1.10
to 1.74) (figure 8.1). The average annual increase in age-adjusted BMI was
0.13kg/m2 (95% CI 0.11 to 0.14) between 1979 and 1984, 0.058kg/m2 (95% CI 0.041
to 0.074) between 1984 and 1992, and 0.087kg/m2 (95% CI 0.063 to 0.112) between
1992 and 1999. The average annual age-adjusted increase in mean population BMI
from 1979 to 1999, that is before and during the period of follow-up for T2DM, was
0.087kg/m2 per annum (95% CI 0.073 to 0.101, p<0.001), corresponding to an
increase of 1.74kg/m2 (95% CI 1.46 to 2.02) over the 20 year period.
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8.3.3 Contribution of time trend in BMI to time trend in T2DM incidence
From Cox modelling, using “current” BMI measurements (that is, BMI immediately
prior to each 8-year follow-up period) to predict T2DM hazard, 26% (95% bootstrap
CI 17.5 to 41.1) of the doubling in T2DM hazard from the period 1984-1992 to 1999-
2007 could be statistically explained by the increase in BMI from 1984 to 1999 (table
8.2). A smaller percentage, 20.5% (95% bootstrap CI 12.5 to 33.2) could be
explained by “lagged” BMI changes (that is, BMI approximately 5-8 years prior to
each follow-up period, corresponding to looking at BMI changes over an earlier
period from 1979 to 1992). The combination of current and lagged BMI
measurements, equivalent to adjusting for the change in BMI from lagged to current
measurements of an individual, did not appreciably increase the contribution of BMI
(percentage explained: 25.8%, 95% CI 17.3 to 41.4).
The contribution of increasing BMI to the trend in T2DM incidence was examined
separately in earlier and later portions of the follow-up. Of the increase in T2DM risk
between 1984-1992 to 1992-1999, 21.7% (95% CI 11.9 to 47.9) could be statistically
explained by an age-adjusted increase in BMI from 1984 to 1992 of 0.40kg/m2 (95%
CI 0.29 to 0.52). During the later periods (1992-1999 to 1999-2007), 31.1% (95% CI
16.8 to 80.6) of the increase in T2DM could be statistically explained by an age-
adjusted increase in BMI from 1992 to 1999 of 0.61kg/m2 (95% CI 0.44 to 0.78).
The results changed little when including the follow-up for men only until the age of
65; the trends in T2DM hazard and mean BMI were very similar leading to a
percentage contribution of BMI to the trend in T2DM of 25.3%, very close to the
percentage contribution for the full dataset. The above analyses include BMI in the
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analysis models as a continuous variable with all significant powers (squared). In
sensitivity analyses including BMI as a categorical variable the proportions of the
T2DM time trends explained by BMI changed little.
Adjustment for potential confounding factors (cigarette smoking, physical activity,
alcohol consumption), both individually and together, made little difference to the
estimated hazard ratios of T2DM comparing the time-periods nor to the proportion of
the increase in hazard of T2DM explained by BMI (table 8.3).
8.4 Discussion
8.4.1 Summary of main findings
In this survivor cohort of British men, the hazard rate of T2DM more than doubled
between the periods 1984-1992 and 1999-2007. An estimated 26% (95% bootstrap
CI 17 to 41) of this increase in T2DM could be attributed to a rise in BMI levels
between 1984 and 1999. The results suggest that an appreciable portion of the
substantial rise in T2DM incidence is associated with the unfavourable population
wide increase in BMI. Nevertheless, a substantial portion of the observed increase in
diagnoses of T2DM was not accounted for by the changes in BMI.
8.4.2 Comparison with other studies
In chapter 4, section 4.6.4.2, it was shown that the trends in T2DM incidence
observed in this cohort are consistent with other available (albeit limited) data on UK
T2DM trends. Information on trends in BMI levels before the 1990s are scarce.
Based on data from the Health Survey for England, mean BMI levels in men aged 55
years and over increased between 1993 and 2000 by an average of 0.11 kg/m2 per
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annum, a figure close to but slightly greater than the per annum increase of 0.09
kg/m2 between 1992 and 1998-2000 estimated in our study73. No other studies to our
knowledge have directly estimated the contribution of increasing BMI, or trends in
other risk factors, to the rise in diabetes, either in the UK or in other settings.
Previous studies on US populations382, in line with a separate study of this cohort in
the UK3 have investigated the trend in diabetes according to adiposity level and found
that the increase in diabetes prevalence was greater among overweight and obese
groups: The per-decade increase in diabetes prevalence in the US in those with
BMI≥35kg/m2 was double that in the general population382. Among men in the
BRHS, the rate of increase in prevalence odds of T2DM over 25 years rose steadily
with increasing BMI, such that the rate of increase in T2DM prevalence among those
with a BMI of over 27.5kg/m2 was roughly four-fold greater than among those with a
BMI of 22.5kg/m2 or less3.
Studies assessing population attributable risks of adiposity in T2DM have reported
similar estimates to those in the present analysis178, 181. However as discussed in
chapter 5 (section 5.5.2) in relation to CHD, in such studies, which examine overall
T2DM incidence in the population, the contribution of modifiable risk factors, such as
adiposity, are necessarily affected by contributions of population static variables
including genetic factors. In contrast our analysis examines time trends in T2DM,
attributable only to modifiable factors which have changed over time in the
population. The information provided by this analysis therefore complements rather
than duplicates studies of attributable risk, and addresses a different question. Note
that although the paper by Atlantis et al178 discusses time trends, the analyses carried
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out to assess the role of BMI in T2DM risk are still classic attributable risk
calculations, distinct from the analysis in this chapter.
8.4.3 Strengths and limitations
A key strength of this analysis is the linkage of diabetes events to corresponding BMI
measurements for each individual, thus avoiding the potential hazards of ecological
approaches often used to examine time trends258. The study was based on a socially
and geographically representative sample of British men. As shown in chapter 4, the
increase in diabetes incidence observed in this cohort was close to that observed in
other studies, while as shown above, the increase in mean BMI was close to estimates
from the relevant national health surveys73. The strength of association between BMI
and T2DM risk in our study was found to be similar to (though slightly stronger than)
the association observed in men of a similar age and during a similar follow-up period
in the large US Health Professionals Follow-Up Study180, once BMI was re-
categorized in the same way. Our model allowed inherently for a time delay from the
BMI measurement to a T2DM diagnosis of between one and about eight years (the
approximate length of the follow-up periods, excluding the first year), and earlier
BMI measurements were incorporated to allow for even longer time-lags, up to 16
years (although these early measurements were found to have limited independent
influence on T2DM risk). The first year of follow-up following each BMI
measurement was excluded to limit the potential impact of reverse causality; weight
loss occurring following the development of T2DM could otherwise have led to
underestimation of the contribution of BMI due to weight tending to fall after T2DM
develops380.
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A potentially important limitation of the analysis is the use of BMI, which was the
only marker of adiposity consistently available over the period of the investigation.
While BMI is the traditional means of assessing adiposity, other measurements exist
including waist circumference and wait-to-hip ratio. These two measurements
capture in particular central, or abdominal, adiposity levels, which is reasoned to be
more strongly associated with risk of T2DM, than BMI, because it is more strongly
associated with visceral adipose tissue compartments383, (that is, the fat that
accumulates around the internal organs), than BMI. Visceral adipose tissue has been
shown to be the component of adiposity particularly implicated in the development of
T2DM as opposed to subcutaneous adipose tissue (fat stored under the skin) or
intramuscular adipose tissue (fat stored in skeletal muscle)43. However, as outlined in
chapter 2, section 2.5.3.1, recent studies indicate that BMI is at least as strong
predictor of T2DM risk as other markers of adiposity such as waist circumference180,
185, 186. This has also been shown to the case among the BRHS men379.
The role of BMI may have been further complicated in the present study population of
middle-aged and older men by the influence of lean mass on BMI; loss of lean mass
in men in their 60s and 70s may have led to underestimation of the true increases in
adiposity over time. However, repeating the analyses including the follow-up for men
only as far as the age of 65, the trends in BMI and T2DM and the consequent
proportion of the T2DM trend explained, changed very little, reflecting that in older
men in this cohort, BMI continues to predict T2DM strongly379.
A second limitation is that diabetes data was available between 1984 and 1990 only
for those men who were alive in 1992. Given this restriction, including all BRHS
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participants in the analysis would have led to underestimation of T2DM incidence in
the first period as we would miss T2DM incidence among men who died before 1992
(but who were alive for some length of time from 1984 so included in the incidence
rate denominators). The resulting bias would be overestimation of the trend in
diabetes incidence over time. Instead, to overcome this bias, in each period, the
population sample was limited to those men who survived to the end of the particular
period. This constraint ensured a fair comparison between time periods (since
population samples in each period are equivalent). The limitation of this approach is
that the analysis is on a restricted cohort of survivors; thus the generalisability of the
trend estimate to the whole population is put into question. However, in chapter 4,
section 4.5.2.3, it was observed that the estimates of the average annual increases in
T2DM among the “survivor” cohort and full cohort (over the period when both could
be estimated) were very consistent, suggesting that the results in this chapter may be
applicable to the whole cohort. To explore this issue further, the analysis comparing
the latter two periods (1992-1999 and 1999-2007) was repeated, this time using the
whole study population in these periods, including individuals who died during the
follow-up, censoring at date of death. The hazard ratio in the full sample comparing
the period 1999-2007 with the period 1992-1999 was 1.55 (95% CI 1.26 to 1.91).
This was similar to the increase reported for the survivor sub-sample (hazard ratio
1.47, 95% CI 1.17 to 1.84). The proportion of the rise in T2DM explained by BMI
was 23% in the full sample, compared to 31% reported for the survivor sub-sample.
The broad similarity of these results for the two samples further supports extension of
the findings to the wider population.
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Model mis-specification (in particular the modelling of BMI) could lead to under or
overestimation of the proportion of the rise in T2DM explained by BMI. However
BMI was modelled both as a continuous variable and categorised; in both forms the
estimate of the proportion of the time trend in T2DM was similar at around one-
quarter. Adjustment was made for potential confounders where data was available
(cigarette smoking, alcohol consumption and physical activity). Dietary factors and
blood pressure and lipid levels could not be considered. However evidence for the
role of lipid levels in T2DM risk in general is weak. Blood pressure may be more
likely to mediate the effect of BMI (since BMI raises blood pressure), rather than be a
confounder.
8.4.4 Interpretation of findings
The results of the present analysis suggest that increasing adiposity (as assessed by
BMI) has made an important contribution to the increase in T2DM incidence
observed. Control and reversal of the recent rise in adiposity levels is therefore an
important priority in controlling the diabetes epidemic. However, the estimated
contribution of BMI was lower than had been expected. Although this may partly
reflect the methodological limitations of the study, particularly the use of BMI as the
measure of adiposity, it suggests that other factors may have played important roles.
The potential influence of changes in the ascertainment of T2DM and in diagnostic
criteria needs consideration, since (as discussed in chapter 4, section 4.6.5.2) these
changes may have influenced the T2DM trends (more so than for the CHD trends). It
was discussed in chapter 4, section 4.6.5.2, that recommendations on cardiovascular
prevention from the late 1990s97, potentially leading to increased ascertainment, may
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have contributed to the observed rise in T2DM incidence from this time onwards. In
terms of the findings of this chapter, a possible resulting bias would therefore be
towards a lower portion of the rise in T2DM explained by BMI after this time, the rise
in T2DM instead partially due to more cases being identified. However, the
proportion of the T2DM increase explained by BMI was actually higher during the
later follow-up periods (1992-1999 to 1999-2007) than during the earlier follow-up
periods (1984-1992 to 1992-1999) (31% versus 22%). Thus changes in case
ascertainment methods are unlikely to have had a large influence on the findings. The
change in diagnostic criteria in 199993, 94 appears to have led to different patients
being diagnosed as having T2DM, but not necessarily an increased number of patients
(see chapter 4, section 4.6.5.2). However, the change in diagnostic criteria might
plausibly influence the extent to which BMI trends explain the T2DM rise if the
association between T2DM and BMI is stronger or weaker among the new patients
than among the patients identified under the former criteria. Nevertheless, in
subsidiary analyses, an interaction between BMI and calendar period in the Cox
models of T2DM hazard was not significant, implying a consistent relationship
between T2DM and BMI over time. Regular reviews of GP records were used to
identify T2DM cases after 1990 (the date that regular reviews of GP records began).
Before 1990, diabetes cases were initially identified from self-report in the 1992
questionnaire. Any self-reported T2DM diagnosis in the questionnaire prompted the
researchers to go back to the GP records to confirm the diagnosis and date of
diagnosis. Thus any self-reported diagnosis may be taken as a true doctor-diagnosis,
consistent with diagnoses after 1990; that is, the false-positive rate will be negligible.
However it is possible that some diabetes cases may have been missed where a patient
with a GP record of diabetes has not reported a diagnosis in the 1992 questionnaire
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(false-negatives). The likely impact of the use of self-report before 1990 would
therefore be to underestimate the incidence of T2DM in the earliest period (1984 to
1992). The result of this bias would be overestimation of the increase in incidence of
T2DM over time and underestimation of the percentage of the T2DM increase
explained by BMI. This limitation thus may help to resolve some of the
“unexplained” portion of the increase in T2DM. However, impact of changing
methods of case identification is unlikely to be marked as all self-reported cases were
verified, and previous studies have shown questionnaire self-report of diabetes to
agree closely with medical records328-331. Indeed, the consistency between self-report
and GP diagnosis was found to be as high as 98% in the BRHS384.
If study limitations or changes in diagnostic criteria or the methods of case
identification do not help to fully resolve the “unexplained” portion of the rise in
T2DM, it may be that time trends in other risk factors for T2DM are playing a role
independently of BMI. In particular, changes in dietary determinants of T2DM,
which could not be assessed in this analysis, could also have been important. For
example, dietary factors associated with reducing T2DM risk include a high fibre
diet192, 195, and daily consumption of fibre declined between 1987 and 2000376. Most
other potential risk factors (physical activity, cigarette smoking, alcohol consumption,
SBP, total and HDL cholesterol) are unlikely to explain the rise in T2DM as the time
trends in these factors have been generally favourable or negligible in the cohort (see
chapter 5, section 5.3), thus in the “opposite” direction to the rise in T2DM. The
possible exception is the apparent rise in diastolic blood pressure (DBP) in this cohort
(see chapter 7, section 7.3). That said, although physical activity data was available,
the data in 1984 was imputed (see chapter 3, section 3.2.7) and the data collected at
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the other time points was not consistent (different questions were used each time).
Thus the robustness of the physical activity time trend estimated from the BRHS (and
consequence influence on T2DM trends) is uncertain. If physical activity has instead
fallen over time, given the strong protective effect on T2DM risk, which operates at
least partly independent of BMI188, physical activity may also help to explain the
trend in T2DM. Secular changes in early life determinants of T2DM212, 213 may have
had an influence, although the major documented changes (such as a secular increase
in maternal gestational diabetes) have occurred too recently to affect the adult
generations studied in this report, suggesting cohort effects (and therefore effects of
trends in early-life determinants) may be limited217. Another possible contributory
factor is the increased use of certain drugs indicated for other conditions, which have
been shown to adversely be associated with an increased risk of developing T2DM.
In particular, recent studies have documented an increased risk of T2DM with use of
statins174. Since statins conversely reduce risk of CHD, the rise in the use of these
drugs over the period is consistent with the divergent trends in these two conditions.
Other drugs such as anti-psychotics have also been shown to have adverse metabolic
effects and increased risk of T2DM385.
The present study is based on older British men of white European origin;
generalisability of these results to other sections of the population (women, younger
men and different ethnic groups) is less clear, particularly since the relationships
between BMI and T2DM are stronger in younger age-groups and differ between
ethnic groups386. Extrapolation of the results to trends in other populations also needs
to be cautious; in the US the secular increase in T2DM incidence has been less
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marked387 and the increase in BMI more marked388, suggesting that a larger portion of
the increase in T2DM in the US is likely to be attributable to increased BMI.
Further time trend studies in other populations are needed to verify the findings and
establish the roles of other risk factors. The presence of other contributing factors
would suggest the need for a more multi-factorial approach to combat rising T2DM in
the population.
8.4.5 Chapter conclusions/ Postscript
In this chapter the reasons for the rise in T2DM have been explored. The key finding
is that while approximately one-quarter of the rise in T2DM in older British men over
the last 23 years or so may be associated with a concurrent rise in mean BMI levels, a
large proportion is not accounted for by BMI trends.
Chapters 5, 6 and 7 sought to identify possible explanations for the favourable decline
in major CHD incidence. In this chapter 8, the potential drivers (in particular rising
adiposity) behind the overlapping unfavourable rise in T2DM were considered. The
aim of the next and final results chapter 9 is to bring the two opposing time trends in
major CHD and T2DM together and investigate the relationship between the trends in
these two associated conditions. Of interest is whether the trends in CHD among
patients with T2DM have been as favourable as the trends in the general population,
and, given that T2DM is a risk factor for CHD, to what extent the rise in T2DM has
curtailed the decline in CHD.
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Table 8.1 Incidence rates of T2DM, per 1000 person-years by age and calendar period
Age group, years
45-49 50-54 55-59 60-64 65-69 70-74 75-79 All
Number of men
1984* to 1992 1,729 1,678 1,623 1,430 0 0 0 6,460
1992 to 1999* 0 453 1,597 1,458 1,228 708 0 5,444
1999* to 2007 0 0 0 1,350 1,107 813 478 3,748
Person-years
1984* to 1992 14,921 14,370 13,850 12,162 55,303
1992 to 1999* 2,950 10,296 9,381 5,963 5,569 34,159
1999* to 2007 11,852 10,721 11,552 7,320 41,445
Incident diabetes cases
1984* to 1992 36 52 39 42 169
1992 to 1999* 12 67 51 47 25 202
1999* to 2007 109 103 81 30 323
Incident rate (95% CI)
1984* to 1992 2.41 (1.74, 3.34) 3.62 (2.76, 4.75) 2.82 (2.06, 3.85) 3.45 (2.55, 4.67) 3.06 (2.63, 3.55)
1992 to 1999* 4.07 (2.31, 7.16) 6.51 (5.12, 8.27) 5.44 (4.13, 7.15) 5.96 (4.48, 7.94) 5.57 (3.76, 8.24) 5.77 (5.03, 6.63)
1999* to 2007 9.20 (7.62, 11.1) 10.7 (8.84, 13.0) 11.6 (9.29, 14.4) 7.32 (5.12, 10.5) 9.92 (8.89, 11.1)
*Year shown is central year of a 2.5-year period.
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Table 8.2 Hazard ratios for T2DM comparing the periods 1984-1992, 1992-1999
and 1999-2007, and percentage of the hazard ratios explained by the higher BMI
levels in the later periods
Comparing the period 1999-2007 with the period 1984 to 1992
Model
β-coefficient for
indicator for
period 1999-
2007
Corresponding
hazard ratio,
(95% CI)
p-
value
% of the hazard
increase explained
by BMI*, (95%
bootstrap CI)
A
Indicator for time-period; 1984-1992=
reference period 0.8468 2.33 (1.75, 3.11) <0.001
B +Adjustment for "current" BMI, kg/m2† 0.6271 1.87 (1.41, 2.49) <0.001 25.9 (17.5, 41.1)
C +Adjustment for “lagged” BMI, kg/m2† 0.6732 1.96 (1.47, 2.61) <0.001 20.5 (12.5, 33.2)
D +Adjustment for current+lagged BMI 0.6281 1.87 (1.41, 2.49) <0.001 25.8 (17.3, 41.4)
Comparing the period 1992 to 1999 with the period 1984 to 1992
Model
β-coefficient for
indicator for
period 1992-
1999
Corresponding
hazard ratio,
(95% CI)
p-
value
% of the hazard
increase explained
by BMI*, (95%
bootstrap CI)
A Indicator for time-period; 1984-1992=reference period 0.4635 1.59 (1.23, 2.05) <0.001
B +Adjustment for "current" BMI, kg/m2† 0.3628 1.44 (1.12, 1.85) 0.005 21.7 (11.9, 47.9)
C +Adjustment for “lagged” BMI, kg/m2† 0.3536 1.42 (1.10, 1.84) 0.007 23.7 (13.6, 52.6)
D +Adjustment for current + lagged BMI 0.3615 1.44 (1.12, 1.85) 0.005 22.0 (12.0, 47.4)
Comparing the period 1999-2007 with the period 1992 to 1999
Model
β-coefficient for
indicator for
period 1999-
2007
Corresponding
hazard ratio,
(95% CI)
p-
value
% of the hazard
increase explained
by BMI*, (95%
bootstrap CI)
A Indicator for time-period; 1992-1999=reference period 0.3833 1.47 (1.17, 1.84) 0.001
B +Adjustment for "current" BMI, kg/m2† 0.2642 1.30 (1.04, 1.63) 0.02 31.1 (16.8, 80.6)
C +Adjustment for “lagged” BMI, kg/m2† 0.3197 1.38 (1.10, 1.72) 0.005 16.6 (6.8, 47.1)
D +Adjustment for current + lagged BMI 0.2666 1.31 (1.04, 1.64) 0.02 30.4 (16.4, 81.2)
“Current” BMI is BMI at start of the relevant period; “lagged” BMI is BMI 5-8 years prior to start of
period
β-coefficients, hazard ratios and corresponding p-values from Cox regression, using age as the
underlying time-scale, thereby automatically adjusting for age
* % of the observed rise in hazard rate explained by BMI = 100% × (β0- β1)/ β0, where β0 is the
coefficient of the indicator for the period in the Cox regression model which only included time period
(Model A), and β1 is the coefficient of the indicator for the period in the Cox regression model
adjusting additionally for the particular BMI measure
† includes a squared term (cubed term is non-significant)
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Table 8.3 Hazard ratios for T2DM comparing the periods 1984-1992 and 1999-
2007, and percentage of the hazard ratio explained by BMI, adjusting for
potential confounding factors
Model
Potential confounding
factors adjusted for*
Hazard ratio
comparing period
1999-2007 with
period 1984-1992
before adjustment
for BMI†, (95% CI)
Hazard ratio
comparing period
1999-2007 with
period 1984-1992
after adjustment for
BMI†, (95% CI)
% of the observed rise in
hazard from period 1984-
1999 to period 1999-2007
explained by BMI‡,
(95% bootstrap CI)
A Smoking (current/ex/never) 2.37 (1.77, 3.17) 1.90 (1.43, 2.53) 20.6 (10.3, 45.5)
B
Physical activity
(inactive/occasional/light/mod
erate/moderately
vigorous/vigorous)
2.39 (1.78, 3.21) 1.90 (1.42, 2.55) 24.3 (14.4, 56.4)
C
Alcohol consumption
(never/occasional/light/modera
te/heavy)
2.32 (1.73, 3.10) 1.85 (1.39, 2.47) 20.2 (10.6, 48.9)
D Smoking + physical activity +alcohol consumption 2.34 (1.74, 3.16) 1.87 (1.38, 2.52) 22.3 (10.9, 53.5)
*Levels of confounding factors at the start of each period
†BMI at start of each period, continuous variable with squared term
‡ % of the observed rise in hazard rate explained by BMI = 100% × (β0- β1)/ β0, where β0 is the
coefficient corresponding to the hazard ratio comparing period 1999-2007 with period 1984-1992
before adjustment for BMI (=log(hazard ratio)), and β1 is the coefficient corresponding to the same
hazard ratio after adjustment for BMI.
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Figure 8.1 Trend over time in incidence of T2DM and in mean BMI, by age
group
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black triangles = 70-74 years.
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Chapter 9: Analysing the relationship between the time trends in
incidence of major coronary heart disease and type 2 diabetes using
data from The Health Improvement Network and the British
Regional Heart Study
9.1 Introduction
In chapter 4 time trends in incidence of both major coronary heart disease (CHD) and
type 2 diabetes (T2DM) in the UK, over overlapping periods from the 1980s to the
present, were examined. The available evidence suggested a favourable decline in
incidence of major CHD over much of the period, while conversely the incidence of
T2DM appears to have increased. In the subsequent results chapters 5 to 8, the
reasons for the time trends in incidence of these two conditions were separately
investigated.
Diabetes is associated with an elevated risk of a major CHD event, with the risk
among patients with diabetes generally shown to be around two-fold greater than that
of patients without diabetes27-33. Thus a natural progression in this study of CHD and
diabetes time trends is to examine the influence of diabetes on the decline in major
CHD incidence and the relationship between the opposing time trends in incidence of
major CHD and T2DM. Questions to consider include whether patients with diabetes
have experienced the same rates of decline in major CHD incidence as patients
without diabetes and, if not, whether the relationship between diabetes and major
CHD incidence has changed over time. A further central issue still to be addressed is
whether the decline in major CHD incidence has been curtailed by the increase in
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T2DM. This would imply that, had the increase in T2DM not occurred, a larger
decline in major CHD incidence than that actually observed would have been feasible.
Assessing whether or not similar declines in major CHD incidence have benefited
both the population of diabetic patients and the population without diabetes will help
to ascertain whether the elevated risk of risk of major CHD among patients with
diabetes has persisted over time. This is turn is important in helping to evaluate
whether the management and treatment of diabetes has improved, for example
following the publication of recommendations on cardiovascular prevention from the
late 1990s97 and the introduction of the Quality and Outcomes Framework (QOF) for
managing patients in General Practice in 2004. Or alternatively, if the elevated risk
remains, whether more concerted efforts are needed to manage diabetes.
Understanding the influence of T2DM on the trend in major CHD incidence could
help to define the likely future CHD disease burden, by helping to gain insight into
whether current or future increases in T2DM could lead to a future attenuation, or
even reversal, of the favourable declines over time in CHD incidence.
Several studies in the US and Scandinavia (but apparently none based in the UK) have
investigated time trends in CHD and/or cardiovascular disease (CVD) mortality in
patients with and without diabetes, with mixed findings32, 389-394. Some studies have
reported faster rates of decline in CHD/CVD mortality among male and/or female
diabetic patients compared with those without diabetes32, 389, 391 (leading to an
attenuation of the elevated risk of CHD/CVD mortality among diabetic patients).
Others have reported slower rates of decline in CHD/CVD mortality392, 394 or even
increasing CHD/CVD mortality rates393 among diabetic patients, while some report
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no difference in the rates of decline in CHD/CVD mortality among patients with and
without diabetes390. Few studies however have investigated time trends in incidence
of CHD/CVD by diabetes status389, 395, 396. These studies (none in the UK) have again
reported mixed findings on the relative improvement in incidence among patients
with and without diabetes. The IMPACT group assessed the role of rising diabetes
prevalence on in the time trend in CHD mortality in England and Wales15. However,
there is a lack of data, from any country, on the extent to which rising diabetes has
curbed the decline in major CHD incidence.
The overall purpose of this chapter is therefore to bring together the two opposing
disease trends and explore the relationship between them. This corresponds to
objective v) of the overall thesis objectives.
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The structure of this chapter is as follows: Section 9.2 details the methods employed
to address the objectives. Results of the analyses in relation to the objectives are
presented in section 9.3. A discussion and an interpretation of the findings are given
in section 9.4.
Objectives
1. Evaluate whether the hazard of a subsequent major CHD event among
patients with a new diagnosis of T2DM has changed over calendar time.
That is, are T2DM patients now surviving longer after their diagnosis free
of a major CHD event?
2. a) Estimate and compare the time trends in incidence of major CHD in
patients with and without T2DM diabetes
and equivalently:
b) Assess whether the relationship between T2DM and risk of a major
CHD event is changing over time. That is, compare the relative survival
from major CHD of patients with and without diabetes in different time
periods
3. Evaluate the extent to which the population-wide decline in major CHD
may have been curtailed by rising T2DM prevalence, and estimate the
decline in major CHD incidence that might have occurred in the absence of
the rise in T2DM.
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9.2 Methods
9.2.1 Data sources
The Health Improvement Network (THIN) database is primarily used to address the
objectives of this chapter as the analyses mostly involve estimation of time trends in
the risk of major CHD among the subset of patients with diabetes. The British
Regional Heart Study (BRHS) and Whitehall II cohorts, once restricted to those
patients with diabetes, are too small for precise estimates of the time trends. In
addition, the THIN database comprises the most generally representative population,
including both men and women, from all regions in the UK, making the findings more
widely applicable to the UK population as a whole, than the cohort studies. The
analyses to address the final objective, assessment of the role of diabetes in the time
trend in major CHD, were also feasible in the BRHS cohort (in which the overall
excess risk of major CHD among diabetic men has already been reported33) and so
results are presented from both THIN and the BRHS for comparison. The THIN data
available cover a 14 year period from 1995 to 2008. As for chapter 5, which assessed
the role of other risk factors in the time trend in major CHD, event data in the BRHS
from baseline (1978-80) up to 31 December 2004 was used, providing 25 years of
follow-up.
9.2.2 Methods to address chapter objective 1 - Temporal trend in survival time
from T2DM diagnosis to a major CHD event
For objective 1, the population sample comprised solely those patients in THIN aged
30 years and over who developed T2DM between 1995 and 2008. That is, the study
sample corresponded to those patients forming the numerators of the T2DM incidence
estimates in chapter 4 (therefore see figure 4.2 for inclusion and exclusion criteria and
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derivation of this study sample). Incident T2DM cases were identified as patients with
a first ever record relating to diabetes (a Read code for T2DM or for non-specific
diabetes, as outlined in chapter 4, section 4.2.5, and listed in Appendix A.3) between
1995 and 2008. As in chapter 4, since patients were aged 30 or over at time of
diagnosis, any non-specific diabetes record was assumed to indicate T2DM, rather
than T1DM. Patients were then followed from the date of the incident T2DM record
for a subsequent major CHD event up to end of 2008 (again identified by relevant
Read codes, as used to estimate major CHD incidence in chapter 4 – see Appendix
A.2).
Statistical methods 1-, 3- and 5-year incident rates of major CHD following a T2DM
diagnosis, according to calendar year of T2DM diagnosis, were computed. Patient
follow-up time was defined as the time from the T2DM diagnosis to the earliest of:
the date of a major CHD event, date of death, date of (patient or practice) exit from
THIN, or 1-/3-/5- years follow-up. 1-year incidence rates of major CHD were
computed for patients diagnosed with T2DM between 1995 and 2008. To ensure an
equal potential follow-up for all patients, 3-year incidence rates were computed for
patients diagnosed with T2DM only up to 2006, while 5-year incidence rates were
computed for patients diagnosed with T2DM up to 2004. Cox regression models
were constructed, regressing each of the three outcomes (1-, 3- and 5- year major
CHD incidence) on year of T2DM diagnosis, adjusting for age at T2DM diagnosis
and gender, to estimate the average annual relative change in the hazard of major
CHD. Robust standard errors were used to account for clustering of patients in
practices.
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9.2.3 Methods to address chapter objective 2 – Temporal trend in incidence of
major CHD among patients with and without T2DM and changing relationship
between T2DM and major CHD incidence over time
To address the second objective, the whole THIN population, both with and without
T2DM, was used. Major CHD incidence rates were compared among patients with
and without T2DM, in three separate equal 4-year length periods: 1995-1998, 2000-
2003 and 2005-2008 (periods chosen to be maximum length possible while still all
equal in length to ensure a fair comparison). To do this, three sub-cohorts of patients
were formed comprising all patients in present in THIN aged 30 years or over on each
of 1 January 1995, 1 January 2000 and 1 January 2005 (the first day of each period).
Inclusion and exclusion criteria correspond to those used to define the population
sample for computation of major CHD incidence rates in chapter 4, as detailed in
figure 4.1, with the additional condition of being present with no prior major CHD
diagnosis on the first day of the relevant period. Patients identified were followed to
the end of each 4-year period for incident major CHD. Patients in each of these
cohorts were categorised according to whether they had prevalent T2DM at the start
of the period or developed incident T2DM during the 4-year follow-up. A patient was
taken to have prevalent T2DM if s/he had a Read code in their patient records relating
to T2DM in the year prior to the start of the period. Patients with no prior diagnosis
were taken to be free from T2DM, unless a new record of T2DM was found during
the follow-up, in which case the patient was considered an incident case and excluded
from the analyses for this second objective. Statistical methods The time trend in
incidence of major CHD according to T2DM status was estimated using grouped
Poisson regression of incidence of major CHD on date of start of period, with 10-year
age group and gender as covariates, and stratified by diabetes status (prevalent T2DM
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at start of follow-up or not). The analysis necessitated grouped Poisson regression, as
opposed to the Cox regression used for the previous objective, as the whole THIN
population is used here, which is too large to analyse ungrouped (see chapter 4,
section 4.2.7). An interaction between T2DM status and period was added to the
models to assess whether the time trends in incidence of major CHD differed
significantly between patients with and without prevalent T2DM, and equivalently,
whether the excess risk of major CHD associated with T2DM varied between
calendar periods. Person-years for each patient were calculated as the time from 1
January of the first year of the relevant period to the first of the date of a subsequent
major CHD event, date of death, date of exit from THIN or end of 4-year period.
Multilevel random intercept models with patients nested in practices were used to
adjust for clustering of patients in practices. Crude absolute incidence rates of major
CHD according to calendar period and T2DM status were estimated, along with
incidence rates standardised to the overall age and gender distribution in THIN (to
account for variations in age and gender between those with and without T2DM).
9.2.4 Methods to address chapter objective 3 – Role of rising T2DM in decline in
major CHD incidence
The same data sample used for objective 2 was used to address objective 3, that is
three sub-cohorts comprising all patients in THIN present and with no history of
major CHD on 1 January of 1995, 2000 and 2005 respectively, categorised according
to T2DM status, and followed for major CHD for 4 years. Incident T2DM cases
occurring during each four-year period were this time included in the analysis.
Statistical methods The contribution of the time trend in T2DM to the decline in
major CHD incidence was assessed by comparing grouped multilevel Poisson
317
regression models regressing incidence of major CHD on date of start of period,
adjusted for age and gender, with and without additional adjustment for the indicator
for T2DM status (prevalent at start of period or incident during period or T2DM-free).
Person-years for each patient were defined as for objective 2. As in previous
chapters, the proportion of the decline in major CHD incidence statistically explained,
or attributable to, the T2DM trend is then given by the expression (β0-β1)/β0, where β0
is the coefficient of time period in the Poisson model without adjustment for T2DM
diagnosis, and β1 is the coefficient of time period in the Poisson model with
adjustment for diabetes diagnosis. A 95% confidence interval (CI) for the estimate
was obtained from bias-corrected bootstrap resampling.
A quirk of the above analysis is that the separate category of incident cases may
include patients who develop a major CHD event before the T2DM diagnosis (if both
occur during the follow-up). The justification for this is that patients will most likely
have T2DM for some time before being diagnosed as such, or at least have some
degree of glucose intolerance, and would therefore be at increased risk of CHD
beforehand. Sensitivity analyses to better account for the date of incident T2DM
diagnosis were carried out. The population sample in chapter 4 to estimate major
CHD incidence trends was used (see section 4.2.2). As well as grouping by age,
gender and calendar year, the follow-up time for each patient was split at the date of
incident T2DM diagnosis, as time before and after diagnosis. An indicator variable
took the value 0 if the patient did not develop T2DM or for patient-time before a
T2DM diagnosis and value 1 for patients with prevalent T2DM at the start of the
follow-up or for patient-time after a T2DM diagnosis. The Poisson model in chapter
4 (see section 4.2.7) used to estimate the relative decline in major CHD incidence was
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then applied to this split dataset and compared with a Poisson model adjusting
additionally for T2DM using the indicator variable. The percentage contribution of
increasing incidence of T2DM to the decline in major CHD incidence was then
estimated in the usual way as (β0-β1)/β0, where β0 is the coefficient of time period in
the Poisson model without adjustment for T2DM diagnosis, and β1 is the coefficient
of time period in the Poisson model with adjustment for T2DM diagnosis.
9.2.5 Validation of findings for objective 3 using the BRHS
To address objective 3 using BRHS data, similar methods were employed to those in
chapter 5 to consider the role of risk factors in the decline in major CHD (see section
5.2.4). That is, the principal outcome was a first major CHD event, defined as a fatal
or non-fatal myocardial infarction (MI), over the 25 year period between baseline
(1978-80) and 31 December 2004. T2DM prevalence was ascertained in each of the
questionnaires during this period (in 1978-80, 1983-5, 1992, 1996 and 1998-2000), as
a self-reported diagnosis of diabetes and/or self-reported use of medication to control
diabetes (it should be noted that this is distinct from the direct ascertainment of (date
of) T2DM incidence from GP records in chapter 8). Medication used for the control
of diabetes was defined as any drug with a British National Formulary code of 6.1.1
(insulin) or 6.1.2 (oral glucose-lowering drugs). All men were included in the analysis
except those who had had a major CHD event before entry to the study in 1978-80
(n=952), or who reported having diabetes before the age of 30 (so presumed to have
T1DM, n=8), or who had missing baseline data on diabetes (n=3). This left 6772 men
available for inclusion in the analyses.
Statistical methods The follow-up for each man was split into separate consecutive
periods, divided by the questionnaire time-points (1978-80, 1983-5, 1992, 1996 and
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2000), resulting in an expanded dataset of pseudo-individuals (one in each period)
with a pseudo-baseline as the date of the questionnaire at the start of the period, as in
chapter 5. The contribution of the time trend in T2DM to the decline in major CHD
hazard was assessed by comparing Cox proportional hazards regression models of
incident MI on “calendar time”, with and without adjustment for an indicator for
T2DM prevalence at the pseudo-baseline for each pseudo-individual (see chapter 5,
section 5.2.4, for details). Age was used as the underlying time scale in these time-
dependent regressions, with date of birth as a time origin, and age at the date of the
“baseline” for each pseudo-individual as a delayed entry time to take account of left
truncation. Follow-up time was defined as the time from the questionnaire at the start
of the period to the earliest of date of major CHD event, death, or the next
questionnaire date or 31 December 2004. Robust standard errors were used to
account for the dependency between the different pseudo-individuals corresponding
to the same man. The proportion of the decline in major CHD hazard statistically
explained, or attributable to, the trend in T2DM is given as before by the expression
(β0-β1)/β0, where β0 is the coefficient of calendar time in a Cox regression model with
just calendar time as a covariate, and β1 is the coefficient of calendar time in a Cox
regression model adjusting additionally for an indicator for T2DM prevalence. Bias-
corrected bootstrap re-sampling was used to give an approximate 95% CI for this
estimate. For a closer comparison with the THIN analyses, the BRHS analyses were
repeated over the restricted period from 1992 to 2004.
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9.3 Results
9.3.1 Objective 1 – Temporal trend in survival time from T2DM diagnosis to a
major CHD event
Figure 9.1 presents trends over calendar time in 1-, 3- and 5- year incidence of major
CHD following a T2DM diagnosis, by year of T2DM diagnosis. The 1-, 3- and 5-
year incidence rates according to year of T2DM diagnosis are also given in table 9.1,
along with the numbers of incident T2DM cases in each year. Steady declines may be
seen in the 3- and 5-year incidence of major CHD following a T2DM diagnosis over
calendar time. This implies an improved prognosis such that in more recent years
patients with T2DM are surviving longer following diagnosis before experiencing a
major CHD event. The trend may be similar for 1-year survival but the pattern is less
clear, reflecting a lack of power due to smaller numbers of CHD events within 1 year
of the T2DM diagnosis. From regression modelling, average annual percentage
relative falls in the rate of 1, 3 and 5 year incidence of major CHD following T2DM
diagnosis were 6.32% (95% CI 3.48 to 9.08), 8.37% (95% CI 5.72 to 10.94) and
8.22% (95% CI 5.1 to 11.24) respectively, adjusting for age at time of T2DM
diagnosis, gender and general practice. The estimated declines were all statistically
significant (p<0.001).
9.3.2 Objective 2 – Temporal trend in incidence of major CHD among patients
with and without T2DM and changing relationship between T2DM and major
CHD incidence over time
Overall time trends in incidence of major CHD events among the whole population,
regardless of diabetes status, were presented in chapter 4, section 4.3. In this section,
the time trend in incidence of major CHD is estimated separately for patients with and
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without prevalent T2DM. Rate ratios comparing incidence in three consecutive 4-
year periods 1995-1998, 2000-2003 and 2005-2008 are presented in table 9.2,
according to T2DM status. The results indicate that incidence of major CHD was
approximately two-thirds lower in the most recent period 2005-2008 compared with
the earliest period 1995-1998 among patients with prevalent T2DM (rate ratio of 0.31,
95% CI 0.28 to 0.35). Among patients without T2DM, a smaller reduction in
incidence occurred (rate ratio of 0.46, 95% CI 0.44 to 0.48). The greater decline in
incidence of major CHD among patients with T2DM occurred consistently across the
whole time-frame. That is, a greater decline occurred among the T2DM population
compared with the rest of the population, between the earlier two periods 1995-1998
and 2000-2003 (rate ratios of 0.39 versus 0.52 for patients with and without T2DM
respectively), and between the later two periods 2000-2003 and 2005-2008 (rate ratios
of 0.79 versus 0.88). An interaction between time-period and T2DM status, reflecting
the difference in the decline in major CHD incidence over time between patients with
and without T2DM, was statistically significant (p<0.001). In analyses stratified by
gender (table 9.2), the declines in major CHD incidence among men and women with
and without T2DM were broadly similar to that for the whole population of men and
women combined. The difference in the major CHD incidence trends among those
with and without T2DM was slightly more marked for women than for men.
Table 9.3 presents crude and age-sex-standardised incidence rates of major CHD
according to calendar period and T2DM status (no T2DM before or during period
versus prevalent T2DM at start of period). Age-sex-adjusted rate ratios of major
CHD comparing patients with and without T2DM, for each calendar period, are also
given. In all periods, incidence of major CHD was higher among those with T2DM at
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the start of the period, than among those without T2DM. However, as well as the
overall incidence rates falling over time, the absolute and relative differences between
the rates among those with and without T2DM have also fallen. Among men and
women combined, the age-sex-adjusted rate ratio comparing those with and without
T2DM was attenuated from 2.70 (95% CI 2.42 to 3.02) in 1995-1998 to 2.23 (95% CI
2.04 to 2.45) in 2000-2003 to 1.90 (95% CI 1.80 to 2.00) in 2005-2008. Table 9.4
presents corresponding results by gender. Among men, the age-adjusted rate ratio
comparing those with and without T2DM was attenuated from 2.16 (95% CI 1.87 to
2.50) in 1995-1998 to 1.88 (95% CI 1.67 to 2.11) in 2000-2003 to 1.68 (95% CI 1.57
to 1.79) in 2005-2008. Among women, the age-adjusted rate ratio comparing those
with and without T2DM was attenuated from 3.30 (95% CI 2.79 to 3.90) in 1995-
1998 to 2.57 (95% CI 2.21 to 3.00) in 2000-2003 to 2.06 (95% CI 1.90 to 2.24) in
2005-2008. This narrowing in the relative difference in major CHD risk among
patients with and without T2DM reflects the observed greater decline in major CHD
incidence among patients with T2DM described above.
9.3.3 Objective 3 – Role of rising T2DM in decline in major CHD incidence
Table 9.5 presents the rate ratios and associated beta-coefficients comparing incidence
of major CHD in the periods 1995-1998, 2000-2003 and 2005-2008, with and without
adjustment for prevalent T2DM at the start of each period. Also shown is the relative
difference between the beta-coefficients with and without adjustment for T2DM,
representing the extent to which the rising prevalence of T2DM may “explain” the
lower major CHD risk in the more recent periods. The results show that rising T2DM
prevalence may “explain” -6.46% (95% bootstrap CI -7.89 to -5.13) of the 53%
reduction in major CHD risk between the earliest period 1995-1998 and the most
323
recent period 2005-2008. The negative sign indicates that the increase in diabetes has
been counter-productive and has reduced the potential scale of the decline in major
CHD by roughly 6%. The findings are similar for men and women, although among
women the negative impact of diabetes was slightly greater: Among men only, the
proportion of the 54% rate reduction from 1995-1998 to 2005-2008 “explained” by
rising diabetes was -5.69% (95% bootstrap CI -7.47 to -4.23). Among women only,
the corresponding figure was -8.08% (95% bootstrap CI -10.9 to -5.57).
In an alternative analysis, taking into account the date of incidence of T2DM, and
including patient-time before a T2DM diagnosis with patient-time of patients who do
not develop T2DM, and comparing the average annual relative declines in major
CHD incidence with and without adjustment for T2DM, the percentage of the decline
in major CHD incidence explained by rising T2DM was -8.38 (95% bootstrap CI -
9.22 to -7.53), similar in magnitude to the estimate from the first analysis.
The results of corresponding analyses carried out using BRHS data examining the
“contribution” of rising T2DM prevalence to the decline in major CHD between 1979
and 2004 are presented in table 9.6. The results suggest that -10.1% (95% bootstrap
CI -17.2 to -6.04) of the average annual age-adjusted 3.65% relative decline in major
CHD hazard over the whole period can be explained by rising T2DM prevalence, that
is, the fall in major CHD incidence was approximately 10% lower than it might have
been in the absence of rising T2DM prevalence. Restricting to the period 1992 to
2004 to reflect more closely the period covered by THIN, the point estimates of the
average annual decline in major CHD hazard and percentage of the decline explained
by rising T2DM prevalence were similar to the overall estimates at 3.74% and -
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11.3%. However, because of the reduced numbers of men contributing data in this
later period, the bootstrap CI for the percentage explained is very wide and largely
uninformative. Similarly, considering the hazard ratio of major CHD comparing the
period 2000-2004 with the period 1992-1996, to reflect more closely the analysis of
the THIN data, the percentage of this hazard reduction explained by rising T2DM
prevalence was -10.4% (95% bootstrap CI -52.1 to -3.78).
9.4 Discussion
9.4.1 Summary of main findings
This chapter has explored the relationship between the time trends in major CHD and
T2DM. It was found firstly that between 1995 and 2008, the prognosis, in terms of
major CHD risk, of patients newly diagnosed with T2DM has improved: patients are
surviving longer after a new T2DM diagnosis before experiencing a major CHD
event. Secondly, while significant declines in incidence of major CHD occurred
among both patients with and without prevalent T2DM over this period, the decline
was slightly larger among those with prevalent T2DM, leading to an attenuation over
time of the excess risk of major CHD among T2DM patients from a relative risk of
2.7 to a relative risk of 1.9. The attenuation was more marked in women than men.
Finally, analysis of THIN data suggests that rising prevalence of T2DM has limited
the decline in major CHD between 1995 and 2008 by approximately 6-8%; that is, in
the absence of a rise in prevalence of T2DM a 6-8% larger decline in major CHD
incidence than that observed might have occurred. Analysis of BRHS data showed
similarly that rising prevalence of T2DM limited the scale of the decline in major
CHD incidence in men between 1979 and 2004 by approximately 10%.
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9.4.2 Strengths and limitations
As in previous chapters, strengths of this study include the large sample size and
nationwide scope of the THIN database, enabling precise estimates of trends across
the UK and in the relative risk of major CHD according to diabetes status. Consistent
methods were used to identify diagnoses of both T2DM and major CHD in THIN
throughout the follow-up period, such that the time trends cannot be biased by
changes in the identification methods. Moreover, in each analysis, consistent length
follow-up times for incident major CHD were used in each calendar period. That is,
for the first objective, the outcome was 1, 3 and 5 year incidence of major CHD from
date of first T2DM diagnosis; for the other objectives, an equal 4 year’s follow-up
was used. Again this limits bias in the time trend estimates which could occur if the
hazard of major CHD varies with time from start of follow-up and patients in different
calendar periods are followed for different lengths of time. Regarding specifically the
third objective to assess the role of the rising T2DM prevalence in the decline in
major CHD, a key strength over and above the one previous comparable analysis15 is
the use of individual-level data, linking individual diabetes status to CHD events. The
previous analysis (IMPACT model), which estimated the role of diabetes in the
decline in CHD mortality, combined different aggregate data sources and is thus
potentially subject to limitations inherent in ecological analyses258. Repetition of the
analysis for this third objective using the BRHS cohort, with broadly consistent
findings, further adds weight to the validity of the results.
The analyses are not without limitations. First, as outlined in chapter 4, section 4.6.2,
it is likely that some fatal major CHD events will not be captured in the analysis due
to the nature of recording of death records in THIN, thus the results may reflect
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mainly non-fatal MI events. However, as discussed in section 4.6.2, this appears to
have had limited impact on the CHD time-trend estimates, and also, since one might
expect similar CHD recording patterns for those with and without diabetes, this
exclusion of fatal events is unlikely to bias estimates of the differences in the CHD
trends between patients with and without diabetes (relevant for objectives 2 and 3).
Second, in the analyses relating to the first objective, which involved identification of
incident T2DM cases, it is possible that some of the incident T2DM events are not
truly incident, if T2DM records before the patient registered or patient data was
captured on computer are not captured in THIN, as discussed in chapter 4, section
4.6.2. However, as detailed in chapter 4, section 4.6.2, allowing a year after
registration before following up patients for incident events (and excluding patients
with an event during that year as prevalent cases), should ensure most new records are
incident cases (as this allows for recording of patient history at or soon after
registration324 and because 99.7% of T2DM records occur less than one year before
the next record, a consistent finding across all calendar years). Third, in the analyses
relating to the second and third objectives, which involved comparing patients with
and without prevalent T2DM on certain dates, patients were considered prevalent
cases if they had a T2DM record in the previous year, and were taken to be T2DM-
free if they did not. If T2DM records for a patient are more than a year apart, it is
possible that some patients with diabetes will be mis-classified as diabetes-free. The
impact would be a dilution of the association between T2DM and CHD risk, and so
also a dilution of the percentage contribution of diabetes to the decline in major CHD.
However again, given that the vast majority of diabetes records occur less than a year
apart, the mis-classification is likely to be small. Moreover, the estimates of the
overall relative risks of incidence of major CHD by T2DM status correspond closely
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to those reported in other studies, particularly substantiating the higher relative risk
among women: reported relative risks for major CHD of 2.13 and 2.95 in men and
women in the UK between 1992 and 199928; and reported relative risks for fatal CHD
of 1.85 and 2.06 in men and 2.58 and 3.50 in women from two recent meta-analyses27,
31. A final limitation is the possible inclusion of T1DM cases among the T2DM
cases, where the diabetes diagnosis was non-specific. However again, as this was the
case throughout the time period covered, importantly this will not bias the estimates
of the time trends. Moreover, previous studies have shown that much of the rise in
prevalence of diabetes reflects a rise in T2DM, rather than T1DM6. Thus in relation to
objective 3, the percentage contribution of rising diabetes to the decline in major
CHD, is likely to primarily reflect a contribution of T2DM. The correspondence
between the results for THIN and the BRHS findings (which do relate specifically to
T2DM) supports this further.
9.4.3 Comparison with other studies
To my knowledge, there have been no previous studies of CVD trends (incidence or
mortality) according to diabetes status in the UK population. Three previous studies
were found which assess in particular time trends in incidence of CHD or CVD by
diabetes status, in North America and Scandinavia. A study in Ontario, Canada395,
found that between 1992 and 2000 the rate of patients aged 20 years or over admitted
for MI fell more sharply in the diabetic than the non diabetic population (declines of
15% versus 9%), consistent with the findings in this chapter. Results by gender were
not presented. A study in Finland389 compared the relative risk of major CHD for
diabetic patients in two separate cohorts in the 1970s and 1990s. Among men, the
relative risk was attenuated from 1.67 in the 1970s to 1.37 in the 1990s but in women
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the relative risk increased from 2.33 to 3.42. This contrasts with the present study
findings, where the attenuation in relative risk over time appeared greater in women.
This could reflect the earlier time-period in a different country. The US Framingham
Heart Study compared 12-year incidence of CVD among 45-64 year olds in two
cohorts: the original cohort in 1950-66 and the “offspring” cohort in 1977-1995396.
Again, a larger decline in incidence was observed comparing participants in the two
cohorts with diabetes than comparing those without (49.3% versus 35.4%), leading to
an attenuation of the excess risk of CVD among diabetic patients (from 2.98 in the
original cohort to 2.48 in the offspring cohort). Results did not differ by gender. A
similar pattern emerged for the outcome of CVD mortality in the Framingham
cohorts32. Despite the attenuation in the relative risks, patients with diabetes still
remained at a much elevated risk of CVD outcomes in the second Framingham cohort
(as in the results of this chapter). A separate, more recent, analysis was based only on
the second cohort, studied between 1970 and 2005222. In that report it was observed
that, among cardiovascular risk factors, blood pressure declined to a similar degree
among participants with and without diabetes, while blood cholesterol fell more
among diabetic patients, who also experienced a larger increase in BMI222. The
authors concluded that because of the larger increase in BMI, despite the favourable
trend in cholesterol, the increased CVD risk among diabetic patients was persisting.
The role of rising diabetes prevalence in the decline in major CHD incidence has not
been previously addressed in the UK population or elsewhere. The IMPACT model
considered the contribution of diabetes to the decline in CHD mortality in England
and Wales between 1981 and 2000, finding that an extra 2900 deaths in 2000
compared with 1981 could be attributable to the rise in diabetes, corresponding to a
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“contribution” to the decline in CHD mortality of -4.7%15. That is, rising diabetes
had an adverse effect, limiting the decline in CHD mortality by 4.7%, in line with the
present study findings.
9.4.4 Interpretation of findings
The positive conclusion to be drawn from the results is that over the 14 year calendar
period from 1995 to 2008, the prognosis for patients with diabetes, in terms of major
CHD risk, appears to have improved. Patients who are given a new diagnosis of
T2DM are surviving longer following the diagnosis before developing major CHD
and the excess risk of major CHD among patients with prevalent T2DM has
attenuated slightly (more noticeably for women). What might be the reasons for these
favourable time trends? First, as in earlier chapters, the potential influences of
changes in diagnostic criteria for major CHD and/or diabetes need to be considered.
As detailed in chapter 4, section 4.6.5.1, the change in 1999 in diagnostic criteria for
MI (to use of troponins) is likely to have led to more patients being diagnosed with
MI and so possibly to underestimation of extent of the decline in major CHD. Thus
this change would not help to explain the improvement in survival seen among
incident T2DM cases. Also, because the increased diagnosis of MI would have
affected both the diabetic and diabetes-free population similarly, the change in
diagnosis does not explain the attenuation of the relative risk of major CHD for
diabetes either. In chapter 4, section 4.6.5.1, it was discussed that while evidence was
inconclusive as regards the extent to which the change in diagnostic criteria for
T2DM in 1999 may have increased or decreased the numbers of people diagnosed,
one consistent finding is that the change in diagnostic criteria has resulted in different
people being diagnosed96. Studies have also shown that one difference is that for
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elderly people the new criteria, focussing on fasting glucose levels, result in elderly
T2DM patients with a lower overall lower excess risk of CVD relative to elderly
people with normal glucose levels, when compared to elderly T2DM patients
identified using the original criteria397, 398. Thus in more recent calendar years, T2DM
cases may include patients with a lower risk of major CHD. The attenuation of the
relative risk for major CHD among diabetics may therefore to some extent be
plausibly explained by the change in diagnostic criteria. However, the difference in
CVD risk among T2DM patients using the different criteria has not been shown
consistently among all populations399 and may therefore be limited to elderly patients.
The policy recommendations for CHD prevention in 1999 and the introduction of the
Quality and Outcomes Framework (QOF) for diabetes in 2003 may also help to
explain the favourable time trends. Both policy interventions may have led on the one
hand to increased testing for diabetes and so improved case-ascertainment, possibly
again with an increase particularly in less advanced/severe diabetes which might
otherwise go undiagnosed. This again would tend to lead to patients with lower CHD
risk among the prevalent diabetes cases and so is consistent with a greater decline in
major CHD risk relative to the diabetes-free population. Perhaps in earlier years, the
presence of CVD prompted testing for a T2DM diagnosis (a type of reverse causal
situation), whereas in more recent years, patients have been tested for T2DM more
widely and regardless of CVD risk. On the other hand, the policy interventions have
been shown to result in better management and treatment of T2DM patients342,
particularly as regards hypercholesterolemia control (a major CVD risk factor) and so
these policies may have alternatively led to an improvement in survival from major
CHD due to improved management and care. Further research is needed to identify
the reasons for the attenuation of the excess risk of major CHD among T2DM patients
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and establish whether the favourable change reflects the better management and
treatment of T2DM or changed diagnosis and improved case ascertainment.
Despite the attenuation of the relative risk, patients with T2DM remain at
approximately double the risk of major CHD than those without T2DM. Thus there is
still considerable scope for improvement and a need for continued concerted efforts to
better the management of T2DM. The need to better manage T2DM is further
emphasized given the increase in incidence of T2DM over time. Thus although the
relative risk comparing those with and without T2DM has attenuated, as more patients
develop T2DM, the proportion of all patients experiencing a major CHD event who
have T2DM is likely to increase – that is, the absolute contribution of T2DM to the
major CHD burden is set to rise, as already demonstrated in the US population395, 400.
The results show that rising T2DM prevalence may have limited the decline in major
CHD incidence by roughly 6 to 10%. That is, had T2DM prevalence remained
constant over time, the decline in major CHD could have been 6 to 10% larger than
that observed. Since in the analysis of BRHS data, rising T2DM prevalence had an
adverse impact on the extent of the decline in CHD incidence both before and after
the changes in diagnostic criteria and various policy interventions, these factors are
unlikely to explain the findings. The negative contribution of T2DM appeared larger
for women than men in THIN (8% versus 6%), which fits with the observed greater
relative risk of CHD among women with diabetes relative to women without diabetes,
compared with the relative risk among men. The similarity in the size of the negative
contribution of T2DM to that of BMI (7-10% in chapters 5 and 6) raises the
possibility that much of the adverse effect of BMI on the major CHD incidence trend
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may operate through rising T2DM. This possibility is supported by the results of
chapter 8 showing the role of BMI on rising T2DM incidence. Although the adverse
impact of rising T2DM appears so far to have been outweighed by the favourable
trends in other cardiovascular risk factors, the concern is that continued increases in
T2DM prevalence may further reduce or even reverse the decline in major CHD
incidence. This emphasizes the need to address the rising incidence of T2DM in the
population.
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Table 9.1 1-, 3-, and 5-year incidence of a major CHD event, following a new T2DM diagnosis, according to calendar year of T2DM
diagnosis
Calendar
period of
T2DM
diagnosis
No. of
incident
T2DM
patients
Major
CHD
events
within 1
year of
diagnosis
Person-
years of
follow-
up
1-year major CHD
incidence rate
(95% CI)
Major
CHD
events
within 3
years of
diagnosis
Person-
years of
follow-
up
3-year major
CHD incidence
rate (95% CI)
Major
CHD
events
within 5
years of
diagnosis
Person-
years of
follow-
up
5-year major
CHD incidence
rate (95% CI)
1995-1996 2,054 18 1,967 9.15 (5.77 to 14.5) 48 5,464 8.78 (6.62 to 11.7) 75 8,504 8.82 (7.03 to 11.1)
1997-1998 3,567 20 3,416 5.85 (3.78 to 9.07) 73 9,507 7.68 (6.10 to 9.66) 116 14,793 7.84 (6.54 to 9.41)
1999-2000 6,856 47 6,585 7.14 (5.36 to 9.50) 126 18,515 6.81 (5.72 to 8.10) 192 28,937 6.64 (5.76 to 7.64)
2001-2002 12,499 107 12,057 8.87 (7.34 to 10.7) 228 33,854 6.73 (5.92 to 7.67) 304 53,275 5.71 (5.10 to 6.39)
2003-2004 15,867 92 15,363 5.99 (4.88 to 7.35) 203 43,534 4.66 (4.06 to 5.35) 282 65,534 4.30 (3.83 to 4.84)
2005-2006 17,075 67 16,548 4.05 (3.19 to 5.14) 159 43,310 3.67 (3.14 to 4.29)
2007-2008 17,344 60 12,714 4.72 (3.66 to 6.08)
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Table 9.2 Decline in major CHD incidence over time, comparing populations with and without T2DM
All participants Men Women
Rate ratio of major CHD
incidence, 2005-2008 versus
1995-1998 (95% CI)
T2DM at start of period 0.31 (0.28 to 0.35) 0.33 (0.28 to 0.38) 0.29 (0.24 to 0.34)
No T2DM at start of period 0.46 (0.44 to 0.48) 0.45 (0.43 to 0.48) 0.47 (0.44 to 0.51)
Rate ratio of major CHD
incidence, 2000-2003 versus
1995-1998 (95% CI)
T2DM at start of period 0.39 (0.34 to 0.45) 0.43 (0.36 to 0.51) 0.35 (0.28 to 0.43)
No T2DM at start of period 0.52 (0.50 to 0.55) 0.54 (0.51 to 0.57) 0.49 (0.45 to 0.53)
Rate ratio of major CHD
incidence, 2005-2008 versus
2000-2003 (95% CI)
T2DM at start of period 0.79 (0.71 to 0.87) 0.76 (0.67 to 0.87) 0.83 (0.70 to 0.97)
No T2DM at start of period 0.88 (0.85 to 0.92) 0.85 (0.81 to 0.89) 0.96 (0.91 to 1.03)
p-value for interaction between time period and diabetes status <0.001 <0.001 <0.001
Estimates from multilevel Poisson regression, adjusting for age and gender, and general practice as a random intercept
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Table 9.3 Crude and age-sex-standardised major CHD incidence rates according to calendar period and T2DM status. Age-sex-adjusted
rate ratios of major CHD incidence, comparing populations with and without T2DM, in each calendar period.
1995-1998 2000-2003 2005-2008
No T2DM before or
during period
T2DM at start of
period
No T2DM before or
during period
T2DM at start of
period
No T2DM before or
during period
T2DM at start of
period
All participants
Number of major CHD
events 2848 366 4202 510 9375 1736
Total person-years 929989 25650 2733892 95558 6373026 391634
Crude incidence rate of
major CHD, per 1000
person years (95% CI)
3.06 (2.95 to 3.18) 14.3 (12.9 to 15.8) 1.54 (1.49 to 1.58) 5.34 (4.89 to 5.82) 1.47 (1.44 to 1.50) 4.43 (4.23 to 4.65)
Age-sex-standardised
incidence rate of major
CHD, per 1000 person years
(95% CI)*
3.26 (3.14 to 3.38) 9.30 (8.20 to 10.4) 1.66 (1.61 to 1.71) 4.23 (3.79 to 4.67) 1.50 (1.47 to 1.53) 3.14 (2.96 to 3.32)
Age-sex-adjusted rate
ratio of major CHD
incidence, T2DM versus
no T2DM (95% CI)†
1 2.70 (2.42 to 3.02) 1 2.23 (2.04 to 2.45) 1 1.90 (1.80 to 2.00)
*Standardised to the age-sex-distribution of the whole THIN population. †From multilevel Poisson regression, adjusting for age and gender, and general practice. Note:
Because of the adjustment for general practice as a random effect in the multilevel modelling, the rate ratios presented in the bottom row do not equate exactly to the ratios of
the age-sex-standardised incidence rates in the third row (which are not adjusted for practice).
336
Table 9.4 Crude and age-standardised major CHD incidence rates according to calendar period and T2DM status, by gender. Age-
adjusted rate ratios of major CHD incidence, comparing populations with and without T2DM, in each calendar period.
1995-1998 2000-2003 2005-2008
No T2DM before
or during period
T2DM at start of
period
No T2DM before
or during period
T2DM at start of
period
No T2DM before
or during period
T2DM at start of
period
Men
Number of major CHD events 1781 207 2781 321 5876 1045
Total person-years 435784 13182 1285331 49481 3026111 199616
Crude incidence rate of major CHD,
per 1000 person years (95% CI)
4.09 (3.90 to 4.28) 15.7 (13.7 to 18.0) 2.16 (2.08 to 2.25) 6.49 (5.82 to 7.24) 1.94 (1.89 to 1.99) 5.24 (4.93 to 5.56)
Age-standardised incidence rate, per
1000 person years (95% CI)*
4.77 (4.54 to 4.99) 11.1 (9.41 to 12.9) 2.45 (2.35 to 2.55) 5.30 (4.62 to 5.99) 2.14 (2.08 to 2.19) 4.06 (3.76 to 4.37)
Age-adjusted rate ratio of major
CHD incidence, T2DM versus no
T2DM (95% CI) †
1 2.16 (1.87 to 2.50) 1 1.88 (1.67 to 2.11) 1 1.68 (1.57 to 1.79)
Women
Number of major CHD events 1067 159 1421 189 3499 691
Total person-years 494205 12467 1448560 46076 3346915 192018
Crude incidence rate of major CHD,
per 1000 person years (95% CI)
2.16 (2.03 to 2.29) 12.8 (10.9 to 14.9) 0.98 (0.93 to 1.03) 4.10 (3.56 to 4.73) 1.05 (1.01 to 1.08) 3.60 (3.34 to 3.88)
Age-standardised incidence rate, per
1000 person years (95% CI)*
2.03 (1.90 to 2.15) 7.66 (6.24 to 9.08) 0.98 (0.93 to 1.04) 3.33 (2.75 to 3.90) 0.95 (0.92 to 0.98) 2.33 (2.12 to 2.54)
Age-adjusted rate ratio of major
CHD incidence, T2DM versus no
T2DM (95% CI) †
1 3.30 (2.79 to 3.90) 1 2.57 (2.21 to 3.00) 1 2.06 (1.90 to 2.24)
*Standardised to the age-distribution of the whole THIN population. †From multilevel Poisson regression, adjusting for age and gender, and general practice. Note: Because
of the adjustment for general practice as a random effect in the multilevel modelling, the rate ratios presented in the bottom row do not equate exactly to the ratios of the age
standardised incidence rates in the third row (which are not adjusted for practice).
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Table 9.5 Fall in rate of major CHD between 1995-1998 and 2005-2008 among men and women in the THIN population, and % of the
fall “explained” by rising T2DM prevalence
Measure of time trend
Point estimate,
(95% CI), age-
adjustment only
Corresponding
β-coefficient,
age-adjustment
only
Corresponding
p-value
Point estimate, (95%
CI), adjusted for age +
T2DM status at start
of each period
Corresponding
β-coefficient,
adjusted for age
+ T2DM status
Corresponding
p-value
% of the time trend
in major CHD
incidence
"explained" by rising
T2DM prevalence,
(95% bootstrap CI)*
All participants
Rate ratio of major CHD
comparing the periods
2005-2008 with 1995-
1998 0.47 (0.45 to 0.49) -0.7610 <0.001 0.44 (0.43 to 0.46) -0.8102 <0.001 -6.46 (-7.89 to -5.13)
Men
Rate ratio of major CHD
comparing the periods
2005-2008 with 1995-
1998 0.46 (0.44 to 0.49) -0.7691 <0.001 0.44 (0.42 to 0.47) -0.8128 <0.001 -5.69 (-7.47 to -4.23)
Women
Rate ratio of major CHD
comparing the periods
2005-2008 with 1995-
1998 0.48 (0.45 to 0.51) -0.7369 <0.001 0.45 (0.42 to 0.48) -0.7965 <0.001 -8.08 (-10.9 to -5.57)
*% of the time trend in major CHD incidence explained by rising T2DM prevalence = 100% × (β0 – β1)/ β0 where β0 is the coefficient for calendar period in the model only
adjusting for age and β1 is the coefficient for calendar period in the model adjusting additionally for T2DM status.
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Table 9.6 Fall in hazard of major CHD between 1979 and 2004 among men in the BRHS cohort, and % of the fall “explained” by rising
T2DM prevalence
Measure of time
trend
Point estimate,
(95% CI), age-
adjustment only
Corresponding β-
coefficient, age-
adjustment only
Corresponding
p-value
Point estimate,
(95% CI), adjusted
for age + T2DM
status at start of
each period
Corresponding β-
coefficient,
adjusted for age +
T2DM status
Corresponding
p-value
% of the time trend
in major CHD
incidence
"explained" by
rising T2DM
prevalence, (95%
bootstrap CI)*
Average annual
percentage decline in
hazard of major CHD
between 1979 and
2004*
3.65 (2.50 to 4.78) -0.0371 <0.001 4.01 (2.85 to 5.15) -0.0409 <0.001 -10.1 (-17.2 to -6.04)
Average annual
percentage decline in
hazard of major CHD
between 1992 and
2004*
3.74 (0.19 to 7.17) -0.0381 0.04 4.15 (0.61 to 7.58) -0.0424 0.02 -11.3 (-56.7 to 38.4)
Rate ratio of major
CHD comparing the
periods 2000-2004
with 1992-1996
0.75 (0.59 to 0.94) -0.2939 0.01 0.72 (0.57 to 0.91) -0.3246 0.006 -10.4 (-52.1 to -3.78)
*% of the time trend in major CHD incidence explained by rising T2DM prevalence = 100% × (β0 – β1)/ β0 where β0 is the coefficient for calendar period in the model only
adjusting for age and β1 is the coefficient for calendar period in the model adjusting additionally for T2DM status.
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Figure 9.1 1-, 3-, and 5-year incidence of a major CHD event, following a new
T2DM diagnosis, according to calendar year of T2DM diagnosis
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Chapter 10: Implications
10.1 Introduction – summary of all main findings
10.1.1 Recap of thesis aim
The motivation for the research in this thesis stemmed from observations of the
striking and divergent time trends in coronary heart disease (CHD) and type 2
diabetes (T2DM) which have occurred in the UK in recent decades. In particular, the
“headline” statistics are a fall in mortality from CHD of almost three quarters from
1961 to the present, compared with a rise in prevalence of T2DM of around 5% per
annum since the 1990s. Understanding the reasons for these contrasting disease time
trends may have potentially important public health implications. In particular,
gaining insight into which associated factors have most influenced the observed trends
may help to inform future efforts to reduce CHD mortality and T2DM prevalence.
However few studies have sought to carry out formal analyses of the reasons for the
time trends.
A key step towards understanding the major CHD mortality and T2DM prevalence
trends is to examine time trends in the incidence of these two conditions. This notion
led to formation of the overall thesis aim to describe and explain time trends in
incidence of major CHD and T2DM.
Recall from chapter 1, section 1.2, the five thesis objectives:
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10.1.2 Findings in relation to thesis objectives
In relation to the first two thesis objectives, to describe trends in major CHD
incidence and T2DM incidence, analysis of data from nationwide The Health
i) Estimate recent time trends in incidence of major CHD in the UK
ii) Estimate recent time trends in incidence of T2DM in the UK
iii) Examine the potential contribution of secular time trends in major
aetiological factors and preventative medications to the time trend in
incidence of major CHD:
iii)a) Examine the possible contribution of secular time trends in major
aetiological factors to the time trend in incidence of major CHD
iii)b) Examine the contribution of increased preventative medication use to the
time trends in the major aetiological factors
iv) Examine the possible contribution of secular time trends in major
aetiological factors (particularly rising adiposity levels) to the time trend in
incidence of T2DM
v) Examine the paradox that CHD has declined while T2DM has increased.
v)a) Estimate whether the time trend in incidence of major CHD among
individuals with T2DM differs from the time trend in incidence of major CHD
among those without T2DM, and if so, how the excess risk of major CHD among
those with T2DM has changed over time.
v)b) Estimate the potential decline in major CHD incidence had no increase in
T2DM occurred and the extent to which rising T2DM prevalence has curtailed the
decline in major CHD incidence.
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Improvement Network (THIN) primary care database in chapter 4, showed a 50%
relative decline in major CHD incidence in the UK over the 14 year period from 1995
to 2008. Over the same period, incidence of T2DM rose by 64%, although the
influence of changes in diagnostic criteria and case ascertainment may account for
some of the T2DM rise in later years. Analysis of data from the British Regional
Heart Study (BRHS) and Whitehall II cohorts in chapter 4 revealed consistent trend
estimates, and also showed that the decline in major CHD incidence occurred from at
least the 1980s, while T2DM incidence appears to have been rising at least since the
mid-1980s.
The analyses presented in chapters 5, 6 and 7 addressed the third objective, to explore
reasons for the decline in major CHD incidence. In chapter 5, it was shown that, of the
decline in the hazard of major CHD in the BRHS over 25 years from 1978-80 to 2004,
46% could be explained by a combination of time trends in the major coronary risk
factors over this time: a fall in the number of cigarette smokers (most powerful of all),
a decrease in the mean SBP among the cohort, an increase in mean HDL cholesterol
and a decrease in mean non-HDL cholesterol. Chapter 6 revealed comparable
findings for the decline in major CHD hazard among men and women in Whitehall II,
supporting the findings from the BRHS, and extending the results to women. Further
analyses of the BRHS men in chapter 7 showed that most (80%) of the fall in SBP and
a smaller proportion (33%) of the fall in non-HDL cholesterol could be attributed to
larger decreases among users of relevant medications over and above the decreases
among men not on medication. The favourable increase in HDL cholesterol however
was independent of medication use. Changes in diet, physical activity and alcohol
consumption appeared to have limited influence on the decline in major CHD
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incidence, but the effects may have been underestimated due to measurement
imprecision. While the overall changes in CHD were generally favourable, it was not
all good news as in both cohorts rising adiposity had an adverse impact, such that had
other favourable risk factor trends not occurred, the unfavourable trend in body mass
index (BMI) may have led to an increase in major CHD incidence.
Chapter 8 addressed the fourth thesis objective, to explore the reasons for the rise in
T2DM incidence, using data from the BRHS. In particular, the possibility that much
of the rise in T2DM (that which is independent of changes in population
demographics) may be connected to rising adiposity levels was investigated.
Approximately one quarter of the rise in T2DM incidence among men in the BRHS
between 1984 and 2007 could be attributed to a rising BMI levels. The results
suggest that an appreciable portion of the substantial rise in T2DM incidence is
associated with the unfavourable population wide increase in BMI but a substantial
portion of the observed increase in T2DM incidence remained unaccounted for.
T2DM is associated with an estimated two-fold increased risk of CHD. The final
results chapter 9 thus investigated the relationship between the opposing trends in
these related conditions (the fifth thesis objective). It was found firstly that between
1995 and 2008, the prognosis, in terms of major CHD risk, of patients newly
diagnosed with T2DM has improved: patients are surviving longer after a new T2DM
diagnosis before experiencing a major CHD event. Secondly, while significant
declines in incidence of major CHD occurred among both patients with and without
prevalent T2DM over this period, the decline was slightly larger among those with
prevalent T2DM, leading to an attenuation over time of the excess risk of major CHD
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among T2DM patients from a relative risk of 2.7 to a relative risk of 1.9. The
attenuation was more marked in women than men. Finally, analysis of THIN data
suggests that the rising prevalence of T2DM has limited the decline in major CHD
between 1995 and 2008 by approximately 6-8%. That is, in the absence of a rise in
prevalence of T2DM a 6-8% larger decline in major CHD incidence than that
observed might have occurred. Analysis of BRHS data showed similarly that rising
prevalence of T2DM limited the scale of the decline in major CHD incidence in men
between 1979 and 2004 by approximately 10%.
10.1.3 Novelty of the present findings (What this study adds)
The research in this thesis provides further evidence on time trends in incidence of
major CHD and T2DM in the UK, using representative populations studied over
extended periods. While there was already some data on time trends in incidence of
major CHD or T2DM, as discussed in chapter 2, sections 2.2.2 and 2.3.2, this data
was limited (for example restricted to a particular region or with gaps in the time
periods covered). This reflects in part a paucity of suitable data sources and the
difficulties in capturing incidence (as opposed to CHD mortality or T2DM
prevalence). Through the consistency of the estimates of the time trends from the
three different data sources studied, this thesis provides strong evidence in support of
declining major CHD incidence and rising T2DM incidence, confirming the findings
from previous studies. The thesis also presents little-reported time trends in incidence
by socio-demographic group, highlighting a possible widening socio-economic
inequality in incidence of both CHD and T2DM.
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The investigations reported in chapters 5 to 8 are also apparently the first studies of
this kind to formally analyse the reasons for the time trends in CHD and T2DM in the
UK, using individual-level data. The results highlight the contribution of favourable
risk factor trends to the decline in major CHD incidence, and also quantify the adverse
role of adiposity on the rise in incidence of T2DM. While several studies have
reported on concurrent trends in CHD and CHD risk factors, and hypothesised a
relationship between the two, just two previous studies have sought to formally relate
risk factor trends to CHD trends in the UK - the IMPACT study12, 15 and the WHO
MONICA study13. However both studies involved a synthesis of different aggregate
data sources, and are thus subject to ecological limitations. Also, the IMPACT study
considered trends in CHD mortality rather than in CHD incidence, while the WHO
MONICA study was limited to two specific UK cities (Glasgow and Belfast) and so
the findings may not be reflective of the UK as a whole. Even worldwide, there are
few studies of time trends of this kind, formally relating individual risk factor levels to
CHD events17. Meanwhile, literature examining the reasons for the rise in T2DM is
even sparser. While rising adiposity levels are thought to contribute to the rising
T2DM prevalence, this is apparently the first study to attempt to quantify the role of
adiposity. The results confirm an appreciable contribution to the increasing T2DM
burden of rising levels of this key risk factor, whilst also suggesting that rising
adiposity levels may not be the whole story, and other factors may be playing a role
too. The excess risk of a CHD event among patients with T2DM, relative to those
without, is well established27-33. On a positive note, the results of the final chapter of
the thesis show further (and apparently for the first time) some evidence of an
improvement and that this excess risk has attenuated over time in the UK population;
this finding is in line with those in other countries.
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The validity of each of these findings, and coherence of the findings with existing
research, were demonstrated in each of the results chapters. In subsequent sections of
this final chapter, the potential implications of the findings, both in terms of public
health and in terms of future epidemiological research, are discussed.
10.2 Public health implications
10.2.1 Implications for the UK
Time trend in incidence of major CHD
The findings of chapter 4 indicate that at least from the 1980s onwards the decline in
mortality from CHD may be partially explained by a fall in incidence of major CHD
events, that is fewer people experiencing a major CHD event in the first place. This
good news story indicates that it has been possible for major CHD incidence to
decline over time, to, in turn, contribute to reduced CHD mortality rates in the UK
population. However, as outlined in chapter 2, section 2.4.1, despite the decline in
CHD mortality, CHD remains the leading single cause of death. Therefore, efforts are
needed to reduce CHD mortality rates further. The present study results suggest that a
major contribution to achieving this can come through reductions in incidence, that is
preventing men and women from developing major CHD in the first place.
Time trend in incidence of T2DM
The rise in prevalence of T2DM, at least from the mid 1980s until the late 1990s, may
be seen to reflect at least in part a rise in incidence of T2DM, that is an increase in the
rate at which people develop T2DM. The observed rise in T2DM incidence, at least
during the 1990s, is apparently independent of population demographic changes and
347
changes in diagnostic criteria and case ascertainment. In chapter 2, section 2.3.2, it
was noted that the extent to which rising T2DM prevalence is an unfavourable
occurrence and an “epidemic” depends on the drivers behind the rising prevalence19,
74, 75. If the rise is seen to reflect mainly improved survival, or a change in the
population structure, these are changes that do not necessarily indicate a public health
problem requiring resolution, and (in the case of improved survival) could be
conceived to be a public health “success story”. The findings from chapter 4 indicate
that, at least in part, the rising prevalence over this period is resulting from rising
incidence, and thus emphasizes the need for urgent action to prevent men and women
from developing T2DM. In the last decade, the extent of the rise in T2DM incidence,
given the possible influence of changing diagnostic criteria and case ascertainment,
was less certain. However, it could be argued that it is more likely for the pattern of
rising incidence in the 1990s to have continued than not, especially since, as was
shown subsequent chapters, adiposity has continued to increase. Indeed, in the BRHS
analyses of chapter 8, the continuing increase in adiposity made a similar contribution
to rising T2DM incidence in the latest period as in earlier years.
Socio-demographic variations in incidence time trends
Chapter 4 also presented previously little reported trends in incidence of major CHD
and T2DM according to different socio-demographic characteristics. The general
pattern was that more favourable trends occurred in higher socioeconomic groups: the
rate of decline in major CHD appeared faster while the rate of increase of T2DM was
slower among those in more professional/ senior employment grades compared with
more junior grades or unskilled occupations and among those living in less deprived
areas compared with more deprived areas. Incidence of both major CHD and T2DM
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was initially greater among more deprived groups. Therefore the results highlight a
concerning widening socio-economic inequality in T2DM and CHD incidence rates,
suggesting that public health measures to reduce incidence of these conditions, while
aiming to reduce both overall rates across the country, should also focus particularly
on reducing rates within more deprived communities.
The least favourable relative changes in incidence of T2DM and major CHD were
shown to have occurred in the youngest age groups. This is concerning as it is these
age groups which will influence the future prevalence and burden of disease. For
major CHD, this finding is corroborated by the observed flattening of the decline in
CHD mortality in younger groups52-54. This highlights that the CHD trends are not
entirely favourable and despite the striking decline in CHD mortality to date, public
health focus should not shift away from CHD, as there may be the possibility of a
resurgence of a CHD epidemic among younger generations.
Contributions of aetiological exposures to the decline in major CHD incidence
The results from chapters 5 and 6 showed that approximately half of the decline in
major CHD incidence may be attributed to favourable trends in major modifiable
exposures in the population. As discussed in chapter 5, section 5.5.2, the analyses are
distinct from studies assessing the more familiar “population attributable risk
fraction” (PARF) of major CHD for given risk factors143. In studies of PARF, the
objective is to assess the degree to which overall risk of major CHD in a population is
attributable to risk factors. In this study the objective is instead to assess the degree to
which the trend over time in major CHD risk in the population is attributable to risk
factor trends; in particular how much of the favourable decline in major CHD may be
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attributable to risk factor improvements. As well as a difference in the interpretation
of the findings, the key difference in the modelling is that overall risk of major CHD
in a PARF calculation may be attributed to a combination of modifiable risk factors,
such as adiposity, and static risk factors, such as genetics, while in contrast, trends
over time in major CHD may be attributed to only modifiable risk factors, which have
changed over time in the cohort. Thus the estimated relative contributions of risk
factors may differ between the present analyses and PARF-based analyses. Since the
trends in major CHD may be attributed only to modifiable risk factors, the analyses
reported here may arguably be considered to have more immediate public health
implications in terms of identifying ways to reduce underlying risk of major CHD in a
population. The results show what can be achieved in terms of reducing smoking,
lipid levels, and blood pressure, and the considerable resultant reductions in CHD
incidence in the population. This highlights the value of population-wide measures to
reduce exposure to the major coronary risk factors. The potential for further
reductions in CHD in the UK population through cigarette smoking may be
constrained by the already low remaining cigarette smoking prevalence. However,
the changes in blood pressure and particularly in blood lipids that have so far occurred
are relatively modest and appreciable further opportunities for the reduction in blood
pressure and lipid levels remain. CHD mortality risk continues to decline to
115/75mmHg for BP, and 3.5mmol/L for non-HDL cholesterol100, 103, lower than the
levels among the participants in both the Whitehall II and BRHS cohorts at the end of
the follow-up periods, despite the favourable declines. A recent analysis of 2006 data
from the Health Survey for England suggested that, even now, BP is controlled in
only about 28% of hypertensive individuals401. This echoes similar findings from the
US population402. The results of chapter 7 highlight that while much of the decline in
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SBP to date may be attributed to use of anti-hypertensive medications, the favourable
trends in non-HDL cholesterol, and especially HDL cholesterol, were more likely to
reflect changes in health behaviours. Both medication-based strategies and non-
medical population-wide strategies still have considerable potential to reduce levels of
these coronary risk factors in the UK. Non-medical strategies include in particular
reduction of saturated fat and salt intakes, given that in 2010, average sodium intake
was estimated to be 2.83 grams per person per day, corresponding to a salt intake
above 7 grams per person per day403, considerably greater than the 5.8 grams per day
advocated by DASH (Dietary Approaches to Stop Hypertension)404. Likewise, the
percentage of energy derived from saturated fat was 14.5%405, roughly twice the
desirable levels seen in Japan406, a country with exceptionally low CHD rates. It has
not been possible to assess the role of hospital interventions (for example bypass
procedures or angioplasties) in the decline in major CHD incidence in these analyses
due to a lack of secondary care data. However arguably it is of greater public health
importance to establish the roles of factors or exposures which are readily modifiable,
as this shows what can be achieved through primary prevention approaches which
could obviate the need for major surgical procedures.
Considering the Whitehall II gender-specific analyses in chapter 6, the risk factor
reductions were of broadly comparable importance for the CHD risk reductions in
men and women, with any differences in the estimated contributions of the risk
factors explained by differences in the time trends in these factors (HDL and SBP).
The findings suggest that similar influences have operated to achieve similar overall
declines in incidence of major CHD among both men and women, such that similar
prevention strategies may be appropriate for both genders.
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Adverse role of rising adiposity levels on the CHD and T2DM time trends
A further implication of the results of chapters 5 and 6 is the apparent counter-
productive role of rising adiposity levels on the time trend in major CHD incidence.
While the negative contribution of rising adiposity over recent decades appears to
have been outweighed by the favourable trends in other coronary risk factors, the
concern is that continued increases in adiposity may further reduce or even reverse the
decline in major CHD incidence. Indeed there may already be some evidence of this
phenomenon within the younger age groups, predominantly affected by rising obesity
levels in early adult life and younger9, 407 and among whom CHD incidence is falling
at a slower rate, while CHD mortality rates (previously falling) may already be
plateauing52-54. The results in chapter 8 show further the appreciable contribution of
rising adiposity levels to the unfavourable rise in T2DM incidence, and, as shown in
chapter 9, the rise in adiposity may have influenced the time trend in major CHD
mainly through increasing in the incidence of T2DM. The relatively modest
improvements in SBP and non-HDL cholesterol may also have been influenced by the
unfavourable secular increase in adiposity levels, which is an important determinant
of these clinical factors. That is, non-HDL and SBP may be pathways by which
adiposity is restricting the decline in CHD. This emphasizes the need to address
rising adiposity levels in the UK, and suggests that by controlling adiposity levels,
there may be considerable potential for reducing levels of chronic disease in the
population.
Chapter 8 also revealed however that rising adiposity levels alone do not appear to
fully account for the rise in T2DM incidence. This is somewhat counterintuitive to
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current perspectives; the public health messages in the media tend to focus on rising
T2DM levels being linked to the growing obesity epidemic and that reducing obesity
levels is the principal requirement for curbing the rise in T2DM. Instead, the results
of this analysis suggest that other factors (for example diet) may be independently
contributing to the rise in T2DM. In which case, broader public health interventions
may be appropriate. For example, dietary factors associated with reducing T2DM risk
include a high fibre diet192, 195, and daily consumption of fibre declined between 1987
and 2000376. Also, the possible adverse impact on T2DM risk of certain drugs
indicated for other conditions warrants further investigation174, 385. The presence of
other contributing factors would suggest the need for a more multi-factorial approach
to combat rising T2DM in the population.
Relationship between T2DM and major CHD trends
In chapter 9 it was shown that the excess risk of a major CHD event among patients
with T2DM compared to those without may have been attenuated to a degree over
time. The results indicate a modest success story, which may in part reflect improved
management and treatment of T2DM patients342. Despite the attenuation of the
relative risk, patients with T2DM remain at approximately double the risk of major
CHD than those without T2DM. Thus there is still much room for improvement and a
need for continued concerted efforts to manage T2DM. The need to better manage
CHD risk in patients with T2DM is further emphasized by the increase in incidence of
T2DM over time. Thus although the relative risk of CHD in those with and without
T2DM has attenuated, as more patients develop T2DM, the proportion of all patients
experiencing a major CHD event who have T2DM is likely to increase – that is, the
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absolute contribution of T2DM to risk of a major CHD event is set to rise, as already
demonstrated in the US population395, 400.
Summary
In summary, the findings show that the rising T2DM prevalence in the UK reflects, at
least in part, rising incidence, which warrants urgent attention. While CHD mortality
rates are falling, in line with a decline in major CHD incidence, comparable declines
are not occurring among all socio-demographic groups. There is some evidence of
widening socio-economic inequalities in CHD incidence and in T2DM incidence that
need to be addressed. The CHD trends appear to have been less favourable in
younger groups, which suggests the potential for future resurgence of major CHD and
that, despite the success in reducing CHD incidence and mortality to date, public
health policy focus should not shift away from CHD. Public health policy to reduce
CHD should include population-wide measures to improve the major modifiable
coronary risk factors, which have considerable potential for reducing CHD incidence.
In particular, a priority is to address the rising population adiposity levels, which
appear to have had an appreciable adverse impact, both limiting the scale of the
decline in major CHD incidence, and contributing appreciably to the rising T2DM
incidence. Management of patients with T2DM is another important public health
consideration, to reduce the continued substantial excess risk of major CHD among
patients with T2DM, and in turn, prevent rising T2DM from curbing the decline in
major CHD incidence.
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10.2.2 Implications for other countries
As discussed in chapter 2, in line with the trends in major CHD in the UK, declines in
CHD mortality and major CHD incidence have also been observed in North
America252, 254, 263 and other countries in Western Europe249-251, 253, 255, 264,
Australasia265, 266 and Japan267. In contrast, in other regions of the world (Asia10, 11,
Eastern Europe268), in predominantly low and middle-income countries, CHD
mortality rates have not been declining, and appear to even be increasing, leading to a
growing CHD healthcare burden. The unfavourable rising CHD burden (along with
other non-communicable diseases) in these countries is seen to reflect the
phenomenon of “epidemiological transition” from the burden and priority of
communicable diseases to non-communicable diseases269, 270. The extent of transition
differs between countries; countries such as China and India, and parts of Eastern
Europe are currently transitioning and as such are experiencing increased CHD
mortality rates. Some countries in Sub-Saharan Africa are yet to transition and may
be faced with a sizeable CHD burden in the future273. It has been estimated that the
number of CHD deaths worldwide may almost double between 1990 and 2020270;
CVD is already the leading cause of death worldwide and the third highest cause of
disability274.
Chapter 2 also highlighted the growing global prevalence of diabetes (primarily
T2DM)282-284. Increases have been observed in many countries in both the developed
and developing world. Current (2010) global prevalence is estimated to be 6.4% (285
million diabetic individuals) and predicted to rise to 7.7% in 2030, corresponding to
622 million people with diabetes283. India, China and the US come out top in terms of
numbers of people with diabetes, while the Middle Eastern countries tended to have
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the highest prevalence rates (estimated to be over 20% in the United Arab Emirates by
2030, and over 15% in Kuwait, Bahrain and Saudi Arabia)283. The projections are
based primarily on the changing population demographics (population growth, ageing
populations and urbanisation285 being particularly implicated in the estimated
increased prevalence rates). If adiposity or other aetiological factors are contributing
to the rise in T2DM, the projected rates are likely to be underestimates.
The growing burden of CHD in other countries, and worldwide increase in T2DM
prevalence, emphasizes the potential value of understanding and exploring the reasons
for the trends in these conditions in the UK, as a means to inform how to reduce the
burden of chronic disease in other countries. The thesis findings indicate that in the
UK, favourable risk factor trends have made an important contribution to reducing
major CHD incidence. This suggests that control of the major modifiable coronary
factors (smoking, blood pressure and blood lipids including both HDL and non-HDL
cholesterol) could also help to reverse the rising CHD epidemics in other countries.
Extrapolation of the results of the risk factor influences to trends in other populations
however needs to be cautious. The potential benefit of favourable risk factor trends on
the trends in incidence of major CHD and T2DM is likely to vary depending on initial
levels of the risk factors, and the strength of the association between the risk factor
and CHD or T2DM in the population. Considering the findings from studies
worldwide analysing trends in CHD mortality (predominantly involving synthesis of
aggregate data and dominated by the IMPACT model studies249-255, 276), where a
decline in CHD mortality has occurred, risk factors have consistently tended to make
a larger contribution than treatments. Three of the established major aetiological
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exposures – cigarette smoking, blood pressure and total cholesterol - feature in most
analyses, and favourable changes in these factors have made contributions to the CHD
mortality declines in most of the countries. However, the relative size of the
contribution of each of these factors appears to vary between populations. In the UK,
declining smoking made a substantially larger percentage contribution (about 40%) to
the CHD mortality decline than the other factors12, 15, in line with the BRHS findings
for major CHD incidence. While smoking also made important contributions to the
mortality declines in Ireland250 and Iceland249 (>20%), the contribution of falling
cholesterol levels in these populations was as high, if not higher (about 30%). In
other Nordic countries (Finland253 and Sweden251) the role of cholesterol was even
larger (about 40%), relative to smoking and blood pressure. In the US252 , Canada254
and Italy255, cholesterol was also the most important factor (almost 25% of the
mortality decline explained), but blood pressure also made an appreciable contribution
(~20%), compared to a more modest contribution from smoking (about 10%). Finally
in Australasia, blood pressure tended to be the most influential266, 296, 297. Although
predominantly populations of European origin, there will be some variations in
ethnicity between populations and it has been suggested that there may be interactions
between risk factors and genetic influences270, such that the size of the risk factor
associations could vary between different ethnic groups. However, other studies
have shown that in fact the associations of these risk factors are broadly comparable
between ethnic groups and populations100, 103, 143. An assumption of such
comparability is made in the IMPACT studies, in which the estimates of the risk
factor associations incorporated in the models applied to different populations are
largely derived from the same studies anyway and so assumed to be same. The
variations in the risk factor contributions to the CHD mortality declines between
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countries are therefore more likely to reflect the different sized trends in the risk
factors – where smoking levels have declined most dramatically, smoking is likely to
have made the greatest contribution to the CHD mortality decline. Variations in the
risk factor trends could reflect the different time periods covered, different starting
levels of the risk factors and also different health policies, focussing on controlling
different risk factors. For example, in Finland, concerted efforts have been made to
improved diet in the population, as part of public health interventions such as the
North Karelia Project, to reduce the very high CHD levels368-370, and declining blood
cholesterol was estimated to make the largest risk factor contribution to the CHD
mortality decline in this population. Meanwhile, in the UK, where smoking made the
greatest contribution, emphasis in the past has been on reducing the previously high
smoking prevalence.
Ultimately, the overall broad comparability of the findings of the risk factor and
treatment contributions to CHD mortality trends in the different countries, and the
similarity in the associations of the risk factors with CHD between populations,
suggests that the findings from the present study on incidence may be applicable to
other countries. That said, the majority of the studies above on CHD mortality are of
developed countries. The extent to which the results may be extrapolated to low or
middle-income countries is less certain. There are factors unique to lower and middle
income countries, such as urbanisation, and the political and economic environment,
which may influence the extent of risk factor changes and so CHD incidence, and
which therefore, which need to be taken into account274. Public health measures to
prevent major CHD events through risk factor changes which work in one setting may
not necessarily be applicable to another setting. While use of blood pressure lowering
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medications or lipid-regulating medications may contribute to lower blood pressure
and lipid levels in the UK, dispensing of such medications in lower or middle income
countries may be limited by lack of infrastructure or prohibitive costs274. Instead,
population level interventions such as tobacco control (for example the successful
total ban in Bhutan408) or restrictions of levels of “hidden” dietary salt intake are seen
to be more feasible measures to implement274.
The adverse role of rising adiposity on the time trends in major CHD and T2DM
incidence in the UK serves to emphasize the potential implications of rising adiposity
worldwide, and the need to address worldwide obesity levels to reduce major CHD
and T2DM incidence. This is particularly concerning for lower and middle income
countries in which it is unlikely that the healthcare systems will have the necessary
resources to provide the level of cardiovascular preventive treatment (particularly
statins and blood pressure lowering medications) needed to compensate for the
increasing prevalence of overweight and obesity already taking place.
10.3 Implications for epidemiology and epidemiological research
10.3.1 Epidemiological implications
The general approach in this thesis has been to make inferences about the role of
different risk factors on the time trends in major CHD and T2DM, under the
assumption of an aetiological association between the factors and CHD and T2DM.
From an alternative perspective, the results themselves may be seen to provide further
evidence of the size and extent of aetiological associations. The findings that
declining blood pressure and lipid levels, and declining smoking may explain falling
major CHD incidence, lends further support for the widely held assumption that these
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relations are causal, particularly though showing reversibility (that reducing risk
factor levels reduces CHD risk), which was highlighted in the original Bradford-Hill
criterion for causality409. The finding that rising BMI is consistent with explaining
one quarter of the rise in T2DM supports previous findings on the extent of the
association between adiposity and T2DM risk, from studies assessing PARFs of
adiposity in T2DM, which have reported PARFs similar in size178, 181.
Moreover, the thesis findings provide further evidence that the effects of risk factor
levels on CHD risk may be realised to some extent in a relatively short time-frame,
supporting the small number of existing studies addressing time-lags to date356-358.
That is, given the structure of the analysis, risk factor levels could be related to major
CHD and T2DM risk within five years and eight years respectively of the risk factor
exposure (the time between subsequent questionnaire time-points in the BRHS). This
limited lag time modelled between the trends in the risk factors and trends in major
CHD or T2DM indicates that changing risk factor levels may have a relatively
immediate impact on subsequent major CHD or T2DM risk.
10.3.2 Lessons learnt from research methods
The principal method used to carry out the research for this thesis was statistical
analysis of data from a combination of different data sources: two cohort studies of
cardiovascular disease, with established follow-up, and a database of routinely
collected general practice longitudinal data. The analyses were all carried out at the
individual level, that is, relating an individual’s risk factor exposure to their
subsequent major CHD or T2DM risk, as opposed to ecological analyses. Key
strengths and pitfalls of the methods, identified through the course of carrying out the
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research, are discussed in this section. Suitable approaches for conducting related
research in the future, based on the lessons learnt, are also considered.
Appropriateness of data sources
The first issue considered is the appropriateness of the data sources. For the main
analyses in chapters 5, 6 and 8 (estimating the contributions of trends in aetiological
exposures to trends in major CHD and T2DM), the benefits of the using the
established BRHS and Whitehall II cohort studies are clear. These include the
continuous and near-complete follow-up over an extended period for CHD and T2DM
events and mortality, and the detailed information on aetiological exposures and
medication use, recorded at repeated intervals. A particular strength here is that the
risk factor (exposure) data has generally either been consistently collected or
validation studies to compare the different ascertainment techniques have been
possible (chapter 3), limiting bias in the estimates of the time trends in the risk factors
and their roles in the trends in major CHD and T2DM.
The use of the BRHS and Whitehall II cohort studies for this research is not however
without limitations. Numbers of events for some analyses are limited, and some of
the confidence intervals (CIs) for the estimated risk factor contributions to the disease
trends are very wide, indicating limited statistical power and precision. This is
particularly evident in sub-group analyses, for example stratified by gender. Second,
the representativeness of each cohort is limited by its restriction to certain sections of
the UK population (BRHS comprises only men, while Whitehall II is restricted to
men and women employed in the Civil Service in London). Further, in both the
BRHS and Whitehall II cohorts, the participants are now reaching old age. This
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renders the cohorts increasingly important data sources for the study of the health of
the elderly (an area of medical research of growing importance, given the ageing of
the UK population), especially since there are few other suitable data sources of
comparable size. However, while the cohorts have proved suitable for the study of
(and reflective of) UK time trends up to now (while the cohort participants were
middle-aged), for future investigations of time trends, a younger sample of people
may be preferred, as the results would provide a better indication of the future burden
of disease, and because it is the apparent slowing of the decline in the CHD epidemic
in the younger population that especially warrants further investigation.
Large well-conducted nationally representative cohort studies, which share the
strengths of the BRHS and Whitehall II cohorts, but with younger age ranges, would
therefore ideally be suited to future analyses of this type. However the availability of
such data sources, with repeated risk factor information, and follow-up for CHD and
T2DM, is limited, while the cost of setting-up and managing cohorts may act as a
barrier to the formation of new suitable and sizable cohorts. An alternative is to
consider the use of routinely collected data, such as The Health Improvement
Network (THIN) primary care database. Other examples include similar primary care
databases, such as the General Practice Research Database (GPRD) and
QRESEARCH, hospital data from the Health Episode Statistics (HES), and disease
registries. The notion of a very large amount of health-related data on the UK
population, already available and being collected, is an exciting research prospect.
Often, as in the case of the THIN database and other primary care databases, the data
source comprises historical information while also being dynamic and continually
updated, so that up-to-date data is also available. The data is also often at the
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individual level, and longitudinal in nature, enabling individuals to be followed over
time, and nested cohorts may be constructed from the data. Further, in the case of
THIN (but also some of the other routine sources), key strengths are the very large
number of patients contributing data, enabling precise estimation, and the nationwide
scope, encompassing men and women of all ages, regardless of health status, and so
including those (typically most vulnerable) groups of patients frequently ineligible to
participate in randomised controlled trials and cohort studies. Thus the findings may
be widely applicable and generalisable, and the data seen to be a reflection of current
UK practice. Therefore tapping into routine data sources may yield considerable
research potential.
The key drawback lies in the very essence of being routinely collected data, obtained
primarily to assist with the day-to-day care of patients, and not collected specifically
for research purposes. The implication is that the data is subject to incompleteness
and inaccuracies, and there may be a lack of uniformity in how the data is entered (for
example variations between practices). Also, with no choice over the data being
collected, it may be that certain variables and factors of interest are simply not
available at all. In addition, the format of the data is such that it generally presents
formidable programming and data management challenges. Using the THIN data for
this thesis (for the other more descriptive analyses) has made me aware of the great
care and effort needed to prepare the data, extract the appropriate information, and
make the data suitable for analysis. Challenges include defining the group of patients
within the database for study, establishing time periods over which to follow patients,
and defining outcomes of interest (through development of lists of Read diagnosis
codes). In the THIN database, while diagnoses and prescriptions are generally well
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recorded, opportunities for epidemiological or aetiological research have been limited
so far by a lack of (timely) information on exposures. For example, in the case of the
research in this thesis, the limited data on coronary and diabetic risk factors (smoking,
adiposity, blood pressure, blood lipids etc), prohibited carrying out analyses
comparable to those using the BRHS and Whitehall II cohorts, to explain disease
trends. Instead, studies using THIN data to date tend to be mainly concerned with
describing patterns of disease410-412 (for example, describing disease trends as in
chapter 4), or analysing health service use313, 413. However, while use of routine data
may have been limited in the past, recent improvements in the collection of the data,
and developments in the methods to handle the data, make the prospects for future
research much more promising. In particular, as regards THIN and other primary care
databases, the introduction of the Quality and Outcomes Framework (QOF) in the
early 2000s, which includes specification of rewards for general practitioners for
measuring and recording health indicators such as smoking status, has led to more
complete and regular recording of these factors in the last few years. There is also a
growing body of methodological research work on methods to manage and handle
routine data, such as imputation of missing data414, and identification of outliers415 (to
distinguish between extreme true values of continuous factors such as blood pressure,
and mis-recorded erroneous data). Therefore routine data sources may prove a more
and more useful resource in the future for epidemiological research in general, and it
may subsequently be possible to carry out analyses of time trends in a manner similar
to that used in the thesis on the BRHS and Whitehall II cohorts.
Arguably superior to using either a suitable cohort study or a routine database for
subsequent research would be to use a combination of different data sources. One
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option is for analyses to be repeated in different data sources, as in this thesis, where
the analysis of major CHD incidence trends in the BRHS are replicated in the
Whitehall II cohort. Consistent results from each data source increases confidence in
the validity and robustness of the findings. Further, if only certain sections of a
population are captured in one cohort/ data source, use of other data sources,
representative of different sections of the population, enables the results to be
generalised to a wider range of people. An alternative would be to be able to combine
data from the different data sources at the individual level, on a patient-by-patient
basis. That is, if certain information is not captured in a routine database, linkage to
other data sources may enable additional information on a patient to be incorporated,
thereby broadening the scope of possible analyses. For example, in the THIN
database, for the analysis in this thesis, limited linked information, related to the
patient’s postcode, was available, enabling inclusion of area deprivation in the
analyses. In the future, it is going to be possible to link THIN data to other data
sources, such as the HES data or disease registries. Linkage to HES is an especially
exciting prospect as it would entail combining primary and secondary care data,
enabling tracking of a patient’s care though both domains. A noted limitation of the
analyses in this thesis is that the role of secondary care (such as surgical interventions)
in the major CHD time trends could not readily be assessed – a linked database of
primary and secondary care could then prove a rich source of data for analysis.
Use of individual-level analyses
The above discussion assumes the need for an individual-level analysis. As well as
the choice of data sources for the different analyses, a second key methodological
consideration in this thesis was the use of an individual-level analysis, over synthesis
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of aggregate data sources, more often used to study time trends. As the data available
allowed for an individual-level analysis, this method was chosen as it avoids
ecological limitations, as outlined in chapter 2, section 2.6.1.3, thereby giving more
confidence in the results and that the associations seen are true and not ecological
fallacy. While an individual level analysis may still be the preferred means of
analysis, it is worth noting (as shown in chapter 5, section 5.5.2) the broad
consistency of the findings from the present analysis of CHD trends to those from the
IMPACT model for Scotland and for England and Wales12, 15, which are based on
synthesis of aggregate data sources. Thus the thesis findings also serve to support and
confirm the results of IMPACT and thereby suggest that ecological studies/ synthesis
studies of this type in other populations may also be valid. This is reassuring,
especially for populations/ countries where this type of group-level (ecological)
analysis may be more readily carried out than an individual-level analysis, due to a
lack of suitable individual level data resources.
Appropriateness of central statistical analyses methods
The central analyses carried out in the thesis were those relating the time trend in
major CHD to the time trends in aetiological exposures in the two cohorts. The
analysis is an adaptation of that used by Hu et al to examine time trends in major
CHD incidence in the US Nurses Health Study17. The analysis methods used are
described in detail in chapter 5, section 5.2.4. The strengths of the analysis include i)
the fit to the format and extent of available data, making use of the repeated measures
of the aetiological exposures in the cohorts, ii) the ability to distinguish between
calendar trends and trends with age due to the ageing of the cohort, iii) that risk factor
levels at each time-point are related to subsequent CHD incidence, thereby limiting
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reverse causal mechanisms, and iv) that the analyses lead to “percentages explained”
by each risk factor, such that the extent of the contribution of each risk factor to the
CHD trend relative to each other may be quantified. The use of bootstrapping to
derive CIs for the percentage explained estimates further enables estimation of the
uncertainty around each estimate, which was not reported in the study by Hu et al.
Within the confines of this thesis, there is only space to consider certain aspects of
time trends, and certain ways to model time trends. There are certainly other aspects
of time trends not considered here and other analyses of time trends that may be
carried out, such as exploration of cohort effects. The next section highlights some of
the potential areas for further related research, towards a fuller understanding of
chronic disease time trends.
10.3.3 Suggestions for further research
This thesis presents recent trends in the incidence of major CHD and T2DM and then
goes some way towards explaining the trends seen. The relationship between the two
incidence trends is also explored. However it is too broad a topic to be feasible to
cover all aspects of the CHD and T2DM time trends in this thesis and as such there
remain some unanswered questions. In addition new questions have arisen as a result
of the findings. In this section, areas for further research, towards addressing these
questions, are summarised.
Verification of observed incidence time trends
The results of chapter 4 showed a decline over time in incidence of major CHD in the
UK, and a concurrent rise in T2DM incidence. It was discussed in section 4.6.5.1
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that, while changes in diagnostic criteria for major CHD had occurred during the
time-period of analysis, these changes are unlikely to have had a substantial impact on
the major CHD incidence trends. For T2DM however, the situation may be somewhat
different. While the rise in T2DM incidence in the 1990s may be seen to be
independent of changes in case ascertainment or diagnostic criteria, beyond 2000, the
extent to which the rise in incidence observed reflected changes in case ascertainment
or diagnostic criteria was less certain. An important area for future research will be to
try to disentangle the effects of changes in ascertainment and diagnostic criteria from
estimates of the most recent T2DM incidence trends, to provide objective estimates of
the extent of an epidemiological change in the population. One way to do this would
be through analysis of data from a cohort, for whom blood glucose levels have been
measured at repeated intervals over time (by the study personnel and using consistent
methods each time). In this way incidence of T2DM may be ascertained from the
blood glucose levels, unaffected by case ascertainment (no undiagnosed cases) and
changes in diagnostic criteria (same methods used throughout; no reliance on GP
diagnosis). With appropriate adjustment for the ageing of the cohort as in the thesis
analyses, an unbiased trend in incidence of T2DM may be obtained. Repeated blood
glucose measurements were not available in the BRHS data at the time of analysis.
However, new glucose measurements are currently being taken in a 30-year follow-up
examination, which, combined with one existing measurement, will make such an
analysis a possibility in the future.
Prediction of future time trends
In chapter 4 recent past trends in major CHD and T2DM incidence were estimated,
from which the current disease burden may be inferred. The analyses could be
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extended to model and make predictions about future trends, in order to gauge future
disease burden, which (if carefully interpreted) could help to inform future policy
regarding health care provision. Such analyses are beyond the scope of this thesis. In
the case of CHD, a particular priority would be to analyse and model future trends
among younger men and women, to assess the future impact of the apparent slowing
of the favourable CHD decline in this section of the population. In the case of T2DM,
there are already some studies to date which have sought to predict future prevalence
worldwide7, 282-284, 286-288. However most studies base future prevalence estimates on
projected changes in the age-gender population structure alone, and do not take into
account other factors such as rising obesity and therefore may underestimate the
future disease burden. Further studies are needed which do incorporate likely future
trends in adiposity, given the observed association between the adiposity and T2DM
trends described here286, 287.
Further exploration of socio-demographic variations in the time trends
Secondary analyses in chapter 4 revealed potentially widening socio-economic
inequalities in major CHD and T2DM incidence over time. Further analyses would
be useful to confirm these findings. The lack of data on ethnicity in THIN, and the
predominantly white European ethnicity of the BRHS and Whitehall II cohort
populations prevented study of time trends in incidence according to ethnicity. Given
the variation in incidence rates by ethnicity, and observed variations in the trends in
CHD mortality and T2DM prevalence by ethnicity62, 73, outlined in chapter 2, sections
2.2.1.3 and 2.3.1.3, assessment of trends in incidence by ethnicity would also be of
value.
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Investigating the “unexplained” portions of the time trends
In subsequent chapters 5 and 6 it was estimated that a substantial portion (around
50%) of the decline in major CHD incidence may be attributed to trends in the
measured major aetiological exposures. However, at the same time, an appreciable
part of the incidence decline was not accounted for by risk factor changes. Further
research is therefore needed to understand the reasons for this unexplained portion of
the decline. The roles of factors not considered in this analysis, particularly hospital
interventions, or early life and life course influences, need to be evaluated. Given the
limited accuracy of self-reported dietary patterns and physical activity levels in
questionnaires (the ascertainment methods in the two cohorts), further analyses using
more objective measures of diet and physical activity to reassess the roles of trends in
these factors would be of value, for example by means of pedometers or actigraphs for
physical activity. The results from analyses stratified by gender and socio-economic
status had limited precision due to a lack of power, and therefore need verifying
through further research. In addition, subject to the availability of large enough
population samples, comparable analyses of the time trends in incidence stratified by
age group would be useful to understand why the decline in CHD appears to have
been less marked in younger age groups.
In chapter 8 it was shown that one quarter of the rise in T2DM incidence could be
attributed to rising BMI levels. This is apparently the first analysis of this kind.
Further time trend studies in other populations are therefore needed to verify the
findings and uncover reasons for the unexplained portion of the increase in incidence.
In particular, studies with more precise measures of adiposity would be valuable.
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Additional related research
Further research is also needed to identify the reasons for the attenuation of the excess
risk of major CHD among T2DM patients (as identified in chapter 9) and establish
whether the favourable change reflects the better management and treatment of T2DM
or changed diagnosis and improved case ascertainment.
Suggestions for related research include investigation of the reasons for the trends in
the contributory aetiological exposures. Chapter 7 addressed to an extent the reasons
for the trends in blood pressure and lipid levels. It would also be of value to establish
what have been the key drivers (including social, political and health policy
influences) behind the trends in the other factors, in particular the smoking decline,
and adiposity increase, to help inform future health policy.
Another suggestion would be to carry out age-period-cohort analyses to try to
disentangle the effects of each of these factors on the overall time trends observed. In
the present analyses, it is assumed that birth cohort effects are minimal; instead,
changes over time in incidence are assumed to reflect age and period effects only.
This is arguably a reasonable assumption as birth cohort effects have been shown to
have limited influence on contemporaneous CHD and T2DM trends52, 145-147, 217.
However it would be worth carrying out analyses to confirm the influence (or lack
thereof) of birth cohort effects, which may in turn imply the influence of early life
influences on the incidence trends.
Methodological research into how best to analyse time trends would also be useful. In
addition, certain aspects of the current modelling methods warrant investigation,
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which may improve future analyses of this type. For example, further research is
needed to evaluate the extent of the time-lags between aetiological exposures and
subsequent major CHD or T2DM risk356-358. The analyses of the time trends in major
CHD incidence assumed only modest lag times between the aetiological exposures
and major CHD incidence. The analyses of the time trends in T2DM incidence
considered longer lag times. The predicted contributions of each exposure to the time
trends from the models will depend on the time-lag allowed; the largest estimated
contribution obtained when the correct lag time is incorporated in the model. The
models may have underestimated the contributions of risk factors if an incorrect lag
time is assumed.
Finally, this thesis considers time trends in major CHD and T2DM incidence, as
contributing to the time trends in CHD mortality and T2DM prevalence. As discussed
in chapter 2, time trends in case fatality following a major CHD event or in relative
survival of patients with T2DM, may also have influenced the CHD mortality and
T2DM prevalence trends. Therefore a logical next step in research would be to
examine the time trends in major CHD case fatality and T2DM relative survival. In
addition, this thesis research could be followed by analyses of time trends in other
related conditions such as stroke and heart failure.
10.4 Concluding statement
Recent public health headlines in the UK have included the dramatic decline in CHD
mortality in recent decades, and the contrasting apparent rise in T2DM prevalence.
This thesis provides evidence of a contemporaneous decline in major CHD incidence
and a contemporaneous rise in T2DM incidence, which have contributed to the CHD
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mortality and T2DM prevalence trends. Analyses reveal that favourable time trends
in major modifiable aetiological exposures (smoking and blood pressure and lipid
levels) may explain much of the decline in major CHD incidence. Conversely, a rise
in adiposity levels has had an adverse impact, limiting the scale of the decline in
major CHD incidence, and explaining an estimated one quarter of the rise in T2DM
incidence. The analysis of the decline in major CHD incidence highlights what can be
achieved, and emphasizes the potential of population-wide public health measures to
reduce exposure to modifiable risk factors to in turn reduce incidence of major CHD
(and by extension CHD mortality rates). The results showing the sizeable adverse
effects of adiposity underlines the urgent need to address rising obesity levels in the
UK as well as in other countries, to reduce the future burden of these chronic diseases.
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Appendix A Lists of Read codes to identify disease cases in The
Health Improvement Network Database
A.1 Read codes312 in THIN indicating forms of diabetes leading to exclusion from
analysis of time trend in T2DM incidence:
Read
code Description
C10B.00 Diabetes mellitus induced by steroids
C10B000 Steroid induced diabetes mellitus without complication
C10H.00 Diabetes mellitus induced by non-steroid drugs
C10H000 DM induced by non-steroid drugs without complication
C10G.00 Secondary pancreatic diabetes mellitus
C10G000 Secondary pancreatic diabetes mellitus without complication
C10N.00 Secondary diabetes mellitus
C10N000 Secondary diabetes mellitus without complication
C10N100 Cystic fibrosis related diabetes mellitus
C10A.00 Malnutrition-related diabetes mellitus
C10A000 Malnutrition-related diabetes mellitus with coma
C10A100 Malnutrition-related diabetes mellitus with ketoacidosis
C10A200 Malnutrition-related diabetes mellitus with renal complicatn
C10A300 Malnutrit-related diabetes mellitus wth ophthalmic complicat
C10A400 Malnutrition-related diabetes mellitus wth neuro complicatns
C10A500 Malnutritn-relat diabetes melitus wth periph circul complctn
C10A600 Malnutrition-related diabetes mellitus with multiple comps
C10A700 Malnutrition-related diabetes mellitus without complications
C10AW00 Malnutrit-related diabetes mellitus with unspec complics
C10AX00 Malnutrit-relat diabetes mellitus with other spec comps
Cyu2100 [X]Malnutrit-relat diabetes mellitus with other spec comps
Cyu2200 [X]Malnutrit-related diabetes mellitus with unspec complics
C10J.00 Insulin autoimmune syndrome
C10J000 Insulin autoimmune syndrome without complication
C10K.00 Type A insulin resistance
C10K000 Type A insulin resistance without complication
C10L.00 Fibrocalculous pancreatopathy
C10L000 Fibrocalculous pancreatopathy without complication
C10M.00 Lipoatrophic diabetes mellitus
C10M000 Lipoatrophic diabetes mellitus without complication
L180.00 Diabetes mellitus during pregnancy/childbirth/puerperium
L180000 Diabetes mellitus - unspec whether in pregnancy/puerperium
L180100 Diabetes mellitus during pregnancy - baby delivered
L180200 Diabetes mellitus in puerperium - baby delivered
L180300 Diabetes mellitus during pregnancy - baby not yet delivered
L180400 Diabetes mellitus in pueperium - baby previously delivered
L180800 Diabetes mellitus arising in pregnancy
L180811 Gestational diabetes mellitus
L180900 Gestational diabetes mellitus
L180z00 Diabetes mellitus in pregnancy/childbirth/puerperium NOS
ZC2CB00 Dietary advice for gestational diabetes
66An.00 Diabetes type 1 review
C100000 Diabetes mellitus, juvenile type, no mention of complication
C101000 Diabetes mellitus, juvenile type, with ketoacidosis
C102000 Diabetes mellitus, juvenile type, with hyperosmolar coma
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C103000 Diabetes mellitus, juvenile type, with ketoacidotic coma
C104000 Diabetes mellitus, juvenile type, with renal manifestation
C105000 Diabetes mellitus, juvenile type, + ophthalmic manifestation
C106000 Diabetes mellitus, juvenile, + neurological manifestation
C107000 Diabetes mellitus, juvenile +peripheral circulatory disorder
C108.12 Type 1 diabetes mellitus
C108.13 Type I diabetes mellitus
C108011 Type I diabetes mellitus with renal complications
C108012 Type 1 diabetes mellitus with renal complications
C108111 Type I diabetes mellitus with ophthalmic complications
C108112 Type 1 diabetes mellitus with ophthalmic complications
C108211 Type I diabetes mellitus with neurological complications
C108212 Type 1 diabetes mellitus with neurological complications
C108311 Type I diabetes mellitus with multiple complications
C108312 Type 1 diabetes mellitus with multiple complications
C108411 Unstable type I diabetes mellitus
C108412 Unstable type 1 diabetes mellitus
C108511 Type I diabetes mellitus with ulcer
C108512 Type 1 diabetes mellitus with ulcer
C108611 Type I diabetes mellitus with gangrene
C108612 Type 1 diabetes mellitus with gangrene
C108711 Type I diabetes mellitus with retinopathy
C108712 Type 1 diabetes mellitus with retinopathy
C108811 Type I diabetes mellitus - poor control
C108812 Type 1 diabetes mellitus - poor control
C108911 Type I diabetes mellitus maturity onset
C108912 Type 1 diabetes mellitus maturity onset
C108A11 Type I diabetes mellitus without complication
C108A12 Type 1 diabetes mellitus without complication
C108B11 Type I diabetes mellitus with mononeuropathy
C108B12 Type 1 diabetes mellitus with mononeuropathy
C108C11 Type I diabetes mellitus with polyneuropathy
C108C12 Type 1 diabetes mellitus with polyneuropathy
C108D11 Type I diabetes mellitus with nephropathy
C108D12 Type 1 diabetes mellitus with nephropathy
C108E11 Type I diabetes mellitus with hypoglycaemic coma
C108E12 Type 1 diabetes mellitus with hypoglycaemic coma
C108F11 Type I diabetes mellitus with diabetic cataract
C108F12 Type 1 diabetes mellitus with diabetic cataract
C108G11 Type I diabetes mellitus with peripheral angiopathy
C108G12 Type 1 diabetes mellitus with peripheral angiopathy
C108H11 Type I diabetes mellitus with arthropathy
C108H12 Type 1 diabetes mellitus with arthropathy
C108J11 Type I diabetes mellitus with neuropathic arthropathy
C108J12 Type 1 diabetes mellitus with neuropathic arthropathy
C10C.12 Maturity onset diabetes in youth type 1
C10E.00 Type 1 diabetes mellitus
C10E.11 Type I diabetes mellitus
C10E000 Type 1 diabetes mellitus with renal complications
C10E011 Type I diabetes mellitus with renal complications
C10E100 Type 1 diabetes mellitus with ophthalmic complications
C10E111 Type I diabetes mellitus with ophthalmic complications
C10E200 Type 1 diabetes mellitus with neurological complications
C10E211 Type I diabetes mellitus with neurological complications
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C10E300 Type 1 diabetes mellitus with multiple complications
C10E311 Type I diabetes mellitus with multiple complications
C10E400 Unstable type 1 diabetes mellitus
C10E411 Unstable type I diabetes mellitus
C10E500 Type 1 diabetes mellitus with ulcer
C10E511 Type I diabetes mellitus with ulcer
C10E600 Type 1 diabetes mellitus with gangrene
C10E611 Type I diabetes mellitus with gangrene
C10E700 Type 1 diabetes mellitus with retinopathy
C10E711 Type I diabetes mellitus with retinopathy
C10E800 Type 1 diabetes mellitus - poor control
C10E811 Type I diabetes mellitus - poor control
C10E900 Type 1 diabetes mellitus maturity onset
C10E911 Type I diabetes mellitus maturity onset
C10EA00 Type 1 diabetes mellitus without complication
C10EA11 Type I diabetes mellitus without complication
C10EB00 Type 1 diabetes mellitus with mononeuropathy
C10EB11 Type I diabetes mellitus with mononeuropathy
C10EC00 Type 1 diabetes mellitus with polyneuropathy
C10EC11 Type I diabetes mellitus with polyneuropathy
C10ED00 Type 1 diabetes mellitus with nephropathy
C10ED11 Type I diabetes mellitus with nephropathy
C10EE00 Type 1 diabetes mellitus with hypoglycaemic coma
C10EE11 Type I diabetes mellitus with hypoglycaemic coma
C10EF00 Type 1 diabetes mellitus with diabetic cataract
C10EF11 Type I diabetes mellitus with diabetic cataract
C10EG00 Type 1 diabetes mellitus with peripheral angiopathy
C10EG11 Type I diabetes mellitus with peripheral angiopathy
C10EH00 Type 1 diabetes mellitus with arthropathy
C10EH11 Type I diabetes mellitus with arthropathy
C10EJ00 Type 1 diabetes mellitus with neuropathic arthropathy
C10EJ11 Type I diabetes mellitus with neuropathic arthropathy
C10EK00 Type 1 diabetes mellitus with persistent proteinuria
C10EK11 Type I diabetes mellitus with persistent proteinuria
C10EL00 Type 1 diabetes mellitus with persistent microalbuminuria
C10EL11 Type I diabetes mellitus with persistent microalbuminuria
C10EM00 Type 1 diabetes mellitus with ketoacidosis
C10EM11 Type I diabetes mellitus with ketoacidosis
C10EN00 Type 1 diabetes mellitus with ketoacidotic coma
C10EN11 Type I diabetes mellitus with ketoacidotic coma
C10EP00 Type 1 diabetes mellitus with exudative maculopathy
C10EP11 Type I diabetes mellitus with exudative maculopathy
C10EQ00 Type 1 diabetes mellitus with gastroparesis
C10y000 Diabetes mellitus, juvenile, + other specified manifestation
C10z000 Diabetes mellitus, juvenile type, + unspecified complication
ZC2C900 Dietary advice for type I diabetes
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A.2 Frequencies of Read codes312 for incident major CHD in THIN by calendar year (patients aged 30 to 100 years):
Medcode Description 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
All
years
G30..00 Acute myocardial infarction 492 690 930 1030 1050 1379 1516 1624 1660 1654 1424 1292 1103 1006 16850
G30..15 MI - acute myocardial infarction 8 65 123 225 355 616 855 1168 1263 1083 901 750 672 573 8657
G30z.00 Acute myocardial infarction NOS 642 490 397 379 357 366 347 308 329 284 214 195 164 120 4592
G307100
Acute non-ST segment elevation
myocardial infarction 1 4 4 101 276 446 679 891 1039 3441
G308.00 Inferior myocardial infarction NOS 5 27 40 74 105 113 115 113 114 118 114 104 92 77 1211
G30X000
Acute ST segment elevation myocardial
infarction 9 33 93 172 241 302 850
G307.00 Acute subendocardial infarction 20 13 25 18 32 43 39 32 14 3 10 4 3 4 260
G301z00 Anterior myocardial infarction NOS 4 5 5 6 12 25 23 39 29 30 29 15 19 241
G30..12 Coronary thrombosis 14 11 18 18 26 29 13 32 20 10 8 12 6 3 220
G301.00
Other specified anterior myocardial
infarction 4 4 10 11 19 21 24 26 17 6 14 18 10 184
G30..14 Heart attack 8 15 18 19 14 15 12 13 10 11 6 11 13 9 174
G307000 Acute non-Q wave infarction 1 1 9 30 39 25 7 9 4 3 6 134
G300.00 Acute anterolateral infarction 5 10 12 13 15 11 13 9 11 14 11 4 128
G302.00 Acute inferolateral infarction 1 3 5 11 11 16 13 12 10 13 10 9 12 126
G301100 Acute anteroseptal infarction 1 3 5 13 12 8 13 18 10 10 11 3 9 116
G304.00 Posterior myocardial infarction NOS 1 6 4 2 4 7 5 6 7 6 6 5 4 63
G30..17 Silent myocardial infarction 2 5 3 9 6 4 13 6 2 4 5 59
G30..16 Thrombosis - coronary 1 3 3 7 6 4 9 3 8 4 7 2 1 58
G303.00 Acute inferoposterior infarction 1 2 3 4 3 2 4 9 6 10 4 2 50
G305.00 Lateral myocardial infarction NOS 2 4 1 5 4 1 4 5 4 2 5 37
G30yz00 Other acute myocardial infarction NOS 7 4 2 5 3 6 6 1 34
G360.00
Haemopericardium/current comp folow
acut myocard infarct 2 2 2 6 5 6 4 2 2 1 1 1 34
G38..00 Postoperative myocardial infarction 2 3 3 2 2 4 2 4 2 4 4 32
ZV71900
[V]Observation for suspected
myocardial infarction 4 4 5 4 2 3 2 3 3 2 32
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G310.11 Dressler's syndrome 1 2 4 1 3 1 9 4 3 3 31
G30A.00 Mural thrombosis 1 3 1 2 3 3 3 1 6 5 28
G30..13
Cardiac rupture following myocardial
infarction (MI) 1 3 2 2 3 6 2 2 3 2 1 27
G30y.00 Other acute myocardial infarction 1 5 1 2 5 1 2 2 2 21
G30X.00
Acute transmural myocardial infarction
of unspecif site 3 1 3 3 2 2 1 3 3 21
G35..00 Subsequent myocardial infarction 1 2 2 2 3 2 3 2 17
G30y200 Acute septal infarction 1 1 3 2 3 1 2 2 2 17
G310.00 Postmyocardial infarction syndrome 2 4 5 11
G309.00 Acute Q-wave infarct 1 3 3 2 1 10
G30..11 Attack - heart 1 1 1 1 1 1 1 7
G350.00
Subsequent myocardial infarction of
anterior wall 1 1 1 2 1 6
G30y000 Acute atrial infarction 1 1 1 2 1 6
G301000 Acute anteroapical infarction 1 1 2 1 5
G30B.00
Acute posterolateral myocardial
infarction 2 3 5
G306.00 True posterior myocardial infarction 1 2 3
G311000 Myocardial infarction aborted 1 1 1 3
G381.00
Postoperative transmural myocardial
infarction inferior wall 2 1 3
G36..00
Certain current complication follow
acute myocardial infarct 1 1 1 3
G362.00
Ventric septal defect/curr comp fol acut
myocardal infarctn 1 1 2
G361.00
Atrial septal defect/curr comp folow acut
myocardal infarct 1 1 2
G38z.00
Postoperative myocardial infarction,
unspecified 1 1 2
G384.00
Postoperative subendocardial
myocardial infarction 1 1 2
G311011 MI - myocardial infarction aborted 1 1 2
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G351.00
Subsequent myocardial infarction of
inferior wall 1 1 2
G501.00 Post infarction pericarditis 1 1
G366.00
Thrombosis atrium,auric
append&vent/curr comp foll acute MI 1 1
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A.3 Frequencies of Read codes312 for incident T2DM in THIN by calendar year (patients aged 30 to 100 years):
Codes include those relating specifically to T2DM, and codes for non-specific diabetes, assumed to indicate T2DM as patients are >30 years. Insulin-treated diabetes codes
have been included as insulin, although predominantly associated with T1DM, may also be indicated for T2DM.
Medcode Description 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
All
years
C10F.00 Type 2 diabetes mellitus 174 263 435 590 934 1519 2253 3185 4375 5894 6748 7600 8375 8454 50799
C10..00 Diabetes mellitus 519 644 840 846 1094 1486 1785 1999 1657 1506 1251 786 581 675 15669
C109.00 Non-insulin dependent diabetes mellitus 42 65 97 176 262 482 764 912 747 472 359 197 97 75 4747
C100112 Non-insulin dependent diabetes mellitus 118 145 202 262 331 542 578 562 566 434 363 227 149 160 4639
C109.12 Type 2 diabetes mellitus 28 29 59 89 120 263 396 638 694 512 521 254 70 81 3754
66A3.00 Diabetic on diet only 21 27 30 53 81 107 116 124 110 84 62 43 46 48 952
C100111 Maturity onset diabetes 70 81 61 82 60 73 92 87 85 51 71 41 20 9 883
C109.13 Type II diabetes mellitus 1 5 2 8 15 25 75 52 49 17 21 8 9 3 290
66A4.00 Diabetic on oral treatment 2 3 4 17 11 28 43 30 30 27 18 14 15 11 253
C109.11
NIDDM - Non-insulin dependent diabetes
mellitus 2 7 13 14 25 27 51 23 26 21 29 238
66A1.00 Initial diabetic assessment 8 10 27 24 24 30 31 24 178
C100100
Diabetes mellitus, adult onset, no mention
of complication 12 14 14 8 11 18 13 6 11 16 9 6 2 3 143
C10F.11 Type II diabetes mellitus 2 3 9 6 5 15 33 26 99
C10FJ00 Insulin treated Type 2 diabetes mellitus 1 1 4 6 3 7 6 7 2 3 12 11 4 67
C108.00 Insulin dependent diabetes mellitus 3 1 1 5 7 11 6 11 8 4 2 2 61
C100011 Insulin dependent diabetes mellitus 3 3 5 8 7 9 6 2 6 6 1 3 1 60
66A5.00 Diabetic on insulin 3 11 3 5 4 5 3 5 5 2 46
C100.00
Diabetes mellitus with no mention of
complication 7 6 2 4 1 4 2 2 2 6 36
66AQ.00 Diabetes: shared care programme 1 2 4 9 2 10 3 2 2 35
C101.00 Diabetes mellitus with ketoacidosis 1 3 1 2 5 3 3 3 2 1 4 1 3 2 34
C109J00 Insulin treated Type 2 diabetes mellitus 5 2 1 5 2 4 5 3 2 2 1 32
C10F900
Type 2 diabetes mellitus without
complication 1 2 3 5 3 8 3 2 1 28
C108.11 IDDM-Insulin dependent diabetes mellitus 1 1 2 5 3 8 2 1 23
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C10D.00
Diabetes mellitus autosomal dominant
type 2 5 4 6 3 18
C10F911
Type II diabetes mellitus without
complication 1 1 7 7 16
C10FK00
Hyperosmolar non-ketotic state in type 2
diabetes mellitus 1 1 4 3 2 11
C109900
Non-insulin-dependent diabetes mellitus
without complication 1 1 3 3 1 1 10
C106.00
Diabetes mellitus with neurological
manifestation 2 1 2 1 1 1 8
C10F700 Type 2 diabetes mellitus - poor control 1 1 1 2 5
C106.12 Diabetes mellitus with neuropathy 2 1 2 5
C10FN00 Type 2 diabetes mellitus with ketoacidosis 1 2 1 1 5
C102.00
Diabetes mellitus with hyperosmolar
coma 1 1 1 1 4
C104.11 Diabetic nephropathy 2 1 1 4
C10FL00
Type 2 diabetes mellitus with persistent
proteinuria 1 2 1 4
C105.00
Diabetes mellitus with ophthalmic
manifestation 1 1 1 3
C100z00
Diabetes mellitus NOS with no mention of
complication 1 1 1 3
66AV.00 Diabetic on insulin and oral treatment 1 1 2
C10C.11 Maturity onset diabetes in youth 1 1 2
C109700
Non-insulin dependent diabetes mellitus -
poor control 1 1 2
C102100
Diabetes mellitus, adult onset, with
hyperosmolar coma 1 1 2
C10FM00
Type 2 diabetes mellitus with persistent
microalbuminuria 1 1 2
C10F000
Type 2 diabetes mellitus with renal
complications 1 1 2
C10F711 Type II diabetes mellitus - poor control 1 1
C107400 NIDDM with peripheral circulatory 1 1
381
disorder
C10E.12 Insulin dependent diabetes mellitus 1 1
C109K00
Hyperosmolar non-ketotic state in type 2
diabetes mellitus 1 1
C10FB00
Type 2 diabetes mellitus with
polyneuropathy 1 1
C10FJ11 Insulin treated Type II diabetes mellitus 1 1
C10FP00
Type 2 diabetes mellitus with ketoacidotic
coma 1 1
C10z100
Diabetes mellitus, adult onset, +
unspecified complication 1 1
C104.00 Diabetes mellitus with renal manifestation 1 1
66AJ.11 Unstable diabetes 1 1
C10F311
Type II diabetes mellitus with multiple
complications 1 1
C101z00 Diabetes mellitus NOS with ketoacidosis 1 1
C109J11
Insulin treated non-insulin dependent
diabetes mellitus 1 1
C10F300
Type 2 diabetes mellitus with multiple
complications 1 1
C109J12 Insulin treated Type II diabetes mellitus 1 1
C10F600 Type 2 diabetes mellitus with retinopathy 1 1
C107.12 Diabetes with gangrene 1 1
C108900 Insulin dependent diabetes maturity onset 1 1
C108800
Insulin dependent diabetes mellitus - poor
control 1 1
C107.00
Diabetes mellitus with peripheral
circulatory disorder 1 1
C10F611 Type II diabetes mellitus with retinopathy 1 1
382
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